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Summary
Stroke is often considered as a significant economy burden
in health care systems worldwide. According to epidemiological
data, there has been a considerable decrease in stroke morbidi-
ty and mortality in most West European countries, mainly be-
cause of the implementation of prevention measures. Quite a
reverse trend has been observed in most of the Central and
East European countries where the epidemic of stroke is ex-
pected in the near future. New research facts from the fields of
molecular science and genetics have enabled better understand-
ing of the stroke pathogenesis while contemporary neuroimag-
ing techniques as well as Doppler ultrasonography have con-
tributed to our perception of stroke. During the last few years,
there has been an increasing demand for redefinition and new
classification of stroke and transient ischemic attack, implying
new definitions such as acute ischemic cerebral syndromes, or
acute neurovascular syndromes. It is important to emphasize
the importance of stroke as a medical emergency that should be
managed in specialized stroke units. The results from large clin-
ical studies have shown that stroke units significantly reduce
the mortality and disability among stroke patients. Treatment
of acute ischemic stroke with rTPA-thrombolysis within the first
3 hours from the stroke onset, and antiaggregation and antico-
agulation therapy have provided better stroke management. The
prevention of risk factors for cardiovascular events is still the
most effective measure that can reduce the risk of stroke. New
clinical evidence has supported some antihypertensives and st-
atins in stroke prevention due to the additional beneficial ef-
fect of the drugs apart from blood pressure and cholesterol low-
ering. Therefore, it is important to decrease the risk of stroke
by implementing primary and secondary prevention, and intro-
ducing in practice the recently published recommendations for
stroke management.
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Saetak
Modani udar je vaan zdravstveni i socijalno-ekonomski
problem, kako u svijetu tako i u Republici Hrvatskoj. Epide-
mioloki podaci iz zapadnih zemalja pokazuju smanjivanje
pobola i smrtnosti od modanog udara u posljednjim deset-
ljeæima prologa stoljeæa, to je izravna posljedica preventivnih
aktivnosti. Meðutim, nepovoljan trend porasta uŁestalosti
modanog udara biljei se u mnogim dravama srednje i istoŁne
Europe, pa se u skoroj buduænosti predviða prava epidemija
obolijevanja od modanog udara. Nova otkriæa u podruŁju
molekularnih znanosti i genetike pridonose boljem razumije-
vanju patogeneze modanog udara, a moderne tehnike sli-
kovnog prikaza mozga i doplerske ultrasonografije svakim da-
nom obogaæuju nae spoznaje o modanom udaru. Posljednjih
godina sve su brojniji prijedlozi da se redefiniraju kriteriji i
klasifikacija modanog udara i prolaznih ishemijskih napadaja,
pa se sve vie govori o akutnim ishemijskim cerebralnim sin-
dromima (AICS), odnosno o akutnim neurovaskularnim sindro-
mima. Vano je naglasiti da je modani udar hitno medicinsko
stanje koje zahtijeva hitnu zdravstvenu skrb u specijaliziranim
jedinicama za lijeŁenje modanog udara. Rezultati velikih kli-
niŁkih ispitivanja pokazali su kako zbrinjavanje bolesnika u je-
dinicama za lijeŁenje modanog udara znaŁajno smanjuje smrt-
nost i invalidnost bolesnika. TrombolitiŁno lijeŁenje primjenom
rekombiniranog tkivnog aktivatora plazminogena unutar prva
tri sata od nastanka inzulta bitno doprinosi uŁinkovitom lijeŁe-
nju ishemijskog modanog udara. Prevencija je i nadalje na-
juŁinkovitiji pristup modanom udaru, jer smanjuje rizik od
nastanka modanog udara djelovanjem na brojne Łimbenike
rizika. Rezultati velikih kliniŁkih studija pokazuju da bi novije
generacije antihipertenziva i statina mogle imati dodatno po-
voljno djelovanje u prevenciji modanog udara. Stoga je nuno
potrebno iriti spoznaju o sprjeŁavanju modanog udara po-
moæu razliŁitih metoda primarne i sekundarne prevencije, a
dosljedno i sveobuhvatno provoðenje objavljenih preporuka za
zbrinjavanje bolesnika s modanim udarom moe tome znaŁaj-
no doprinijeti.
KljuŁne rijeŁi: modani udar, primarna i sekundarna prevencija
modanog udara, jedinice za lijeŁenje modanog udara, terapija
modanog udara, preporuke za zbrinjavanje modanog udara
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Stroke is on the third place of all death causes in the
world and the leading cause of death and disability in
Croatia. The prevalence of stroke has been on an increase
not only in the elderly but also in middle-age population,
thus adversely affecting their productivity and quality of
life. These aspects contribute to a significant health as well
as economy and social burden of stroke. Epidemiological
data show a considerable decrease in stroke morbidity and
mortality in most West European countries, mainly be-
cause of the implementation of prevention measures. The
age-specific incidence of major stroke in the Oxford Vas-
cular Study has fallen by 40% over the past 20 years in as-
sociation with the increased use of preventive treatments
and major reductions in premorbid risk factors. On the
contrary, there has been a constant increase in the morbid-
ity and mortality of stroke in Croatia. A similar trend has
been observed in most Central and East European coun-
tries implying an epidemic of stroke in the near future. In
the last few years, there has been increasing evidence from
most fundamental research studies that have contributed
to better understanding of stroke pathogenesis, from the
association of ischemic type of stroke and specific genes
(gene encoding phosphodiesterase 4D in Island and 5-ly-
pooxigenase protein activation gene), the role of neu-
rotransmitters and excitoxicity of brain tissue damage, the
association of hyperhomocysteinemia and stroke, through
the role of oxidative stress and angiotensin II in vascular
wall damage, which can contribute to stroke.
Modern neuroimaging techniques have significantly
contributed to our perception of stroke, thus increasing the
demand for redefinition and new classification of stroke
and transient ischemic attack (TIA), and indicating new
definitions such as acute ischemic cerebral syndromes
(AICS) or acute neurovascular syndromes. Noninvasive
diagnostic methods for functional and morphological brain
imaging like magnetic resonance (MR), computed tomog-
raphy (CT), single photon emission tomography (SPECT)
and positron emission tomography (PET) can provide
valuable information on cerebral perfusion patterns and
help in assessment of post-stroke brain tissue damage.
Doppler ultrasonography has the leading role in the assess-
ment of cerebral blood flow pathology. In addition to ex-
tracranial and transcranial Doppler (TCD), methods which
allow prompt evaluation of cerebrovascular status and
detection of blood vessel pathology, power Doppler, 3D
ultrasonography, transcranial color coded sonography
(TCCS) and functional TCD have frequently been used
in clinical practice. Furthermore, measurement of the in-
tima-media thickness (IMT) of carotid bifurcation and
Modani udar je i nadalje treæi uzrok smrtnosti u svi-
jetu, a prvi uzrok smrtnosti u Republici Hrvatskoj. Uz to,
modani udar je prvi uzrok invalidnosti u nas i u svijetu.
Svjedoci smo i Łinjenice da modani udar vie ne zahvaæa
samo starije dobne skupine; u zadnje vrijeme od modanog
udara sve Łeæe obolijevaju i bolesnici u najproduktivnijim
godinama ivota. Sve to Łini modani udar velikim
zdravstvenim kao i dutvenim i ekonomskim problemom.
Epidemioloki podaci iz zapadnih zemalja pokazuju sma-
njivanje pobola i smrtnosti od modanog udara u posljed-
njim desetljeæima prologa stoljeæa, to je izravna posljedica
preventivnih aktivnosti. ZnaŁajan pad incidencije mo-
danog udara od Łak 40% zabiljeen je u velikoj popu-
lacijskoj studiji, Oxfordshire Community Stroke Project,
koja je provedena u Velikoj Britaniji tijekom posljednjih 20
godina. Rezultati studije pokazali su kako primjena mjera
prevencije znaŁajno smanjuje predmorbidne riziŁne Łim-
benike sniavajuæi serumski kolesterol i povien krvni tlak
te smanjujuæi broj puaŁa uz preventivnu primjenu anti-
agregacijske terapije i lijekova za sniavanje lipida i hi-
pertenzije. Nasuprot tome, podaci za Hrvatsku pokazuju
stalan porast pobola i smrtnosti od modanog udara. SliŁan
nepovoljan trend porasta uŁestalosti modanog udara
biljei se i u ostalim dravama srednje i istoŁne Europe, kao
i u veæini zemalja u razvoju, pa se u dolazeæim desetljeæi-
ma predviða prava epidemija obolijevanja od modanog
udara.
Posljednjih godina svjedoci smo brojnih novih funda-
mentalnih otkriæa o modanom udaru koja bi se mogla
pokazati znaŁajnima u razumijevanju patogeneze moda-
nog udara: od povezanosti obolijevanja od ishemijskog
modanog udara i prisutnosti odreðenih gena (npr. pove-
zanosti gena za fosfodiesterazu 4D u Islandu, gen za pro-
tein koji aktivira 5-lipooksigenazu) preko uloge neurotrans-
mitera i ekcitotoksiŁnosti u oteæenju modanog parenhi-
ma, povezanosti hiperhomocisteinemije i modanog udara,
pa sve do uloge oksidativnog stresa i angiotenzina II. u ote-
æenju stijenka modanih krvnih ila, Łime se stvaraju predu-
vjeti za nastanak modanog udara.
Nove metode i tehnike slikovnog prikaza svakim da-
nom obogaæuju spoznaje o modanom udaru, tako da su
posljednjih godina sve brojniji prijedlozi da se redefiniraju
kriteriji i klasifikacija prolaznih ishemijskih napadaja (TIA)
i modanog udara, pa se sve vie govori o akutnim ishemij-
skim cerebralnim sindromima (AICS), odnosno o akutnim
neurovaskularnim sindromima. Neinvazivne metode za
funkcionalni i anatomski prikaz mozga, modanog krvoto-
ka i metabolizma poput magnetske rezonancije (MR)i
kompjutorizirane tomografije (CT), jednofotonske emi-
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carotid arteries by means of extracranial Doppler has an
important role as an independent factor for stroke predic-
tion. The advantages of Doppler ultrasonography meth-
ods are noninvasiveness, low cost, and the possibility of
repeat examination at bedside. Doppler diagnostic meth-
ods are invaluable tools often used in cerebral blood eval-
uation in primary stroke prevention as well as in second-
ary stroke prevention after carotid surgery. At this point,
we are able to treat efficiently ischemic stroke with rTPA-
thrombolysis, within the first 3 hours from stroke onset.
Thrombolysis treatment must be performed according to
clinical protocol because any protocol deviation can pro-
duce serious adverse events. Although, thrombolysis can
only be used in a small number of patients, it is regarded
as a guideline to urgent and efficient ischemic stroke treat-
ment. Besides research studies about TCD-enhanced
thrombolysis, numerous investigations of penumbra region
have been conducted. Unfortunately, the risk of hemor-
rhage is another serious obstacle in thrombolysis treat-
ment. New clinical evidence show that some enzymes like
metalloproteinase might induce secondary hemorrhage
after thrombolysis. Preliminary research studies of the use
of neuroimaging methods (perfusion MRI and diffusion
MRI, PET) might prolong the 3-hour window in a strictly
selected group of ischemic stroke patients.
Besides thrombolysis, antiaggregation therapy has an
important role in ischemic stroke management. It is rec-
ommended not only in acute ischemic stroke treatment
but also after TIA and in patients with risk factors for
stroke. Anticoagulation therapy is indicated in specific
circumstances of acute ischemic stroke and also in second-
ary prevention of cardiac diseases (atrial fibrillation). In
patients with high-grade carotid artery stenosis, endarter-
ectomy is still therapy of choice. Besides classic endarter-
ectomy, there has been an increasing number of carotid
artery surgeries performed in local anesthesia, while blood
vessel dilatation and stenting are restricted to controlled
clinical trials.
Results of large clinical studies have shown that stroke
management in specialized stroke units can significantly
reduce the mortality and neurologic disability even with-
out thrombolysis treatment.
Therefore, restructuring of health care services is ur-
gent because stroke must be accepted as medical emer-
gency that requires emergency transport to an appropri-
ately equipped medical center where stroke patients can
be treated properly. In spite of all this, stroke is associated
with high mortality rates. Stroke patients are often disabled
by severe neurologic and functional limitations in move-
sijske tomografije mozga (SPECT) i pozitronske tomo-
grafije mozga (PET) pomau u procjeni cerebrovaskularnih
poremeæaja te stupnja oteæenja nakon vaskularnog inzul-
ta. U dijagnostici patologije modane cirkulacije dopler-ska
je sonografska dijagnostika postala nezaobilaznom meto-
dom. Osim ekstrakranijskog obojenog doplera i transk-
ranijskog doplera koji omoguæuju brzu procjenu cere-
brovaskularnog statusa bolesnika te prikaz raznih patolok-
ih stanja na krvnim ilama, sve vie se upotrebljavaju
osnaeni dopler, trodimenzijski dopler, bojom kodirana
transkranijska sonografija i funkcionalni transkranijski
dopler. Osim toga, doplerska ultrasonografija omoguæuje
mjerenje debljine intime i medije (intima-media thickness,
IMT) karotidnih arterija i karotidne bifurkacije kao znaŁa-
jnog predskazatelja za nastanak modanog udara. Sve te
pretrage su neinvazivne, mogu se ponavljati bez rizika za
bolesnika, a pogodne su i za primjenu uz bolesniŁki kre-
vet. Time su postale glavnom dijagnostiŁkom metodom
kako u primarnoj prevenciji cerebrovaskulamih bolesti, u
praæenju promjena modane cirkulacije, tako i u sekundar-
noj prevenciji i u praæenju bolesnika nakon operacijskih
zahvata.
Prvi put u povijesti na raspolaganju nam stoji uŁinko-
vito lijeŁenje ishemijskog modanog udara otapanjem
ugruka, tj. trombolizom uz primjenu rekombiniranog
tkivnog aktivatora plazminogena, ali samo unutar prva tri
sata od nastanka modanog udara. LijeŁenje se provodi po
toŁno odreðenom protokolu, jer svako odstupanje donosi
velik rizik komplikacija. Iako je trombolizu moguæe provesti
samo u malog broja bolesnika, ona je putokaz da terapija
ishemijskog modanog udara postoji i da treba naglaavati
potrebu brze reakcije bolesnika, njegove okoline i medicin-
skog osoblja. Uz najnovija istraivanja usmjerena ka pot-
pomaganju trombolize pomoæu kontinuiranog promatranja
transkranijskim doplerom (TCD-om) provode se brojna
istraivanja koja imaju za cilj djelovati na penumbru.
Naalost, opasnost od sekundarnih krvarenja dodatno ko-
mplicira primjenu trombolitiŁne terapije. Novija istra-
ivanja ukazuju na ulogu metaloproteinaza u nastanku se-
kundarnih krvarenja nakon trombolize i moda otvaraju
nove moguænosti u poveæanju sigurnosti primjene rekom-
biniranog tkivnog aktivatora plazminogena. Nadalje, pre-
liminarna istraivanja primjene novih, sofisticiranih metoda
slikovnog prikaza (npr. perfuzijske i difuzijske tehnike
magnetske rezonancije, perfuzijska kompjutorizirana to-
mografija) pobuðuju nadu u produenje trosatnog ter-
apijskog prozora u odreðenih, strogo odabranih bolesnika.
U terapiji ishemijskog modanog udara se uz tromboli-
zu primjenjuje i antiagregacijsko lijeŁenje. Uz terapiju akut-
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ment, communication, perception, cognition, and many
have neuropsychological deficits like cognitive impair-
ment, post-stroke dementia and post-stroke depression.
Rehabilitation is the key word in post-stroke care. Early
rehabilitation might reduce disability and functional sys-
tem impairment. Although rehabilitation programs do not
alter neurologic deficit, they may contribute to the pa-
tients physical independence. Rehabilitation team that
comprises multidisciplinary collaboration helps the pa-
tients in every day activities including their families.
The best approach to stroke management is preven-
tion. Primary endpoint of stroke prevention is reduction
in the risk of stroke by influencing stroke risk factors. The
major risk factors for stroke include hypertension, elevat-
ed serum lipid levels, myocardial infarction, atrial fibrilla-
tion, carotid artery stenosis, diabetes, smoking and alco-
hol consumption, inappropriate dietary habits and inade-
quate physical activity.
Recently published data from large, randomized clin-
ical trials show that lowering of blood pressure and elevat-
ed cholesterol is associated with a significant decrease in
stroke risk. Besides blood pressure and cholesterol lower-
ing it seems that the use of angiotensin-converting enzyme
inhibitors (ACEI), angiotensin receptor blockers (ARB),
calcium antagonists (CA) and statins could provide some
additional beneficial effects in reducing the risk of stroke.
Statins could have a beneficial effect on stabilizing athero-
sclerotic plaque. In the last few years, stroke management
has significantly improved, mainly due to numerous re-
search studies.
Considering new clinical evidence in stroke manage-
ment, we must recognize stroke as a medical emergency
that should be treated at specialized stroke units, empha-
sizing the need of establishing such units in all major health
institutions throughout the country. Recommendations for
stroke management could significantly improve stroke care
organization and contribute to the reduction of stroke
mortality in Croatia.
nog ishemijskog modanog udara primjena antiagre-
gacijskih lijekova preporuŁa se i osobama s Łimbenicima ri-
zika, te nakon TIA. Antikoagulantna terapija indicirana je
u posebnim sluŁajevima akutnog ishemijskog modanog
udara, a u sekundarnoj prevenciji nalazi mjesto kod odre-
ðenih srŁanih bolesti (atrijska fibrilacija). Kod simpto-
matskih bolesnika sa znaŁajnom stenozom karotidnih ar-
terija kirurki zahvat je i nadalje terapija izbora. Uz klasiŁnu
endarterektomiju sve Łeæe se primjenjuje operacijski za-
hvat na karotidnim arterijama u lokalnoj anesteziji, dok su
metode dilatacije arterija i stentinga i dalje ograniŁene
samo na kontrolirana kliniŁka ispitivanja.
Rezultati velikih kliniŁkih ispitivanja pokazali su kako
se zbrinjavanjem bolesnika u primjereno opremljenim
odjelima (jedinice za lijeŁenje modanog udara, stroke units)
Łak i bez primjene trombolize znaŁajno smanjuju smrtnost
i invalidnost bolesnika. Stoga je neophodna reorganizacija
medicinske slube kako bi se modani udar shvatio kao
hitno stanje koje zahtijeva hitan transport u primjereno
opremljenu ustanovu gdje æe se bolesnike moæi odgovara-
juæe zbrinuti.
UnatoŁ znaŁajnom napretku u zbrinjavanju bolesnika
s modanim udarom, modani udar je i nadalje je povezan
sa znaŁajnom smrtnoæu. U bolesnika nakon preboljelog
modanog udara vrlo Łesto zaostaju teka neuroloka o-
teæenja i funkcionalna ograniŁenja u kretanju, komuni-
kaciji, percepciji, spoznaji, a sve vie se govori i o psihiŁkim
i neuropsiholokim promjenama nakon preboljelog
modanog udara, od vaskularnih kognitivnih oteæenja do
vaskularne demencije i depresije. Rehabilitacija je kljuŁna
u zbrinjavanju bolesnika s preboljelim modanim udarom.
Rano zapoŁetom rehabilitacijom moguæe je dodatno sma-
njiti invalidnost i oteæenja funkcionalnih sustava. Iako re-
habilitacijski programi ne mijenjaju neuroloki deficit
bolesnika, mogu znaŁajno pridonijeti osamostaljivanju
bolesnika. Kvalitetnu rehabilitaciju treba provoditi multi-
disciplinski tim struŁnjaka, a bolesnici i Łlanovi njihovih
obitelji moraju biti ukljuŁeni u rehabilitacijski proces.
Prevencija je i nadalje najbolji pristup modanom uda-
ru. Cilj prevencije je smanjiti rizik od nastanka modanog
udara djelovanjem na Łimbenike rizika. NajŁeæi Łimbeni-
ci rizika ukljuŁuju hipertenziju, poviene vrijednosti lipi-
da u serumu, infarkt miokarda, atrijsku fibrilaciju i karotid-
nu stenozu, eæernu bolest, puenje i konzumiranje alko-
hola, neprimjerenu prehranu te smanjenu tjelesnu ak-
tivnost. Rezultati velikih kontroliranih, dvostruko slijepih,
placebom kontroliranih studija objavljeni posljednjih god-
ina pokazuju kako bi novije generacije antihipertenziva
(npr. inhibitori konvertaze angiotenzina /ACEI/, blokatori
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kalcijevih kanala, blokatori angiotenzinskih receptora)
mogli uz djelovanje na sniavanje tlaka imati i dodatne
povoljne uŁinke na smanjivanje rizika od modanog udara.
Tako i za statine postoje neizravni dokazi da bi mogli imati
dodatno djelovanje u prevenciji modanog udara, uz njiho-
vo povoljno djelovanje na sniavanje razine kolesterola,
najvjerojatnije djelovanjem na stabiliziranje ateroskle-
rotskih plakova.
Posljednjih godina svjedoci smo znaŁajnog napretka u
zbrinjavanju bolesnika s modanim udarom. Uzimajuæi u
obzir brojna istraivanja koja su u tijeku, za vjerovati je da
æemo u buduænosti biti svjedoci i veæih iskoraka.
Naalost, sve navedene spoznaje jo uvijek nisu opæe
prihvaæene i Łesto se u praksi ne primjenjuju. Stoga je
nuno potrebno meðu zdravstvenim djelatnicima i u
puŁanstvu iriti spoznaju da se modani udar moe sprijeŁi-
ti dosljednom primjenom razliŁitih metoda primarne i
sekundarne prevencije. Takoðer valja stalno naglaavati
kako je modani udar hitno medicinsko stanje koje zahtije-
va hitan zdravstveni tretman u primjereno opremljenim
jedinicama, tj. jedinicama za lijeŁenja modanog udara, koje
bi trebalo osnovati u svim veæim zdravstvenim ustanova-
ma u Republici Hrvatskoj. Dosljedna i sveobuhvatna
primjena objavljenih preporuka za zbrinjavanje bolesnika
s modanim udarom moe tome znaŁajno doprinijeti.
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Svjetska zdravstvena organizacija (SZO) upozorava
kako na godinu u svijetu od kardiovaskularnih bolesti umire
preko 16,5 milijuna, a u Europi vie od 5 milijuna ljudi. Udio
cerebrovaskularnih bolesti na razini svijeta iznosi 32,9%, a
u Europi 29,4%. Globalno cerebrovaskularne bolesti uzrok
su smrti u oko 5,5 milijuna ljudi, a od toga blizu 1,5 mili-
jun u Europi. Cerebrovaskularne bolesti 1990. godine nala-
zile su se na drugom mjestu iza ishemijskih bolesti srca
meðu 15 najŁeæih uzroka smrti, a projekcije za 2020. go-
dinu govore da æe ove dvije skupine i dalje biti vodeæi uzrok
smrti u svijetu. Prema studiji Globalnog optereæenja boles-
tima izraeno u godinama ivota s invaliditetom (disability
adjusted life year, DALY) meðu 15 vodeæih uzroka bolesti i
ozljeda u svijetu 1990. godine cerebrovaskularne bolesti
bile su svrstane na esto mjesto. U procjenama za 2020.
godinu predviða da æe se na razini svijeta nalaziti na Łetvr-
tom mjestu, iza ishemijskih bolesti srca, velike depresije i
ozljeda u prometnim nesreæama, a u razvijenim zemljama
na drugom mjestu iza ishemijskih bolesti srca.
Epidemioloke analize na razini Europe pokazuju ve-
like razlike u stopama smrtnosti za kardiovaskularne bolesti
ukupno. Najnie stope smrtnosti biljei se u zemljama
Zapadne Europe, osobito u mediteranskim zemljama, a
najvie su stope smrtnosti od ovih bolesti u zemljama Sre-
dinje i IstoŁne Europe.
Glavni uzroci smrti iz skupine kardiovaskularnih bolesti
su ishemijske bolesti srca i cerebrovaskularne bolesti. Kako
za ishemijske bolesti srca tako su i za cerebrovaskularne
bolesti stope smrtnosti najnie u zemljama Zapadne Eu-
rope, a najvie u zemljama IstoŁne Europe. Prema analizi
podataka o smrtnosti iz 30 europskih zemalja Sansa i surad-
nika, standardizirana stopa smrtnosti od cerebrovaskularnih
bolesti  za dobnu skupinu od 45-74 godine 1990-1992.
godine za mukarce bila je najnia u vicarskoj (54/
100.000), Francuskoj (67/100.000) i Islandu (75/100.000),
a najvia u Bugarskoj (396/100.000), Ruskoj Federaciji (409/
100.000) i Ukrajini (606/100.000). Za ene najnie stope
zabiljeene su takoðer u vicarskoj (32/100.000), Fran-
cuskoj (35/100.000) i Islandu (48/100.000), a najvie u
Bugarskoj (259/100.000), Ruskoj Federaciji (271/100.000)
The World Health Organization (WHO) calls attention
to the serious fact that more than 16.5 million people in
the world and more than 5 million people in Europe die
from cardiovascular disease per year. The proportion of
cerebrovascular diseases in the world and in Europe is
32.9% and 29.4%, respectively. Globally, cerebrovascular
diseases are the cause of death in some 5.5 million peo-
ple, 1.5 million of these in Europe. In 1990, cerebrovascu-
lar diseases ranked second, immediately following ischemic
heart disease, of the 15 most common causes of death.
Projections for 2020 show that these two groups of diseas-
es will continue to be the leading causes of death world-
wide. According to the Global Burden of Disease study,
expressed as Disability Adjusted Life Years (DALY), cere-
brovascular diseases ranked sixth among the 15 leading
causes of disease and lesions in the world in 1990. The
estimates for 2020 predict these diseases to rank fourth
at the global level, immediately after ischemic heart dis-
ease, major depression and injuries inflicted in traffic ac-
cidents, and second in industrialized countries, immedi-
ately following ischemic heart disease.
Epidemiological studies for Europe show great differ-
ences in the cardiovascular disease overall mortality rates.
The lowest rates are recorded in the countries of West
Europe, especially in Mediterranean countries, and high-
est in the countries of Central and East Europe.
In the group of cardiovascular diseases, the main caus-
es of death are ischemic heart diseases and cerebrovascu-
lar diseases. As for ischemic heart diseases, the mortality
rates for cerebrovascular diseases are also lowest in the West
Europe countries and highest in East Europe countries.
The analysis of mortality records from 30 European coun-
tries performed by Sans et al. has shown the standardized
mortality rate of cerebrovascular diseases in men aged 45-
74 in the 1990-1992 period to be lowest in Switzerland (54/
100,000), France (67/100,000) and Island (75/100,000),
and highest in Bulgaria (396/100,000), Russian Federation
(409/100,000) and Ukraine (606/100,000). In women, the
lowest rates were also recorded in Switzerland (32/
100,000), France (35/100,000) and Island (48/100,000),
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i Ukrajini (408/100000). Najvie stope u mukaraca bile su
11 puta veæe u odnosu na najnie stope, a u ena je omjer
najviih stopa u odnosu na najnie bio Łak 13:1.
Meðutim, za razliku od kardiovaskularnih bolesti ukup-
no i ishemijskih bolesti srca, standardizirane stope smrt-
nosti od cerebrovaskularnih bolesti u mediteranskim zem-
ljama pokazuju dosta velik raspon. Primjerice, za mukarce
u dobi od 45-74 godine 1990-1992. godine stopa je u Fran-
cuskoj iznosila 67, a u Portugalu 276/100.000. Odgovara-
juæe stope za ene kretale su se od 35 u Francuskoj do 158/
100.000 u Portugalu. U svim su zemljama dobno specifiŁne
stope smrtnosti nie u ena nego u mukaraca, a i kretanje
smrtnosti je povoljnije za ene nego za mukarce.
Prema American Heart Association Scientific State-
ment iz 2001. godine incidencija ishemijskog modanog
inzulta od 55. godine ivota udvostruŁuje se za svako
desetljeæe ivota. Incidencija je via u mukaraca (174/
100.000) nego u ena (122/100.000), dok ukupna inciden-
cija iznosi 145/100.000.
Isti izvor sabrao je suvremene spoznaje o Łimbenicima
rizika za ishemijski modani inzult. Meðu Łimbenicima na
koje se ne moe utjecati su dob, spol i inzult ili TIA u
obiteljskoj anamnezi. Meðu Łimbenike na koje se moe
utjecati ubraja hipertenziju, puenje, eæernu bolest, asim-
ptomatsku stenozu karotide, hiperlipidemije, atrijsku fib-
rilaciju i jo neke srŁane bolesti. Pretilost, tjelesnu neak-
tivnost, nepravilnu prehranu, prekomjerno uzimanje alko-
hola, hiperhomocisteinemiju, hiperkoagulabilnost, hor-
monsko nadomjesno lijeŁenje, uzimanje oralnih kontracep-
tiva i upalne procese ubraja u dosad nedovoljno dokumen-
tirane ili potencijalno izmjenjive Łimbenike rizika. Navo-
di se da godinja stopa inzulta raste s dobi i prisutnoæu
riziŁnih Łimbenika, tako da oŁekivana godinja stopa inzul-
ta iznosi:
 do 65 godina, bez Łimbenika rizika 1,0%
 do 65 godina, s Łimbenicima rizika 4,9%
 65-75 godina, bez Łimbenika rizika 4,3%
 65-75 godina, s Łimbenicima rizika 5,7%
 75 i vie godina, bez Łimbenika rizika 3,5%
 75 i vie godina, s Łimbenicima rizika 8,1%
Epidemioloki prikaz cerebrovaskularnih
bolesti u Hrvatskoj
Za prikaz kretanja smrtnosti i pobola od cerebrovasku-
larnih bolesti u Hrvatskoj u radu se rabe opæe, specifiŁne i
dobno standardizirane stope smrtnosti ukupno i za dobnu
skupinu od 0-64 godine, te stope hospitalizacije i bolesti
registrirane u opæoj medicini. U Hrvatskoj su kardiovasku-
and highest in Bulgaria (259/100,000), Russian Federation
(271/100,000) and Ukraine (408/100,000). In men, the
highest rates were 11-fold lowest rates, whereas in wom-
en the highest to lowest rate ratio was as high as 13:1.
However, unlike cardiovascular diseases in total and
ischemic heart diseases, the standardized mortality rates
of cerebrovascular diseases in Mediterranean countries
show quite a wide range. For example, during the 1990-
1992 period the rate for men aged 45-74 was 67/100,000
in France and 276/100,000 in Portugal. The respective rates
for women were from 35/100,000 and 158/100,000. In all
countries, the age specific mortality rates are lower in
women than in men, and the mortality pattern is more
favorable for the former.
According to the American Heart Association Scientific
Statement from 2001, the incidence of ischemic stroke
increases from the age of 55 with each decade of life. The
incidence is higher in men (174/100,000) than in women
(122/100,000), with the overall incidence of 145/100,000.
The same institution summarized the current concepts
on the risk factors for ischemic stroke. The nonmodifiable
risk factors are age, sex, and family history of stroke or TIA.
The modifiable risk factors include hypertension, smok-
ing, diabetes mellitus, asymptomatic carotid stenosis, hy-
perlipidemias, atrial fibrillation and some other cardiac
diseases. Obesity, lack of physical activity, unfavorable di-
etary habits, alcohol abuse, hyperhomocysteinemia, hyper-
coagulability, hormone replacement therapy, oral contra-
ceptives and inflammatory processes are considered as yet
inadequately documented or potentially modifiable risk
factors. It is reported that the annual rate of stroke increas-
es with age and presence of risk factors, thus the expect-
ed rate of stroke is as follows:
 age ≤ 65, without risk factors 1.0%
 age ≤ 65, with risk factors 4.9%
 age 65-75, without risk factors 4.3%
 age 65-75, with risk factors 5.7%
 age ≥ 75, without risk factors 3.5%
 age ≥  75, with risk factors 8.1%
Epidemiologic Survey of Cerebrovascular
Diseases in Croatia
The general, specific and age standardized mortality
rates in total population and in the 0-64 age group, the rates
of hospitalization and of the diseases recorded at general
medicine service were used to present the patterns of ce-
rebrovascular disease mortality and morbidity in Croatia.
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larne bolesti vodeæi uzrok smrti. Godine 2003. zabiljeene
su 27.872 osobe umrle zbog bolesti srca i krvnih ila, a udio
u ukupnoj smrtnosti iznosio je 53,0%. NajŁeæe dijag-
nostiŁke podskupine kao uzrok smrti su ishemijska bolest
srca (ifre I20-I25 MKB SZO) s udjelom od 33,1% i cere-
brovaskularne bolesti (ifre I60-I69 MKB SZO) s udjelom
od 31,3%.
Meðutim, treba istaknuti da se meðu 10 vodeæih uzro-
ka smrti u Hrvatskoj 2003. godine (analizirano sukladno
pokazateljima za program Zdravlje za sve SZO) cere-
brovaskularne bolesti nalaze na drugom mjestu, iza ishe-
mijske bolesti srca, a njihov udio u ukupnoj smrtnosti iznosi
15,9%. One se nalaze na drugom mjestu s udjelom od 13,2%
odnosno 18,7% u ukupnoj smrtnosti mukaraca i ena. To
zapravo znaŁi da svaki sedmi do osmi mukarac i gotovo
svaka peta ena u Hrvatskoj umiru od cerebrovaskularne
bolesti.
Opæa stopa smrtnosti od cerebrovaskularnih bolesti
rasla je do 1989. godine, kada je iznosila 182,5/100.000, a
potom se zapaa zaustavljanje trenda porasta ovih stopa.
Godine 1990. stopa iznosi 181,1/100.000, u razdoblju od
1991. do 1995. oscilira na neto nioj razini, 1996. se penje
na 184,4, 1998. iznosi 184,0/100.000 (uz napomenu da je
te godine dolo do metodolokih promjena registracije vi-
talnih dogaðaja tako da se uz dravljane Hrvatske regis-
triraju i osobe koje u Hrvatskoj borave due od godinu
dana). Godine 2000. stopa iznosi 191,3/100.000, a 2003.
godine 188,4/100.000.
U Hrvatskoj je u razdoblju od 1985. do 2003. godine
najnii apsolutni broj umrlih od  cerebrovaskularnih bolesti
zabiljeen 1992. godine, a iznosio je 7925 ili 32,0% svih
uzroka smrti iz skupine kardiovaskularnih bolesti. Najveæi
broj umrlih od cerebrovaskularnih bolesti (8901 osoba)
zabiljeen je 1999. godine s udjelom od 32,9% u ukupnom
broju umrlih od kardiovaskularnih bolesti srca, dok je 2003.
godine taj broj iznosio 8360, a udio 30,0%.
Opæa stopa smrtnosti od cerebrovaskularnih bolesti bila
je do 1991. via (177,14/100.000) nego stopa smrtnosti od
ishemijskih bolesti srca (136,43/100.000). Nagliji porast
dijagnostiŁke skupine ishemijskih bolesti srca kao uzroka
smrti zabiljeen je 1991. (136,43/100.000) i 1992. (182,26/
100.000) godine u odnosu na 1990. godinu (82,40/
100.000), to je bilo uzrokovano promjenama u registriranju
i obradi uzroka smrti, otkada su stope smrtnosti za ishe-
mijske bolesti srca kontinuirano vie od stopa smrtnosti za
cerebrovaskularne bolesti.
Analiza prema dobi pokazuje kako broj umrlih i dobno
specifiŁne stope smrtnosti od cerebrovaskularnih bolesti
rastu s dobi, a izrazitiji porast biljei se poslije 50. godine
ivota. U Hrvatskoj su stope smrtnosti od cerebrovasku-
In Croatia, cardiovascular diseases are the leading cause
of death. In 2003, there were 27,872 deaths due to cardio-
vascular diseases, accounting for 53.0% of overall mortali-
ty. The most common diagnostic subgroups specified as
the cause of death are ischemic heart disease (WHO ICD
I20-I25) with 33.1% and cerebrovascular diseases (WHO
ICD I60-I69) with 31.3%.
It should be emphasized, however, that cerebrovascu-
lar diseases ranked second, immediately following ischemic
heart disease, among the 10 leading causes of death in 2003
(analyzed according to parameters for the WHO Health
for All program), and accounted for 15.9% of overall mor-
tality. Cerebrovascular diseases are the second most com-
mon cause of death in both men and women, where they
account for 13.2% and 18.7% of overall mortality, respec-
tively. This means that every seventh to eighth man and
almost every fifth woman in Croatia die from cerebrovas-
cular disease.
The general rate of cerebrovascular disease mortality
rose until 1989, when it was 182.5/100,000, whereafter the
rising trend was observed to stop. In 1990, the rate was
181.1/100,000, then stagnating at a lower level between
1991 and 1995 to increase to 184.4/100,000 in 1996. In
1998, the rate was 184.0/100,000 (it should be noted that
in this year, the methodology of vital events registration
was changed, i.e. persons staying in Croatia for more than
one year were also recorded in addition to Croatian citi-
zens). In 2000, the rate was 191.3/100,000, and in 2003 it
was 188.4/100,000.
During the 1985-2003 period, the lowest absolute
number of deaths from cerebrovascular diseases in Croat-
ia was recorded in 1992, i.e. 7925 or 32.0% of all causes of
death from the group of cardiovascular diseases. The high-
est number of deaths due to cerebrovascular diseases
(n=8901) was recorded in 1999, accounting for 32.9% of
all deaths from cardiovascular diseases, whereas in 2003
there were 8360 (30.0%) such deaths.
Until 1991, the general mortality rate for cerebrovas-
cular diseases (177.14/100,000) exceeded the mortality
rate for ischemic heart diseases (136.43/100,000). An
abrupt increase in the diagnostic group of ischemic heart
diseases as the cause of death occurred in 1991 (136.43/
100,000) and 1992 (182.26/100,000) as compared with
1990 (82.40/100,000). The reason for this was the changed
methodology of death cause registration and processing,
and since then the mortality rates for ischemic heart dis-
eases have been continuously higher than the mortality
rates for cerebrovascular diseases.
Analysis according to age reveals the number of deaths
and age specific mortality rates due to cerebrovascular
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larnih bolesti u svim dobnim skupinama vie u mukaraca
nego u ena.
Analiza smrtnosti prema spolu pokazuje da su za cere-
brovaskularne bolesti opæe stope smrtnosti 2003. godine,
kao i ranijih godina, vie u ena (211.7/100.000) nego u
mukaraca (163,33/100.000), dok ukupna stopa iznosi
188,4/100.000. Razlog tome je veæi broj umrlih ena u sta-
rijim dobnim skupinama, kao i znatno veæi broj starijeg en-
skog nego mukog stanovnitva, to rezultira viom ukup-
nom stopom smrtnosti od cerebrovaskularnih bolesti u
ena.
NajuŁestaliji uzrok smrti kao pojedinaŁna dijagnoza iz
skupne cerebrovaskularnih bolesti u Hrvatskoj je modani
udar nespecificiran kao krvarenje ili infarkt (I64 X. rev.
MKB SZO). Udio ove dijagnoze u broju umrlih od cere-
brovaskularnih bolesti 2003. godine iznosio je 72,9%.
Slijede posljedice cerebrovaskularnih bolesti (I69) s udje-
lom od 9,5% i intracerebralno krvarenje (I61) s udjelom od
8,1%.
Dobno standardizirane stope smrtnosti iz baze poda-
taka SZO za program Zdravlje za sve za Hrvatasku
iznosile su 2002. godine (zadnji usporedivi raspoloivi
podaci) 482,5/100.000 za bolesti srca i krvnih ila ukupno,
za ishemijsku bolest srca 159,5/100.000 te za cerebrovasku-
larne bolesti 145,3/100.000. Navedene stope bile su nie
od prosjeka stopa zemalja Srednje i IstoŁne Europe za
bolesti srca i krvnih ila ukupno (526,2/100.000) i ishe-
mijske bolesti srca (184,1/100.000), a neznatno vie za
cerebrovaskularne bolesti (144,7/100.000). Navedne stope,
meðutim, vie su od prosjeŁnih stopa za Europu ukupno
2001. godine (zadnji usporedivi raspoloivi podaci) za kar-
diovaskularne bolesti (469,0/100.000) i cerebrovaskularne
bolesti (137,5/100.000), a nie za ishemijske bolesti srca
(219,9/100.000).
Meðutim, za umrle od cerebrovaskularnih bolesti u
dobi do 64 godine za Hrvatsku stopa je 2002. godine iznosi-
la 24,5/100.000 i bila je nia od standardizirane stope za
zemlje Srednje i IstoŁne Europe (30,0/100.000), kao i od
prosjeka za Europu 2001. godine (30.0/100.000).
Kardiovaskularne bolesti su i vodeæi uzrok hospitaliza-
cija s ukupno preko 76.871 hospitalizacija i udjelom od
13.8% u ukupnom broju hospitalizacija u Hrvatskoj 2002.
godine, a ispred novotvorina udio kojih iznosi 13,1%. Sto-
pa hospitalizacije iznosila je 2002. godine 1736,8/100.000.
Cerebrovaskularne bolesti nalazile su se na treæem mjes-
tu uzroka hospitalizacije meðu kardiovaskularnim boles-
tima s udjelom od 22,9%, iza ishemijskih bolesti srca
(26,5%) i ostalih oblika srŁanih bolesti (ifre I30-I32 MKB
SZO) (25,0%). Stopa hospitalizacije za cerebrovaskularne
bolesti iznosila je 2002. godine 396,7/100.000.
diseases to increase with age, the increase being more pro-
nounced after the age of 50. In Croatia, the cerebrovascu-
lar disease mortality rates are higher in men than in wom-
en for all age groups.
Mortality analysis according to sex shows the general
mortality rates for cerebrovascular diseases in 2003, like-
wise previous years, to be higher in women (211.7/100,000)
than in men (163.33/100,000), whereas the overall rate was
188.4/100,000. The reason for this was the greater num-
ber of deaths among females from older age groups and the
considerably higher proportion of elderly women as com-
pared with elderly men, all this resulting in a higher over-
all mortality rate from cerebrovascular diseases in women.
In Croatia, the most common cause of death as indi-
vidual diagnosis from the group of cerebrovascular diseas-
es is stroke unspecified as hemorrhage or infarction (WHO
ICD X rev., I64). In 2003, this diagnosis accounted for
72.9% of all deaths from cerebrovascular diseases, followed
by cerebrovascular disease sequels (I69) with 9.5% and
intracerebral hemorrhage (I61) with 8.1%.
For Croatia, the age adjusted mortality rates for from
the WHO Health for All program database for 2002 (the
latest comparable data available) were as follows: 482.5/
100,000 for overall cardiovascular diseases; 159.5/100,000
for ischemic heart disease; and 145.3/100,000 for cere-
brovascular diseases. These rates were lower than the av-
erage rates for the Central and East Europe countries for
overall cardiovascular diseases (526.2/100,000) and ischem-
ic heart disease (184.1/100,000), and slightly higher than
the average rates for cerebrovascular diseases (144.7/
100,000). However, the Croatian rates exceeded the aver-
age rates for Europe as a whole in 2001 (the latest compa-
rable data available) for cardiovascular diseases (469.0/
100,000) and cerebrovascular diseases (137.5/100,000),
but were lower in case of ischemic heart disease (219.9/
100,000).
Considering deaths due to cerebrovascular diseases in
the £64 age groups, the 2002 rate for Croatia was 24.5/
100,000 and was below the standardized rate for Central
and East Europe countries (30.0/100,000) and 2001 Eu-
ropean average rate (30.0/100,000).
Cardiovascular diseases also are the leading cause of
hospitalization with more than 76,871 hospitalizations in
total and accounted for 13.8% of overall hospitalizations in
Croatia in 2002, even before neoplasms with 13.1%. In
2002, the hospitalization rate was 1736.8/100,000. Cere-
brovascular diseases were the third most common cause
of hospitalization among cardiovascular diseases, account-
ing for 22.9%, immediately following ischemic heart dis-
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NajŁeæi uzrok hospitalizacije iz skupine cerebrovasku-
larnih bolesti 2002. godine bili su modani infarkt (I63 X.
rev. MKB SZO) s udjelom od 41,0%, inzult nespecificiran
kao krvarenje ili infarkt (I64) s udjelom od 29,4% i intrace-
rebralno krvarenje (I61) s udjelom od 8,3%.
Po broju dijagnoza zabiljeenih u opæoj medicini u
Hrvatskoj 2002. godine kardiovaskularne bolesti nalaze se
na drugom mjestu s udjelom od 12,0 %, iza bolesti dinog
sustava udio kojih je iznosio 25,0%. Stopa kardiovaskularnih
bolesti registriranih u djelatnosti opæe medicine iznosila
je 184,9/1.000. NajuŁestalija dijagnostiŁka podskupina bile
su hipertenzivne bolesti s udjelom od 54,2%, dok su se
cerebrovaskularne bolesti nalazile na petom mjestu s ud-
jelom od 5,8% i stopom od 10,8/1.000 bolesti zabiljeenih
u opæoj medicini.
eases (26.5%) and other cardiac diseases (WHO ICD I30-
I32) (25.0%). In 2002, the rate of hospitalization for cere-
brovascular diseases was 396.7/100,000.
In 2002, the most common cause of hospitalization
from the group of cerebrovascular diseases was cerebral
infarction (WHO ICD X rev., I63) with 41.0%, followed
by stroke unspecified as hemorrhage or infarction (I64)
with 29.4%, and intracerebral hemorrhage (I61) with 8.3%.
According to the number of diagnoses recorded in gen-
eral medicine service in Croatia in 2002, cardiovascular
diseases ranked second with 12.0%, immediately follow-
ing respiratory diseases accounting for 25.0%. The rate of
cardiovascular diseases registered at general medicine ser-
vice was 184.9/1000. The most common diagnostic sub-
group were hypertensive diseases with 54.2%, whereas
cerebrovascular diseases ranked fifth with 5.8% and rate
of 10.8/1000 diagnoses recorded at general medicine offic-
es.
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CLINICAL RELEVANCE OF STROKE EPIDEMIOLOGY STUDIES
KLINI¨KO ZNA¨ENJE PROU¨AVANJA EPIDEMIOLOGIJE MODANOG UDARA
Dragutin Kadojiæ
University Department of Neurology, Osijek University Hospital, Osijek, Croatia
Klinika za neurologiju, KliniŁka bolnica Osijek, Osijek
Epidemiologija kao znanost koja prouŁava distribuciju
bolesti i invalidnosti u ljudskoj populaciji i Łimbenike koji
utjeŁu na takvu distribuciju (Svjetska zdravstvena organiza-
cija /SZO/, 1967.) ima svoje specifiŁne zadatke i ciljeve.
Najvaniji zadaci odnose se na prouŁavanje epidemiolo-
kog znaŁenja bolesti i Łimbenika koji utjeŁu na zdravlje
pojedinca i populacije, identifikaciju uzroka i Łimbenika
koji pridonose pojavi bolesti, rasprostranjenosti i naŁina
irenja bolesti, provoðenje epidemiolokih istraivanja
bolesti, te predlaganje i provoðenje mjera sprjeŁavanja,
suzbijanja, uklanjanja i iskorjenjivanja bolesti. Na taj naŁin
moguæe je ostvarivanje ciljeva epidemiologije, a to su:
sniavanje pobola, smrtnosti i letaliteta odreðene bolesti,
sprjeŁavanje invalidnosti i nesposobnosti te smanjenje
ukupnog socijalnog i ekonomskog tereta bolesti za drut-
venu zajednicu.
U neuroepidemiolokom praæenju modanog udara
(MU), kao i u epidemiolokim istraivanjima opæenito rabe
se deskriptivne, analitiŁke i eksperimentalne studije. Pri-
mjena epidemiolokih naŁela i metoda u praksi kliniŁke
medicine naziva se kliniŁka epidemiologija. Definira se jo
i kao epidemiologija uz bolesniŁki krevet ili kao znanost
o umijeæu medicine. Ona ima za cilj doæi do jasne i racio-
nalne odluke o tome kada lijeŁiti, kako lijeŁiti, koji lijek
odabrati itd. To je baziŁna znanost koja omoguæuje da se
na dokazima utemeljena medicina primijeni u kliniŁkoj
praksi. Populacijske neuroepidemiologijske studije MU
vane su za utvrðivanje pobola (incidencije i prevalencije)
i smrtnosti, te dugoroŁnog ishoda ove bolesti. KliniŁke
epidemioloke studije omoguæuju procjenu ranog letaliteta
i kratkoroŁnog ishoda MU.
U epidemiolokim istraivanjima MU u dananje je
vrijeme nuno rabiti meðunarodno prihvaæene standarde.
SZO definira MU kao naglo razvijanje kliniŁkih znakova
arinog (ili globalnog) poremeæaja modanih funkcija sa
simptomima koji traju 24 sata ili due ili vode k smrti, bez
drugog jasnog uzroka uza znakove oteæenja krvnih ila.
U kliniŁkom radu iroko je prihvaæena klasifikacija koja
uzima u obzir patoloko-anatomske i patofizioloke
parametre, te razlikuje hemoragijski modani udar (HMU)
Epidemiology as a science investigating the distribu-
tion of diseases and disability in human population as well
as factors influencing this distribution (World Health Or-
ganization /WHO/, 1967) has specific tasks and goals. The
most important tasks refer to investigation of the epide-
miological importance of a disease and factors influencing
individual and population health, identification of the caus-
es and factors that contribute to the occurrence, spread and
mode of disease dissemination, conducting epidemiolog-
ical studies of a disease, and proposal and implementation
of measures for prevention, control, elimination and erad-
ication of diseases. In this way, the preset goals of epide-
miology can be achieved, i.e.: reduction of morbidity, mor-
tality and lethality of a particular disease, prevention of
disability and disablement, and reduction of overall social
and economic burden of the disease.
Like epidemiological investigations in general, the
neuroepidemiological monitoring of stroke implies the use
of descriptive, analytical and experimental studies. The
use of epidemiological principles and methods in clinical
medicine practice is known as clinical epidemiology. It is
also defined as bedside epidemiology or science of med-
ical skill. Its goal is to reach a clear and rational decision
on when and how to treat, what drug to choose, etc. It is a
basic science allowing for evidence based medicine to be
applied in clinical practice. The population based neuroep-
idemiological studies of stroke are important to determine
stroke morbidity (incidence and prevalence) and mortal-
ity as well as longterm outcome of the disease. Clinical
epidemiological studies enable early lethality and short-
term outcome of stroke to be estimate.
The internationally accepted standards need to be
employed in the epidemiological studies of stroke. WHO
defines stroke as abrupt development of clinical signs of
focal (or global) impairment of cerebral functions with
symptoms lasting for 24 hours or more, or leading to death,
without any other apparent cause besides the signs of vas-
cular lesion. In clinical practice, a classification has been
widely accepted which takes in consideration the patho-
logic-anatomic and pathophysiologic parameters, and
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differentiates between hemorrhagic stroke accounting for
15%-20% and ischemic stroke accounting for 80%-85% of
cases. Hemorrhagic stroke subtypes are intracerebral hem-
orrhage of typical or atypical localization, which accounts
for some 15%, and subarachnoid hemorrhage (SAH), which
accounts for 5% of stroke cases. Subtypes of ischemic
stroke include thrombotic, embolic and hemodynamic
stroke. The International Classification of Diseases clas-
sifies cerebrovascular diseases (CVD) in almost the same
way, listing the following subgroups encoded I60-I69: SAH,
intracerebral hemorrhage, other nontraumatic hemorrhag-
es, cerebral infarction caused by extracerebral or intrace-
rebral occlusion, and nonspecific stroke. The TOAST clas-
sification of ischemic stroke has proved quite convenient
and has recently been widely used, distinguishing the fol-
lowing categories: large blood vessel infarction, lacunar
infarction, cardioembolic infarction, infarction due to other
causes, and infarction of unknown causes.
Concepts on the presence of risk factors in stroke pa-
tients have resulted in numerous epidemiological studies
of these factors conducted in the last few decades in Croat-
ia and worldwide. The impact of some of these factors has
been definitely demonstrated, whereas the role of others
is still being investigated. Risk factors for stroke are gen-
erally classified according to the possibility of their preven-
tion into nonmodifiable risk factors, including age, sex,
heredity, race and/or ethnicity, and modifiable risk factors
that include arterial hypertension, atrial fibrillation, diabe-
tes mellitus, hyperlipidemia, asymptomatic carotid steno-
sis, smoking and excessive alcohol consumption. Also, lif-
estyle related factors have been continuously investigat-
ed; these include inadequate physical activity, obesity,
dietary habits, stress, socioeconomic factors, and illicit drug
abuse. The role of hematology parameters (hematocrit,
homocysteine, lipoprotein(a), fibrinogen, etc.), cardiac
diseases (mitral valve prolapse, patent foramen ovale, atrial
septal aneurysm) and other risk factors has also been in-
vestigated. The latest studies conducted in Croatia show
a high level of risk factors in the healthy population, good
population information on their harmful health impact, and
quite a low level of motivation to modify unhealthy habits
and lifestyle.
The basic neuroepidemiological parameters are impor-
tant for every clinician dealing with a particular disease or
group of diseases. Stroke incidence is the number of pa-
tients newly affected with stroke in a defined population
over a particular period of time. The criteria for a properly
designed study of the incidence of stroke imply the use of
the standard WHO definition of stroke; prospective re-
koji se javlja u 15%-20% i ishemijski modani udar (IMU)
koji Łini 80%-85% sluŁajeva. Podtipovi HMU su intrace-
rebralno krvarenje tipiŁne ili atipiŁne lokalizacije, koje
predstavlja oko 15%, te subarahnoidno krvarenje (SAH)
koje predstavlja oko 5% sluŁajeva MU. Podtipovi IMU su
trombotiŁni, embolijski i hemodinamski udar. Meðuna-
rodna klasifikacija bolesti razvrstava CVB na priblino isti
naŁin, navodeæi pod iframa I60-I69 slijedeæe podskupine:
SAH, intracerebralno krvarenje, ostala netraumatska
krvarenja, cerebralni infarkt uzrokovan ekstracerebralnom
ili intracerebralnom okluzijom, te nespecificirani modani
udar. PraktiŁna je i u zadnje vrijeme u iroj uporabi klasi-
fikacija IMU nazvana TOAST koja razlikuje slijedeæe ka-
tegorije: infarkte velikih krvnih ila, lakunarne infarkte,
kadioembolijske infarkte, infarkte koji su posljedica drugih
uzroka, te infarkte nepoznatog uzroka.
Spoznaje o prisutnosti riziŁnih Łimbenika u bolesnika
s MU rezultirala su brojnim epidemiolokim istraivanjima
o ovim Łimbenicima koja su provedena tijekom zadnjih
nekoliko desetljeæa u svijetu i u Hrvatskoj. Utjecaj nekih
Łimbenika nedvojbeno je dokazan, a znaŁenje drugih jo
uvijek se istrauje. RiziŁni Łimbenici obiŁno se svrstavaju
prema moguænostima njihovog sprjeŁavanja u slijedeæe
skupine: nepromjenjivi Łimbenici rizika (nonmodifiable stroke
risk factors), meðu koje se ubrajaju dob, spol, nasljedni Łim-
benici, rasa i/ili etniŁka pripadnost i promjenjivi Łimbeni-
ci rizika (modifiable stroke risk factors) kao to su arterijska
hipertenzija, atrijska fibrilacija, eæerna bolest, hiperlipi-
demija, asimptomatska karotidna stenoza, puenje, zloupo-
raba alkohola. Pod stalnim epidemiolokim istraivanjima
su i riziŁni Łimbenici povezani s naŁinom ivota (lifestyle
factors), meðu koje spadaju tjelesna aktivnost, pretilost,
prehrana, stres, socioekonomski Łimbenici, zlouporaba
opojnih droga. Istrauje se i uloga hematolokih parame-
tara (hematokrit, homocistein, lipoprotein(a), fibrinogen
itd.), srŁanih bolesti (prolaps mitralne valvule, otvoren
foramen ovale, atrijska septalna aneurizma) i drugih ri-
ziŁnih Łimbenika. Najnovija istraivanja provedena u na-
oj zemlji pokazuju visoku zastupljenost riziŁnih Łimbeni-
ka u zdravoj populaciji, dobru obavijetenost puŁanstva o
njihovoj tetnosti za zdravlje, ali i nisku razinu motivacije
za promjenu navika i naŁina ivljenja.
Osnovni neuroepidemioloki pokazatelji vani su za
svakog kliniŁara koji se bavi problematikom odreðene
bolesti ili skupine bolesti. Incidencija je broj novoobolje-
lih bolesnika od MU u definiranoj populaciji tijekom odre-
ðenog vremenskog razdoblja. Kriteriji dobro dizajnirane
studije incidencije MU ukljuŁuju upotrebu standardne
definicije MU koju je dala SZO, prospektivno utvrðivanje
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cording of cases in a large, well defined and representative
sample; and comprehensive and distinct methodology of
detecting the diseased and identifying nonfatal cases that
have been treated outpatiently or died soon after the dis-
ease onset. The incidence of stroke in strict terms would
refer to the cases of first-ever stroke, however, some stud-
ies also include recurrent stroke.
It is estimated that some 4 million people are affected
with stroke in the world per year. International epidemio-
logical studies show the stroke rates to grow exponential-
ly with age, ranging between 0.3/1000 in the third and
fourth decades of life to up to 30/1000 in the eighth and
ninth decades of life, yielding a mean of 1/1000 to 2/1000.
In Croatia, the last population based studies were per-
formed some 20 years ago. Studies carried out on hospital
material in the Osijek region over the past 15 years have
indicated the number of stroke cases and of cerebral hem-
orrhages to be on constant increase (Fig. 1). Dietary and
other daily habits and climatic factors have been identi-
fied as the main culprits for such a trend. However, the
impact of socioeconomic factors (decline in living stan-
dards, social and economic problems, demographic chang-
es, etc.) as well as of war and postwar stress on the inci-
dence of stroke has also been investigated. These studies
have pointed to the effect of prolonged stress on an in-
creased expression of risk factors for CVD (arterial hyper-
tension, hyperlipidemia, adiposity and smoking); adverse
effects of stress and risk factors on cerebral hemodynam-
ics; and association of stress with an increased incidence
of cerebral hemorrhages, especially hypertensive intrace-
rebral hemorrhage and SAH. Such trends have also been
recorded in other war areas.
sluŁajeva u velikom, dobro definiranom i reprezentativ-
nom uzorku te sveobuhvatnu i razumljivu metodologiju ot-
krivanja oboljelih i identifikacije nefatalnih sluŁajeva
lijeŁenih izvan bolnice ili umrlih ubrzo nakon nastupa
bolesti. Incidencija MU, strogo gledajuæi, odnosila bi se na
incidente koji se javljaju prvi put u ivotu neke osobe (first-
ever stroke), ali neke studije obuhvaæaju i opetovane MU.
Procjenjuje se da u svijetu na godinu od MU oboli oko
4 milijuna ljudi. Meðunarodne epidemioloke studije poka-
zuju kako stope rastu eksponencijalno s dobi i kreæu se
izmeðu 0,3 promila u treæem i Łetvrtom desetljeæu ivota
sve do 30 promila u osmom i devetom desetljeæu ivota,
to u prosjeku iznosi 1-2 promila. U naoj zemlji posljed-
nje populacijske studije provedene su prije dvadesetak go-
dina. Istraivanja provedena na osjeŁkom podruŁju tijekom
zadnjih petnaestak godina na bolniŁkom materijalu poka-
zuju stalan porast broja oboljelih od MU i stalan porast broja
modanih krvarenja (slika 1.). NaŁin prehrane, ivotne
navike i klimatski Łimbenici navedeni su kao glavni
uzroŁnici ovakvog stanja. Meðutim, istraeno je i djelovanje
socioekonomskih Łimbenika (pad ivotnog standarda, so-
cijalni i ekonomski problemi, demografske promjene itd.),
te ratnog i poratnog stresa na incidenciju MU. Istraiva-
njima je utvrðen utjecaj produljenog stresa na poveæanu
izraenost Łimbenika rizika za cerebrovaskularnu bolest
(arterijske hipertenzije, hiperlipidemije, adipoziteta i
puenja), nepovoljan utjecaj stresa i riziŁnih Łimbenika na
cerebralnu hemodinamiku, kao i povezanost stresa s po-
veæanom incidencijom cerebralnih hemoragija, osobito hi-
pertenzivnih intracerebralnih krvarenja i subarahnoidnih


















































































































































































































































































































































































































Figure 1. Number of hemorrhagic
strokes treated at Department of
Neurology Osijek in the threeteen
years period (1988-2000).
Slika 1. Kretanje broja hemoragiŁkih
modanih udara lijeŁenih na
Neurolokoj klinici u Osijeku u
trinaestgodinjem razdoblju
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Prevalence is a parameter describing the magnitude of
a disease and represents the frequency of the disease at a
particular point of time. Data on stroke prevalence are the
best indicator of the spread of the disease in a particular
population, allowing for setting an appropriate strategy of
health actions and overall health care in the area. The
stroke prevalence rates vary from 5/1000 to several percent.
The last data on stroke prevalence in Croatia were pub-
lished in 1984. A study performed in a small sample of 1000
subjects indicated a stroke prevalence of 2.5%, and of 3.1%
in the population over 25 years of age.
Lethality is the proportion of stroke patients that died
within a specified period from the disease onset. It is usu-
ally expressed as the percentage of deaths over a period of
one month or one year. The predictors influencing early
lethality are localization and size of infarction or hemor-
rhage, degree of consciousness impairment, severity of
neurologic deficit, advancing age, male sex, presence of
diabetes, arterial hypertension, cardiac disease, elevated
temperature, dysphagia, sphincter incontinence, etc. Fa-
tal stroke outcome may be caused by central or peripheral
complications. The most common central complications
include cerebral edema, transtentorial herniation, hemor-
rhagic transformation of ischemia, epileptic seizures, and
depression. In stroke patients death is considerably more
frequently caused by peripheral (systemic) complications
such as deep venous thrombosis and pulmonary embolism,
bronchopneumonia, urinary infection, septicemia, aspira-
tion, cardiac arrhythmia, myocytolysis, nonregulated hy-
potension, and sudden death.
Mortality is the number of deaths due to stroke in a
defined population. Stroke mortality rates, mostly ex-
pressed as the number of deaths per 100,000 population
per year, greatly vary across Europe. The highest stroke
mortality rate has been reported from Bulgaria (249/
100,000), and lowest from Switzerland (27/100,000). East
European countries have a higher total mortality, whereas
lowest mortality rates have been recorded in Scandinavian
countries, Switzerland and the Netherlands. Stroke mor-
tality rates have been dramatically reduced over the last
few decades in Japan and West European countries. In
contrast to this, a constantly growing trend has been ob-
served in this period for stroke mortality rates in East
European countries, which is evidently being continued
in the conditions of transition in these countries. Studies
revealing secular changes in the particular disease mortal-
ity over a longterm period of years or decades are of spe-
cial interest. On analyzing the secular death pattern, data
on the age, period and cohort (generation) effects have to
Prevalencija je pokazatelj koji opisuje veliŁinu proble-
ma neke bolesti i predstavlja uŁestalost te bolesti u odre-
ðenom trenutku. Podaci o prevalenciji modanog udara
najbolji su pokazatelj proirenosti bolesti u populaciji i
omoguæuju postavljanje ispravne strategije zdravstvenih
akcija i cjelokupne zdravstvene zatite na odreðenom po-
druŁju. Stope prevalencije MU u svijetu kreæu se izmeðu
5 promila i nekoliko postotaka. Zadnji podaci o prevalen-
ciji MU u Hrvatskoj objavljeni su 1984. godine. Istraiva-
njem provedenim u malom uzorku od 1000 stanovnika
utvrðena je prevalencija MU od 2,5% odnosno 3,1% za
populaciju iznad 25 godina starosti.
Letalitet je udio bolesnika oboljelih od MU koji su
umrli unutar specifiŁnog razdoblja nakon nastupa bolesti.
Izraava se obiŁno kao postotak umrlih u razdobljima od
jednog mjeseca i jedne godine. Predskazatelji koji utjeŁu
na ranu smrtnost su: lokalizacija i veliŁina infarkta ili krva-
renja, stupanj poremeæaja svijesti, teina neurolokog de-
ficita, rastuæa dob, muki spol, prisutnost eæerne bolesti,
arterijske hipertenzije, srŁane bolesti, poviene tempera-
ture, disfagije, inkontinencije sfinktera itd. Fatalan ishod
MU uzrokuju sredinje i periferne komplikacije. NajŁeæe
sredinje komplikacije su: cerebralni edem, transtentori-
jalna hernijacija, hemoragijska transformacija ishemije,
epileptiŁni napadaji, depresija. Znatno Łeæe smrt bolesni-
ka s MU uzrokuju periferne (sistemske) komplikacije:
duboka venska tromboza i pluæna embolija, bronhopneu-
monija, mokraæni infekt, septikemija, aspiracija, srŁana
aritmija, miocitoliza, nekontrolirana hipotenzija, nagla
smrt.
Smrtnost je broj umrlih od MU u definiranoj populaciji.
Stope smrtnosti koje se najŁeæe izraavaju kao broj umr-
lih od MU na 100.000 stanovnika u jednoj godini u Europi
znaŁajno variraju. Najvie stope od 249 zabiljeene u Bugar-
skoj, a najmanje od 27 u vicarskoj. IstoŁnoeuropske zem-
lje imaju viu ukupnu smrtnost, dok su najnie stope zabi-
ljeene u skandinavskim zemljama, vicarskoj i Nizozem-
skoj. Stope smrtnosti dramatiŁno su smanjene tijekom
zadnjih nekoliko desetljeæa u Japanu i zapadnoeuropskim
zemljama. Nasuprot tome, u istoŁnoeuropskim zemljama
u tom razdoblju biljei se stalan porast stope srmtnosti od
MU, to se nastavlja i u uvjetima tranzicije ovih zemalja.
Od osobitog su znaŁenja studije koje pokazuju sekularne
promjene u smrtnosti od neke bolesti kroz dugo razdoblje
od vie godina ili desetljeæa. Za analizu sekularnog trenda
umiranja treba uzeti u obzir dobne, periodske i kohortne
(generacijske) uŁinke. Analiza sekularnog kretanja umira-
nja od CVB u Hrvatskoj u razdoblju od 1957. do 1997. (Ka-
dojiæ D. i Babu V.) pokazala je da se nastavlja sekularni
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be taken in consideration. Analysis of the secular death
pattern due to CVD in Croatia during the 1957-1997 pe-
riod (Kadojiæ D and Babu V) has shown the secular rising
trend of the number of deaths (Table 1) and of the pro-
portional rate of CVD mortality (Table 2) in the 35-74 age
groups to continue. The mortality rates are especially high
in the inland area, in the towns of Osijek and Varadin,
occasionally being 2- to 3-fold those recorded in the coastal
area. Comparison of our data with those from other coun-
tries has shown the overall age-adjusted mortality rates in
Croatia to exceed European average rate as well as the
average rates in Central and East Europe for all age groups,
whereas the rates for the 0-64 age group were lower than
the latter.
The disease risk shows the likelihood for an individual
to be affected by a particular disease during life. This anal-
ysis implies the use of at least two criteria for the confi-
dence of association between a particular risk factor expo-
sure and the risk of disease. Relative risk is the relation-
ship between the disease incidence among those with and
without exposure to a particular risk factor. Attributive risk
is absolute incidence of a disease in exposed individuals
that can be ascribed to the risk exposure. This measure is
calculated by subtracting the disease incidence in unex-
posed individuals from total disease incidence. It is usual-
ly presented as the number of individuals from a popula-
tion who will be affected with a particular disease and is
expressed as the rate per 1000 population.
Clinical studies of short-term and longterm stroke
outcomes and of the economic burden of the disease also
are of great interest. It has been estimated that approxi-
mately one third of stroke patients still die, one third suf-
trend rasta ukupnog broja umrlih (tablica 1.) i rast propor-
cionalne stope smrtnosti od CVB (slika 2.) u populaciji od
35 od 74 godina starosti. Stope umiranja su osobito visoke
na kontinentalnom podruŁju, u gradovima Osijeku i
Varadinu, te ponegdje dostiu 2-3 puta vie vrijednosti
negoli u priobalnom podruŁju. Usporedba naih podataka
s podacima iz drugih zemalja pokazuje da su u nas dobno
standardizirane stope smrtnosti za sve dobi ukupno vie
od europskog prosjeka i prosjeka zemalja Srednje i IstoŁne
Europe, dok su ove stope za dobnu skupinu od 0 do 64.
godine nie od prosjeka Srednje i IstoŁne Europe.
Table 1. Number of deaths and proportional mortality rates for CVD in the population aged 35-74 in Croatia, by 5-years periods
Tablica 1. Broj umrlih i proporcionalne stope smrtnosti od CVB u populaciji u dobi od 35-74 godina u Hrvatskoj prema petgodinjim
razdobljima
Petgodinje Number of death / Broj umrlih Prportional mortality rates % Chain indeks
razdoblje All causes CVD Proporcionalna stopa LanŁani indeks*
Svi uzroci CVB smrtnosti %
1958.-1962. 18.913 2.831   9,0   
1963.-1967. 20.806 2.072 10,0 111
1968.-1972. 25.751 2.918 11,3 113
1973.-1977. 24.658 3.318 13,5 119
1978.-1982. 25.975 3.656 14,1 104
1983.-1987. 25.611 3.822 14,9 106
1988.-1992. 25.311 3.588 14,2   95
1993.-1997. 26.788 3.959 14,8 104
* index according to previous period
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Figure 2. Standardized mortality rates for CVD in Croatia in
the population aged 35-74 in Croatia, by 5-years periods
Slika 2.Standardizirane stope mortaliteta od CVB u populaciji
35-74 godina starosti u Republici Hrvatskoj, prema petogodi-
njim razdobljima
Death Rates for CVD: 1958-1997
Stope smrtnosti od CVB: 1958-1997
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fer severe neurologic deficit, and one third sustain milder
or no neurologic deficit. The factors predicting poor stroke
prognosis and outcome are advanced age, male sex, coex-
istence of diabetes mellitus, arterial hypertension, cardi-
ac disease, elevated temperature, dysphagia, incontinence,
consciousness disturbances, severe neurologic deficit, cog-
nitive impairment, localization and size of infarction, ede-
ma and central structure dislocation, biochemistry and
hematology disorders, etc. Our studies of short-term and
longterm ischemic stroke outcome have shown that ap-
proximately one fourth of patients die within one month,
and a half within six months. The 5-year mortality for is-
chemic stroke is even up to 60%. First-ever strokes account
for some 75%, and recurrent strokes for 25% of cases. The
risk of stroke recurrence is highest during the first year after
stroke, being around 10%, then 5% for each year. The most
important predictors of recurrent stroke are type of stroke,
previous TIA, arterial hypertension, cardiac valve disease,
atrial fibrillation, congestive heart failure, elevated blood
glucose, male sex, and alcohol abuse.
Conclusion
Epidemiological data show stroke to be the leading
medical and public health problem in Croatia. While large
population based epidemiological studies are lacking, the
analyses performed on hospital material over the last 15
years provide an insight into the current state and point
to unfavorable trends in stroke morbidity and mortality in
our country. The present system of care for stroke patients
does not meet the needs and is not in accordance with the
modern trends in Europe and elsewhere in the world.
Thus, there is a real need of the system restructuring. One
of the options might be the development and implemen-
tation of the National Project of Stroke Prevention and
Treatment, on the model of other transition countries in
Europe that have faced similar problems and epidemiolog-
ical parameters. The following strategic points should be
set for the Project: 1) analysis of stroke epidemiology in
Croatia, with due reference to regional variation (popula-
tion-based studies, hospital-based studies, hospital stroke
registers, etc.); b) reducing the incidence of stroke through
improved primary and secondary prevention; and c) reduc-
ing stroke lethality, disability and mortality through estab-
lishment of stroke units and improving the system of pa-
tient rehabilitation. In the interim, the current principles
of diagnosis, management and prevention of stroke, ac-
cepted in the USA and West European countries, should
be followed, and favorable experience of the leading Croat-
ian neurologists engaged in the field should be used. In
Rizik obolijevanja je broj koji govori koliki su izgledi da
odreðena osoba tijekom svoga ivota oboli od neke boles-
ti. U analizi postoje barem dva mjerila za pouzdanost po-
vezanosti izmeðu izloenosti odreðenom riziŁnom Łimbe-
niku i rizika obolijevanja. Relativan rizik je odnos inciden-
cije bolesti onih koji su izloeni i incidencije onih koji nisu
izloeni nekom Łimbeniku rizika. Atributivni rizik je ap-
solutna incidencija bolesti kod izloenih pojedinaca koja
se moe pripisati toj izloenosti. Ova se mjera dobije tako
da se incidencija odreðene bolesti kod neizloenih osoba
oduzme od ukupne incidencije. ObiŁno se izraava brojem
osoba koje æe u populaciji oboljeti od neke bolesti i izraava
se stopom na 1000 stanovnika.
Od velikog su znaŁenja i kliniŁke studije kratkoroŁnog
i dugoroŁnog ishoda MU i ekonomskog tereta bolesti.
Procjenjuje se kako jo uvijek otprilike jedna treæina obo-
ljelih od modanog udara umire, druga treæina ima tei, a
treæa treæina laki ostatni neuroloki deficit ili je bez de-
ficita. ¨ imbenici koji predviðaju lou prognozu i ishod MU
su: visoka ivotna dob, muki spol, postojanje eæerne
bolesti, arterijske hipertenzije i srŁane bolesti u oboljelih,
temperatura, disfagija, inkontinencija, pogoranje svijesti,
teak neuroloki deficit, kognitini poremeæaji, lokalizacija
i veliŁina infarkta, edem i pomak sredinjih struktura,
biokemijski i hematoloki poremeæaji itd. Naa istraivanja
kratkoroŁnog i dugoroŁnog ishoda ishemijskog MU poka-
zuju kako u prosjeku oko Łetvrtine bolesnika umire u pr-
vom mjesecu, a oko polovice unutar est mjeseci. Smrtnost
u petgodinjem razdoblju nakon ishemijskog MU kreæe se
i do 60%. Meðu oboljelima otprilike 75% sluŁajeva Łine prvi,
a 25% sluŁajeva recidivirajuæi MU. Rizik recidiva modanog
udara najveæi je u prvoj godini i kreæe se oko 10%, a svake
slijedeæe godine oko 5%. Najvaniji predskazatelji recidi-
va MU su: vrst udara, raniji prolazni ishemijski napadaji
(TIA), arterijska hipertenzija, bolest srŁanog zaliska, atrij-
ska fibrilacija, kongestivna srŁana slabost, visoka razina glu-
koze u krvi, muki spol i zlouporaba alkohola.
ZakljuŁak
Epidemioloki podaci pokazuju da u naoj zemlji MU
predstavlja vodeæi medicinski i javnozdravstveni problem.
Iako nedostaju opsenije populacijske epidemioloke
studije, analize provedene na bolniŁkom materijalu u zad-
njih petnaestak godina ipak daju odreðenu sliku stvarnog
stanja i ukazuju na nepovoljne trendove u obolijevanju i
umiranju od ove bolesti. Postojeæi sustav zbrinjavanja
bolesnika s MU ne zadovoljava potrebe i nije u skladu sa
suvremenim trendovima u Europi i svijetu. Postoji realna
potreba reorganizacije toga sustava. Jedna od moguæih
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addition, the Guidelines for Stroke Prevention and Treat-
ment, issued by the Croatian Society for Neurovascular
Disorders, are of great help to the clinicians.
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opcija je priprema i provoðenje Nacionalnog projekta pre-
vencije i lijeŁenja modanog udara, po uzoru na druge tran-
zicijske zemlje u Europi koje imaju sliŁne probleme i epi-
demioloke pokazatelje. Strateke toŁke toga projekta tre-
baju biti: a) analiza epidemiologije MU u Hrvatskoj s os-
vrtom na regionalne razlike (populacijske studije, bolniŁke
studije, bolniŁki registri MU), b) sniavanje incidencije
MU kroz bolju primarnu i sekundarnu prevenciju, c) sni-
avanje letaliteta, invaliditeta i smrtnosti od ove bolesti
organizacijom jedinica za lijeŁenje MU i unapreðenjem
sustava rehabilitacije bolesnika. U meðuvremenu treba sli-
jediti suvremena naŁela u dijagnostici, lijeŁenju i sprjeŁa-
vanju MU, koja su prihvaæena u zapadnoeuropskim ze-
mljama i SAD, te rabiti pozitivna iskustva vodeæih domaæih
neurolokih struŁnjaka koji se bave ovom problematikom.
Uz to, za lijeŁnike kliniŁare od velikog su znaŁenja i pomoæi
Smjernice za lijeŁenje i prevenciju modanog udara  koje
izdaje Hrvatsko drutvo za neurovaskularne poremeæaje.
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Uvod
Mada su zadnjih godina razvijeni terapijski postupci
kojima se moe smanjiti oteæenje mozga nastalo ishem-
ijskim modanim udarom (tromboliza), prevencija je i na-
dalje najuŁinkovitija strategija za smanjivanje uŁestalosti
modanog udara. U veæini zapadnih zemalja zabiljeen je
znaŁajan pad smrtnosti od modanog udara u zadnjim
desetljeæima. U Sjedinjenim AmeriŁkim Dravama smrt-
nost od modanog udara smanjena je za 60% od poŁetka
sedamdesetih do kraja devedesetih godina prologa sto-
ljeæa. Smatra se da je taj trend postignut gotovo iskljuŁivo
modificiranjem Łimbenika rizika za nastanak modanog
udara. Pokazalo se da se modani udar moe sprijeŁiti, kao
i da se moe smanjiti rizik recidiva modanog udara.
Introduction
Although therapeutic procedures to reduce cerebral
damage cuased by ischemic stroke (thrombolysis) have
recently been developed, prevention remains the most
efficient strategy to decrease the prevalence of stroke.
In the last few decades, a significant decrease in the
stroke mortality has been recorded in most western coun-
tries. In the USA, the mortality of stroke was reduced by
60% from the beginning of the 1970s to the end of 1990s.
This trend is believed to have been almost exclusively
achieved through modification of the risk factors for stroke.
It has been demonstrated that stroke can be prevented and
the risk of stroke recurrence reduced.
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Prevention implies the procedures taken in patients to
prevent the onset of stroke. Prevention has traditionally
been divided into primary and secondary prevention. Pri-
mary prevention refers to the measures taken in healthy
subjects who have not yet been affected with stroke. Sec-
ondary prevention refers to identification and management
of subjects at a very high risk of stroke in order to prevent
its onset, and treatment and rehabilitation of patients who
have sustained a stroke to prevent its recurrence.
Primary and secondary prevention of stroke improve
the patient quality of life, reduce the need of surgical pro-
cedures, prolong overall survival, and decrease the inci-
dence of stroke recurrence. There is major overlapping
between the procedures and strategies of primary and
secondary prevention of stroke.
The following measures are used in primary prevention
of stroke:
1) lifestyle related risk factors should be addressed in
order to modify an unhealthy lifestyle and to promote
a health one;
2) diseases that represent risk factors for stroke should be
treated, thus reducing the effect of these risk factors
increasing the prevalence of stroke;
3) in case of ischemic stroke, certain drugs such as per-
oral anticoagulants and antiaggregation therapy are pre-
scribed in addition to addressing the risk factors in-
volved; and
4) in case of significant carotid artery stenosis, operative
therapy for carotid stenosis is performed.
There is ample evidence that various circumstances,
conditions, behavior, daily habits and diseases are associ-
ated with the incidence of stroke, and are thus called risk
factors for the occurrence of stroke.
Risk Factors for Stroke





 family history of stroke
 personal history of stroke and/or transient ischem-
ic attack (TIA)
 Modifiable risk factors:




physical inactivity and obesity
Prevencija oznaŁava postupke koji se poduzimaju kod
bolesnika kako bi se sprijeŁio nastanak modanog udara.
Tradicionalno se prevencija dijeli na primarnu i sekundar-
nu. Primarna prevencija obuhvaæa prevenciju u zdravih
osoba koje jo nisu oboljele, odnosno koje jo nisu zadobile
modni udar. Sekundarna prevencija predstavlja identi-
ficira-nje i lijeŁenje osoba s vrlo visokim rizikom za nastanak
modanog udara kako bi se sprijeŁio njegov nastanak, te
lijeŁenje i rehabilitaciju bolesnika koji su preboljeli modani
udar kako bi se sprijeŁio nastanak novog modanog udara.
Primarnom i sekundarnom prevencijom modanog
udara moe se poboljati kvaliteta ivota, smanjiti potreba
za kirurkim zahvatima, produiti ukupno preivljavanje te
smanjiti uŁestalost buduæih modanih udara. Postupci i
strategije primarne i sekundarne prevencije modanog
udara uvelike se preklapaju.
U okviru prevencije modanog udara primjenjuju se
slijedeæi postupci:
1. potrebno je djelovati na Łimbenike rizika povezane s
naŁinom ivota u cilju otklanjanja nezdravog naŁina
ivota i promicanja zdravog naŁina ivota
2. lijeŁiti bolesti koje predstavljaju riziŁne Łimbenike i na
taj naŁin smanjivati utjecaj tih riziŁnih Łimbenika na
poveæanje uŁestalosti modanog udara
3. u sluŁaju ishemijskog modanog udara uz djelovanje na
Łimbenike rizika propisuju se i odreðeni lijekovi: per-
oralni antikoagulansi i antiagregacijska terapija
4. u sluŁaju znaŁajne stenoze karotidnih arterija pristupa
se operacijskom lijeŁenju karotidne stenoze
Postoji mnotvo dokaza da su razne okolnosti, stanja,
ponaanje, ivotne navike i bolesti znaŁajno povezani s
incidencijom modanog udara, pa se stoga nazivaju Łimbe-
nicima rizika za nastanak modanog udara.
¨imbenici rizika za nastanak modanog udara





 modani udar u obiteljskoj amanezi
 podatak o prethodnom modanom udaru i/ili pret-
hodnim prolaznim ishemijskim napadajima (TIA)
 ¨imbenici na koje se moe utjecati:




tjelesna neaktivnost i pretilost
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 diseases and states:
hypertension









transient ischemic attacks (TIA)





elevated hematocrit and blood hyperviscosity
vasculitides
Nonmodifiable risk factors for stroke
Age is one of the most significant risk factors for stroke.
The risk of stroke is known to rise by approximately 10%
with each decade of life after the age of sixty.
Considering sex, men are known to be more prone to
stroke in the reproductive age than women. However, af-
ter the menopause the risk of stroke rises in female popu-
lation. This and the fact that life expectancy is longer in
women result in female predominance in the absolute
number of stroke cases in the advanced age groups.
A family history of stroke and/or personal history of
stroke or TIA significantly increase the likelihood of stroke
in such a patient. The incidence of stroke is higher in sub-
jects with prior TIA or stroke.
Nonmodifiable risk factors for stroke
Lifestyle related risk factors
Cigarette smoking contributes significantly to the prev-
alence of stroke. A meta-analysis of 32 studies has shown
that smoking increases the risk of stroke by 50%. A dose-
dependent relationship was also demonstrated, i.e. the risk
of stroke increased with the number of cigarettes. Quit-
ting smoking was associated with a rapid decrease in the




 bolesti i bolesna stanja:
hipertenzija









prolazni ishemijski napadaji (TIA)






povien hematokrit i stanja hiperviskoznosti krvi
vaskulitisi
¨imbenici rizika za nastanak modanog udara na
koje se ne moe utjecati
Dob. Dob je jedan od najznaŁajnijih Łimbenika rizika
za nastanak modanog udara. Poznato je da nakon
ezdesete godine ivota rizik za nastanak modanog udara
raste za otprilike 10% sa svakim slijedeæim desetljeæem
starosti.
Spol. Poznato je da su mukarci skloniji nastanku
modanog udara u generativnoj ivotnoj dobi. Meðutim,
nakon menopauze rizik od nastanka modanog udara ras-
te u enskoj populaciji. Ta Łinjenica i podatak da je prosjeŁ-
ni ivotni vijek u ena dui dovodi do pojave da u starijoj
ivotnoj dobi u apsolutnom broju ima vie ena s modanim
udarom.
Podatak o modanom udaru u obiteljskoj anamnezi i/
ili podatak o preboljelom modanom udaru ili TIA u osob-
noj anamnezi znaŁajno podiu moguænost nastanka
modanog udara u dotiŁnog bolesnika. Osobe s prebolje-
lim TIA ili modanim udarom Łeæe zadobivaju ponovni
modani udar.
Second Congress of Croatian Society for Neurovascular Disorders of Croatian Medical Association
Drugi kongres Hrvatskoga drutva za neurovaskularne poremeæaje Hrvatskoga lijeŁniŁkog zbora
Acta Clin Croat, Vol. 43, Suppl. 1,  2004 29
after 5 years of stopping smoking to be the same as in
nonsmokers.
Physical inactivity and overweight
Framingham study pointed to a negative correlation
between physical activity and stroke prevalence in male
population. Recent studies indicate that an increased lev-
el of physical activity is associated with a decrease in the
risk of stroke also in women, and that abdominal obesity
is a significant independent risk factor for stroke. The fa-
vorable effect of increased physical activity on lowering the
risk of stroke is considered to be due to its action in de-
creasing elevated blood pressure and body weight as well
as to improved glucose tolerance. Also, a higher level of
physical activity increases HDL cholesterol, lowers LDL
cholesterol, and promotes a healthy lifestyle.
Alcohol abuse certainly is a significant risk factor for
stroke. Our studies have shown that blood vessels of an
alcoholic are on an average 10 years older than the subjects
biological age. However, the intake of small amounts of
alcohol (up to two drinks daily) has been associated with
reduction of the risk of ischemic stroke. According to some
data, one glass of red wine daily is optimal, as red wine
contains flavonoids that act as antioxidants. The risk of
ischemic stroke rises abruptly with the intake of more than
two alcoholic drinks daily. A J-shaped association has been
determined between the intake of alcoholic drinks and
incidence of stroke: the incidence of ischemic stroke de-
creases with the intake of up to two drinks daily, whereas
an increased intake of alcohol is associated with a higher
incidence of both ischemic and hemorrhagic stroke.
Stress reaction enhances platelet aggregation and ac-
tivates renin-angiotensin system, thus increasing the pro-
duction of angiotensin II which leads to blood pressure
elevation. In this way, stress increases the prevalence of
cardiovascular and cerebrovascular diseases. However,
there are difficulties in exact stress defining as well as in
the methodology of measuring stress intensity. Only a
limited number of studies investigating the impact of
stress on the prevalence of stress are available in the liter-
ature, most of them describing the relationship between
war related stress and prevalence of stroke. Data from these
studies are suggestive of an association between stress and
an increased prevalence of hemorrhagic stroke.
As for drug abuse, the use of cocaine, especially in its
alkaloid form (crack) has been association with an in-
creased prevalence of cerebrovascular disease, both is-
chemic and hemorrhagic.
Considering oral contraceptives, the risk of stroke is
increased in women taking these agents, especially those
¨imbenici rizika za nastanak modanog udara na
koje se moe utjecati
¨imbenici povezani s naŁinom ivota
Puenje. Puenje cigareta znaŁajno doprinosi uŁesta-
losti modanog udara. Metaanaliza 32 studije pokazala je
kako puenje povisuje rizik od nastanka modanog udara
za 50%. Takoðer je pokazana ovisnost o dozi: rizik od nas-
tanka modanog udara poveæava se s brojem popuenih ci-
gareta. Prestanak puenja povezan je s brzim smanjivanjem
rizika nastanka modanog udara; Framinghamska studija
pokazala je da se nakon pet godina nepuenja rizik od nas-
tanka modanog udara izjednaŁava s rizikom u nepuaŁa.
Tjelesna neaktivnost i prekomjerna tjelesna
teina. U Framinghamskoj studiji pokazana je negativna
povezanost tjelesne aktivnosti i uŁestalosti modanog
udara u mukoj populaciji. Novija istraivanja pokazuju da
je poveæana tjelesna aktivnost povezana sa smanjivanjem
rizika modanog udara i u ena, te da je abdominalni tip
pretilosti znaŁajan neovisan Łimbenik rizika za nastanak
modanog udara. Smatra se da je povoljan uŁinak poveæane
tjelesne aktivnosti na sniavanje rizika za nastanak
modanog udara posljedica uŁinka na sniavanje povienih
vrijednosti tlaka, smanjivanje tjelesne teine i poboljanje
tolerancije glukoze. Poveæana tjelesna aktivnost takoðer
dovodi do povienja HDL kolesterola i sniavanja LDL
kolesterola, te do promicanja zdravog naŁina ivota.
Alkohol. Zlouporaba alkohola svakako predstavlja
znaŁajan Łimbenik rizika za nastanak modanog udara.
Naa istraivanja pokazala su da su krvne ile alkoholiŁara
prosjeŁno deset godina starije od bioloke starosti alkoho-
liŁara. Meðutim, pijenje malih koliŁina alkohola (do dva
piæa na dan) povezano je sa sniavanjem rizika za nastanak
ishemijskog modanog udara. Postoje podaci koji govore
kako je najbolje uzimanje jedne Łae crnog vina na dan, jer
se u crnom vinu nalaze flavonoidi koji djeluju kao antiok-
sidansi. Rizik od nastanka ishemijskog modanog udara
znaŁajno raste ako se popiju vie od dva alkoholna piæa na
dan. Utvrðena je povezanost pijenja alkoholnih piæa i
uŁestalosti modanog udara u obliku slova J: incidencija
ishemijskog modanog udara se smanjuje pri pijenju do dva
alkoholna piæa na dan, a kod poveæanog unosa alkohola raste
uŁestalost ishemijskog i hemoragijskog modanog udara.
Stres. Reakcija na stres poveæava agregaciju trombo-
cita, aktivira sustav renina-angiotenzina i na taj naŁin po-
veæava stvaranje angiotenzina II. koji povisuje krvni tlak.
Stoga stres uzrokuje poveæanu uŁestalost kardiovaskularnih
i cerebrovaskularnih bolesti. Meðutim, postoje tekoæe u
toŁnom definiranju stresa i naŁinu mjerenja jaŁine stre-
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containing high estrogen. Whether oral contraceptives with
a low dose of estrogen increase the risk of stroke yet re-
mains a matter of dispute. The use of oral contraceptives
has been demonstrated to increase the risk of stroke in
those women who also have other stroke risk factors (age
>35, hypertension, smoking). A World Health Organiza-
tion study conducted in developing countries showed the
risk of cerebral hemorrhage to be significantly higher in
women taking oral contraceptives. Oral contraceptives
have also been associated with an increased risk of sub-
arachnoidal hemorrhage, which is especially pronounced
in women with coexistent hypertension.
Treatment of Diseases Representing Risk Factors
for Stroke
Hypertension
Hypertension is the most significant risk factor for
stroke. The prevalence of stroke increases with diastolic
and systolic pressure elevation. The prevalence of stroke
rises by 46% with every 7.5 mm Hg increase in diastolic
pressure. The Systolic Hypertension in the Elderly Pro-
gram (SHEP) has shown the treatment of isolated systol-
ic hypertension in subjects older than 60 leads to a 36%
decrease in the prevalence of stroke.
The risk of stroke is considerably reduced by the treat-
ment of hypertension. A meta-analysis of 14 randomized
clinical trials has shown a diastolic arterial pressure reduc-
tion of 5-6 mm Hg to significantly decrease the prevalence
of stroke by 42%. It should be noted that hypertension has
to be treated and arterial pressure values maintained within
the normal limits, i.e. at least below 140/90 mm Hg rather
than just reduce the level of arterial pressure. May some
other risk factor be also present (e.g., diabetes mellitus),
the blood pressure level should be maintained below 130/
80 mm Hg. It has recently been shown that in addition to
their favorable effect on blood pressure lowering, the use
of newer antihypertensives (angiotensin converting en-
zyme /ACE/ inhibitors, new generations of lipophilic cal-
cium channel blockers, and angiotensin receptor blockers)
also has an additional beneficial action in the prevention
of vascular diseases. This has been attributed to their pos-
sible effect on vascular walls, especially on endothelial cells.
Such an action of new antihypertensives may also be ob-
served in patients with normal blood pressure.
Atrial fibrillation
Atrial fibrillation is one of the most significant indepen-
dent risk factors for stroke. Atrial fibrillation has been asso-
sa. Objavljeno je svega nekoliko radova o utjecaju stresa na
uŁestalost modanog udara, a veæina Łlanaka opisuje utje-
caj stresa povezanog s ratnim zbivanjima i uŁestalosti
modanog udara. Podaci iz navedenih studija upuæuju ne
moguæu povezanost stresa i poveæane uŁestalosti hemo-
ragijskog modanog udara.
Zlouporaba opojnih droga. Upotreba kokaina, pogoto-
vo u njegovom alkaloidnom obliku (crack), povezana je s
poveæanom uŁestaloæu cerebrovaskularne bolesti, kako
ishemijske tako i hemoragijske.
Oralni kontraceptivi. Rizik od nastanka modanog
udara poveæan je u ena koje uzimaju oralne kontraceptive,
pogotovo oralne kontraceptive s visokim sadrajem estro-
gena. Jo uvijek nije jasno poveæavaju li oralni kontracep-
tivi s malom dozom estrogena rizik od nastanka modanog
udara. Dokazano je kako uzimanje oralnih kontraceptiva
poveæava rizik nastanka modanog udara u ena koje ima-
ju i druge Łimbenike rizika (ene starije od 35 godina, hi-
pertenzija, puenje). U studiji Svjetske zdravstvene orga-
nizacije u zemljama u razvoju rizik od modanog krvarenja
bio je znaŁajno veæi kod ena koje su uzimale oralne kon-
traceptive. Oralni kontraceptivi su povezani i s poveæa-
njem rizika subarahnoidnog krvarenja, to je naroŁito iz-
raeno u ena koje imaju i hipertenziju.
LijeŁenje bolesti koje predstavljaju Łimbenike riz-
ika za nastanak modanog udara
Hipertenzija
Hipertenzija je najznaŁajniji Łimbenik rizika za nas-
tanak modanog udara. UŁestalost modanog udara po-
veæava se kod povienog dijastoliŁnog i sistoliŁnog tlaka.
UŁestalost modanog udara raste 46% za svakih 7,5 mm Hg
porasta dijastoliŁnog tlaka. U studiji Systolic Hypertension
in the Elderly Program (SHEP) pokazalo se je kako lijeŁe-
nje izolirane sistoliŁne hipertenzije u osoba starijih od 60
godina dovodi do smanjenja uŁestalosti modanog udara za
36%.
LijeŁenje hipertenzije znaŁajno smanjuje rizik od
modanog udara. Metaanaliza 14 randomiziranih kliniŁkih
pokusa pokazala je kako smanjenje dijastoliŁnog arterijskog
tlaka od 5-6 mm Hg uzrokuje znaŁajno smanjenje uŁesta-
losti modanog udara od 42%. ZnaŁajno je napomenuti da
treba lijeŁiti hipertenziju i odravati vrijednosti arterijskog
tlaka u normalnim granicama, tj. barem ispod 140/90 mm
Hg, a ne samo sniziti arterijski tlak. Ako je prisutan i neki
drugi Łimbenik rizika (npr. eæerna bolest), tada treba tlak
odravati ispod 130/80 mm Hg.
U zadnje vrijeme pokazalo se je kako primjena novijih
antihipertenziva (inhibitori enzima konverzije angioten-
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ciated with approximately 5-fold increase in the incidence
of first ever stroke. Controlled clinical trials have shown
that the risk of stroke in patients with atrial fibrillation can
be reduced by 70% with the use of oral anticoagulant (war-
farin).
In patients below the age of 65 with atrial fibrillation,
therapy with oral anticoagulants should be introduced and
INR (international normalized ratio) values maintained at
2.5 (range 2.0-3.0), which appears to be adequate for suc-
cessful prevention of stroke while not being associated
with an increased risk of hemorrhage. Patients aged >65
with isolated atrial fibrillation and those who cannot take
oral anticoagulants for any reason can take acetylsalicylic
acid (ASA) at a dose of 100-300 mg/day. Anticoagulant
therapy should not be prescribed in patients with a histo-
ry of hemorrhagic stroke.
Elevated cholesterol
Data from recent studies indicate that there is an as-
sociation between elevated levels of cholesterol and inci-
dence of stroke. Subsequent analysis of for pravastatin
studies (where stroke was not set as a primary endpoint)
revealed a significant reduction in the incidence of stroke
in patients taking pravastatin. Subsequent analysis of data
obtained in the Scandinavian Simvastatin Survival Study
(4S) showed a 28% relative stroke and TIA risk reduction.
The Cholesterol And Recurrent Events (CARE) study
showed a 31% relative stroke risk reduction, whereas in the
Long-term Intervention with Pravastatin in Ischemic Dis-
ease (LIPID) study the relative risk reduction for stroke
was 19%. Subsequent analysis of 16 published studies on
the impact of statins on the incidence of stroke and gen-
eral mortality revealed that the relative risk of stroke was
decreased by 19% with the use of statins, thus pointing to
the beneficial effect of cholesterol lowering on the inci-
dence of stroke. Besides cholesterol lowering, statins may
also have some additional favorable effects, i.e. soft plaque
stabilization, improved endothelial function, and reduced
platelet aggregation. Statins may also lead to a decrease in
the intimal-medial thickness, thus offering the possibili-
ty of their use in patients with atherosclerotic plaques but
normal cholesterol levels.
Diabetes mellitus
Diabetes mellitus is an independent risk factor for the
development of atherosclerosis and stroke. A twofold
mortality rate following ischemic stroke has been found in
diabetic patients relative to nondiabetic subjects. Howev-
er, a strict control of blood glucose has not been definitely
zina /inhibitori ACE/, novije generacije lipofilnih blokato-
ra kalcijevih kanala, te blokatori angiotenzinskih recepto-
ra) uz povoljno djelovanje na sniavanje krvnog tlaka ima i
dodatan povoljni uŁinak u prevenciji krvoilnih bolesti, koji
se pokuava objasniti uŁinkom na stijenku krvnih ila, a
prvenstveno na endotelne stanice. Takvo djelovanje novijih
antihipertenziva moda je moguæe i u bolesnika s nor-
malnim krvnim tlakom.
Atrijska fibrilacija
Atrijska fibrilacija je jedan od najznaŁajnijih neovisnih
Łimbenika rizika za nastanak modanog udara. Atrijska fib-
rilacija povisuje uŁestalost modanog udara otprilike pet
puta za prvi modani udar. Kontrolirane kliniŁke studije su
pokazale kako se primjenom peroralnih antikoagulansa
(varfarin) moe smanjiti rizik od nastanka modanog udara
u bolesnika s atrijskom fibrilacijom za otprilike 70%.
U bolesnika mlaðih od 65 godina s atrijskom fibrilaci-
jom u okviru prevencije modanog udara potrebno je uvesti
terapiju peroralnim antikoagulansima i odravati vrijednos-
ti INR (international normalized ratio) na 2,5 (raspon izmeðu
2,0 i 3,0), to je dovoljno za uspjenu prevenciju nastanka
modanog udara, a nije povezano s poveæanim rizikom
krvarenja. Bolesnici stariji od 65 godina koji imaju izoliranu
atrijsku fibrilaciju i oni bolesnici koji iz bilo kojeg razloga
ne mogu uzimati peroralne antikoagulanse, mogu uzimati
acetilsalicilnu kiselinu u dozi izmeðu 100 i 300 mg na dan.
Antikoagulantna terapija ne smije se propisivati bolesnici-
ma koji su preboljeli hemoragijski modani udar.
Povien kolesterol
Podaci iz novijih studija pokazuju da postoji povezanost
izmeðu povienih vrijednosti kolesterola i uŁestalosti
modanog udara. Naknadna analiza Łetiri studije s pravas-
tatinom (u kojima modani udar nije bio unaprijed post-
avljen kao primarni krajnji ishod) pokazala je znaŁajno
smanjenje uŁestalosti modanog udara u bolesnika koji su
uzimali pravastatin. U Skandinavskoj studiji preivljavanja
sa simvastatinom (Scandinavian Simvastatin Survival
Study  4S) naknadna analiza podataka otkrila je relativno
smanjenje rizika za modani udar i TIA za 28%. U studiji
Cholesterol And Recurrent Events (CARE) pokazano je
relativno smanjenje rizika od modanog udara za 31%, a u
studiji Long-term Intervention with Pravastatin in Ischem-
ic Disease (LIPID) relativno smanjenje rizika za modani
udar iznosilo je 19%. Naknadna analiza 16 objavljenih studi-
ja o utjecaju statina na uŁestalost modanog udara i opæu
smrtnost pokazala je kako primjenom statina dolazi do
smanjivanja relativnog rizika modanog udara za 29%, to
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confirmed to act favorably on the prevention of stroke. In
type 2 diabetic patients, therapy with oral hypoglycemic
agents and/or insulin has been demonstrated to improve
systemic microvascular complications but not macrovas-
cular complications such as stroke. A more precise deter-
mination of the independent impact of diabetes mellitus
on the occurrence and development of stroke is believed
to be hampered by the presence of many other risk factors
for stroke that are already present at the time of diabetes
diagnosis.
Significant carotid artery stenosis
A stenosis of ‡75% of the lumen is considered as sig-
nificant carotid arterial stenosis (according to the criteria
set by the European Carotid Surgery Trial, ECST), or of
‡50% of the lumen (according to the criteria set by the
North American Symptomatic Carotid Endarterectomy
Trial, NASCET). In Croatia, the ECST criteria are gener-
ally used. Significant carotid arterial stenosis is associated
with a high risk of ipsilateral stroke.
All patients diagnosed with significant carotid artery
stenosis should be referred to a vascular surgeon for endar-
terectomy, which should be performed at an institution
with perioperative and postoperative mortality and mor-
bidity below 3%. In case of asymptomatic carotid stenos-
is, the ACAS study demonstrated favorable impact in men
with 60%-99% stenosis but in female population. Most
experts now believe that patients with significant carotid
artery stenosis should be operated on at an institution with
a perioperative risk below 3%, however, some think that
in case of asymptomatic carotid stenosis the decision
should be made on an individual basis.
Medication in Secondary Prevention of Ischemic
Stroke
Antiaggregation therapy
Antiaggregation agents are prescribed for secondary
prevention of ischemic stroke. The most commonly pre-
scribed agents are ASA, ticlopidine, clopidogrel and dipy-
ridamole. A collaborative group of antiaggregation thera-
py investigators has published an overview of controlled
clinical trials of the use of antiaggregation agents in the
prevention of vascular diseases. The analysis included 145
studies with more than 51,000 patients, and concluded
that the use of antiaggregation therapy led to a 22% rela-
tive risk reduction for all vascular diseases and 23% rela-
tive risk reduction for stroke.
ukazuje na povoljan uŁinak sniavanja vrijednosti koleste-
rola na uŁestalost modanog udara. Uza sniavanje koles-
terola, izgleda da bi statini mogli imati i dodatne povoljne
uŁinke: stabiliziranje mekanih plakova, poboljanje funk-
cije endotela, smanjenje agregacije trombocita. Statini bi
mogli smanjivati debljinu intime i medije (intimal-medial
thickness), Łime se otvara moguænost primjene statina u
bolesnika s aterosklerotskim plakovima, a s normalnim
vrijednostima kolesterola.
eæerna bolest
eæerna bolest predstavlja neovisan Łimbenik rizika za
nastanak ateroskleroze i modanog udara. U osoba sa eæer-
nom boleæu utvrðena je dvostruko via smrtnost nakon
ishemijskog modanog udara u odnosu na osobe bez eæer-
ne bolesti. Meðutim, nije dokazano da stroga kontrola kon-
centracije glukoze u krvi djeluje povoljno na sprjeŁavanje
modanog udara. U bolesnika s dijabetesom tip II. poka-
zalo se je kako terapija peroralnim hipoglikemicima i/ili
inzulinom poboljava sistemske mikrovaskularne kom-
plikacije, ali ne i makrovaskularne komplikacije kao to je
modani udar. Smatra se da je preciznije odreðivanje neo-
visnog udjela eæerne bolesti u nastanku i razvoju mo-
danog udara oteano zato to postoji niz drugih Łimbeni-
ka rizika za nastanak modanog udara koji su veæ prisutni
pri otkrivanju eæerne bolesti.
ZnaŁajna stenoza karotidnih arterija
ZnaŁajnom stenozom karotidnih arterija smatra se
stenoza jednaka ili veæa od 75% lumena (prema kriteriji-
ma European Carotid Surgery Trial - ECST), odnosno jed-
naka ili veæa od 50% (prema kriterijima North American
Symptomatic Carotid Endarterectomy Trial - NASCET).
U Hrvatskoj se uglavnom primjenjuju kriteriji ECST-a.
ZnaŁajna stenoza karotidne arterije povezana je s izraenim
rizikom od nastanka istostranog modanog udara.
Sve bolesnike u kojih se dijagnosticira znaŁajna steno-
za karotidne arterije treba uputiti vaskularnom kirurgu da
se uŁini endarterektomija u centru koji ima perioperacijsku
i poslijeoperacijsku smrtnost i pobol nie od 3%.
Za asimptomatsku karotidnu stenozu je studija ACAS
pokazala povoljan uŁinak u mukaraca sa stenozom od 60%-
99%, ali ne i u enskoj populaciji. Veæina struŁnjaka danas
smatra kako bolesnike sa znaŁajnom stenozom karotidne
arterije treba operirati u centru koji ima rizik operacije
manji od 3%, mada u sluŁaju asimptomatske karotidne
stenoze neki smatraju da odluku treba donijeti individu-
alno.
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Acetylsalicylic acid
Acetylsalicylic acid (ASA) is a medication discovered
more than a hundred years ago. ASA inhibits cyclo-oxyge-
nase, thus preventing the synthesis of thromboxane A2
(TXA2) in platelets, and the synthesis of prostacycline
(PGI2) in endothelial cells. The collaborative group of
investigators for antiplatelet agents found a 25% relative
stroke risk reduction in patients taking ASA. The optimal
dose of ASA in the prevention of stroke has not yet been
definitely determined. ASA doses from 30 to 1500 mg/day
have been used in various trials. Studies failed to show any
major differences among low (<100 mg/day), medium
(100-500 mg/day) and high (>500 mg/day) ASA doses.
Low doses have been postulated to be more efficacious
than medium and high doses, because the former act on
TXA2 synthesis in platelets but not to the same extent on
PGI2 synthesis in endothelial cells. It seems that ASA in
any dose greater than 30 mg/day reduces the risk of stroke,
whereby higher doses are associated with an increased
incidence of ASA side effects (gastrointestinal bleeding,
gastrointestinal discomfort, heartburn, nausea, vomiting).
Therefore, lower ASA doses (100-300 mg/day) should be
prescribed for ischemic stroke prevention.
Ticlopidine
Ticlopidine is a tienopyridine derivative blocking the
adenosine-diphosphate pathway of platelet aggregation. In
the Canadian-American Ticlopidine Study (CATS), ticlo-
pidine in a dose of 500 mg/day led to a 33% stroke risk
reduction. In the Ticlopidine Aspirin Stroke Study
(TASS), ticlopidine in a dose of 500 mg/day reduced the
risk of stroke or death by 12% in comparison with ASA in
a dose of 1300 mg/day. Ticlopidine is as efficacious or even
more efficacious than ASA in secondary stroke prevention.
However, the drug is associated with a major disadvantage
of common side effects such as diarrhea, rash, as well as
serious side effects such as neutropenia, thrombocytope-
nia, thrombocytopenic thrombocytic purpura and pancy-
topenia. Ticlopidine is a drug with more serious side ef-
fects than ASA. Most side effects related to bone marrow
functioning occur within three months of ticlopidine in-
troduction in therapy, therefore patients should undergo
frequent blood count controls during this period. Howev-
er, thrombocytopenic thrombocytic purpura may also de-
velop after this initial period.
Clopidogrel (not registered in Croatia)
Clopidogrel is chemically similar to ticlopidine, also
blocking the adenosine-phosphate pathway of platelet
Lijekovi u sekundarnoj prevenciji ishemijskog
modanog udara
Antiagregacijska terapija
U sekundarnoj prevenciji ishemijskog modanog udara
propisuju se antiagregacijski lijekovi. Najpropisivaniji su
lijekovi acetilsalicilna kiselina (ASK), tiklopidin, klopi-
dogrel i dipiridamol.
Suradna grupa ispitivaŁa za antiagregacijske lijekove
objavila je pregled kontroliranih kliniŁkih studija primjene
antiagregacijskih lijekova u prevenciji krvoilnih bolesti.
Analizirane su 145 studije u kojima je bilo ukljuŁeno vie
od 51.000 bolesnika. ZakljuŁeno je kako primjena antiagre-
gacijskih lijekova dovodi do relativnog smanjenja rizika od
svih vaskularnih bolesti za 22%. U sluŁaju modanog udara
relativno smanjenje rizika iznosilo je 23%.
Acetilsalicilna kiselina
Acetilsalicina kiselina (ASK) je lijek otkriven pred vie
od stotinu godina. ASK inhibira ciklooksigenazu i na taj
naŁin sprjeŁava sintezu tromboksana A2 (TXA2) u trom-
bocitima, ali i sintezu prostaciklina (PGI2) u endotelnim
stanicama. U publikaciji Suradna grupa ispitivaŁa za anti-
trombocitne lijekove utvrdila je relativno smanjenje rizika
modnog udara za 25% u bolesnika koji su uzimali ASK.
Optimalna doza ASK u prevenciji modanog udara jo
uvijek nije nedvojbeno utvrðena. U raznim istraivanjima
primjenjivale su se doze ASK od 30 do 1500 mg/dan.
Istraivanja nisu pokazala znaŁajnih razlika izmeðu malih
(<100 mg/dan), srednjih (100-500 mg/dan) i visokih doza
(>500 mg/dan). Pretpostavlja se da su male doze uŁinko-
vitije od srednjih i visokih, jer djeluju na sintezu trombok-
sana A2 u trombocitima, a ne djeluju u tolikoj mjeri na sin-
tezu prostaciklina u stanicama endotela. Izgleda da ASK u
svakoj dozi veæoj od 30 mg/dan smanjuje rizik modanog
udara, a veæe doze povezane su s viom uŁestaloæu nus-
pojava ASK (krvarenje iz probavnog trakta, probavne smet-
nje, garavica, muŁnina, povraæanje). Stoga bi u prevenciji
ishemijskog modnog udara trebalo propisivati nie doze
ASK od 100-300 mg/dan.
Tiklopidin
Tiklopidin je tienopiridinski derivat koji blokira ade-
nozin-difosfatni put agregacije trombocita. U istraivanju
Canadian-American Ticlopidine Study (CATS) tiklopidin
u dozi od 500 mg/dan doveo je do 33%-tnog smanjenja ri-
zika nastanka modanog udara. U istraivanju Ticlopidine
Aspirin Stroke Study (TASS) tiklopidin u dozi od 500 mg/
dan smanjio je rizik nastanka modanog udara ili smrti za
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aggregation. In the Clopidogrel versus Aspirin in Patients
at Risk of Ischemic Events (CAPRIE) study, clopidogrel
at a dose of 75 mg/day in comparison with ASA at a dose of
325 mg/day led to an 8.7% relative risk reduction for vas-
cular disease. As differentiated from ticlopidine, clopi-
dogrel does not induce substantially more side effects than
ASA. Clopidgrel is slightly more efficient than the medi-
um doses of ASA. Clopidogrel is the drug of choice for
secondary stroke prevention in patients who cannot toler-
ate ASA. Considering their different mechanisms of action,
a combination of ASA and clopidogrel proved quite inter-
esting. However, results of the recently published
MATCH study indicate that the addition of ASA to clopi-
dogrel did not lead to any significant difference in the
vascular event reduction, whereas a higher incidence of
bleeding was recorded in the group of patients coadmin-
istered ASA and clopidogrel.
Dipyridamole (not registered in Croatia)
Dipyridamole is considered to prevent platelet aggre-
gation in a number of ways, i.e. by inhibiting phosphodi-
esterase, thus increasing the level of antithrombotic cyclic
adenosine monophosphate in platelets; by inhibiting cel-
lular uptake and metabolism of adenosine, thus increas-
ing the plasma concentration of adenosine; and by direct-
ly stimulating the release of prostacycline from endothe-
lial cells. In the European Stroke Prevention Study 1
(ESPS-1), a combination of ASA in a dose of 990 mg/day
and dipyridamole in a dose of 225 mg/day led to a 38%
relative stroke risk reduction. The European Stroke Pre-
vention Study 2 (ESPS-2) demonstrated a relative reduc-
tion of 18% for ASA at a dose of 50 mg/day, 16% for dipy-
ridamole at a dose of 400 mg/day, and 37% for the combi-
nation of ASA and dipyridamole in the same doses. Previ-
ous small studies failed to show any significant difference
between the use of ASA alone and in combination with
dipyridamole. A combination of ASA at a dose of 25 mg and
dipyridamole at a dose of 200 mg used twice daily could
be the therapy of choice in the prevention of stroke.
Most authors believe that in the secondary prevention
of stroke, antiaggregation agents should be used as long as
there is the risk of stroke occurrence, which in the major-
ity of patients means for life.
Oral anticoagulants for stroke prevention
Some 20% of strokes are of cardioembolic origin, most
commonly due to with atrial fibrillation, acute myocardial
infarction, left ventricular wall thrombosis, rheumatic heart
disease, artificial valves. Therapy with oral anticoagulant
12% u usporedbi s ASK u dozi od 1300 mg/dan. Tiklopi-
din je ili podjednako uŁinkovit u sekundarnoj prevenciji
modanog udara kao i ASK ili Łak i uŁinkovitiji od ASK.
Medutim, glavni nedostatak ovoga lijeka su nuspojave kao
dijareja, osipi, te ozbiljne nuspojave kao neutropenija, trom-
bocitopenija, trombocitopeniŁna trombotiŁna purpura i
pancitopenija. Tiklopidin je lijek s vie ozbiljnih nuspoja-
va od ASK. Veæina nuspojava povezanih s funkcijom ko-
tane sri nastaje u prva tri mjeseca nakon uvoðenja tiklo-
pidina u terapiju, pa u tom vremenu treba bolesnicima
uŁestalo kontrolirati krvnu sliku. Meðutim, tromboci-
topeniŁna trombotiŁna purpura moe nastati i nakon tog
vremena.
Klopidogrel (lijek nije registriran u Hrvatskoj)
Klopidogrel je lijek kemijski sliŁan tiklopidinu, koji
takoder blokira adenozin-difosfatni put agregacije trom-
bocita. U studiji Clopidogrel versus Aspirin in Patients at
Risk of Ischemic Events (CAPRIE) je klopidogrel u dozi
od 75 mg/dan u usporedbi s ASK u dozi od 325 mg/dan
doveo do relativnog smanjenja rizika vaskularnih bolesti za
8,7%. Za razliku od tiklopidina, klopidogrel nema bitno
veæih nuspojava od ASK. Klopidogrel je neto uŁinkovitiji
od srednjih doza ASK. Klopidogrel predstavlja lijek izbora
u sekundarnoj prevenciji modnog udara u bolesnika koji
ne podnose ASK. S obzirom na razliŁit mehanizam djelo-
vanja zanimljiva je bila kombinacija ASK i klopidogrela. Me-
ðutim, rezultati nedavno objavljene studije MATCH poka-
zali su kako dodavanjem ASK klopidogrelu nije postignu-
ta znaŁajna razlika u smanjenju vaskularnih dogaðaja, a u
skupini bolesnika koja je primala ASK i klopidogrel
zabiljeena je veæa uŁestalost krvarenja.
Dipiridamol (lijek nije registriran u Hrvatskoj)
Smatra se da dipiridamol sprjeŁava agregaciju trom-
bocita na vie naŁina: inhibirajuæi fosfodiesterazu, to dovo-
di do poveæanja razine antitrombotskog cikliŁnog adenozin
monofosfata u trombocitima; inhibiranjem staniŁnog preu-
zimanja i metabolizma adenozina, a time poveæanja kon-
centracije adenozina u plazmi; te izravnim poticanjem
otputanja prostaciklina iz endotelnih stanica. U Europe-
an Stroke Prevention Study (ESPS-1) je kombinacija ASK
u dozi od 990 mg/dan i dipiridamola u dozi od 225 mg/dan
dovela do relativnog smanjenja rizika modanog udara za
38%. Ispitivanje European Stroke Prevention Study 2
(ESPS-2) pokazala je relativno smanjenje rizika od 18% za
ASK u dozi od 50 mg/dan, 16% za dipiridamol u dozi od
400 mg/dan i 37% za kombinaciju ASK i dipiridamola u
istim dozama. Prijanja manja istraivanja nisu pokazala
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agents for the prevention of cardioembolic stroke should
be considered in all these conditions that are associated
with the potential causes of embolism. Dicumarol oral
anticoagulants are used in the prevention of stroke to
achieve INR between 2.0 and 3.0. In patients with atrial
fibrillation, the risk of stroke is thus reduced while not
increasing significantly the risk of hemorrhage. Although
data from large, controlled studies are lacking, oral antico-
agulants have been routinely prescribed to patients with
artificial cardiac valves, where INR should be maintained
between 3.0 and 4.0. Longterm therapy with oral antico-
agulants to maintain INR between 2.0 and 3.0 should also
be considered in patients with rheumatic disease of car-
diac valves, other cardiac arrhythmias (except for atrial fi-
brillation), myocardial infarction, cardiac failure, cardiomy-
opathy, and in those with open foramen ovale. Patients who
cannot take oral anticoagulants for whatever reason, can use
ASA in a dose of 100-300 mg/day.
Conclusion
Each and every physician can contribute to stroke pre-
vention in his/her daily practice. A healthy lifestyle should
be encouraged on a daily basis, i.e. nonsmoking, giving up
smoking, graded physical activity (30-minute exercise
daily), overweight reduction and maintenance of desirable
body weight (body mass index /BMI/ 18.5-24.9 kg/m2), and
healthy dietary habits (large amounts of fruit and vegeta-
bles, and reduced intake of saturated fat, cholesterol, salt
and meat  Mediterranean diet), advising one to two al-
coholic drinks daily (especially red wine), and discourag-
ing excessive alcohol intake.
In hypertensive subjects, hypertension should be treat-
ed and arterial blood pressure maintained within the nor-
mal limits, i.e. at least up to 140/90 mm Hg or 130/80 mm
Hg in diabetic persons. Patients with elevated cholester-
ol levels should be advised to adopt appropriate dietary
habits, along with introducing statin therapy and maintain-
ing cholesterol below 5 mmol/L and LDL cholesterol be-
low 3 mmol/L. In diabetic patients, blood glucose values
should be maintained as close to normal as possible. Pa-
tients with atrial fibrillation should be prescribed antico-
agulant (INR 2.5, range 2.5-30) or ASA (300 mg/day) ther-
apy. Patients with significant carotid arterial stenosis
(>75%) should be advised to undergo operative treatment.
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RECOGNITION AND SIGNIFICANCE OF RISK FACTORS IN CROATIAN POPULATION
SPOZNAVANJE I ZNA¨ENJE RIZI¨NIH ¨IMBENIKA HRVATSKOG PU¨ANSTVA
Stjepan Turek
HGK, Zagreb, Croatia / HGK, Zagreb
Summary
It is of utmost importance to identify the population risk
factors for cerebrovascular diseases in order to determine the
pathology and prevention as well as management of these dis-
eases. Numerous studies have been published on the topic of
risk factors in the population of Croatia, however, mostly for a
particular region and in a small number of people. It was only
in the 1995-1997 period  that a comprehensive investigation
of risk factors was conducted including 10,000 individuals of
both sexes aged 18-65. Data on the prevalence of risk factors
among the Croatian population were obtained by statistical
analysis of data on 5,840 individuals from all parts of Croatia.
These data are quite disturbing, as they have revealed a
high prevalence of bad habits with adverse health impact
among the Croatian population (inappropriate dietary habits,
inadequate physical activity, cigarette smoking) and an emerg-
ing necessity of undertaking an organized action within the
health insurance system and health care system. Despite our
knowledge, the epidemiologic indicators of cerebrovascular
disease morbidity and mortality have not yet started to im-
prove.
Introduction
The dynamics of new knowledge and scientific advanc-
es has enabled an unimaginable development of technol-
ogies that fundamentally change human life and living
habits even within a single generation. The picture of dis-
eases and disease states has also been altered accordingly,
along with increase in life expectancy. In the second half
of the 20th century, an association was recognized between
certain living habits and occurrence of longterm, chronic
noncontagious diseases. Then, systematic studies in the
field were launched, the first and most famous of them
being the Framingham Study, which confirmed the exist-
ence of risk factors that favor the onset of circulation dis-
orders. Numerous other studies and projects followed to
verify the great possibilities of preventive measures in the
control of circulatory disorders, among which cerebrovas-
cular diseases rank highest on the scale of death causes.
In the 1980s and 1990s, similar investigations were con-
ducted in Croatia, however, only in a limited number of
individuals.
Saetak
Spoznavanje riziŁnih Łimbenika je vrlo vano kako bi se pro-
cijenila patologija i prevencija te lijeŁenje cerebrovaskularnih
bolesti. Objavljeni su brojni radovi na temu riziŁnih Łimbenika
u puŁanstvu Republike Hrvatske, ali veæinom za pojedinu regi-
ju i mali broj ljudi. Sveobuhvatnije istraivanje riziŁnih Łimbe-
nika na 10.000 osoba obaju spolova u dobi od 18 do 65 godina
provedeno je tek u razdoblju izmeðu 1995. i 1997. godine. Po-
daci o uŁestalosti riziŁnih Łimbenika u hrvatskom puŁanstvu
dobili su se statistiŁkom obradom podataka za 5.840 osoba iz svih
dijelova Hrvatske. Ovi su podaci uznemirujuæi, jer otkrivaju vi-
soku uŁestalost loih ivotnih navika meðu stanovnitvom (loe
prehrambene navike, nedovoljna tjelesna aktivnost, puenje) i
pozivaju na pokretanje organiziranog djelovanja unutar sustava
zdravstvenog osiguranja i zdravstva opæenito. Usprkos ovim
spoznajama, epidemioloki pokazatelji pobola i smrtnosti od ce-
rebrovaskularnih bolesti jo se ne popravljaju.
Uvod
Dinamika  novih spoznaja i znanstvenih otkriæa omo-
guæila je nesluæeni razvoj tehnologija koje iz temelja mije-
njaju ivot i ivotne navike Łovjeka veæ u jednoj generaciji.
Sukladno se mijenja slika bolesti i bolesnih stanja uz
produenje ivotnog vijeka. U drugoj polovici 20. stoljeæa
uoŁena je povezanost odreðenih ljudskih navika s nas-
tankom dugotrajnih kroniŁnih nezaraznih bolesti. ZapoŁeta
su i sustavna istraivanja, od kojih je prvo i najpoznatije
obuhvaæeno Framinghamskom studijom, koja su potvrdila
postojanje riziŁnih Łimbenika koji pospjeuju nastajanje
cirkulacijskih bolesti. Slijedila su brojna druga istraivanja
i projekti koji su potvrdili velike moguænosti primjene pre-
vencijskih mjera u suzbijanju cirkulacijskih bolesti, od kojih
cerebrovaskularne bolesti zauzimaju na ljestvici uzroka
smrti najvia mjesta.
Osamdesetih i devedesetih godina prologa stoljeæa
provedena su sliŁna istraivanja u Hrvatskoj, no uglavnom
na manjem broju ispitanika.
Epidemioloki podaci
Cerebrovaskularne bolesti su jedan od vodeæih uzroka
smrti u nas, a noviji epidemioloki podaci ukazuju na sve
veæi pobol od bolesti cirkulacijskog sustava (tablica 1.).
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Epidemiologic Data
Cerebrovascular diseases are one of the leading causes
of death in Croatia, and recent epidemiologic data indicate
an ever increasing tendency in the circulatory system
morbidity (Table 1).
Table 1. Number of hospitalized patients according to years
Disease
Year
1976 1981 1992 2000 2002
Circulation 44,235 45,715 44,991 77,095 76,871
Nervous
20,842 20,859 19,894 14,459 15,240system
Source: Croatian Health Statistics Annals 1976,1981,1992, 2003.
The role of major risk factors reflects in the epidemi-
ologic data presented. According to the HZZJZ report for
2002, the number of deaths according to the mortality rate
(1980-2002) was quite constant, with some changes of up
to 0.7%. There was an obvious increase in the number of
deaths among those older than 65, which was due to the
prolonged life expectancy (Table 2). According to the same
source, in 1985 the life expectancy for women and men was
75.19 and 67.63 years, respectively, whereas in 2001 it was
78.17 for women and 71.03 for men.





of deaths age group
1992 51,800 11.6 33,727
1993 50,846 11.4 34,522
1994 49,482 11.1 33,928
1995 50,536 11.3 34,970
1996 50,636 11.3 35,841
1997 51,964 11.4 37,234
1998 52,311 11.6 38,394
1999 51,953 11.4 38,384
2000 50,246 11.5 37,749
2001 49,552 11.2 37,429
2002 50,569 11.4 38,832
Source: Croatian Health Statistics Annals 2002.
According to the Croatian Health Statistics Annals
2002, analysis of the leading causes of death in the Croat-
ian population showed cerebrovascular disease to be on the
high second place. In 2002, a total of 8,369 (16.55%) indi-
viduals of both sexes died from cerebrovascular diseases,
Tablica 1. Broj  bolniŁki lijeŁenih osoba po godinama
Bolesti
Godina
1976 1981 1992 2000 2002
Krvotoka 44,235 45,715 44,991 77,095 76,871
ivŁanog
20,842 20,859 19,894 14,459 15,240sustava
Izvor: HZZJZ, Hrvatski zdravstveno statistiŁki ljetopis 1976.,1981.,1992.,
2003.
ZnaŁenje riziŁnih Łimbenika ogleda se u postojeæim
epidemiolokim podacima. Prema izvjeæu HZZJZ za 2002.
godinu broj umrlih po godinama prema stopi umrlih (1980.-
2002.) je gotovo stabilan uz promjene unutar  0,7% . OŁit
je porast broja umrlih starijih od 65 godina, to je odraz
produenog ivotnog vijeka (tablica 2.). Prema istom izvoru
oŁekivani prosjeŁni ivotni vijek bio je 1985. za ene 75,19
godina, a za mukarce  67,63 godine, dok je 2001. godine
bio za ene 78,17 godina, a za mukarce 71,03 godine.





1992 51,800 11.6 33,727
1993 50,846 11.4 34,522
1994 49,482 11.1 33,928
1995 50,536 11.3 34,970
1996 50,636 11.3 35,841
1997 51,964 11.4 37,234
1998 52,311 11.6 38,394
1999 51,953 11.4 38,384
2000 50,246 11.5 37,749
2001 49,552 11.2 37,429
2002 50,569 11.4 38,832
Izvor: HZZJZ, Hrvatski zdravstveno statistiŁki ljetopis 2002.
Analiza vodeæih uzroka smrti hrvatskog puŁanstva za
2002. godinu prema Hrvatskom zdravstveno statistiŁkom
ljetopisu na drugo mjesto stavlja cerebrovaskularnu bolest.
Te je godine zbog cerebrovaskularnih bolesti umrlo ukup-
no 8.369 (16,55%) osoba obaju spolova, tj. 3.616 (14,05%)
mukaraca i 4.753 (19,14%) ena. Za ene je 2002. godine
poremeæaj modane cirkulacije bio na prvom mjestu
vodeæih uzroka smrti. Sveukupno je od bolesti cirku-
lacijskog sustava te godine umrlo 52,80% svih umrlih u
Hrvatskoj.
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i.e. 3,616 (14.05%) men and 4,753 (19.14%) women. In
2002, cerebrovascular disorder was the leading cause of
death in female population. In 2002, 52.80% of all deaths
were caused by circulation disorders.
During the year 2002, 76,871 (13.8%) patients were
hospitalized for circulation disorders during 108,875 days.
About 50% of those hospitalized at neurology departments
were treated for cerebrovascular disease.
Risk Factors in the Crotian Population
During the 1995-1997 period, a study of risk factors in
Croatia was carried out as part of the First Croatian Health
Project. It was the first multicenter, randomized, compre-
hensive study including 10,000 subjects from urban and
rural settings in the littoral and inland of Croatia. Field
studies were performed at 30 locations in the Osijek,
Zagreb, Rijeka and Split areas. The final sample included
5,840 subjects of both sexes aged 18-65. Analysis of the data
collected by a questionnaire and blood sample testing
showed the prevalence of risk factors in the Croatian pop-
ulation. Study results indicated a high prevalence of mod-
ifiable risk factors.
The prevalence of elevated blood pressure (BP ‡140/
90 mm Hg) was found to be 45%, with a male predomi-
nance (52% vs 37.9%). Blood pressure values increased
significantly with age.
Smoking was recorded in 32.6% of adults, also show-
ing a male predominance (34.1% vs 26.6%).
Physical activity was present in only 4.3% of women and
17.1% of men, with 2-4 and 4-5 hours weekly, respectively.
Overweight (body mass index, BMI 25.0-29.9) was
recorded in 41.4%, and obesity (BMI >30.0) in 18.0% of
study subjects. The proportion of obese subjects increased
with age in both sexes, showing highest rate in the Zagreb
area. The rate of obesity was significantly higher in men
(21%) than in women (15%).
The mean (c–SD) concentration of cholesterol
(mmol/L) was higher in men than in women (5.81–1.36
vs 5.66–1.29). Ten percent of men and women had a mean
cholesterol level exceeding 7.55 mmol/L and 7.39 mmol/
L, respectively.
Triglyceride concentrations (mmol/L) were also greater
in men (2.13–1.69) than in women (1.41–0.94). Some
10% of men and women had triglyceride levels exceeding
3.94 mmol/L and 2.5 mmol/L, respectively.
The averaged prevalence of diabetes mellitus was 6.1%,
increasing with age (age 18-29: 1.9%;  30-39: 2.0%; 40-49:
6.9%; 50-65: 12.1%).
Tijekom godine lijeŁen je u bolnicama 76.871 (13,8%)
bolesnik zbog cirkulacijskih bolesti tijekom 108.875 dana.
Oko 50% lijeŁenih u neurolokim odjelima lijeŁilo se je zbog
cerebrovaskularne bolesti.
RiziŁni Łimbenici hrvatskog puŁanstva
Tijekom razdoblja od 1995. do 1997. provedeno je
istraivanje riziŁnih Łimbenika na podruŁju Hrvatske u
okviru Prvog hrvatskog projekta zdravstva. To je prva ran-
domizirana multicentriŁna studija kojom je provedeno
sveobuhvatno istraivanje u 10.000 ispitanika urbane i
ruralne sredine priobalnog i kontinentalnog podruŁja Hr-
vatske. Terensko istraivanje provedeno je na 30 lokalite-
ta osjeŁke, zagrebaŁke, rijeŁke i splitske regije. KonaŁan
uzorak obuhvatio je 5.840 ispitanika obaju spolova u dobi
od 18-65 godina. Obradom prikupljenih podataka pomoæu
anketnog upitnika i uzoraka krvi utvrðena je prevalencija
riziŁnih Łimbenika za hrvatsku populaciju. Rezultati
istraivanja pokazali su visoku prevalenciju promjenjivih
riziŁnih Łimbenika.
Prevalencija povienog krvnog tlaka (RR ≤140/90 mm
Hg) iznosi 45%, s veæim udjelom u mukaraca (52%) u
odnosu na ene (37,9%). Vrijednosti krvnog tlaka znaŁaj-
no rastu s dobi ispitanika.
Ukupno 32,6% odraslih osoba su puaŁi. Puenje je vie
zastupljeno kod mukaraca (34,1%) u odnosu na ene
(26,6%).
Tjelesnom aktivnoæu aktivno se bavi samo 4,3% ena
i 17,1% mukaraca. Kod mukaraca je zastupljena s 4-5 sati
na tjedan, a kod ena s 2-4 sata na tjedan.
Prekomjernu tjelesnu teinu (indeks tjelesne mase,
ITM 25,0-29,9) ima 41,4% ispitanika, a u skupini debelih
(ITM >30.0) je 18,0% ispitanika. Udio pretilih se poveæava
s dobi kod oba spola, s najveæim udjelom u zagrebaŁkoj
regiji. ZnaŁajno je veæi udio pretilih mukaraca (21%) u
odnosu na ene (15%).
ProsjeŁna (c–SD) koncentracija kolesterola (mmol/L)
veæa je kod mukaraca (5,81–1,36) nego u ena (5.66–
1.29). Ukupno 10% mukaraca ima prosjeŁnu vrijednost
kolesterola iznad 7,55 mmol/L, a 10% ena iznad 7,39
mmol/L.
Koncentracije triglicerida (mmol/L) takoðer su veæe u
mukaraca (2,13–1,69) nego u ena (1,41–0,94). Pribli-
no 10% mukaraca ima prosjeŁnu vrijednost triglicerida
iznad 3,94 mmol/L, dok jednaki udio ena ima vrijednosti
triglicerida iznad 2,5 mmol/L.
UprosjeŁena prevalencija eæerne bolesti iznosi 6,1%,
a u porastu je s dobi ispitanika (18-29 godina 1,9%; 30-39
godina 2,0%; 40-49 godina 6,9%; 50-65 godina 12,1%).
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Accordingly, it is concluded that risk factors in the
Croatian population have been defined and found to show
no major geographical specificities. However, their rates in
the general population of Croatia are highly disturbing, as
confirmed by the epidemiologic data on cerebrovascular
and cardiovascular disease morbidity and mortality. The
respective experience from other countries that have
achieved favorable results in successful control and preven-
tion of cerebrovascular disease morbidity and mortality is
therefore of paramount importance (Table 3).
Table 3.Number of deaths per 100,000 population
1970 1980 1990 2001
Austria 176.24 150.27 98.85 67.81
¨zech Republic 204.65 224.53 202.77 136.13
Croatia 117.5 171.56 176.35
Hungary 184.52 217.96 177.42 149.07
Slovenia 126.15 92.01
Poland 55.9 76.96 73.07 103.61
Europe 142.54 158.54 142.55 140.18
Source: Croatian Health Statistics Annals 2001. Zagreb, 2002.
Conclusion
Comprehensive knowledge of the risk factor epidemi-
ology is of utmost importance for the entire health care
system. It is highly useful in setting priorities in the orga-
nization and financing of the health insurance system and
health care system. Therefore, a well defined program of
the measures of prevention, early detection and manage-
ment of cerebrovascular diseases should be designed in
order to reduce the related morbidity and mortality rates.
Dakle, moemo ustvrditi da su danas poznati riziŁni
Łimbenici hrvatske populacije i da oni nemaju izrazite zem-
ljopisne znaŁajnosti. Meðutim, njihov udio u opæoj popu-
laciji Hrvatske je vie no zabrinjavajuæi. Upravo epidemi-
oloki podaci o pobolu i smrtnosti od cerebrovaskularnih i
kardiovaskularnih bolesti to potvrðuju. Osobito su znaŁaj-
na iskustva drugih zemalja koje u tom podruŁju biljee
zapaene rezultate uspjenog suzbijanja pobola i smrtno-
sti od cerebrovaskularne bolesti (tablica 3.).
Tablica 3. Broj umrlih na 100.000 stanovnika
1970 1980 1990 2001
Austria 176.24 150.27 98.85 67.81
¨zech Republic 204.65 224.53 202.77 136.13
Croatia 117.5 171.56 176.35
Hungary 184.52 217.96 177.42 149.07
Slovenia 126.15 92.01
Poland 55.9 76.96 73.07 103.61
Europe 142.54 158.54 142.55 140.18
Izvor podataka: Hrvatski zdravstveno-statistiŁki ljetopis za 2001. Zagreb,
2002..
ZakljuŁak
Spoznavanje epidemiologije riziŁnih Łimbenika neo-
biŁno je vano za cijeli zdravstveni sustav. Ono je znaŁajno
za utvrðivanje prioriteta u organizaciji i financiranju sus-
tava zdravstvenog osiguranja i  zdravstvene zatite. Nuno
je stoga osmisliti jasan program mjera sprjeŁavanja, ranog
otkrivanja i lijeŁenja cerebrovaskularnih bolesti u cilju
smanjenja pobola i osobito smrtnosti.
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Neurosonologija ukljuŁuje neinvazivnu procjenu ek-
strakranijske i intrakranijske modane hemodinamike,
kako u bolesnika s modanim udarom, tako i u visokoriz-
iŁkih osoba. Zbog neinvazivnosti se moe ponavljati koli-
ko je god puta potrebno, to omoguæava praæenje modane
hemodinamike u ivom vremenu. Visokorezolutni ultra-
zvuk daje vrhunske podatke o morfologiji karotidnih, ver-
tebralnih i potkljuŁnih arterija, to omoguæava procjenu
debljine intime-medije (intima-media thickness, IMT), mor-
fologije plaka, ehogenosti, povrine plaka i stupnja stenoze.
Fina analiza daje podatke o aterosklerotskim ili upalnim
promjenama stijenke ile ili o disekciji. Dupleks ultrazvuŁ-
ni prikaz kombinira visokorezolutni prikaz sive skale sa
spektralnom frekvencijskom analizom pulsnog doplera
kako bi se dobili podrobni podaci o anatomiji i fiziologiji.
Standardna oprema u pregledu ekstrakranijskog modanog
krvoilja je obojeni dupleks sustav. Superpozicija bojom
kodiranog protoka pomae ispitivanje i interpretaciju in-
formacija o orijentaciji krvne ile, anatomskim varijantama,
procjenu hemodinamike i razliŁitih fiziolokih varijanta, kao
i procjenu patologije. Boja i sustavi doplerske angiografije
omoguæavaju dodatne informacije o ekstrakranijskoj
modanoj hemodinamici, to Łini procjenu preciznijom i
pouzdanijom.
Upotrebom sive skale iskljuŁene boje prvo se prikazuje
lumen i stijenka ile.  Visokorezolutan ultrazvuk omoguæava
procjenu stijenke ile, mjerenje IMT buduæi da se njezi-
no zadebljanje pokazalo ranim pokazateljem ateroskleroze.
U ranim studijama mjerenje IMT je bilo ruŁno, s velikom
varijabilnoæu unutar i izmeðu ispitivaŁa. Danas se upotre-
bljavaju automatski kompjutorizirani sustavi, to pojed-
nostavljuje Łitanje, poboljava toŁnost i smanjuje varijabil-
nost mjerenja IMT. Postoje brojni protokoli za procjenu
IMT. Iz podataka epidemiolokih studija zamijeæena je
varijabilnost u IMT zajedniŁke karotidne arterije (ACC)
(u 65-godinjeg mukarca oko 0,8-0,73 mm). Mukarci
imaju deblje IMT u usporedbi sa enama, a debljina raste
za 0,01 mm na godinu. Izgleda da svi poznati Łimbenici
NEUROSONOLOGIC METHODS IN STROKE DIAGNOSIS
NEUROSONOLOKE METODE U DIJAGNOSTICI MODANOG UDARA
Arijana LovrenŁiæ-Huzjan
University Department of Neurology, Sestre milosrdnice University Hospital, Reference Center for Neurovascular Disorders of
the Croatian Ministry of Health,
Klinika za neurologiju, KliniŁka bolnica Sestre milosrdnice, Zagreb
Neurosonology includes both extracranial and intrac-
ranial noninvasive cerebrovascular evaluation in stroke
patients and high-risk individuals. Due to its noninvasive-
ness it can be repeated as often as needed, allowing mon-
itoring of the real time cerebral hemodynamics. High-res-
olution ultrasound provides high-class information on the
carotid, vertebral and subclavian artery morphology, giving
an insight into the intima-media thickeness (IMT), plaque
morphology, echogenicity, plaque surfaces and degree of
stenosis. The fine analysis provides information on athero-
sclerotic or inflammatory vessel wall diseases and on dis-
section. Duplex ultrasound imaging combines high-reso-
lution gray scale imaging and pulsed Doppler spectral anal-
ysis to yield excellent anatomic and physiologic data. The
standard diagnostic tool used to examine the extracranial
cerebrovascular system is color-coded duplex ultrasound
imaging. The superposition of color-flow imaging aids the
examiner and interpreter the information of the vessel
orientation, anatomic variants, hemodynamic evaluation
and various physiologic variants as well as pathologies. The
color and power Doppler imaging provides additional in-
formation on extracranial brain hemodynamics, making the
evaluation more precise and reliable.
Complete appreciation of vessel wall is performed first,
using gray-scale imaging with the color turned off. High-
resolution ultrasound enables vessel wall evaluation and
IMT measurement since the thickening of the IMT is an
early marker of atherosclerosis. In earlier studies IMT
measurements were performed manually, with the high
inter- and intraobserver variability. Nowadays automated
computerized systems are available, simplifying reading
and improving both accuracy and variability of IMT mea-
surements. There are numerous protocols for evaluation
of IMT. Epidemiological studies obtained from different
investigations have shown variability in CCA IMT (in 65-
year-old males about 0.8-0.73 mm). The results mostly
show that males have greater IMT compared to females,
and the rate of progression is 0.01 mm per year. It seems
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rizika ateroskleroze utjeŁu na IMT, kao npr. hipertenzija,
te osobito porast sistoliŁnog krvnog tlaka, poviena razina
kolesterola i LDL kolesterola, puenje, eæerna bolest, neki
hematoloki parametri kao razina fibrinogena, fibrinopep-
tida A, D-dimera, tkivni aktivator plazminogena i inhibi-
tor aktivatora plazminogena, razina bakra u serumu i razi-
na homocisteina. Nije naðena povezanost s razinom triglic-
erida niti s razinom HbA1C u bolesnika sa eæernom bo-
leæu, kao ni s uporabom alkohola. U bolesnika s koronar-
nom srŁanom boleæu naðen je porast IMT koji je bio po-
vezan s porastom rizika za srŁani udar, modani i ishemij-
ski modani udar. Studije u bolesnika s hiperlipidemijom
pokazale su smanjenje IMT tijekom terapije statinima
(PLACII, REGRESS). U hipertenzivnih bolesnika studi-
ja ELSA je pokazala smanjenje rasta IMT usporedno sa
smanjenjem rizika za modani ili srŁani udar.
Usporedno s analizom stijenke ile rutinski se traga za
plakovima. U analizi plaka procjenjuje se morfologija,
duina, ehogenosti, znaŁajke povrine plaka i stupanj ste-
noze. Ovisno o ehogenosti, plakovi se opisuju kao homogeni
ili heterogeni. Homogeni plakovi se jednoliko prikazuju, a
mogu ali ne moraju imati akustiŁnu sjenu. Heterogeni pla-
kovi imaju mjeavinu niske, srednje i visoke razine odjeka.
Niske razine odjeka su posljedica masti, kolesterola,
staniŁnog debrisa, nekrotiŁnog materijala ili krvarenja unu-
tar plaka uslijed pucanja malih, vulnerabilnih ila. Nemo-
guæa je razlika izmeðu tih tvari, ali bez obzira na to one sve
predstavljaju nestabilnost plaka s visokim rizikom za em-
bolizaciju ili rast plaka. Vie razine odjeka obiŁno predstav-
ljaju fibrozni materijal, dok su visoke razine odjeka poslje-
dica kalcifikacija. Kalcifikacije se prepoznaju potpunom
refleksijom ultrazvuŁne zrake, te na taj naŁin tvore akustiŁ-
ne sjene koje onemoguæuju analizu tkivnih slojeva ispod
plaka. Takvi su plakovi manje opasni, imaju nizak poten-
cijal za embolizaciju ili rast plaka. Na Drugom internacio-
nalnom koncenzusnom sastanku definirani su kriteriji za
karakterizaciju plakova. Prema sastavu plaka oni se klasi-
ficiraju u pet skupina: 1. uniformno anehogeni plakovi s
visokim rizikom za nastanak modanog udara, 2. preteito
hipoehogeni plakovi u kojima hipoehogeni dijelovi zauzi-
maju vie od 50% strukture, 3. preteito hiperehogeni pla-
kovi u kojima se hipoehogeni dijelovi nalaze u manje od
50% strukture plaka, 4. kalcificirani plakovi, a plakovi tipa
2. ,3., 4. imaju nii rizik za nastanak modanog udara i 5.
kalcificirani plakovi koji tvore akustiŁne sjene koje onemo-
guæuju pregled krvne ile i kod kojih se tek treba ustano-
viti rizik za nastanak modanog udara.
Povrina plaka se opisuje kao ravna, nepravilna (katkad
je vidljiv prekid endotela ili ulkusi od 0,4-2 mm) ili ulcerira-
that all known atherosclerosis risk factors influence IMT,
e.g., hypertension, especially the increase in systolic blood
pressure, elevated cholesterol and LDL cholesterol, ciga-
rette smoking, diabetes mellitus, some hematologic param-
eters like fibrinogen levels, fibrinopeptide A, D-dimer, tis-
sue plasminogen activator and plasminogen activator in-
hibitor, serum copper, and homocysteine level. No corre-
lation was found with the triglyceride levels and HbA1C
levels in patients with diabetes mellitus, or with alcohol
consumption. An increased IMT was found in patients
with coronary heart disease, and individuals with increased
IMT were found to be at a greater risk of myocardial inf-
arction, stroke and ischemic stroke. Studies in patients
with hiperlipidemia have shown a reduction in IMT with
lipid lowering therapy (PLACII, REGRESS). In hyperten-
sive patients ELSA study has shown a reduction of IMT
progression in parallel with the risk of stroke and myocar-
dial infarction reduction.
In parallel with vessel wall analysis, the search for
plaque is performed. In plaque analysis the morphology,
length and echogenicity are evaluated, along with the
plaque surface characteristics and the degree of vessel
stenosis. Plaques are characterized as being homogeneous
or heterogeneous depending on their echogenicity. Homo-
geneous plaques have a uniform appearance with or with-
out acoustic shadowing. Heterogeneous plaques have a
mixture of low, mid and high-level echoes. Low level ech-
oes are the results of lipid, cholesterol, cell debris, necrot-
ic material or interplaque hemorrhage due to rupture of
small, vulnerable vessels. The differentiation between
these substances is impossible, nevertheless, all of these
substances represent unstability of the plaque, with a high
risk of embolization or growth. A higher level of echoes
usually represents fibrinous material, and high levels of
echoes are the result of calcifications. Calcifications can be
recognized by total reflection of the ultrasound beam,
performing acoustic shadow which makes the analysis of
tissue layers under the plaque impossible. These plaques
are less harmful and have a lower potential of emboliza-
tion or smaller growing potential. At the second interna-
tional consensus meeting, criteria were determined for
characterization of carotid plaques. Plaque composition is
thus characterized in five steps as follows: 1) uniformly
anechogenic plaques with a high risk of stroke; 2) predom-
inantly hypoechoic plaques with hypoechoic areas of more
than 50% of plaque structure; 3) predominantly hypere-
choic plaques with hypoechoic areas of less than 50% of
plaque structure; 4)  calcified plaques with the types 2,
3,and 4 of lower stroke risk; and 5) calcified plaques with
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na (s ulkusima veæim od 2 mm). Ulkusi plaka se prikazuju
kao nie ili formacije kratera na B-mod slici. PopreŁni prikaz
æe omoguæiti razlikovanje ulkusa plaka od nakupine vie
plakova koji se tada mogu prikazivati kao neravna povri-
na u longitudinalnom prikazu.
U izvjetaju se opisuje duina i poloaj plaka. Buduæi
da u veæine bolesnika neæe biti uŁinjena angiografija, vasku-
larnim kirurzima æe takve dodatne informacije biti od po-
moæi. Duina plaka je vana u procjeni odluke za operaci-
ju, buduæi da je duina insonacije ujedno i duina do koje
je dostupan operacijski zahvat. Bolesnici s plakovima koji
se proteu u C2 ili intrakranijski segment nisu kandidati
za kirurku intervenciju. U analizi hemodinamike duina
plaka, poloaj i sadraj utjeŁu na izmjerenu brzinu u
stenoziranom podruŁju.
Tro- i Łetverodimenzionalni ultrazvuk moe pruiti
dodatne informaciji u procjeni stabilnosti plaka.
Uspjenost karotidne endarterektomije u sekundarnoj
prevenciji modanog udara je dokazana u velikim studija-
ma (ECST, NASCET). One su bile zasnovane na nalazu
angiografije, iako su upotrebljavale razliŁite metode mje-
renja stenoze. Buduæi da neinvazivan prikaz treba zamije-
niti angiografiju, potrebno je toŁno definirati kriterije mje-
renja karotidne stenoze u usporedbi s angiografijom. Pret-
hodne su studije usporeðivale osjetljivost i specifiŁnost
razliŁitih kriterija u procjeni razine karotidne stenoze. Dok
su neka istraivanja pokazala maksimalnu sistoliŁnu brzinu
u unutarnoj karotidnoj arteriji (ACI) kao najbolji pojedi-
naŁni parametar brzine za odreðivanje stenoze veæe od
70%, u drugim istraivanjima je to bio odnos maksimalnih
sistoliŁnih brzina u unutarnjoj i zajedniŁkoj karotidnoj ar-
teriji. Neka istraivanja su pokazala i da je bojom kodirana
doplerska sonografija osjetljivija metoda za otkrivanje pseu-
dookluzije, Łak bolja od angiografije. Primjena ultrazvuŁnih
dijagnostiŁkih kriterija maksimalnih sistoliŁnih brzina u dva
ultrazvuŁna laboratorija sliŁne opreme je pokazala razliŁi-
tu osjetljivost i specifiŁnost u procjeni karotidne stenoze.
Postignuta je veæa osjetljivost ultrazvuŁnog pretraivanja
kada su bili upotrebljeni specifiŁni dijagnostiŁki kriteriji za
svaki pojedini laboratorij. Objavili smo kombinaciju raz-
liŁitih kriterija naeg laboratorija kako bismo procijenili
karotidnu stenozu. Stupnjevanje je bilo uŁinjeno u kliniŁke
svrhe, buduæi da se blae stenoze ne trebaju Łesto kontro-
lirati, Łeæe se kontroliraju umjerene stenoze, dok su znaŁa-
jne stenoze kandidati za kirurku intervenciju. Bolesnici s
karotidnom okluzijom se prate. Takvi su rezultati pokaza-
li visoku korelaciju izmeðu angiografije i ultrasonografije
u procjeni razliŁitih stupnjeva karotidne stenoze. Ultra-
zvuk je bio osjetljiviji u procjeni znaŁajne karotidne stenoze
acoustic shadow making the vessel lumen evaluation im-
possible, in which the risk of stroke is still under investi-
gation.
Plaque surface can be characterized as regular, irregu-
lar (sometimes disruption of the endothelium is visible,
or ulcers of 0.4-2 mm), or ulcerated (with the ulcer depth
of >2 mm). Plaque ulcers appear as niche or crater forma-
tions on a B-mode image. The imaging in transverse plane
is of great help, allowing for differentiation between plaque
ulcer and accumulation of more plaques that may appear
as irregular surface.
Plaque length and position should be described. Since
angiographies are often omitted, surgeon benefits greatly
from these additional ultrasound details. The length is also
important for the decision on the operation since the
length of insonation is the length of the possibility for
surgical intervention. Patients with plaques extending to
the C2 or intracranial segment are not candidates for sur-
gical intervention. In hemodynamic analysis the plaque
length, position and composition influences velocity mea-
surement.
The possibility of assessment of the plaque stability
may be offered by three- and four-dimensional ultrasound.
The benefit of carotid endarterectomy in stroke pre-
vention in advanced carotid stenosis was proved in large
studies (ECST and NASCET). They were based on an-
giographic findings, although using different methods of
stenosis measurement. If noninvasive imaging is to replace
angiography, the exact relationship between the degree of
stenosis measured by ultrasonographic technique and that
measured by angiography must be accurately defined. The
previously reported studies evaluated sensitivity and spec-
ificity of different criteria used for assessment of the de-
gree of carotid stenosis. While in some investigations the
peak systolic velocity (PSV) in ICA was found to be the
best single velocity parameter for quantifying a >70%
stenosis, in others it was the PSV ratio in ICA and CCA.
The more so, color Doppler flow imaging enabled visual-
ization of pseudo-occlusion, thus being superior to angiog-
raphy. The application of the same ultrasonographic diag-
nostic criterion of PSV at two ultrasonographic laborato-
ries using similar equipment showed different sensitivity
and specificity in grading of carotid stenosis. A higher sen-
sitivity of ultrasound screening was achieved by use of
diagnostic criteria specific to each laboratory. The combi-
nation of different criteria used at our laboratory to esti-
mate the degree of carotid stenosis has been published.
Grading was made for clinical purposes, since mild steno-
sis does not require frequent controls, moderate stenosis
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(gotovo okluzija, pseudookluzija), to je veæ bilo zamijeæeno
u drugim studijama. Takva se kombinacija ultrazvuŁnih
parametara pokazala osjetljivom u otkrivanju razliŁitih
stupnjeva karotidne stenoze, uz vrlo visoku specifiŁnost,
to je dovelo do visoke pozitivne prediktivne vrijednosti
za takvu klasifikaciju.
Iako je Łetvrtina ishemijskih modanih udara smjete-
na u vertebrobazilarnom teritoriju, istraivanja vertebralnih
arterija nisu postala u toj mjeri popularna. Razlog je teh-
niŁki problem zbog anatomskog poloaja ila, niske razine
vertebralih endarterektomija i niske razine vertebralnih
stenoza kao uzroka vertebrobazilanog modanog udara.
Vertebralna okluzija se moe kliniŁki prikazati kao prolaz-
ni ishemijski napadaj (TIA) ili blagi modani udar. Oboje-
ni dopler vertebralnih arterija moe pokazati fizioloke
varijacije vertebralnih arterija kao asimetrije dijametra,
hipoplaziju ili varijacije poloaja u ekstrakranijskom dije-
lu. Doplerski parametri mogu ukazivati na varijacije intrak-
ranijskog dijela. Superpozicija bojom kodiranog protoka (u
boji ili doplerskoj angiografiji) omoguæava bolji prikaz pa-
tolokih promjena vertebralnih arterija kao stenoze, oklu-
zije ili disekcije.
Vaskulitis ivŁanog sustava ukljuŁuje skupinu pore-
meæaja koji su obiljeeni histolokim znaŁajkama upale
krvnih ila. Na osnovi kliniŁke prezentacije postavlja se
sumnja na dijagnozu, a potvrðuje se znacima upale koji se
otkivaju laboratorijskom analizom ili biopsijom. Dopler-
ska sonografija moe pomoæi u neinvazivnoj vizualizaciji
bolesti ako je lokalizacija bolesti prisutna u segmentu koji
je dostupan ultrazvuŁnoj pretrazi, kao u arteritisu orijakih
stanica koji najŁeæe zahvaæa grane luka aorte, u kranijskom
arteritisu i Takayasuovu arteritisu. Takayasuov arteritis
zahvaæa grane luka aorte, trunkus brahiocefalikus, uæe
zajedniŁke karotidne arterije, potkljuŁne ili bubrene ar-
terije (to dovodi do hipertenzije). U skladu s lokalizaci-
jom oŁekuje se dobar prikaz lezije obojenim doplerom.
Katkada se ne moe izravno vidjeti znaŁajna stenoza bra-
hiocefaliŁnog trunkusa, ali se biljei promijenjeni, atenui-
rani hemodinamski spektar u karotidnoj i potkljuŁnoj ar-
teriji. Zadebljanje stijenke zajedniŁke karotidne arterije se
lagano vidi. ZnaŁajna stenoza ili okluzija potkljuŁne arte-
rije se katkada dobro prikazuje, a dodatne informacije se
dodatno postiu prikazom vertebralnih arterija. ZnaŁajna
okluzivna bolest potkljuŁne arterije ispod polazita verte-
bralne arterije dovodi do kompenzacijskih promjena hemo-
dinamike vertebralne arterije, pojave koja se naziva djelo-
miŁan ili potpun sindrom kraðe krvi potkljuŁne arterije.
Perfuzija ruke je potpomognuta iz suprotne potkljuŁne
arterije preko kontralateralne u ipsilateralnu vertebralnu
has to be controlled more frequent, and advanced stenos-
is patients are candidates for surgical intervention. The
carotid occlusion patients are monitored. These results
showed a high correlation between angiography and ultra-
sonography in detecting various degrees of carotid steno-
sis. Ultrasound was more sensitive in detecting the cate-
gory of severe stenosis (near occlusion, pseudo-occlusion),
as also demonstrated in other studies. Such a combination
of various ultrsonographic parameters proved to be sensi-
tive for the detection of various degrees of carotid steno-
sis, with a very high specificity and yielding high positive
predictive values for such classification.
Although one fourth of ischemic strokes are related to
the vertebrobasilar territory, the investigations of vertebral
arteries have not become so popular. The reason is the
technical problem due to the anatomic position of the
vessels, a low rate of vertebral endarterectomies, and a low
rate of vertebral stenosis as a cause of vertebrobasilar stroke.
Vertebral occlusions may clinically present as a TIA, or a
mild stroke. Vertebral color Doppler imaging may show
physiologic variations in vertebral arteries such as asymme-
try in diameter, hypoplasia or variation in the positioning
in the extracranial part. Doppler parameters may indicate
variation of the intracranial part. Superposition of color
coded flow (in color and in power mode) enabled better
visualization of vertebral artery pathology such as stenos-
is, occlusion or dissection.
Vasculitis of the nervous system includes a group of
disorders characterized by the histologic feature of inflam-
mation of blood vessels. The diagnosis is suspected on
clinical presentation, and confirmed by signs of inflamma-
tion obtained by laboratory analysis or biopsy. Doppler
sonography may help in noninvasive visualization of the
disease, if the disease is localized in a segment that is ac-
cessible to the ultrasound investigation, as in giant cell
arteritis that affects mostly branches of the aortic arch, in
cranial arteritis or Takayasus arteritis. Takayasus arteritis
is affecting the branches of the aorta, brachiocephalic
trunk, ostium of the common carotid artery or subclavian
artery, or renal artery (which results in hypertension). Ac-
cording to localization, good visualization of the lesions by
color Doppler is expected. Advanced stenosis of the bra-
chiocephalic trunk cannot be always directly visualized, but
attenuated, changed spectra in both the carotid and sub-
clavian arteries can be recorded. Mural thickening of the
common carotid arteries can be easily seen. Advanced
stenosis or occlusion of the subclavian arteries can be some-
times directly seen, and more information can be addition-
ally obtained by visualization of vertebral arteries. Ad-
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arteriju. Stoga se hemodinamika djelomice ili potpuno
okreæe u ipsilateralnoj vertebralnoj arteriji, dok je u kon-
tralateralnoj ubrzana.
Vaskulitis koji zahvaæa manje arterije moe utjecati na
intrakranijsku hemodinamiku koja moe biti promijenjene
vazoreaktivnosti kao biljeg zahvaæanja manjih ila.
Bolest moyamoya je kliniŁki entitet nepoznate etiologije
koji se javlja Łeæe u djece u Japanu, rjeðe u bijelaca, a
obiljeena je angiografskim nalazom bilateralnih okluzija
terminalnih dijelova unutarnje karotidne arterije uz razvoj
kolateralne vaskularne mree baze mozga. Kao sindrom u
drugim bolestima dovodi do sporo progresivne stenoze
bazalnih modanih arterija. U ekstrakranijskim karotidnim
arterijama se biljee neizravni znaci intrakranijske ok-
luzivne bolesti.
Fibromuskularna displazija je neateromska arterijska
bolest nepoznate etiologije koja je obiljeena segmentnim
suavanjima arterija srednje veliŁine u razliŁitim dijelovi-
ma tijela. Proliferacija razliŁitih arterijskih slojeva dovodi
do suavanja, disekcije i stvaranja aneurizme. Moe nas-
tati potpuna okluzija unutarnje karotidne ili vertebralnih
arterija, to dovodi do nastanka modanog udara. Bojom
kodirana doplerska sonografija pokazuje isti nalaz kao an-
giografija, vidljiva je formacija poput ice ili niske bisera,
unifokalne ili multifokalne tubularne stenoze ili proire-
nja poput divertikula ili aneurizme. Asimptomatski steno-
tiŁki proces obiŁno je lokaliziran u segmentu C2, a ako je
bolest lokalizirana u bifurkaciji Łeæe dovodi do pojave
ishemijske simptomatologije. Takve krvne ile su podlone
disekciji, iako se disekcija moe javiti tijekom traume s ili
bez poznatih Łimbenika rizika.
Disekcija moe razliŁito izgledati na slikama obojenog
doplera. Kada se protee iz luka aorte moe se vidjeti dvo-
struki lumen. Stenoze u podruŁju bifurkacije mogu diseci-
rati i tvoriti bojom kodirani protok u bazi plaka. U mlaðih
osoba disekcija obiŁno zahvaæa distalne dijelove unutarn-
jih karotidnih ili vertebralnih arterija. Tada se mogu vidje-
ti suavanja lumena ila hipoehogenom masom u distal-
nom dijelu, a ako se proteu intrakranijski i dovode do pot-
pune okluzije, tada su prisutni neizravni znaci distalne
okluzije. Takvi znakovi ukljuŁuju izrazitu atenuaciju pro-
toka, odgoðene sistoliŁne akceleracije protoka, visoku re-
zistenciju u hemodinamskom spektru i katkad obrnutu
hemodinamiku tijekom dijastole.
Godine 1982. uveden je u kliniŁku uporabu transk-
ranijski dopler (TCD) i pokazao se je neinvazivnom, br-
zom i toŁnom dijagnostiŁkom metodom u procjeni mo-
dane hemodinamike. Glavna je prednost TCD moguænost
vremenske rezolucije mjerenja. Takva tehnika omoguæava
praæenje i razumijevanje promjena modane cirkulacije u
vanced occlusive disease of subclavian artery before the
origin of vertebral artery lead to compensatory changed
hemodynamics in vertebral artery, the phenomenon being
known as partial or complete subclavian steal syndrome.
Arm perfusion is supported from the other subclavian ar-
tery via contralateral and then ipsilateral vertebral artery.
Therefore, the hemodynamics is partially or completely
inversed in ipsilateral vertebral artery and accelerated in
the contralateral one.
Vasculitis affecting smaller arteries may alter intracra-
nial hemodynamics, which can be measured as impaired
vasoreactivity as a marker of smaller vessel involvement.
Moyamoya disease is a clinical entity of unknown eti-
ology, occurring mainly in Japanese children, rarely in Cau-
casians, and characterized by angiographic findings of bi-
lateral occlusion at the terminal portions of the internal
carotid artery together with a vascular network at the base
of the brain. As a syndrome in other disease it leads to slow-
ly progressive basal cerebral artery stenosis. In extracrani-
al carotid arteries indirect signs of intracranial occlusive
disease can be detected.
Fibromuscular dysplasia is a nonatheromatous arterial
disease of unknown etiology characterized by segmental
narrowing of intermediate-sized arteries in many areas of
the body. Proliferations of different artery layers are lead-
ing to narrowing, dissections and aneurysm formation.
Complete occlusion of the internal carotid or vertebral
artery may develop, leading to stroke. Color-coded Dop-
pler sonography reveals the same findings as angiography,
as a string-pearl formation, unifocal or multifocal tubular
stenosis, diverticulum-like or aneurysmal dilatation. As-
ymptomatic stenotic process is usually localized in C2
portion, while the symptomatic is usually found at bifur-
cation, leading to ischemic symptoms. Such vessels are
candidates for dissection, although dissection may appear
in trauma, or without known risk factors.
Dissections may appear as different findings in color-
coded Doppler mode. When extending from the aortic
arch, double lumina can be seen. Bifurcation stenosis may
dissect leading to the formation of color-coded flow in the
plaque base. In younger persons dissections are usually
affecting distal parts of the internal carotid arteries or ver-
tebral arteries. Hypoechoic stenosis of the vessels in dis-
tal parts can be seen, or when located intracranially and
leading to complete occlusion, then indirect signs of dis-
tal occlusions are present. Such signs include dampened
flow with a high resistance pattern, and possible inversed
hemodynamics during diastole.
Transcranial Doppler (TCD) was introduced in clini-
cal use in 1982, and proved to be a noninvasive, fast and
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normalnim i patolokim uvjetima. Relativne promjene
modane hemodinamike mogu se objektivno mjeriti koli-
ko je god dugo potrebno. Ova kvaliteta Łini TCD neza-
mjenjivom metodom u kliniŁkom praæenju bolesnika i pri-
mamljivom tehnikom u znanstvenim istraivanjima. Prva
je primjena bila otkrivanje i praæenje modanog vazospaz-
ma, a prvi ju je primijenio Rune Aaslid i otada se nairoko
primjenjuje u razliŁitim kliniŁkim uvjetima. Glavna primje-
na TCD je u otkrivanju i praæenju bolesnika s akutnom
vaskularnom patologijom kao okluzivnom bolesti intra-
kranijskih krvnih ila, praæenju i pospjeivanju rekanaliza-
cije upotrebom tkivnog aktivatora plazminogena, procje-
na intrakranijskog kolateralnog kapaciteta i redistribucije
hemodinamike u ekstra- ili intrakranijskoj okluzivnoj boles-
ti, hemodinamska procjena tandemskih lezija, potraga za
vaskularnim malformacijama i evaluacija ila hraniteljica,
praæenje vazospazma, modanog edema i modane smrti,
intraoperacijsko praæenje itd. Novije moguænosti TCD
omoguæavaju procjenu modane vazoreaktivnosti, stres
testovi mozga i modana autoregulacija analizom cerebral-
nog mikrocirkulacijskog odgovora na podraaje kao reak-
tivnost na ugljiŁni dioksid, acetazolamid ili funkcijske te-
stove kognitivnom stimulacijom. Primjena novih programa
omoguæava otkrivanje cerebralnih mikroembolijskih signa-
la. Sustavi koji imaju ujedinjeni dupleks prikaz i pulsni
dopler omoguæavaju prikaz modanog parenhima uza su-
perpoziciju bojom kodiranog protoka. Na taj je naŁin procje-
na modane hemodinamike pouzdanija nego ranije. Ipak
TCD zahtijeva spretnost i iskustvo izvoðaŁa i dobru men-
talnu orijentaciju o modanom krvoilju.
Brojni fizioloki uvjeti mogu utjecati na nalaz TCD, kao
Łeste anatomske varijacije Willisova kruga i vertebrobazilar-
nog sustava. Stoga, ako nedostaje neki signal (osobito A1
ili P1), asimetrija se ne tumaŁi kao abnormalna. Brzine
strujanja krvi se smanjuju s dobi, hipertenzija povisuje sred-
nje brzine strujanja uz porast pulsatilnosti protoka. Hip-
erkapnija povisuje srednje brzine protoka i smanjuje pul-
satilnost, dok hiperventilacija snizuje srednje brzine pro-
toka i povisuje pulsatilnost. RazliŁiti Łimbenici utjeŁu na
izgled signature vala, a ukljuŁuju ekstra- ili intrakranijsku
stenozu ili okluziju, promijenjene cirkulacijske uvjete niz-
vodno kao porast intrakranijskog tlaka ili proirene ili
spastiŁne rezistentne ile. Promjene krvnih parametara
utjeŁu na brzine te tako anemija povisuje brzine strujanja
krvi, dok porast viskoznosti u policitemiji ili povienim
razinama fibrinogena snizuje brzine strujanja krvi.
Uz procjenu intrakranijskih fiziolokih uvjeta mogu se
ustanoviti i locirati patoloki uvjeti kao stenoza ili okluzi-
ja. TCD moe predvidjeti ishod modanog udara ovisno o
exact diagnostic tool for the evaluation of cerebral hemo-
dynamics. One of the advantages of TCD is the possibil-
ity of time resolution of the measurements. This technique
allows for monitoring and thus understanding changes in
the cerebral circulation under normal and pathologic con-
ditions. Relative changes in cerebral hemodynamics can be
measured objectively, and as long and often as necessary.
This quality makes TCD irreplaceable in the clinical fol-
low-up of patients and an attractive tool for dealing with
scientific issues. The first application was detection and
monitoring of cerebral vasospasam, invented by Rune
Aaslid, and ever since it has been extensively employed in
a variety of clinical settings. The major advantage of TCD
application is the revealing and screening patients with
acute vascular pathology such as intracranial blood vessel
occlusive disease, to monitor and enhance rt-TPA throm-
bolysis recanalization, evaluation of intracranial collateral
capacity and redistribution of hemodynamics in extra- or
intracranial occlusive disease, hemodynamic evaluation of
tandem lesions, screening for vascular malformations, and
evaluation of feeding arteries, monitoring of vasospasm,
brain edema and brain death, intraoprative monitoring, etc.
Recent TCD modalities enable estimation of cerebral
vasoreactivity, brain stress test and cerebral autoregula-
tion by analyzing cerebral microcirculatory responses after
stimulation test such as CO2 reactivity, acetazolamide or
functional tests by cognitive tasks. Introduction of new
software has enabled detection of cerebral microembolic
signals. The union of duplex scan image and pulsed Dop-
pler has enabled imaging of the brain parenchyma with
superposition of color-coded Doppler flow. By this appli-
cation the brain hemodynamic evaluation has become
more reliable than before. Yet, TCD requires operators
skill, experience and good mental imaging of the brain
vessels.
Various physiologic conditions may influence TCD
findings, e.g., common anatomic variations of the circle of
Willis and vertebrobasilar system. Therefore the missing
signal (especially A1 or P1), asymmetry should not be in-
terpreted as abnormal. The blood flow velocities decrease
with age, hypertension increases mean flow velocities with
increased flow pulsatility. Hypercapnia increases mean flow
velocities and decreases flow pulsatility, whereas hyperven-
tilation decreases mean flow velocities and increases pul-
satility. Various factors including extra- or intracranial steno-
sis or occlusions, or changed downstream circulatory con-
ditions like increased intracranial pressure, or dilated or
spastic resistance vessels determine the waveform pat-
terns. Changes of blood parameters alter blood flow veloci-
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lokalizaciji intrakranijske okluzije ile. Moe se pratiti re-
kanalizacija okludirane ili stenozirane ile. DijagnostiŁki
ultrazvuk u kombinaciji s tkivnim aktivatorom plazmino-
gena (tPA) pospjeuje tPA-om izazvanu rekanalizaciju i
poboljava ishod u bolesnika.
U hemoragiŁnom modanom udaru TCD prua infor-
macije o intrakranijskoj patologiji, kao o prisutnosti vasku-
larnih malformacija ili razvoju vazospazma. Buduæi da je
prijenosan i neinvazivan, moe se vie puta ponavljati, to
omoguæava praæenje tijeka vazospazma ili porasta intra-
kranijskog tlaka. Moguæe je pratiti razvoj cerebralnog cir-
kulacijskog aresta u dijagnostici modane smrti.
Transkranijska bojom kodirana doplerska (TCCD)
sonografija prua pouzdanije informacije u procjeni intra-
kranijske normalne i patoloke hemodinamike. Bojom ko-
dirani protok se superponira na sivu skalu prikaza moda-
nog parenhima, gdje se rabe dijelovi mozga kao orijen-
tacijske toŁke. UkljuŁivanjem boje prikazuje se bojom kodi-
rani protok u ilama Willisova kruga. Kada se osjetljiv uzorak
postavi na definirani bojom kodirani signal, prikazuje se
hemodinamika u eljenom segmentu. ToŁnost analize
prikazane intrakranijske hemodinamike je veæa. Postavlja-
njem sonde subokcipitalno, ispod velikog otvora, prikazuje
se vertebrobazilarni sustav. Zbog vijugavosti ila rijetko se
primjereno prikae polazite i tijek bazilarne arterije.
Upotrebom TCCD mogu se prikazati vaskularne mal-
formacije i procijeniti ile hraniteljice. Aneurizme se prika-
zuju kao dodatna struktura boje uz arteriju, uz znakovito
bojenje kolorom kodiranog protoka. U subarahnoidnom
krvarenju ile su uske zbog vazospazma. Vazospazam je
prolazna kontrakcija modanih krvnih ila koja nastaje u
razliŁitim bolestima koje zahvaæaju sredinji ivŁani sustav,
uzrokuje modanu ishemiju i moe dovesti do prolazne ili
trajne neuroloke disfunkcije. NajŁeæe nastaje nakon
spontanog subarahnoidnog krvarenja, Łesto nakon rupture
intrakranijske aneurizme, ali moe nastati i nakon modane
traume, u sklopu meningitisa ili eklampsije. Vazospazam
je primarni uzrok odgoðenih ishemijskih neurolokih de-
ficita i smrtnosti. Stoga je vano imati moguænost njegova
neinvazivnog otkrivanja i praæenja kako bi se moglo primi-
jeniti uŁinkovito lijeŁenje. TCD je pouzdana metoda u
dijagnostici modanog vazospazma mjerenjem porasta brzi-
na strujanja krvi u bazalnih modanim arterijama. Odnos
ACM/ACI se moe izraŁunati kako bi se iskljuŁila hiper-
perfuzija.
Doplerski spektar sadri informacije koje se odnose na
intenzitet ili koliŁinu zvuka koja se reflektira prema son-
di. To je odnos broja crvenih krvnih stanica i oznaŁava
koliŁinu krvi unutar osjetljivog uzroka. Intenzitet reflek-
ties, anemia increases blood flow velocities, whereas in-
creased viscosity in polycythemia or increased fibrinogen
levels lowers blood flow velocities.
Besides evaluation of intracranial physiologic condi-
tions, pathologic conditions like stenosis or occlusion can
be seen and located. TCD may predict stroke outcome
depending on the localization of the intracranial vessel
occlusion. Recanalization of the occluded or stenosed ves-
sel can be monitored. Diagnostic ultrasound in combina-
tion with the tissue plasminogen activator (tPA) enhanc-
es tPA-induced recanalization thus improving outcome.
In hemorrhagic stroke TCD provides information on
intracranial pathology like vascular malformations or devel-
opment of vasospasm. Due to transportability and nonin-
vasiveness it can be repeated many times, thus enabling
monitoring of the time course of vasospasm or intracranial
pressure increase. The development of cerebral circulatory
arrest can be monitored as part of brain death protocol.
Likewise the evaluation of normal hemodynamics,
transcranial color-coded Doppler (TCCD) sonography
provides more reliable information in the assessment of
intracranial pathology. The color-coded flow is superim-
posed on gray scale image of the brain parenchyma using
several brain markers for orientation. Switching the color
on, the color-coded flow images through the vessels of the
circle of Willis are displayed. Placing the sample volume
on a defined color-coded signal, the hemodynamics of the
desired segment is displayed. The accuracy of the intrac-
ranial hemodynamic analysis is more reliable. By placing
the transducer suboccipitally, under the foramen magnus,
the vertebrobasilar system is displayed. Due to the tortu-
osity of the vessels, an adequate image of the basilar artery
origin and course is rarely obtained.
Vascular malformation can be visualized by means of
TCCD, and brain-feeding arteries can be assessed. Aneu-
rysms can be displayed as an additional color-coded struc-
ture adjacent to the artery, with a characteristic color-cod-
ed flow pattern. In subarachnoid hemorrhage the vessels
will be thinny due to vasospasm. Vasospasm of the cere-
bral vessels refers to a transient contraction of the intrac-
ranial arteries, which can occur in a variety of disorders
affecting the central nervous system and can produce tran-
sient or permanent neurologic dysfunction by inducing
cerebral ischemia. The most common clinical setting is
following spontaneous subarachnoid hemorrhage, fre-
quently secondary to rupture of intracranial aneurysms, but
may also follow brain trauma, meningitis and preeclamp-
sia. Vasospasm is the primary cause of delayed ischemic
neurologic deficit and mortality. Therefore it is important
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tiranog zvuka na odreðenoj frekvenciji ovisi o broju crvenih
krvnih stanica koje se kreæu odreðenom brzinom. Signal
snage svake komponente brzine se moe kodirati u boji ili
intenzitetom sive skale na zaslonu raŁunala, upotrebom
tehnike spektralne analize. Embolus koji prolazi kroz os-
jetljiv uzorak poveæava koliŁinu ultrazvuka koji se reflek-
tira prema sondi, tako da hiperintenzivno prolazno po-
veæanje signala (high intensity transient signal, HITS) dople-
rovog spektra odgovara mikroembolijskom signalu (MES)
kada Łestica embolijskog materijala prolazi kroz modanu
cirkulaciju. Veæa je vjerojatnost otkrivanja MES kada se
ponavljano, u vie dana, testira pojedinac kod kojeg se
oŁekuje njegova pojava ili kod produenog snimanja. Pri-
mjenom sadanje tehnologije  zasad nije moguæe toŁno i
pouzdano odrediti veliŁinu embolusa i njegov sastav. Neko-
liko Łimbenika, ukljuŁujuæi znaŁajke opreme, utjeŁu na
moguænost otkrivanja embolija. VeliŁina embolusa i eho-
genost odreðuju intenzitet signala. ¨ eæe se otkrivaju MES
u bolesnika sa simptomatskom nego u bolesnika s asim-
ptomatskom karotidnom stenozom. Veæinom su MES
asimptomatski, ali se ipak vjeruje da predstavljaju biljeg
rizika za nastanak ishemijskih dogaðaja. SliŁni su podaci za
bolesnike s atrijskom fibrilacijom, umjetnim srŁanim val-
vulama, muralnim trombom u lijevom atriju. Otkrivanje
MES se moe upotrijebiti kako bi se lokalizirao izvor em-
bolija i identificirali visoko riziŁni bolesnici s karotidnim
ili arterijskim izvorom embolija, pratilo bolesnike za vrijeme
invazivnih postupaka ili operacije i procijenio uŁinak anti-
trombotske ili antikoagulantne terapije. Potrebna je stan-
dardizacija opreme, metodologije i metode za analizu i
interpretaciju (i u manjoj mjeri varijabilnost unutar i izme-
ðu ispitivaŁa i algoritam poluautomatskog otkrivanja em-
bolija), kako bi se postigla visoka osjetljivost i specifiŁnost
nalaza.
ParadoksiŁni embolizam moe nastati preko otvorenog
foramena ovale ili prisutnosti atrijske septalne aneurizme.
Primjenjuje se test mjehuriæa tako da se injicira fizioloka
otopina koja sadri zraŁne mjehuriæe ili eho-kontrastno
sredstvo u kubitalnu venu. Pomoæu TCD biljee se HITS
koji se pojavljuju u lijevoj srednjoj modanoj arteriji. Moe
se javiti jedan embolus, vie embolija, tu emoblija bez
zastora ili zastor pun embolusa. Senzitivnost kontrastnog
TCD se kreæe od 70% do 100% uza specifiŁnost koja prelazi
95% u otkrivanju desno-lijevih srŁanih ili pluænih arterio-
venskih komunikacija. Rutinsko izvoðenje Valsalvina
manevra za vrijeme testa poveæava osjetljivost i speci-
fiŁnost.
Modana vazoreaktivnost je fizioloki zatitni mehani-
zam koji Łuva mozak od oteæenja tako to odrava njego-
vu opskrbu krvlju stalnom. Cerebralna arterijska autoreg-
to have a noninvasive possibility for its detection and
monitoring, so that effective treatment can be used. TCD
is a reliable method for detecting cerebral vasospasm by
measuring the increased blood flow velocities in basal ce-
rebral arteries. The MCA/ICA ratio can be calculated to
exclude hyperperfusion.
Doppler spectrum contains information regarding the
intensity or amount of sound that is reflected back to the
transducer. It is in proportion to the number of red blood
cells and indicates the amount of blood in the sample vol-
ume. The intensity of the reflected sound at a particular
frequency depends on the number of red blood cells mov-
ing at a particular velocity. The signal power of each ve-
locity component can be coded in a color or gray scale on a
computer display using the spectrum analysis technique.
An embolus moving through the sample volume increases
the amount of ultrasound being reflected back to the trans-
ducer, so this hyperintensive transient signal increase
(HITS) in the Doppler spectrum corresponds to the mi-
croembolic signal (MES) as the embolic particle passes
through the cerebral circulation. MES are more frequent-
ly detected when retesting a suspected individual on dif-
ferent days, or on prolonged monitoring. The accurate and
reliable characterization of embolus size and composition
is not yet possible using current technology. The ability to
detect emboli is hampered by several factors including
equipment characteristics. Embolus size and echogenici-
ty determine the intensity of the signal. MES can be found
more frequently in patients with symptomatic than in
those with asymptomatic carotid stenosis. Most MES are
asymptomatic, but are still believed to be a marker of the
risk of ischemic events. Similar are data for patients with
atrial fibrillation, prosthetic heart valves, and mural throm-
bus in the left atrium. MES detection can be used to lo-
calize an embolic source and to identify high-risk patients
with carotid or arterial sources of embolism, to monitor
patients during invasive procedures or operations, and to
assess the effect of antithrombotic or anticoagulant treat-
ment. The standardization of the equipment, methodol-
ogy, and methods for analysis and interpretation (to less-
en inter- and intraobserver variability and semi-automatic
embolus detection algorithms) is required to obtain high
report sensitivity and specificity.
Paradoxical embolism may occur via a patent foramen
ovale or presence of an atrial septal aneurysm. Bubble test
is performed by injection of saline containing air bubbles
or echo-contrast enhancing agents into the cubital vein.
TCD registers the HITS appearing in the left MCA. They
may appear as single emboli, multiple emboli, shower with-
out curtain, and curtain of emboli. The sensitivity of con-
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ulacija je praæena promjenama rezistencije na razini malih
modanih arterija, dok bazalne cerebralne arterije ostaju
iste irine promjera za vrijeme umjerenih promjena krvnog
tlaka. Modana se vazoreaktivnost moe procijeniti tako
da se pomoæu TCD mjere promjene srednjih brzina stru-
janja krvi za vrijeme testa stimulacije modanih ila. Svi su
zasnovani na biofiziologiji odgovora stijenke ila. Naj-
poznatiji je test stimulacije ugljiŁnim dioksidom ili aceta-
zolamidom u kombinaciji s TCD. Ti testovi uzrokuju pro-
mjene promjera modanih arteriola i na taj naŁin mijenja-
ju modani protok krvi. Inducirana hiperkapnija snano
stimulira vazodilataciju modanih arteriola, snizuje perifer-
ni krvni tlak i poveæava brzine strujanja krvi. U bolesnika s
iscrpljenom modanom vazomotornom reakcijom rezis-
tentne ile su osnovno proirene do najveæe moguæe mjere
i nije moguæa daljnja dilatacija. Oni pokazuju poremeæen
cerebralni vazoreaktivni odgovor na vazodilatacijske
podraaje. Takvi su bolesnici pod poveæanim rizikom za
razvoj cerebrovaskularnog ishemijskog dogaðaja. U bolesni-
ka sa znaŁajnom stenozom unutarnje karotidne arterije
smanjena vazomotorna reaktivnost je povezana s poveæa-
nim rizikom za nastanak modanog udara i spontano se
poboljava nakon endarterektomije.
Ultrasonografija modanih krvnih ila je posljednjih
desetljeæa doivjela eksponencijalni rast. Dostupne su
mnoge ultrazvuŁne tehnike za rutinsko neinvazivno ispi-
tivanje ekstrakranijskih arterija u otkrivanju i kvantifikaciji
stenoze, procjeni stabilnosti plaka, dijagnozi i praæenju
disekcija, procjeni intrakranijske hemodinamike i pre-
raspodjeli hemodinamike u prisutnosti kolateralnog pro-
toka. Primijenjena uz tkivni aktivator plazminogena pospje-
uje trombolizu. Noviji programi omoguæavaju neinvazivno
otkrivanje embolijskih signala i funkcionalni prikaz. Sve to
omoguæava potpunu dijagnostiku bolesnika s modanim
udarom i pojedinaca pod rizikom za njegov nastanak. Veli-
ka je prednosti metoda to to su jednostavne, pouzdane,
neinvazivne i mogu se ponavljati koliko je god puta potreb-
no. Oprema je mala i prijenosna, to omoguæava procjenu
uz krevet bolesnika.
trast TCD ranges between 70% and 100%, with the spec-
ificity exceeding 95% in detecting right to left cardiac or
pulmonary arteriovenous shunts. The routine performance
of Valsalva maneuver during the test can improve sensitiv-
ity and specificity.
Cerebral vasoreactivity is a psychological protective
mechanism that prevents brain damage by keeping stable
blood flow supply. Cerebral arterial autoregulation is ac-
complished by resistance changes that occur at the level
of smaller cerebral arteries, while the basal cerebral arter-
ies remain constant in diameter during moderate pressure
fluctuations. Cerebral vasoreactivity could be estimated by
measuring mean blood flow velocity changes during cere-
bral vessel stimulation tests by TCD. They all are based
on the biophysiology of vessel wall responsiveness. The
best known are CO2 and acetazolamide tests, which can
be combined with TCD. These tests provoke changes in
cerebral arteriolar diameters, influencing cerebral blood
flow changes. Induced hypercapnia strongly stimulates
vasodilatation of cerebral arterioles, lowers peripheral blood
pressure, and increases blood flow velocities. In patients
with exhausted cerebral vasomotor reaction, the resistance
bed is dilated at baseline and no further dilatation is pos-
sible. They express impaired cerebral vasoreactivity to
vasodilator stimuli. Such patients are at an increased risk
of development of cerebrovascular ischemic event. In pa-
tients with severe extracranial internal carotid disease,
diminished vasomotor reactivity has been associated with
an increased risk of stroke, and spontaneously improved
following endarterectomy.
Cerebrovascular ultrasonography has shown an almost
exponential growth over the last decades. Many ultrasound
techniques are available for routine noninvasive examina-
tion of extracranial arteries in the detection and quantifi-
cation of stenosis, evaluation of plaque stability, diagnosis
and follow up of dissections, evaluation of intracranial
hemodynamics and redistribution in the presence of col-
lateral flow. Applied with rt-TPA, it enhances thromboly-
sis. New software enables noninvasive embolus detection
and functional imaging. All this enables complete diagno-
sis of stroke patients and of individuals at stroke risk. The
great advantage is that the methods are easy, reliable, non-
invasive, and can be repeated as much as needed. The
equipment is small and transportable, enabling evaluation
at patient bedside.
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NEUROPHYSIOLOGIC METHODS IN STROKE DIAGNOSIS
NEUROFIZIOLOKE METODE U DIJAGNOSTICI MODANOG UDARA
Ivan Bielen
Department of Neurology, Sveti Duh General Hospital, Zagreb, Croatia
Odjel za neurologiju, Opæa bolnica Sveti Duh, Zagreb
KliniŁke neurofizioloke metode Łesto se definiraju kao
metode za registriranje bioelektriŁne staniŁne aktivnosti.
U sluŁaju modane patologije dosad su prevladavale elek-
troencefalografija (EEG) i iz nje izvedene metode. Za istu
namjenu mogu se rabiti razliŁite inaŁice evociranih poten-
cijala (EP), senzornih i motornih. ZajedniŁko obiljeje svih
ovih tehnika je vizualni prikaz prostorno i vremenski sum-
irane neuronske aktivnosti, to je omoguæeno specifiŁnom
strukturnom i funkcijskom organizacijom mozga. Glede
podrijetla EEG aktivnosti, velike populacije usporedno
orijentiranih neurona omoguæavaju stvaranje prolaznih ele-
ktriŁnih gradijenata napona kojih su dostatni da bi se zabi-
ljeili na povrini vlasita. U usporedbi s metodama neu-
roprikazivanja, glavna prednost neurofiziolokih metoda je
njihova visoka vremenska rezolucija kakvu nije moguæe
postiæi niti posljednjim generacijama funkcijskog prikazi-
vanja magnetskom rezonancom (fMRI), kao i brzina ko-
jom se elektrofizioloki parametri pojavljuju tijekom pato-
fiziolokih procesa u mozgu. Meðutim, zajedniŁko obiljeje
zabiljeenih neurofiziolokih parametara je to to su oni
rezultat sloene mozgovne integracije prostorno udaljenih
neuralnih mrea. To pak za sobom povlaŁi znatno slabiju
prostornu rezoluciju u usporedbi sa standardnim tehnika-
ma slikovnog prikazivanja.
U rutinskoj dijagnostici modanog udara koji se moe
definirati kao iznenadna pojava neurolokog deficita koji
se moe pripisati arinoj vaskularnoj patologiji1, neurofi-
zioloke metode u veæini sluŁajeva nisu indicirane. One ne
mogu zamijeniti suvremene tehnike slikovnog prikazivanja
niti po vrijednosti u lokalizaciji niti specifiŁnoæu nalaza.
Uz to, ne moe se donijeti nikakav izravan zakljuŁak u svezi
s vaskularnom patologijom. Ipak, postoje situacije u dijag-
nostici modanog udara kad neurofizioloke metode ima-
ju prednost pred onima neuroprikazivanja. Primjerice, tak-
va je situacija kad ishemijsko oteæenje jo nije postalo vid-
ljivo na prikazima kompjutorizirane tomografije (CT). Za
razliku od CT, EEG æe nenormalnosti prikazati gotovo
istodobno s poremeæajem krvnog protoka. ObiŁno se moe
razlikovati supratentorijalno od infratentorijalnog oteæenja
ili od manjih hemisfernih oteæenja u subkortikalnim
Clinical neurophysiology methods are commonly de-
fined as methods for recording the bioelectrical cellular
activity. In case of cerebral pathology, electroencephalog-
raphy (EEG) and methods derived from it have so far been
dominant techniques. With the same purpose different
variations of evoked potentials (EP), sensory and motor,
can be applied. A common feature of all of these techniques
is visual presentation of the spatially and temporarily
summed neuronal activity, which is enabled by specific
structural and functional organization of the brain. Con-
cerning the origin of EEG activity, great populations of
parallelly-oriented neurons make possible the formation
of transient electrical gradients, their voltages being suf-
ficient to be recorded on the scalp surface. In comparison
to neuroimaging methods, the main advantage of the neu-
rophysiologic methods is their high temporal resolution
that cannot be reached even by the last generations of the
functional magnetic resonance imaging (fMRI), as well as
their promptness by which the electrophysiologic param-
eters appear during the pathophysiologic brain processes.
However, the common characteristic of the registered
neurophysiologic parameters is that they are the result of
a complex cerebral integration of the spatially remote neu-
ral networks. Consequently, the implication of this is a
considerably weaker spatial resolution if compared to the
standard neuroimaging techniques.
In the routine diagnosis of stroke, which can be defined
by a sudden appearance of the neurologic deficit that may
be attributable to focal vascular pathology1, in the majori-
ty of cases the neurophysiologic methods are not indicat-
ed. Neither by the localization value, nor by the specifity
of the findings can they replace contemporary neuroimag-
ing techniques. In addition to this, no direct conclusion
regarding vascular pathology can be made. Nevertheless,
there are situations in the stroke diagnosis when neuro-
physiologic methods have the advantage over the neuroim-
aging ones. For instance, this is the situation when the is-
chemic lesion has not yet become apparent on the com-
puterized tomography images (CT). In contrast to this,
EEG shows abnormalities almost simultaneously with the
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blood flow failure. It is commonly possible to differenti-
ate cortical supratentorial from infratentorial lesion, or from
minor hemispheric lesions in the subcortical structures.
Cortical lesions are characterized by the slow activity with
maximal changes in parietotemporal regions. The period-
ical lateralized epileptiform discharges (PLEDs) can be
seen less frequently. This pattern is not nosologically spe-
cific, but in the context of stroke diagnosis the possibility
of the watershed infarction that has some diagnostic and
therapeutic implications should be kept in mind. In mi-
nor subcortical hemispheric lesions, except those affect-
ing mesencephalic tegmentum and thalamic structures,
EEG is normal or shows only slight abnormalities. Also,
EEG can be useful in the diagnosis of the infarcts in the
inferior part of the brainstem. In some patients with this
syndrome EEG pattern is characterized by the normal al-
pha rhythm that does not show expected desynchroniza-
tion after sensory stimulation. In some centers EEG re-
cording is part of the operative monitoring during the ca-
rotid surgery. During these procedures arterial clamping
is promptly followed by EEG changes that can be visually
and digitally analyzed, and the information thus obtained
can be helpful in further operative decisions, especially
regarding shunting.
The application of digital processing of the recorded
bioelectrical potentials can significantly increase diagnos-
tic sensitivity of the EEG. In terms of frequency spectra
and the potential amplitude, the EEG signal can by ana-
lyzed in the chosen sequence of time. The data obtained
in this way can be displayed as a quantitative analysis and/
or topographic map on the scalp projection. These tech-
niques are sometimes referred to as brain mapping, al-
though some authors think that this term should be used
more restrictively, only for topographic displays2. By the use
of quantitative analysis, it is possible to reveal discrete
changes in EEG records that are very difficult to diagnose
only by visual analysis. During the acute phase of stroke
lateralized abnormalities can be found by visual analysis in
40%-70% of patients2. This percentage can be increased
to up to 90% by the use of quantitative EEG3,4. The local-
izational value can also be increased, as in terms of projec-
tion of pathologic electrogenerator on the scalp surface5,
so in relation to deeper structures6. However, even by use
of the mentioned technical progress, it has not been pos-
sible to increase the nosologic specificity that is necessary
to differentiate cerebral infarcts from hemorrhage and
other expansive processes.
Quantitative analysis confirmed the high sensitivity of
EEG for changes of the cerebral blood flow. The EEG
strukturama. Kortikalne lezije su obiljeene polaganom ak-
tivnoæu s maksimalnim promjenama u parietotempo-
ralnim podruŁjima. Rjeðe se mogu vidjeti periodiŁni la-
teralizirani epileptiformni izboji (PLED). Ovakva situacija
nije nozoloki specifiŁna, ali u kontekstu modanog udara
valja imati na umu moguænost infarkt sliva (watershed in-
farction) s dijagnostiŁkim i terapijskim implikacijama. Kod
manjih subkortikalnih hemisfernih oteæenja, osim onih
koja zahvaæaju mezencefalni tegment i strukture talamusa,
EEG je normalna ili pokazuje samo blae nenormalnosti.
EEG moe isto tako biti korisna u dijagnostici infarkta
donjeg dijela modanog debla. U nekih bolesnika s ovim
sindromom EEG zapis je obiljeen normalnim alfa ritmom
koji ne pokazuje oŁekivanu desinkronizaciju nakon osjetil-
ne stimulacije. U nekim centrima je zapis EEG dio opera-
cijskog praæenja tijekom zahvata na karotidama. Tijekom
ovih zahvata promjene u EEG slijede odmah nakon po-
stavljanja stezaljka na karotidu i mogu se vizualno i digi-
talno analizirati, a tako dobiveni podaci mogu pomoæi u
daljnjim operacijskim odlukama, poglavito glede postav-
ljanja meðuspoja (shunting).
Digitalnom obradom zabiljeenih bioelektriŁnih poten-
cijala moe se znaŁajno poveæati dijagnostiŁka osjetljivost
EEG. to se tiŁe frekvencijskih spektara i amplitude po-
tencijala, EEG signal se moe analizirati u odabranom vre-
menskom slijedu. Tako dobiveni podaci mogu se prikazati
kao kvantitativna analiza i/ili topografska karta na projekciji
vlasita. Ove tehnike ponekad se nazivaju mapiranjem
mozga, iako neki autori smatraju kako ovaj izraz treba stroe
primjenjivati i to samo za topografske prikaze2. Uz primjenu
kvantitativne analize mogu se otkriti fine promjene u EEG
zapisima koje je teko dijagnosticirati samo vizualnom
analizom. Za vrijeme akutne faze modanog udara latera-
lizirane nenormalnosti mogu se naæi vizualnom analizom
u 40%-70% bolesnika2. Ovaj se postotak moe povisiti do
90% primjenom kvantitativne EEG3,4. Moe se poveæati i
lokalizacijska vrijednost, kako u smislu projekcije patolo-
kog elektrogeneratora na povrini vlasita5, tako i glede
dubljih struktura6. Meðutim, Łak ni uporabom spomenu-
tog tehniŁkog napretka nije se mogla poveæati nozoloka
specifiŁnost koja je potrebna za razlikovanje modanih
infarkta od krvarenja i drugih ekspanzivnih procesa.
Kvantitativna analiza je potvrdila visoku osjetljivost
EEG za promjene modanog krvotoka. Spektri EEG,
poglavito oni delta-frekvencije, pokazali su visoke koefi-
cijente korelacije (oko 90%) s regionalnim krvotokom i me-
tabolizmom kisika mjerenim tomografijom s emitiranjem
pozitrona (PET)7. KliniŁka primjena analize frekvencija
ponovno je potvrdila potencijal EEG da biljei promjene
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bioelektriŁnih potencijala uzrokovane modanom hipop-
erfuzijom Łak i prije nego to se oni mogu dokazati na CT.
Uz to, uporabom ovih metoda dokazano je kako se ponekad
mogu otkriti nenormalnosti koje se ne mogu, Łak ni kas-
nije, prikazati pomoæu CT mozga, to je sluŁaj u nekim
prolaznim i reverzibilnim ishemijskim ispadima8. Na osnovi
ovih i sliŁnih ispitivanja moe se zakljuŁiti kako je EEG
osjetljiva i odgovarajuæa metoda u otkrivanju modane dis-
funkcije uzrokovane hipoperfuzijom i hipometabolizmom.
Spektralna analiza EEG zapisa poveæala je osjetljivost i
pouzdanost praæenja tijekom karotidnih endarterektomi-
ja9,10. Usprkos ovim prednostima EEG se relativno rijetko
rabi u standardnoj dijagnostici modanog udara. Glavni
razlog tome je to to nakon potpunog neurolokog pregle-
da dopunjenog pregledima pomoæu neuroprikazivanja i
neurosonologije preostaje malo vanijih kliniŁkih pitanja.
Nema sumnje da kvantitativna EEG i s njom povezane
tehnike imaju veliku vrijednost u znanstvenim istraiva-
njima, no njihova kliniŁka primjena je donekle ograniŁena
problemima povezanim s ispravnim tumaŁenjem nalaza
koji se nerijetko i dalje pogorava nekolicinom egzogenih i
endogenih artefakata.
KliniŁka korisnost preostalih neurofiziolokih tehnika
u dijagnostici modanog udara ima sliŁna ograniŁenja kao
EEG. Na primjer, nalazi senzornih evociranih potencijala
u kliniŁkom kontekstu dijagnostike akutnog modanog
udara ne pokazuju specifiŁnost promjena koja je oŁita kod
nekih drugih bolesti. tovie, lokalizacijska vrijednost evo-
ciranih potencijala daleko zaostaje za onom kod nalaza
neuroprikazivanja. Meðutim, postoje kliniŁka pitanja na
koja ne mogu odgovoriti niti ispitivanja suvremenom MR,
dok se primjenom dodatnih elektrofiziolokih pregleda
ipak mogu dobiti korisni podaci. Primjer za to je pontinski
infarkt nakon kojega moe uslijediti i kohlearni infarkt.
Zahvaæenost ili nezahvaæenost kohleje kod ovakve kliniŁke
slike moe se otkriti pomoæu slunih evociranih potenci-
jala modanog debla (BAEP)11. Neurofizioloke tehnike
mogu se isto tako rabiti u lokaliziranju drugih sindroma
modanog debla, osobito ako MRI nije dostupno. Primjer
za takvu primjenu BAEP je sindrom zabravljenosti
(locked-in syndrome)12. SliŁno tome, lokalizaciju infarkta kod
Wallenbergova sindroma olakati æe analiza refleksa mir-
kanja13. Vidni i somatosenzorni evocirani potencijali mogu
se isto tako primijeniti u objektiviranju oteæenja uzroko-
vanih modanim udarom, no u rutinskoj dijagnostici oni
obiŁno nisu indicirani.
Kako je gore naglaeno, neurofizioloke metode danas
kod veæine bolesnika imaju dopunsku ulogu u standardnoj
dijagnostici modanog udara14. Meðutim, ako se pojam
spectra, especially those of delta-frequency, showed high
correlation coefficients (~90%) with regional blood flow
and oxygen metabolism measured by positron emission
tomography (PET)7. Clinical applications of frequency
analysis reaffirmed the EEG potential to be able to record
changes of bioelectrical potentials caused by cerebral hy-
poperfusion even before they could be demonstrated by
CT. Besides, by use of these methods it was demonstrat-
ed that it could be sometimes possible to reveal the ab-
normalities that could not, even later on, be shown by brain
CT, which is the case in some transient and reversible is-
chemic episodes8. Based on these and similar studies, it
can be concluded that EEG is a sensitive and adequate
method in the detection of cerebral dysfunction caused by
hypoperfusion and hypometabolism. The spectral analy-
sis of EEG records increased the sensitivity and reliability
of monitoring during carotid endarterectomies9,10. Despite
these advantages, EEG is relatively rarely used in standard
stroke diagnosis. The main reason is that, after a complete
neurologic examination supplemented by neuroimaging
and neurosonologic investigations, there are only a few
relevant clinical questions  left. There is no doubt that
quantitative EEG and related techniques have a great
value in the scientific studies, but its clinical use is to some
extent limited by the problems related to the correct in-
terpretation of finding that is not rarely further aggravat-
ed by several exogenous and endogenous artefacts.
The clinical usefulness of the remaining neurophysio-
logic techniques in the stroke diagnosis has similar limita-
tions as EEG. For instance, the findings of sensory evoked
potentials in the clinical context of the acute stroke diag-
nosis do not show a specificity of changes that is evident
in some other diseases. Moreover, the localizational value
of evoked potentials is far behind the neuroimaging find-
ings. However, there are clinical questions that cannot be
answered even by modern MR studies, but by use of ad-
ditional electrophysiologic examinations useful informa-
tion can still be obtained. An example is the pontine inf-
arct that can be followed by the cochlear infarct, too. Af-
fection or nonaffection of cochlea in this clinical picture
can be detected by brainstem auditory evoked potentials
(BAEP)11. The neurophysiologic techniques can also be
used in localization of other brainstem syndromes, espe-
cially if MRI is not available. The example for such applica-
tions of BAEP is a locked-in syndrome12. Similarly, local-
ization of the infarct in Wallenbergs syndrome can by fa-
cilitated by the analysis of blink-reflex13. Visual and soma-
tosensory evoked potentials can also be used in objectify-
ing the lesions caused by stroke, but in the routine diag-
nosis they are commonly not indicated.
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As emphasized above, neurophysiologic methods have
nowadays a supplemental role in the standard stroke di-
agnosis for the majority of patients14. However, if the term
stroke diagnosis is considered more widely and if it includes
the process of diagnosing clinical consequences of the ini-
tial accident, and also the follow-up of the neurologic im-
pairment, the neurophysiologic methods will be in quite
different position. In that case they are complementary or
leading in comparison to neuroimaging and  neuropsycho-
logic methods. In this context, it can be expected from the
neurophysiologic methods to bring information with a pri-
marily functional value. So, the quantitative EEG proved
to be a valuable tool for monitoring effects of antiedemic
therapy in patients with stroke15,16, and in some prognos-
tic evaluations17,18. Among evoked potentials, the priority
could be given to the endogenous evoked potentials. The
endogenous EPs are less dependent on the characteristics
of peripheral stimulations. They are in principle an expres-
sion of cortical and/or subcortical processing. The synon-
ymously used term is the Event Related Potentials (ERP),
and the best known technique is P 300 or P3 wave. This
method may also be referred to as cognitive potential
because it is a potential that is evoked by active process-
ing of the perceived stimulus in the state of complete alert-
ness. The ERP methods are aimed to define the neuro-
physiologic correlates of some language functions19,20, and
some studies of the applicability in neurorehabilitation
after stroke are conducted21,22.
All of these methods are still developing, and their role
in stroke diagnosis and in the follow-up of its consequences
must yet be defined by well designed clinical studies.
The transcranial magnetic stimulation (TMS) is prob-
ably the most valuable technique among the motor evoked
potentials. By this method it is possible to detect cerebral
regions that are engaged in the performing of various mo-
tor patterns. It is particularly helpful in studies investigat-
ing cerebral plasticity that implies processes of cerebral
reorganization. Using TMS, it is possible to block certain
transitory neural networks, which can also lead to detec-
tion of cortical structures participating in the activities that
are of interest. According to its capacities TMS might be
an important tool in diagnosing functional and structural
changes that occur during the stroke rehabilitation22,23.
dijagnostike modanog udara razmatra u irem smislu i ako
ona ukljuŁuje proces dijagnosticiranja kliniŁkih posljedica
poŁetnog dogaðaja, kao i praæenje neurolokog poremeæa-
ja, tada su neurofizioloke metode u sasvim drukŁijem
poloaju. U tom sluŁaju one su komplementarne ili vodeæe
u usporedbi s metodama neuroprikazivanja i neuropsiho-
lokim metodama. U tom kontekstu se od neurofiziolo-
kih metoda moe oŁekivati da æe pruiti podatke koji su
prvenstveno od funkcijske vanosti. Tako se je kvantita-
tivna EEG pokazala korisnom u praæenju uŁinaka protue-
demske terapije u bolesnika s modanim udarom15,16, te kod
nekih prognostiŁkih procjena17,18. Meðu evociranim poten-
cijalima prednost bi se mogla dati endogenim evociranim
potencijalima. Endogeni EP su manje ovisni o znaŁajkama
perifernih podraaja. Oni su u naŁelu izraz kortikalne i/ili
subkortikalne obrade. Kao sinonim se rabi izraz potenci-
jali povezani s dogaðajem (event related potentials, ERP), a
najpoznatija tehnika je val P300 ili P3. Ovu metodu moe
se nazvati i spoznajnim potencijalom, jer je moguæe da
se evocira aktivnom obradom zapaenog podraaja u stan-
ju potpune budnosti. Cilj metoda ERP je definirati neu-
rofizioloke korelate nekih jeziŁnih funkcija19,20, a prove-
dene su i neke studije njihove primjenjivosti u neuroreha-
bilitaciji21,22. Sve ove metode se jo razvijaju i njihovu ulo-
gu u dijagnostici modanog udara i praæenju njegovih po-
sljedica treba tek utvrditi u dobro zamiljenim kliniŁkim
ispitivanjima.
Transkranijska magnetna stimulacija (TMS) vjerojat-
no je najvrijednija tehnika meðu motornim evociranim
potencijalima. Ovom metodom se mogu otkriti modane
regije koje su ukljuŁene u izvoðenje raznih motornih ak-
tivnosti. Ona je osobito korisna u ispitivanju plastiŁnosti
mozga koja ukljuŁuje procese modane reorganizacije. Uz
primjenu TMS mogu se blokirati odreðene tranzitorne
neuralne mree, to moe takoðer dovesti i do otkrivanja
kortikalnih struktura koje sudjeluju u aktivnostima koje nas
zanimaju. Zahvaljujuæi njenim moguænostima TMS bi
mogla biti vano sredstvo u dijagnosticiranju funkcijskih i
strukturnih promjena koje se dogaðaju za vrijeme rehabi-
litacije od modanog udara22,23.
2. NUWER MR. Topographic mapping, frequency analysis, and other
digital techniques in electroencephalography. In: AMINOFF MJ,
ed. Electrodiagnosis in clinical neurology. New York: Churchill Liv-
ingstone, 1999:1899-209.
3. JONKMAN EJ, POORTVLIET DCJ, VEERING MM et al. The use
of neurometrics in the study of patients with cerebral ischaemia.
Electroencephalogr Clin Neurophysiol 1985;6:333-41.
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Kompjutorizirana tomografija (CT) ima prednost pred
drugim tehnikama neuroprikazivanja u dijagnostici
modanog udara. Metoda se zasniva na mjerenju gustoæe
strukture tkiva izraene u Hounsfieldovim jedinicama
(HU), a posljednjih je godina usavrena te su u upotrebi
spiralni CT ureðaji s kontinuiranom rotacijom rentgenske
cijevi uz istodobno neprekidno pomicanje rentgenskog
stola. Na taj naŁin se ubrzava pretraga na samo nekoliko
minuta. Uporabom sve boljih detektora poboljava se i
rezolucija slike. Napredak u tehnologiji omoguæio je i prikaz
krvnih ila pomoæu CT (CT angiografija), te se uvelike
smanjuje uporaba invazivnih metoda kao to je digitalna
subtrakcijska angiografija (DSA).
Magnetska rezonanca (MR) radi na naŁelu egistriran-
ja H iona u elektromagnetskom polju. Za razliku od CT ona
omoguæuje multiplanarni prikaz u tri ravnine, a s obzirom
na postizanje bolje rezolucije omoguæuje bolji prikaz ana-
tomskih intrakranijskih struktura, te raniju dijagnostiku
mnogih intrakranijskih patolokih promjena. Primjenom
sofisticiranih kompjutorskih elemenata, poboljanjem pro-
grama i samih ureðaja, pojaŁanjem magnetskog polja i upo-
trebom specifiŁnih sekvenca snimanja MR zasad Łini ide-
alnu neinvazivnu metodu u dijagnostici razliŁitih oblika
modanog udara. MR omoguæuje i prikaz intrakranijskih
te ekstrakranijskih arterija (MRA), ali i prikaz venskog su-
stava s venskim sinusima (MRV).Tako MRA i MRV sma-
njuju indikacije za DSA u probiru intrakranijskih vasku-
larnih bolesti mozga zbog moguænosti neinvazivnog mul-
tiplanarnog pregleda krvnih ila mozga. Nedostatak ove
metode je nedostatan prikaz malih distalnih ogranaka
krvnih ila, nedostatni podaci o smjeru protoka, ovisnost o
protoku krvi te o bolesnikovoj suradnji  bolesnik mora biti
miran za vrijeme snimanja, a s obzirom na to da su bolesnici
s cerebrovaskularnim inzultom u akutnoj fazi nemirni, u
toj fazi prednost ima CT.
MR i MRA se preporuŁuju u procjeni intrakranijske
vaskularne patologije: cerebrovaskularnog inzulta, arte-
rijskih stenoza i obliteracija, aneurizma, arterijsko-venskih
malformacija, u dijagnostici razliŁitih entiteta vaskularne
patologije, naroŁito u dijagnostici venskih bolesti, u nejas-
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In the diagnosis of stroke, computed tomography (CT)
has an advantage over other neuroimaging techniques. CT
is based on the measurement of tissue structural density
expressed in Hounsfield units (HU). Over the last few
years, sophisticated advancements have been achieved in
CT, so that spiral CT devices with continuously rotating
x-ray tube with simultaneous continuous movement of x-
ray table, thus reducing the examination to only a few
minutes. The use of ever better detectors has also entailed
improved image resolution. Technologic advances have
enabled CT imaging of blood vessels (CT angiography),
thus greatly reducing the use of invasive methods such as
digital subtraction angiography (DSA).
Magnetic resonance (MR) operates on the principle of
recording H ions in the electromagnetic field. As differen-
tiated from CT, MR allows for a multiplanar image in three
projections and because of higher resolution enables bet-
ter visualization of anatomic intracranial structures and
earlier diagnosis of many intracranial pathologic changes.
With the use of sophisticated computer elements, im-
proved software and hardware, magnetic field enhance-
ment, and specific imaging sequences MR is currently an
ideal, noninvasive method for the diagnosis of various types
of stroke. Also, MR enables visualization of intracranial and
extracranial arteries (MRA) as well as of the venous sys-
tem with venous sinuses (MRV). Thus, MR has reduced
indications for DSA on screening for intracranial vascular
disease of the brain, offering an opportunity for noninva-
sive multiplanar study of cerebral blood vessels. A disad-
vantage of the method is inadequate visualization of small,
distal vascular branches, inadequate information on flow
direction, dependence on blood flow and on patients com-
pliance, as the patient must stay still during the imaging
process. As stroke patients are quite restless in the acute
stage of the disease, CT is preferred in this stage.
MR and MRA are recommended for evaluation of in-
tracranial vascular pathology, e.g., stroke, arterial stenosis
and obliteration, aneurysm, arteriovenous malformations,
then on diagnosis of various entities of vascular pathology,
especially venous diseases, vague clinical cases, on differ-
ential diagnosis, etc.
Second Congress of Croatian Society for Neurovascular Disorders of Croatian Medical Association
Drugi kongres Hrvatskoga drutva za neurovaskularne poremeæaje Hrvatskoga lijeŁniŁkog zbora
58 Acta Clin Croat, Vol. 43,  Suppl. 1,  2004
nim kliniŁkim sluŁajevima, u diferencijalnoj dijagnostici i
sl.
Modani udar je akutni ili subakutni nastanak simpto-
ma uzrokovanih lokaliziranim poremeæajem arterijske cir-
kulacije mozga. Pobol i smrtnost rastu s porastom ivotne
dobi, osobito iznad 50. godine. RiziŁni Łimbenici za razvoj
modanog udara su arterijska hipertenzija, srŁane bolesti
(osobito aritmije), hiperkolesterolemija, eæerna bolest i sl.
U  85% sluŁajeva cerebrovaskularnog inzulta nalazi se
ishemijski infarkt ili onaj nastao smanjenjem modanog
protoka zbog trombotiŁne ili embolijske okluzije modanih
arterija, a u 15% hemoragijski infarkt.
Ishemijski infarkt prikazuje se na CT kao zona sniene
gustoæe (hipodenzna zona) koja je odraz nekrotiŁnog pro-
cesa koji pak ima svoj tijek razvoja. Kako nekrotiŁni proces
prolazi kroz razliŁite faze, tako se mijenja i gustoæa slike.
Te se promjene mogu pratiti pomoæu CT, a osobito pomoæu
MR.
Kod svake arine ishemije u mozgu razlikuju se dvije
zone: sredinja zona ishemije i periferna zona, tj. zona
penumbre. Sredinja zona je podruŁje potpune ishemije
u kojem je dolo do potpunog prekida dotoka krvi, odnos-
no sredite lezije. MetaboliŁne i morfoloke promjene koje
nastaju u ovoj zoni progresivno se razvijaju i ireverzibilne
su. U perifernoj zoni, meðutim, jo uvijek postoji cirkulaci-
ja, ali hipoperfuzijske naravi. Ovisno o daljnjem razvoju
procesa u ovom podruŁju mogu se razviti popravljive ili
nepopravljive promjene. U sluŁaju popravljivih promjena
dolazi do poboljanja u kliniŁkoj slici, a na nalazima CT i
MR vide se regresivne promjene u rubnom podruŁju u
subakutnoj fazi. Kod nepopravljivih promjena, meðutim,
dolazi do izjednaŁavanja procesa u sredinjem i rubnom
podruŁju koja se vie ne mogu razlikovati.
Vrlo vanu ulogu u procjeni ishemijske lezije i njezinog
ishoda ima cerebralni edem. Cerebralni edem se razvija kao
posljedica ishemije, ali isto tako potiŁe daljnje poveæanje
ishemijske lezije zbog svog mehaniŁkog djelovanja. Kolik-
vacijska nekroza tijekom procesa demarkira proces pa in-
farktom zahvaæeno podruŁje poprima oblik klina. Dulje
trajanje kolikvacijske nekroze uzrokuje stvaranje cistiŁnih/
pseudocistiŁnih formacija jasno prikazanih na CT i MR.
Nalaz CT u akutnoj fazi je obiljeen hipodenzitetom
homogenije, njenije naravi, nalik na maglu. Oblik
promjene je u ovoj fazi ovalan, neotro ograniŁen od okol-
nog zdravog tkiva. U perifernom podruŁju ishemije CT
pokazuje blagu hiperdenznu sjenu koja odgovara pokua-
ju stvarnja kolateralne cirkulacije i poputanju hematoence-
falne barijere.
CT nam omoguæuje preciznu lokalizaciju ne samo
promjena na samom mozgu, nego i posredno otkrivanje
Stroke
Stroke is an acute or subacute occurrence of symptoms
caused by localized impairment of cerebral arterial circu-
lation. Stroke morbidity and mortality rise with age, espe-
cially after the age of 50. The risk factors for stroke include
arterial hypertension, cardiac diseases (especially arrhyth-
mias), hypercholesterolemia, diabetes mellitus, etc.
Ischemic infarction or infarction due to decreased cere-
brovascular flow caused by thrombotic or embolic occlu-
sion of cerebral arteries underlie 85% of stroke cases,
whereas hemorrhagic infarction is found in the rest of 15%.
Ischemic infarction is visualized on CT as a hypodense
zone, which reflects a necrotic process and follows its own
course of development. The image density varies as the
necrotic process passes through various stages. These al-
terations can be followed by CT and especially by MR.
Two areas are differentiated in every focal ischemia of
the brain, i.e. central ischemic area and peripheral area of
so-called ischemic penumbra. The central area is an area
of total ischemia where complete interruption of the blood
supply has occurred, i.e. center of the lesion. The meta-
bolic and morphological alterations occurring in this area
are progressive and irreversible. In the peripheral area,
however, some circulation has yet been preserved but is
characterized by hypoperfusion. Either reparable or irrep-
arable lesions may develop in this area, depending on fur-
ther course of the process. In case of reparable lesions, the
clinical picture will improve and a regression pattern is seen
on CT or MR in the marginal region in the subacute stage
of the disease. In case of irreparable lesions, in contrast,
the process in the central and peripheral areas is unified
and they cannot be differentiated anymore.
Cerebral edema has a very important role in the evalu-
ation of ischemic lesion and its outcome. Cerebral edema
develops consequentially to ischemia, and also stimulates
further expansion of ischemic lesion due to its mechani-
cal action. Colliquative necrosis will demarcate the process,
so that the infarcted area becomes wedge shaped. Pro-
longed duration of colliquative necrosis leads to the occur-
rence of cysic/pseudocystic formations that are clearly vi-
sualized on CT and MR.
CT finding in the acute stage of stroke is characterized
by homogeneous, subtle hypodensity resembling mist. In
this stage, the lesion appears oval, unsharply delineated
from the surrounding intact tissue. In the peripheral is-
chemic area, CT shows slight hyperdense shadow that
corresponds to an attempt at forming collateral circulation
and blood-brain barrier failure.
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CT allows for precise localization of not only brain le-
sions but indirectly also detection of the occluded vessel.
Detection of lesions depends on the size and age, local-
ization, shape and relation of the brain lesion to the sur-
rounding structures. The regions rather difficult for CT
analysis because of numerous artifacts from the adjacent
osseous structures are medulla oblongata, pons and hip-
pocampal structures. However, with the introduction of
spiral CT for diagnostic purpose, some problems such as
restless patients with difficult breathing, seriously ill pa-
tients, comatose patients, etc., have been eliminated.
Ischemic Infarction
Ischemic disease of the brain is a necrotic or necrotiz-
ing process that develops due to the loss or reduction of
blood flow through cerebral circulation, evolving through
a number of morphological stages, from initial edema and
tissue disintegration through demarcation, incapsulation
and possible cicatricial reparation. Ischemic infarcts are
largely involved by colliquative necrosis that ultimately
leads to encephalomalacia. The evolution of ischemic in-
farction can be followed on CT, by measuring the density
of absorption coefficients of the affected region. A hy-
podense zone in the particular vessel irrigation area points
to a recent onset of ischemia (within few hours); its quan-
titative value varies during the course of the disease and
shows progressive decrease to form a cystic structure con-
taining CSF resembling fluid after three weeks.
The superacute stage (up to 24 h) is characterized by
hypodensity of the infarcted area due to water absorption
to the necrotic tissue and formation of a cytotoxic edema
of not only neurons but also of other infarcted cells. CT
shows an extensive hypodense area in the supply region
of the occluded artery as well as hemorrhages.
In the acute stage (24 h  day 7) a vasogenous edema
becomes apparent due to the blood-brain barrier failure
consequential to extravasal edema, especially in the white
matter. CT shows progressive density decrease and ever
clearer demarcation of the involved area. The mass effect
increases over the first 3 days and CT shows a wedge
shaped, hypodense area involving both white and gray
matter.
In the subacute stage (day 8-21), especially in case of
embolic incidents, hemorrhage (transformation) to the
infarcted area may occur. The blood is shed to the periph-
eral parts of the involved area secondary to the abrupt onset
of blood vessel occlusion along with undeveloped collat-
eral flow, which results in rupture of small blood vessels
and hemorrhages due to high pressure and large amount
okludirane krvne ile. Otkrivanje lezija ovisi o veliŁini i
starosti lezije, lokalizaciji, obliku i odnosu promjene u
mozgu prema okolnim strukturama. ProblematiŁna po-
druŁja za analizu pomoæu CT, gdje se pojavljuje Łitav niz
artefakata zbog okolnih kotanih struktura, su medula
oblongata, pons i hipokampusne strukture. Meðutim,
uvoðenjem u dijagnostiku spiralnog CT uklonjeni su neki
od problema, kao to su nemirni bolesnik s oteanim dis-
anjem, teki bolesnici, npr. oni u komi i sl.
Ishemijski infarkt
Ishemijska bolest mozga je nekrotiŁni ili nekrotizira-
juæi proces nastao gubitkom ili smanjenjem protoka kroz
modanu cirkulaciju, koji prolazi kroz Łitav niz morfolok-
ih stadija razvoja: od poŁetnog edema i dezintegracije tki-
va do demarkacije, inkapsulacije i moguæeg oiljkastog
popravljanja. Velik dio ishemijskih infarkata zauzima ko-
likvacijska nekroza koja kao krajnji rezultat ima encefalo-
malaciju. Evolucija ishemijskog infarkta moe se pratiti
pomoæu CT mjerenjem gustoæe koeficijenata apsorpcije
oteæenog podruŁja. PodruŁje sniene gustoæe (hipoden-
zitet) u irigacijskom podruŁju odreðene krvne ile ukazuje
na nedavni nastup ishemije (traje unatrag nekoliko sati).
Njegova se kvantitativna vrijednost mijenja tijekom bolesti,
tako da se progresivno snizuje te nakon tri tjedna dolazi do
stvaranja cistiŁne strukture koja sadri tekuæinu gustoæe
likvora.
U superakutnoj fazi (do 24 h) dolazi do hipodenziteta
infarciranog podruŁja zbog uvlaŁenja vode u nekrotiŁno
tkivo i nastanka citotoksiŁnog edema ne samo neurona,
nego i ostalih infarciranih stanica. CT pokazuje eksten-
zivno podruŁje niske gustoæe u opskrbnom podruŁju zaŁe-
pljene arterije, kao i zone krvarenja.
U akutnoj fazi (24 h do 7. dan) postaje oŁit vazogeni
edem zbog kraha krvnomodane barijere kao posljedica
ekstravazalnog edema, osobito u bijeloj tvari. CT pokazuje
progresivno smanjenje gustoæe i sve jasniju demarkaciju
zahvaæenog podruŁja. UŁinak mase se poveæava tijekom
prva 3 dana i CT pokazuje klinasto oblikovano podruŁje
niske gustoæe koje obuhvaæa i sivu i bijelu tvar.
U subakutnoj fazi (8.-21. dan), osobito kod embolijskih
incidenata, moe se pojaviti krvarenje (transformacije) u
infarcirano podruŁje. Zbog naglog nastupa okluzije krvne
ile i nerazvijenog kolateralnog krvotoka krv naglo navre u
periferne dijelove zahvaæenog podruŁja, te zbog visokog
tlaka i velike koliŁine dolazi do pucanja sitnih  krvnih ila
i krvarenja. U sluŁajevima pomicanja tromba distalno od
mjesta gdje je nastupilo zaŁepljenje krvne ile dolazi do
ekstravazacije kroz oteæeni dio sada osloboðene krvne ile
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i ponovno do krvarenja u infarcirano podruŁje. Navedeni
Łimbenici odgovorni su za to to je slika ishemijskog infark-
ta u ovoj fazi bolesti arolika te u pojedinim sluŁajevima sliŁi
tumorskom procesu. Za daljnju procjenu rabi se CT prikaz
s kontrastom koji pokazuje patoloko nakupljanje (luxury
perfusion) kortikalnih zona podruŁja opskrbe modane ar-
terije.
U ovom razdoblju zbog razvoja jakog edema moe doæi
do ekspanzivnog ponaanja infarciranog podruŁja, tako da
tijek i prognoza bolesti ovise upravo o intenzitetu ovog
dogaðaja te o moguæoj transtentorijalnoj hernijaciji.
U kroniŁnoj fazi  (nakon 21. dana) dolazi do djelo-
miŁnog otrog demarkiranja ili oiljavanja procesa, te æe
ovisno o promjeni biti i razliŁita gustoæa na CT.
U veæini sluŁajeva nativni CT je dovoljan za postavljanje
dijagnoze modanog udara, osobito u akutnoj i superakut-
noj fazi kada su moguæe i komplikacije. Meðutim, u sluŁa-
jevima nesigurne dijagnoze ili neuobiŁajene lokalizacije
promjena potrebno je uŁiniti pretragu na ureðaju MR.
Kontrastno sredstvo se ne primjenuje u akutnoj fazi, a
u subakutnoj fazi oblik imbibicije moe biti potpun ili pak
moe pokazati imbibiciju u obliku giralnog crtea (nalaz
nije patognomoniŁan i stvara potekoæe u diferencijalnoj
dijagnozi u odnosu na druge krvnoilne bolesti).
Hemoragijski infarkt
Incidencija hemoragijskih infarkata unutar svih moda-
nih udara je 5%-21%. Nastaje kao posljedica sekundarnog
krvarenja u ishemijski promijenjeno podruŁje mozga koje
je najŁeæe nastalo embolijom. Krvarenje nastaje za vrijeme
ishemije ili kao posljedica infarkta unutar 24 h, meðutim,
hemoragijska transformacija je vidljiva tek 24 h nakon nas-
tupa krvarenja.
Prema kliniŁkoj slici i nalazu CT lako se razlikuje od
modanog krvarenja druge etiologije. Hemoragijski infarkt
razvija kliniŁku sliku odmah u punom intenzitetu bez zna-
kova poveæanja intrakranijskog tlaka, za razliku od moda-
nog krvarenja koje uz nagli razvoj kliniŁke slike pokazuje i
znakove povienja intrakranijskog tlaka. Hemoragijski in-
farkt je najŁeæi kod embolije i velikih infarkata.
Gustoæa hemoragijskog infarkta na CT slici je odreðe-
na gustoæom krvi i iznosi 40 do 80 HU; obiljeen je neo-
trim rubom, omeðen zonom sniene gustoæe koja odgo-
vara ishemijskom dijelu infarkta ili edemu. Daljnji izgled
infarkta ovisi o ponaanju krvnih komponenata u ishemi-
jom zahvaæenom podruŁju. S vremenom se gustoæa tako
mijenja da nakon nekoliko tjedana postaje izodenzna u
odnosu na okolne strukture.
U 25% sluŁajeva CT nalaz moe biti potpuno norma-
lan kod jasnih kliniŁkih sluŁajeva cerebrovaskularnog inzul-
of blood. In case of thrombus migration distally from the
site of blood vessel occlusion, extravasation through the
damaged segment of the now released blood vessel occurs,
again with hemorrhage to the infarcted area. These factors
are responsible for the variegated picture of ischemic inf-
arction at this stage of the disease, which may mimic tu-
morous process in some cases. CT image with a contrast
showing pathologic, luxury perfusion of cortical areas of
the cerebral artery supply is used for further evaluation.
In this period, an expansive pattern may be observed
in the infarcted area due to the development of consider-
able edema, thus the course and prognosis of the disease
depend just on the intensity of this event as well as on the
possible transtentorial herniation.
In the chronic state (from day 21 on), partial sharp
demarcation or cicatrization of the process occur, and CT
density will change according to these alterations.
In most cases, native CT proves adequate to make the
diagnosis of stroke, especially in the acute and superacute
stage when complications may occur. However, in case of
uncertain diagnosis or unusual localization of lesions, a MR
scan should be obtained.
Contrast medium should not be used in the acute
stage; in the subacute stage, complete imbibition or gyral
imbibition may be observed (the finding is not pathogno-
monic and causes difficulties on differential diagnosis from
other vascular diseases).
Hemorrhagic Infarction
The incidence of hemorrhagic infarctions in all strokes
ranges from 5% to 21%. Hemorrhagic infarction occurs due
to secondary hemorrhage into the ischemically altered
cerebral region, mostly due to embolism. The hemorrhage
occurs during ischemia or consequentially to infarction
within 24 h, however, hemorrhagic transformation is only
visible 24 h from the onset of hemorrhage.
Hemorrhagic infarction is easily differentiated from
cerebral hemorrhage of some other etiology by clinical pic-
ture and CT finding. In case of hemorrhagic infarction, the
clinical picture develops immediately in full intensity,
without signs of intracranial pressure elevation, as differ-
entiated from cerebral hemorrhage which shows signs of
intracranial pressure increase along with an abrupt devel-
opment of clinical picture. Hemorrhagic infarction is most
common in embolism and large infarcts.
The hemorrhagic infarction density on CT image is
determined by blood density and is between 40 and 80
HU. It is characterized by unsharply delineated margins
demarcated by a hypodense area corresponding to the
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ischemic part of infarction or edema. Further infarct ap-
pearance depends on the behavior of blood components
in the ischemic area. Density changes with time and the
area becomes isodense with the adjacent structures with-
in a few weeks.
CT finding can be completely normal in 25% of clear
cases of stroke. In these cases, MR scanning should be
performed. Some 80% of acute infarctions can be detect-
ed by MR in the initial stage within 24 h. The earliest
change detectable on MR occurs at 2 h of the onset of
infarction, is characterized by the sign of intravascular MR
signal enhancement, and is caused by slow and decreased
intracranial blood flow through the vessel. Cortical edema
(hyperintensity, increased thickness and vague border
between the cortex and the white matter) is earliest de-
tectable at 3 h of the infarction onset, especially on spe-
cific images such as DWI sequence.
MR has multiple role in the diagnosis of stroke; the fast
spin echo image shows the extent of ischemic lesion,
whereas MRA shows extensive changes in the cerebrovas-
cular system. The diffusion weight image (DWI) based on
the change in the content of water in the intracellular and
extracellular area is used for early ischemia visualization.
As cytotoxic edema is one of the first characteristics of is-
chemia, these lesions can be very early detected by MR.
Thus, MR enables easy differentiation between previous
vascular lesions and recent changes. MR has an important
role in the detection of ischemic lesions immediately upon
the onset of stroke and leads to the cause of stroke.
MRA is used to visualize occluded vessels of the brain,
mostly internal carotid artery, antrior cerebral artery, mid-
dle cerebral artery, and vertebral artery.
Venous Infarction
Venous infarction (ischemic or hemorrhagic) occurs
due to thrombophlebitis or thrombosis of dural arterio-
venous fistulas, thus localization of the process depend-
ing on the cause (cortical structures or structures along the
intracranial sinuses). Morphologically, the infarct resem-
bles arterial infarct. MR is the method of choice.
Specific forms of infarction: borderline infarcts are
ischemic lesions at the border of irrigation systems of large
cerebral arteries. They account for 10% of cerebral infarcts,
and usually are ischemic, less frequently hemorrhagic or
mixed. They are well visualized by CT and MR.
Lacunae are small cystic cavities that can be ascribed
to primary arterial diseases of deep penetrant branches of
large cerebral arteries. The predilection sites are lentiform
nucleus, thalamus, caudate nucleus, and internal capsule.
Lacunae are better visualized by MR.
ta. U tim sluŁajevima potrebno je uŁiniti snimanje mag-
netskom rezonanacom (MR).
MR moe otkriti 80% akutnih infarkata u poŁetnoj fazi
do 24 h. Najranija promjena vidljiva na MR je 2 h od nas-
tupa infarkta; obiljeava ju znak intravaskularnog pojaŁa-
nja MR signala, a uzrokovana je sporim i smanjenim intra-
kranijskim protokom krvi kroz krvnu ilu. Kortikalni edem
(hiperintenzitet, poveæana debljina i nejasna granica kor-
teksa i bijele tvaari) vidljiv je najranije 3 h od nastupa in-
farkta, osobito na specifiŁnim snimakama kao to je sekven-
ca DWI.
Vanost MR u dijagnostici modanog udara je viestru-
ka: tzv. fast spin echo prikaz pokazuje opseg ishemijske
promjene, a MRA pokazuje opsene promjene na
krvoilnom sustavu mozga. Za rani prikaz ishemije rabe se
tzv. diffusion weight prikaz (DWI) koji se temelji na promje-
ni sastava vode u unutarstaniŁnom i  izvanstaniŁnom po-
druŁju. S obzirom na to da je citotoksiŁni edem jedan od
prvih znaŁajka ishemije, ove promjene se na MR mogu vrlo
rano otkriti. Ova znaŁajka MR omoguæuje lako razlikova-
nje starih vaskularnih lezija od novih promjena. MR igra
vanu ulogu u otkrivanju ishemijskih promjena neposred-
no nakon nastupa modanog udara te nas vodi k uzroku
modanog udara.
MRA se rabi za prikaz okludiranih krvnih ila mozga,
najŁeæe a. carotis interna, a. cerebri anterior, a. cerebri me-
dia i a. vertebralis.
Venski infarkt (ishemijski ili hemoragiŁni) nastaje zbog
tromboflebitisa ili tromboze duralnih arteriovenskih fistula,
pa æe lokalizacija procesa ovisiti o uzroku (kortikalne struk-
ture ili pak strukture uz intrakranijske sinuse). Morfolo-
ki izgled infarkta sliŁan arterijskom. MR je metoda izbora.
Posebni oblici infarkta: graniŁni infarkti su ishemijske
lezije na granici irigacijskih sustava veæih modanih arte-
rija. ¨ine 10% modanih infarkta, a obiŁno su ishemijski,
rjeðe hemoragiŁni ili mijeani. Dobro se vizualiziraju po-
moæu CT odnosno MR.
Lakune su male cistiŁne upljine koje se mogu pripi-
sati primarnim arterijskim bolestima dubokih penetrant-
nih ogranaka velikih cerebralnih arterija. Predilekcijska
podruŁja su n. lentiformis, talamus, n.caudatus, capsula
interna. Bolje se vizualiziraju pomoæu MR.
Multiinfarktne lezije istodobno se javljaju u oko 4%
sluŁajeva, dok se u oko 30% sluŁajeva nalaze viestruke
infarktne lezije razliŁitih irigacijskih podruŁja koje su ra-
zliŁite starosti. Ovakove lezije se u oko 20% sluŁajeva nalaze
kod dementnih osoba s progresivnom kliniŁkom slikom i
visokom smrtnoæu.
Razni kliniŁki entiteti mogu uzrokovati sliku cere-
brovaskularnog inzulta:
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Hipertenzivna encefalopatija je posljedica znaŁajnog
povienja krvnog tlaka s  bijegom tekuæine i proteina kroz
stijenke krvnih ila, to uzrokuje difuzni ili lokalni edem.
Hipertenzivna encefalopatija predstavlja kroniŁnu kom-
plikaciju hipertenzije bez obzira na etiologiju. ¨ esto se jav-
lja kod bubrene insuficijnecije, hemolitiŁno-uremiŁnog
sindroma, u fazi toksemije u trudnoæi, kod trombotiŁne
trombocitopeniŁne purpure.
Patohistoloke promjene koje nastaju kao posljedica
dugotrajno povienog krvnog tlaka su fibrinoidna nekroza,
tromboza modanih arterija, mikroinfarkti i petehijska
krvarenja. ¨ esto ove promjene proðu kliniŁki nezapaene
pa se nalaze kao sluŁajan nalaz na CT i MR. U akutnoj fazi
nalazi se modani edem koji se povlaŁi uz terapiju, a u kro-
niŁnoj fazi lakunarni infarkti gustoæe likvora na CT, odnos-
no na MR signala likvora.
Fibromuskularna displazija je rijetka anomalija koja
u 90% sluŁajeva zahvaæa ene od 40-60 godina starosti.
Zahvaæa visoko podruŁje unutarnje karotidne arterije (95%)
i/ili vertebralne arterije (25%). U 60% sluŁajeva je bilate-
ralna. ¨esto je udruena s intrakranijskim aneurizmama
(20%-50%), arterijskovenskim fistulama i bubrenom fi-
bromuskularnom displazijom. ¨esto je kliniŁki mukla, no
ponekad izaziva arine neuroloke deficite s glavobolja-
ma.
Cerebralni vaskulitis je obiljeen upalom i fibroid-
nom nekrozom medije i intime arterija uzrokujuæi okluzije,
infarkte ili krvarenja. UzroŁnici mogu biti infektivni (bak-
terijski, virusni i dr.) ili neinfektivni (poliarteritis nodosa,
temporalni arteritis, granulomatozni angiitis, sarkoidoze i
dr.).
Spontana modana krvarenja posljedica su hiper-
tonije, ateroskleroze, rupture aneurizme ili A-V malfor-
macije, posljedica amiloidne angiopatije, antikoagulantne
terapije, krvarenja u tumoru i sl. Vrijednost CT je u dobrom
i ranom otkrivanju krvnih elemenata pomoæu HU. S
duinom trajanja krvarenja opada gustoæa procesa od 60
HU nanie. NajŁeæe obolijevaju mukarci od 60-80 godi-
na starosti s anamnezom hipertenzije. NajŁeæa lokaliza-
cija su bazalni gangliji (60%-70%), talamus (10%-20%),
pons (5%), n. dentatus (1%-5%) te hemisfere (1%-2%).
MR omoguæuje razlikovanje razliŁitih faza intracere-
bralnih krvarenja te se na taj naŁin moe priliŁno toŁno
odrediti starost krvarenja. Promjenom MR signala razlikuje
se faza oksihemoglobina (unutar 12 sati), deoksihemoglo-
bina (1-7 dana), unutarstaniŁnog methemoglobina (3-7
dana), izvanstaniŁnog methemoglobina (poslije 5 dana).
Hemosiderin koji nastaje nakon nekoliko tjedana posjeduje
paramagnetska svojstva s razliŁitim signalima u razliŁitim
tehnikama snimanja.
Multiinfarct lesions occur simultaneously in some 4%
of cases, whereas multiple infarct lesions of various irriga-
tion systems and different age occur in in 30% of cases. In
20% of cases, these lesions are found in demented persons
with a progressive clinical picture and high mortality.
Various clinical entities may cause the picture of stroke,
e.g.:
Hypertensive encephalopathy is a sequel of significant
elevation of blood pressure with fluid and protein escape
through blood vessel walls, which causes diffuse or local
edema. Hypertensive encephalopathy is a chronic compli-
cation of hypertension irrespective of etiology. It is com-
mon in renal insufficiency, hemolytic-uremic syndrome, in
the stage of toxemia in pregnancy, and in thrombotic
thrombocytopenic purpura.
The pathohistologic changes occurring consequentially
to longterm blood pressure elevation include fibrinoid
necrosis, cerebral arterial thrombosis, microinfarcts and
petechial hemorrhages. These changes frequently proceed
unnoticed and are found accidentally on CT or MR. Ce-
rebral edema is found in the acute stage and resolves with
therapy, whereas in chronic stage lacunar infarcts of CSF
density are detected on CT or of CSF signal on MR.
Fibromuscular dysplasia is a rare anomaly with 90%
of cases recorded in women aged 40-60. It involves the high
segment of internal carotid artery (95%) and/or vertebral
artery (25%), with bilateral involvement in 60% of cases.
Fibromuscular dysplasia is frequently associated with in-
tracranial aneurysms (20%-50%), arteriovenous fistulas,
and renal fibromuscular dysplasia. It frequently assumes
a silent course clinically, however, occasionally it may cause
focal neurologic deficits with headaches.
Cerebral vasculitis is characterized by inflammation
and fibroid necrosis of the arterial media and intima, caus-
ing occlusions, infarcts and hemorrhages. The causes may
be infective (bacterial, viral, etc.) or noninfective (pol-
yarteritis nodosa, temporal arteritis, granulomatous angii-
tis, sarcoidosis, etc.).
Spontaneous cerebral hemorrhages occur consequen-
tially to hypertension, atherosclerosis, ruptured aneurysm,
A-V malformation, amyloid angiopathy, anticoagulant ther-
apy, tumor hemorrhage, etc. CT is valuable for appropri-
ate and early detection of blood components expressed in
HU units. The process density decreases with the dura-
tion of hemorrhage from 60 HU down. Men aged 60-80
with a history of hypertension are most commonly affect-
ed. The most common localizations are basal ganglia (60%-
70%), thalamus (10%-20%), pons (5%), dentate nucleus
(1%-5%) and hemispheres (1%-2%).
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MR allows for different stage of intracerebral hemor-
rhage to visualize, thus being able to quite precisely de-
termine the age of hemorrhage. By changing MR signal,
the stages of oxyhemoglobin (within 12 h), deoxyhemo-
globin (day 1-7), intracellular methemoglobin (day 3-7)
and extracellular methemoglobin (day 5 on) can be distin-
guished. Hemosiderin, formed after a few weeks, possesses
paramagnetic properties with different signals on differ-
ent imaging techniques.
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LijeŁenje bolesnika s ishemijskim modanim udarom
u jedinicama za lijeŁenje modanog udara (JLMU) doka-
zano znaŁajno sniava smrtnost, invaliditet i potrebu za
trajnim smjetajem u usporedbi s lijeŁenjem bolesnika na
opæim odjelima. Jedinica za lijeŁenje modanog udara je
bolniŁki odjel koji se iskljuŁivo skrbi o bolesnicima s
modanim udarom, a obiljeena je primjereno obrazovanim
i multidisciplinskim timom. Multidisciplinski ui tim Łine
neurolog obrazovan za lijeŁenje bolesnika s modanim
udarom, internist, primjereno obrazovane medicinske
sestre i fizioterapeut, a u irem timu su jo logoped, radni
terapeut i socijalni radnik.
Organizacijski su moguæi razni modeli JLMU: inten-
zivna skrb, jedinica za akutno lijeŁenje modanog udara,
kombinirane akutno-rehabilitacijske jedinice, te mobilni
timovi.
Intenzivna  skrb: specijalni odjel s opremom (respirator,
intenzivno i neinvazivno monitoriranje) za hitno zbrinja-
vanje bolesnika s tekom kliniŁkom slikom modanog
udara (komatozni bolesnici, bulbarna paraliza). Slaba ili
nikakva rehabilitacija.
THE ROLE OF ACUTE STROKE UNIT
ULOGA  JEDINICE ZA LIJE¨ENJE MODANOG UDARA
Vesna Vargek-Solter
University Department of Neurology, Sestre milosrdnice University Hospital, Zagreb, Croatia
Klinika za neurologiju, KliniŁka bolnica Sestre milosrdnice, Zagreb
Treatment of patients with ischemic stroke at a stroke
unit significantly reduces mortality, disability and need of
institutional care compared with treatment at general
medical wards.
Stroke unit is a hospital unit that exclusively takes care
of stroke patients. Stroke units are characterized by spe-
cifically trained staff and a multidisciplinary approach to
treatment and care. The multidisciplinary core team at
stroke unit consists of a neurologist, an internist, nurses
and physiotherapists, whereas the extended multidisci-
plinary team includes speech therapists, occupational ther-
apists and social workers.
There are different types of stroke units: intenisive care
units, acute stroke unit, combined acute and rehabilitation
stroke unit, and mobile stroke team.
Intensive care units: dedicated stroke units with facilities
like ventilators and intensive and nonintensive monitor-
ing. The units are focused on very acute care for a select-
ed group of acute stroke patients and have little focus on
rehabilitation.
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JLMU: Odjeli koji primaju akutne bolesnike, ali ih i rano
otputaju (unutar 7 dana); bez respiratora i invazivnog mo-
nitoriranja, opremljeni ureðajima za stalno kardijalno mo-
nitoriranje. Mali naglasak na rehabilitaciji.
Kombinirane akutno-rehabilitacijske jedinice: Specijalni odjel
koji prihvaæa bolesnike za akutno lijeŁenje. Rano se zapo-
Łinje s mobilizacijom i rehabilitacijom, boravak 1-2 tjedna.
Mobilni timovi: Multidisciplinski timovi organizirani su
za bolesnika s modanim udarom za ustanove u kojima nije
moguæe organizirati JLMU.
Najbolje rezultate pokazale su kombinirane akutno-re-
habilitacijske jedinice. Ukupno je bilo ispitano 4911 bole-
snika u 23 randomizirane  studije. Rezultati studija poka-
zali su smanjenje smrtnosti prema opæim odjelima za 18%,
potrebe za tuðom pomoæi za 29%, potrebe za trajnim smje-
tajem za 25%, dok je duina lijeŁenja skraæena za 30%.
Indikacije za lijeŁenje u JLMU su slijedeæe:
 akutni modani udar sa simptomima ne duim od 24 h
 nestabilni ili progresivni neuroloki deficit
 potreba za specifiŁnim lijeŁenjem (tromboliza)
 potreba za ranom rehabilitacijom
Dobri rezultati lijeŁenja bolesnika u JLMU vjerojatno
su u tome to ispunjavaju sve potrebe  bolesnika s
modanim udarom u raznim fazama lijeŁenja.
Dobro organizirana JLMU mora zadovoljiti sve potrebe
bolesnika za vrijeme hitne, akutne i subakutne faze. Za
vrijeme hitne faze (izmeðu 6 i 12 sati od nastanka moda-
nog udara) teite je na dijagnozi i smanjenju modanog
oteæenja. U akutnoj fazi od 12 do 72 sata od poŁetka bolesti
prioritet je sprjeŁavanje komplikacija, rana mobilizacija i
poŁetak rehabilitacije. U subakutnoj fazi od 3. do 14. dana
bolesti provodi se rehabilitacija i prevencija komplikacija,
kao i prevencija recidiva cerebrovaskularnog inzulta i drugih
vaskularnih zbivanja.
Zbrinjavanje bolesnika u JLMU (zasnovano na
dokazima)
Akutno zbrinjavanje i monitoriranje
Medicinsko zbrinjavanje








Acute stroke units: stroke units that provide acute care for
patients but discharge them early (usually within 7 days)
and have no or at best a modest focus on rehabilitation. The
units do not have intensive care facilities but usually facil-
ities for noninvasive monitoring of vital signs.
Combined acute-rehabilitation stroke units: dedicated stroke
units which accept stroke patients for acute treatment
combined with early mobilization and rehabilitation for a
period of at least 1-2 weeks.
Mobile stroke team: established for hospitals where stroke
units are not available. This is a team consisting of differ-
net professionals who treat stroke patients throughout the
hospital wherever the patients may be.
The combined acute-rehabilitation stroke units have
shown best results. In 23 trials with 4911 patients a sig-
nificant (18%) mortality reduction, 23% reduction in de-
pendence on other peoples help and 25% reduction in the
need of institutional care were recorded in comparison with
patients treated at general wards.
The main indications for admission to acute stroke unit
are:
 acute stroke with symptoms manifesting for less than
24 hours
 unstable or progressive neurologic deficit
 need of specific therapy (thrombolysis)
 need of early rehabilitation
The favorable results recorded at stroke unit probably
are due to the fact that the needs of acute stroke patients
can be met across different phases of the disease. A well
organized stroke unit should meet all stroke patient needs
during the emergency, acute and subacute phases of the
disease.
During the emergency phase within the first 6-12 h of
stroke onset, focus should be on the diagnosis and reduc-
tion of brain injury. In the acute phase from 12 to 72 h, focus
should be on complication prevention, early mobilization,
and start of rehabilitation. In the subacute phase from day
3 to day 14, the care is focused on rehabilitation combined
with prevention of complications as well as prevention of
new strokes and other vascular events.
The processes of Care in Stroke Units (evidence
based)
Acute care and monitoring
Medical assessment
Medical history and examination
 biochemistry
 hemathology
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 unos i iznos tekuæine
 prevencija dekubitusa






 paljivo praæenje unosa tekuæine/hrane (Łesto i.v. otopi-
na soli u prvih 12-24 sata)
 antibiotici (infekcija)
 paracetamol kod poviene tjelesne temperature
 kisik (hipoksija, omaglice, kardiorespiracijska bolest)
 inzulin (hiperglikemija)
 praæenje krvnog tlaka
 rehabilitacija
 rana mobilizacija
 paljivo namjetanje bolesnika
 Łesta promjena poloaja
 prevencija dekubitusa
 izbjegavati urinarni kateter
Rehabilitacija
 rano postavljanje ciljeva
 rano ukljuŁivanje u proces rehabilitacije
 uŁinkovita razmjena informacija
 povezanost njege i rehabilitacije












 pressure area risks






 careful management of fluid/food (often i. v. saline so-
lutions over first 12-24 h)
 antibiotics for suspected infection
 paracetamol for pyrexia
 oxygen (if hypoxia, drowsiness, cardiorespiratory dis-
ease)
 insulin (if hyperglycemia)




 careful positioning and handling
 pressure area care
 avoid urinary catheters
Ongoing rehabilitation
 early goal setting
 early involvement in rehabilitation
 provision of information
 close linking of nursing and rehabilitation
 discharge plans  cooperation with primary health care
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Na svim listama Łimbenika rizika za nastanak ishe-
mijskog i hemoragijskog modanog udara (MU) povien
tlak uvijek zauzima nezahvalno prvo mjesto. Upravo je us-
pjeno lijeŁenje arterijske hipertenzije bilo vjerojatno jedan
od vodeæih razloga za smanjenu incidenciju MU.
Definicija povienog krvnog tlaka (SZO)
Optimalni tlak sistoliŁki <120 mm Hg,
dijastoliŁki <80 mm Hg
Normalni tlak sistoliŁki <130 mm Hg,
dijastoliŁki <85 mm Hg
Povien tlak  hipertenzija sistoliŁki >140 mm Hg,
dijastoliŁki >90 mm Hg
LijeŁenje povienog krvnog tlaka (SZO)
Mijenjanje ivotnih navika
 smanjenje tjelesne teine, prestanak puenja, tjelo-
vjeba, smanjen unos soli, odravanje odgovarajuæeg
unosa kalija, kalcija i magnezija
Farmakoloko lijeŁenje
 diuretici, beta blokatori, inhibitori ACE, blokatori kal-
cijevih kanala, antagonisti angiotenzinskih receptora,
vazodilatatori
Suvremeno poimanje antihipertenzivne terapije odnosi
se na specifiŁnu i individualnu terapiju prilagoðenu svakom
bolesniku, uzimajuæi pritom u obzir dob i prisutnost drugih
Łimbenika rizika (lipidi, eæerna bolest, atrijska fibrilacija,
hipertrofija lijeve klijetke), ali i ranijih vaskularnih bolesti
(MU, srŁani infarkt) te napokon i drugih komorbidnih Łim-
benika (stenoza bubrene arterije, astma).
Kako lijeŁiti povien krvni tlak?
Nefarmakoloko lijeŁenje  promjena ivotnih navika
 prestanak puenja
 smanjenje tjelesne teine
 smanjenje unosa alkohola
 smanjenje unosa soli
TREATMENT OF ELEVATED BLOOD PRESSURE IN ACUTE STROKE
LIJE¨ENJE POVIENOG KRVNOG TLAKA U AKUTNOM MODANOM  UDARU
Tomislav Breitenfeld
University Department of Neurology, Sestre milosrdnice University Hospital, Zagreb, Croatia
Klinika za neurologiju, KliniŁka bolnica Sestre milosrdnice, Zagreb
Elevated blood pressure takes the unenviable leading
position at all lists of risk factors for either ischemic or
hemorrhagic stroke. It was just the successful treatment
of arterial hypertension that probably contributed most to
reduction in the incidence of stroke.
Definition of Hypertension (WHO)
Optimal blood pressure systolic <120 mm Hg,
diastolic <80 mm Hg
Normal blood pressure systolic <130 mm Hg,
diastolic <85 mm Hg
Elevated blood pressure systolic <140 mm Hg,
 hypertension diastolic <90 mm Hg
Treatment of Hypertension (WHO)
Lifestyle modifications
 diuretics, beta blockers, ACE inhibitors, calcium chan-
nel blockers, angiotensin receptor blockers, vasodila-
tators
Currently, antihypertensive therapy implies specific
and individualized therapy adjusted to each individual
patient, taking into account age and presence of other risk
factors (lipids, diabetes mellitus, atrial fibrillation, left
ventricular hypertrophy) as well as previous vascular dis-
eases (stroke, myocardial infarction) and other comorbid-
ities (renal artery stenosis, asthma).
How to Treat Hypertension?
Nonpharmacologic Management  Lifestyle Modifications
 quit smoking
 weight loss
 reduced alcohol intake
 reduced salt intake
 increase in physical activity
 other dietary measures (greater intake of fish and veg-
etables, reduced intake of saturated fat)
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Pharmacologic Therapy
 all 6 classes of antihypertensive agents are efficient in
blood pressure lowering and can be used as first choice
medication
 dual combinations of antihypertensives from different
classes have been recommended and found wide ap-
plication in clinical practice
 AB/CD protocol
Blood Pressure Lowering Drugs
1) Alfa-adrenergic receptor blockers  a-blockers
There are no randomized data for drugs like prazosin
and doxazosin, labetalol was investigated in a small study,
and only doxazosin (Tonocardin) is commercially available
in Croatia.
2) Angiotensin convertase enzyme inhibitors  ACE inhibitors
A small randomized trial has shown perindopril to lower
elevated blood pressure by 11% without affecting general
cerebral flow or MBFV in the middle cerebral artery. This
group of antihypertensives is now one of the most com-
monly prescribed drug classes because of their relatively
good effects and low rate of adverse events. The Croatian
Institute of Health Insurance (CIHI) list of drugs includes
enalapril (Enazil, Enap, Olivin), lisinopril (Irumed), per-
indopril (Prexanil), ramipril (Tritace), cilazapril (Cilazil),
fosinopril (Monopril) and trandolapril (Gopten).
3) Angiotensin receptor antagonists  AT1 antagonists
ACCESS, a randomized study (unpublished, discon-
tinued), showed candesartan to influence stroke outcome
in terms of lower mortality and disability. The CIHI list
includes losartan (Cozaar), valsartan (Diovan) and telm-
isartan (Pritor).
4) Beta-adrenergic receptor blockers  b-blockers
There is only one study demonstrating a tendency of
the disease and outcome deterioration in patients admin-
istered atenolol or propranolol. Earlier, these drugs were
considered a gold standard in the management of hyper-
tension. In Croatia, oxprenolol (Trasicor), propranolol (Pro-
pranolol), atenolol (Ormidol, Atenolol, Tenormin), biso-
prolol (Concor) and carvedilol (Carvetrend, Carvelol) are
commercially available.
5) Calcium antagonists
Calcium antagonists are definitely the most common-
ly prescribed group of antihypertensives. Studies have
shown calcium antagonists administered in the initial stage
of stroke or later during stroke management failed to pro-
 poveæana tjelesna aktivnost
 ostale prehrambene mjere (vie ribe i povræa, manje
zasiæenih masnoæa)
Farmakoloko lijeŁenje
 svih 6 skupina antihipertenziva uŁinkovito sniavaju
krvni tlak i mogu biti prvi lijek izbora
 preporuŁene su i u kliniŁkoj praksi uhodane mnoge
dvojne kombinacije antihipertenziva iz razliŁitih skupi-
na
 protokol AB/CD
Lijekovi za sniavanje krvnog tlaka
1) Blokatori alfa adrenergiŁnih receptora (alfa blokatori)
Nema randomiziranih podataka za lijekove poput pra-
zosina i doksazosina, labetalol je istraen u maloj studiji, a
u Hrvatskoj na tritu je samo doksazosin (Tonocardin).
2) Inhibitori enzima angiotenzin konvertaze (inhibitori
ACE)
Malo randomizirano istraivanje pokazalo je da perin-
dopril sniava povien krvni tlak za 11%, ali bez mijenjanja
globalnog cerebralnog protoka ili SBSK u srednjoj modanoj
arteriji. Ova skupina antihipertenziva danas spada meðu
one koje se najvie primjenjuju zbog razmjerno dobrog
uŁinka i niskog postotka neeljenog djelovanja. Na listi
lijekova HZZO-a nalaze se enalapril (Enazil, Enap, Oli-
vin), lizinopril (Irumed), perindopril (Prexanil), ramipril
(Tritace), cilazapril (Cilazil), fosinopril (Monopril), tran-
dolapril (Gopten).
3) Blokatori angiotenzinskih receptora (AT1 antagonisti)
Jedno randomizirano istraivanje (neobjavljeno, preki-
nuto) pokazalo je utjecaj kandesartana  na ishod modanog
udara u smislu manje smrtnosti i invaliditeta (studija
ACCESS).
Na listi lijekova HZZO-a nalaze se losartan (Cozaar),
valsartan (Diovan), telmisartan (Pritor).
4) Blokatori beta adrenergiŁnih receptora (beta bloka-
tori)
Postoji tek jedno istraivanje koje je pokazalo trend
pogoranju stanja i ishoda bolesnika koji uzimaju atenolol
ili propranolol. Ranije su predstavljali zlatni standard u
lijeŁenju hipertenzije. Na naem tritu nalaze se okspre-
nolol (Trasicor), propranolol (Propranolol), atenolol (Or-
midol, Atenolol, Tenormin), bisoprolol (Concor), karvedilol
(Carvetrend, Carvelol).
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duce any change in the patient functional outcome. The
CIHI list includes amlodipine (Norvasc, Amlopin, Amon-
ex), nifedipine (Nifedipin, Cordipin), lacidipine (Lacip-
il), verapamil (Isoptin) and diltiazem (Diltiazem, Al-
dizem).
6) Diuretics
These are inexpensive and efficacious antihyperten-
sives, however, as yet without appropriate randomized clin-
ical trials of their efficacy in terms of stroke outcome. In
Croatia, furosemide (Fursemid, Edemid), spironolactone
(Aldactone, Priul), chlorthalidone (Hygroton), indapam-
ide (Tertensif, Amoron), triamteren with hydrochlorothi-
azide (Tiaren) and amyloride with hydrochlorothiazide
(Moduretic) are available.
7) Vasodilatators  nitrates
These agents are rarely used for the treatment of ele-
vated blood pressure in stroke. In Croatia, glyceryl trini-
trate (Angised, Nitrolingual, Trinitrosan, Nitronal), isos-
orbide dinitrate (Tinidil) and isosorbide mononitrate (Ol-
icard, manufactured by ISMN Genericon or Jadran) are
commercially available. Two small randomized trials have
shown the transdermally applied glyceryl trinitrate to de-
crease blood pressure by 6%-8% without affecting BFV.
AB/CD Rule
(Dickerson et al., University of Cambridge, UK; Lancet
1999)
A  ACE inhibitors, B  Beta blockers,
C  Ca antagonists, D  Diuretics
1) monotherapy: age £55 A or B
age £55 C or D
2) dual combination: A + B or C + D
3) triple combination: A + C + D or B + C + D
add alfa blocker to A + B or C +
D combination
4) consider specialist consultation for arterial hyperten-
sion
Shortcoming: angiotensin receptor blockers (AT1 an-
tagonists) are ignored.
Treatment of Hypertension in Acute Stroke
The majority of patients have elevated blood pressure
during the first few hours of stroke onset. Blood pressure
may be elevated for a number of reasons such as:
 pre-existing arterial hypertension
 neuroendocrine system activation
5) Antagonisti kalcija
Meðu antihipertenzivnim lijekovima zasigurno skupi-
na koja se najŁeæe propisuje. Provedena istraivanja poka-
zala su pak kako antagonisti kalcija primjenjivani odmah
na poŁetku MU ili kasnije tijekom lijeŁenja nisu promije-
nili funkcionalni ishod kod bolesnika. Na listi HZZO-a
nalaze se amlodipin (Norvasc, Amlopin, Amonex), nife-
dipin (Nifedipin, Cordipin), lacidipin (Lacipil), verapamil
(Isoptin) i diltiazem (Diltiazem, Aldizem).
6) Diuretici
Ovo su jeftini i uŁinkoviti antihipertenzivi zasad bez
odgovarajuæih randomiziranih kliniŁkih ispitivanja to se
tiŁe uŁinkovitosti za ishod lijeŁenja MU. Na naem tritu
nalaze se furosemid (Fursemid, Edemid), spironolakton
(Aldactone, Priul), klortalidon (Hygroton), indapamid
(Tertensif, Amoron), triamteren sa hidroklortiazidom
(Tiaren), amilorid s hidroklortiazidom (Moduretic).
7) Vazodilatatori - nitrati
Ovi lijekovi se rijetko rabe u lijeŁenju povienog krvnog
tlaka u MU. Na tritu u Hrvatskoj nalazimo gliceril tri-
nitrat (Angised, Nitrolingual, Trinitrosan, Nitronal), zatim
izosorbid dinitrat (Tinidil) te izosorbid mononitrat (Oli-
card, ISMN Genericon ili Jadran). Dva mala randomdi-
zirana ispitivanja pokazala su kako transdermalno aplici-ran
gliceril trinitrat smanjuje krvni tlak za 6%-8% bez mije-
njanja BSK.
Pravilo AB/CD (Dickerson et al., University of Cam-
bridge, UK, Lancet 1999.)
Primjena antihipertenzivne terapije i kombinacije antihi-
pertenziva u 4 stupnja:
A  ACE inhibitori, B   Beta blokatori,
C  Ca antagonisti, D   Diuretici
1) monoterapija: mlaði od 55 godina A ili B
stariji od 55 godina C ili D
2) dvostruka kombinacija: A + B ili C + D
3) trostruka kombinacija: A + C + D ili B + C + D
dodati alfa blokator kombina-
ciji A + B ili C + D
4) razmisliti o konzultiranju specijalista za arterijsku hi-
pertenziju
Nedostatak: ignoriranje blokatora angiotenzisnskih re-
ceptora, AT1 antagonista.
LijeŁenje povienog krvnog tlaka u modanom
udaru
Najveæi broj bolesnika imaju povien krvi tlak tijekom
prvih sati nakon modanog udara. Tlak moe biti povien
Second Congress of Croatian Society for Neurovascular Disorders of Croatian Medical Association
Drugi kongres Hrvatskoga drutva za neurovaskularne poremeæaje Hrvatskoga lijeŁniŁkog zbora
Acta Clin Croat, Vol. 43, Suppl. 1,  2004 69
 pain
 nausea, vomiting
 elevated intracranial pressure (Cushings reflex)
 restlessness and disorientation
 anxiety
 stress due to stroke
 full bladder
 physiologic response to hypoxia
Also, elevated blood pressure may act as a compensa-
tory mechanism to maintain adequate cerebral perfusion.
In ischemic stroke, cerebral autoregulation is impaired.
In this case, the brain needs elevated blood pressure, and
abrupt blood pressure reduction may result in deteriora-
tion of the neurologic deficit. Elevated blood pressure is
present in more than 75%-80% of stroke patients (Inter-
national Stroke Trial  IST, Lancet 1997).
Blood pressure is generally higher in patients with pri-
mary cerebral hemorrhage in comparison with ischemic
stroke patients.
Blood pressure will usually spontaneously resume pre-
stroke values in about a week, however, it may remain el-
evated in one third of stroke patients.
The value of blood pressure at the onset of stroke may
be directly connected to stroke outcome. Greatly elevat-
ed or decreased blood pressure increases the risk of death
and disability, as demonstrated in a number of small stud-
ies as well as in meta-analyses. Small studies point to the
fact that Ca blockers, ACE inhibitors and nitrates but not
thiazide diuretics cause acute blood pressure decrease.
On the other hand, subsequent longterm antihyperten-
sive therapy as a secondary prevention of stroke should be
taken in consideration in all patients with hypertension.
Scientific research and clinical trials on stroke treat-
ment are now primarily focused on reperfusion and neu-
roprotection, while neglecting the need of homeostasis
regulation, which firstly refers to the management of hy-
pertension, hyperglycemia, hyperpyrexia and cerebral ede-
ma. Each of these factors is associated with aggravated
outcome of stroke.
Large studies to investigate the rationale for blood
pressure lowering in the acute stage of stroke are expect-
ed to be launched or are just under way.
Main dilemma: to treat or not to treat hypertension
in acute stroke?
The physicians managing acute stroke patients are
daily faced with this serious dilemma.
Unfortunately, definite evidence to help them decide
are greatly lacking.
zbog mnogo razloga, na primjer:
 od ranije postojeæa arterijska hipertenzija
 aktiviranje neuroendokrinog sustava
 bol
 muŁnina, povraæanje
 poveæan intrakranijski tlak (Cushingov refleks)
 nemir i dezorijentacija
 tjeskoba
 stres od modanog udara
 pun mokraæni mjehur
 fizioloki odgovor na hipoksiju
Isto tako povien krvni tlak moe biti kompenzacijski
mehanizam za odravanje odgovarajuæe modane perfu-
zije.
Prilikom ishemijskog modanog udara dolazi do pore-
meæaja modane autoregulacije. U tim sluŁajevima mozgu
je potreban povien krvni tlak i naglo sniavanje tlaka moe
rezultirati pogoranjem neurolokog deficita. Povien krv-
ni tlak prisutan je kod vie od 75%-80% bolesnika s MU
(International Stroke Trial  IST, Lancet 1997.).
Krvni tlak preteno je vii kod bolesnika s primarnim
modanim krvarenjem u usporedbi s ishemijskim MU.
ObiŁno se tlak spontano regulira nakon prvog tjedna,
iako kod treæine bolesnika i dalje ostaje povien.
Vrijednost krvnog tlaka pri nastupu modanog udara
moe biti izravno povezana s njegovim ishodom. Izrazito
povien ili pak nizak krvni tlak poveæava rizik od smrti i
invalidnosti, to je pokazano u mnogim manjim studijama
ali i u meta-analizama.
Manje studije ukazuju na Łinjenicu da blokatori Ca,
inhibitori ACE i nitrati akutno sniavaju krvni tlak, ali ne
i tijazidski diuretici.
S druge strane, za sve bolesnike s povienim tlakom
treba uzeti u obzir potrebu za kasnijom dugotrajnom anti-
hipertenzivnom terapijom u smislu sekundarne prevencije
MU.
Znanstvena istraivanja i kliniŁki pokusi u lijeŁenju
modanog udara danas su prvenstveno usredotoŁeni na
reperfuziju i neurozatitu, a zanemaruje se potreba regu-
lacije homeostaze, to se prvenstveno odnosi na lijeŁenje
povienog krvnog tlaka, hiperglikemije, hiperpireksije,
modanog edema. Svaki taj Łimbenik povezan je s pogor-
anjem ishoda MU.
OŁekuju se ili su u tijeku velike studije koje istrauju
ima li smisla sniavati krvni tlak u akutnoj fazi MU.
Glavna dvojba: treba li lijeŁiti povien krvni tlak u
akutnom MU ili ne?
LijeŁnici koji lijeŁe bolesnike u akutnoj fazi MU sva-
kodnevno su suoŁeni s tom ozbiljnom dvojbom. Naalost,
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postoji izrazit manjak primjerenih dokaza koji bi utjecali
na njihove odluke.
U odsutnosti dokaza na koje se struŁnjak moe zasi-
gurno osloniti ne iznenaðuje to to postoje potpuno razliŁi-
ta miljenja o tome kako postupati s krvnim tlakom u akut-
nom MU.
NajŁeæa pitanja:
 uvoðenje antihipertenzivne terapije
 nastavak ili prekid antihipertenzivne terapije koju je
bolesnik uzimao prije MU
 pitanje podizanja krvnog tlaka
Oni koji zastupaju tezu sputanja krvnog tlaka pod
utjecajem su prvenstveno dokaza da je sputanje krvnog
tlaka najdjelotvornija strategija kako u primarnoj preven-
ciji tako i u sekundarnoj prevenciji u bolesnika s cere-
brovaskularnom boleæu.
S druge pak strane oni koji zagovaraju prestanak anti-
hipertenzivne terapije i preporuŁuju povienje krvnog tla-
ka objanjavaju to potrebom za odravanjem modane per-
fuzije i time smanjenjem modane ishemije.
Koristan doprinos ovoj raspravi moemo naæi u studiji
ACCESS (Acute Candesartan Citexetil Therapy in Stroke
Survivors  Stroke 2003), randomiziranoj, dvostruko slije-
poj, placebom kontroliranoj studiji zamiljenoj tako da se
ispita sigurnost umjerenog sniavanja krvnog tlaka dava-
njem kandesartana bolesnicima s hipertenzijom (RR >180
-200/105-110) u prvih 36 h od akutnog ishemijskog MU.
Studija ACCESS: primarni krajnji ishod (smrt i invaliditet,
nakon 3 mjeseca) nije pokazao razliku meðu dvjema skupi-
nama, dok je sekundarni krajni ishod (smrt, recidiv MU,
srŁane komplikacije, invaliditet, nakon 12 mjeseci) poka-
zao znaŁajno smanjenje za 48% (odds ratio = 0,48) u sku-
pini bolesnika koji su dobivali kandesartan. Time je potvr-
ðena djelotvornost u MU koja je ranije za isti lijek dokaza-
na i za ishemiju miokarda, iako mehanizam djelovanja nije
razjanjen. U toj je fazi studija prekinuta.
UŁinjeno je i mnogo malih pokusa o sniavanju krvnog
tlaka u akutnoj fazi MU, a rabljene su sve skupine antihi-
pertenziva. Neke studije pokazale su povoljan uŁinak u
ishemijskom MU i modanom krvarenju, dok su druge
pokazale kodljive ishode. Ipak, u veæini sluŁajeva ne radi
se o velikim, dobro dizajniranim i randomiziranim pokusi-
ma, dakle, niti o relevatnim podacima koji bi dali koristan
doprinos u procjeni potrebe lijeŁenja krvnog tlaka u MU.
Uz velike kliniŁke studije potrebne su i daljnje patofi-
zioloke studije koje æe istraiti uŁinak promjena krvnog
tlaka na modani protok i hemostazu u razliŁitim tipovi-
ma MU, na primjer, primjena PET (positron emission tomo-
In the absence of evidence to rely on, it is no surprise
that there are quite controversial opinions on how to man-
age blood pressure in acute stroke.
Most common questions:
 introduction of antihypertensive therapy
 continuation or discontinuation of antihypertensive
therapy the patient was taking prior to stroke
 blood pressure increase
Those advocating blood pressure reduction are prima-
rily influenced by the evidence indicating that blood pres-
sure lowering is the most efficient strategy in both prima-
ry prevention and in secondary prevention in patients with
cerebrovascular disease.
On the other hand, those giving preference to discon-
tinuation of antihypertensive therapy and recommending
blood pressure increase explain it by the need to maintain
cerebral perfusion thus to reduce cerebral ischemia.
A useful contribution to this debate is found in the
report on ACCESS (Acute Candesartan Citexetil Thera-
py in Stroke Survivors, Stroke 2003), a randomized, dou-
ble blind, placebo controlled study designed so as to in-
vestigate the safety of moderate blood pressure lowering
by the administration of candesartan to patients with hy-
pertension (BP >180-200/105-110 mm Hg) over the first
36 hours of acute ischemic stroke. The primary ACCESS
end-points (death and disability at 3 months) showed no
difference between the two patient groups, whereas sec-
ondary end-points (death, recurrent stroke, cardiac com-
plications, and disability at 12 months) showed a signifi-
cant, 48% reduction (odds ratio = 0.48) in the group of
patients administered candesartan. These results con-
firmed the drug efficacy in stroke, as previously also dem-
onstrated in myocardial ischemia, although the mechanism
of action has not yet been elucidated. The study was dis-
continued at that point.
There have been a number of small studies of blood
pressure lowering in acute stroke using all groups of hyper-
tensives. Some studies have shown a favorable effect in
ischemic stroke and cerebral hemorrhage, whereas others
point to unfavorable outcomes. Yet, these mostly were not
large, properly designed and randomized studies, thus the
data could not be considered relevant and reliable enough
to contribute to the assessment of the need of blood pres-
sure management in stroke.
Besides large clinical trials, additional pathophysiolo-
gy studies are also needed to investigate the effect of blood
pressure modification on cerebral circulation and hemo-
stasis in various types of stroke by use of, e.g., PET
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graphy), SPECT (single photon emission CT), TCD, perfu-
zijske i difuzijske MR (s procjenom penumbre, mismatch),
kvantitativne perfuzijske CT i ksenon CT.
Preporuke za regulaciju krvnog tlaka u
akutnom modanom udaru
1) International Society of Hypertension (ISH)
2) American Stroke Association (ASA)
3) European Stroke Initiative (EUSI)
4) Ministarstvo zdravstva RH
1) International Society of Hypertension (ISH)
Statement on the Management of Blood Pressure in
Acute Stroke (J Hypertens, 2003.)
Sadanja kliniŁka praksa: aktualne objavljene smjernice
nisu temeljene na dokazima i meðusobno se razlikuju u
savjetima kako lijeŁiti povien tlak u bolesnika s akutnim
MU koji nisu dobili trombolitiŁnu terapiju. Iako se ovdje
ne radi o medicini zasnovanoj na dokazima, postoji priliŁno
jak konsenzus o tome da povien krvni tlak treba sniziti u
bolesnika s modanim krvarenjem radi smanjenja rizika od
poveæanja hematoma ili ponovnog krvarenja. Savjetuje se
da bolesnicima s izrazito povienim krvnim tlakom (>200/
120 mm Hg) u modanom krvarenju krvni tlak treba ak-
tivno sniavati. Posljednje smjernice naglaavaju potrebu
promjene krvnog tlaka u relativnim razmjerima (na primjer,
snienje za 20% u modanom krvarenju).
Preporuke za buduæa istraivanja: kako zasad nema zavr-
enih velikih studija sigurnosti i djelotvornosti mijenjanja
krvnog tlaka u akutnom MU, tako i neurolozi koji se bave
cerebovaskularnim bolestima vape za slijedeæim odgo-
vorima temeljenim na medicini zasnovanoj na dokazima:
 treba li sniavati krvni tlak u akutnom ishemijskom
MU?  ovo pitanje nije vano samo po sebi, nego i sto-
ga to preporuke za trombolitiŁnu terapiju navode kako
treba pratiti krvni tlak tijekom terapije pomoæu al-
teplaze
 treba li povisivati krvni tlak u akutnom ishemijskom
MU kada postoji dokaz za hipoperfuziji?
 treba li sniavati krvni tlak u modanom krvarenju?
 treba li nastaviti prethodnu antihipertenzivnu terapi-
ju ili ju privremeno obustaviti?
 koju vrstu ili kombinaciju antihipertenziva treba rabi-
ti?
 kada zapoŁeti s lijeŁenjem?
 koliko mora krvni tlak biti povien?
 koja je ekonomska opravdanost lijeŁenja krvnog tlaka?
(positron emission tomography), SPECT (single photon
emission CT), TCD, perfusion and diffusion MR (with
evaluation of penumbra, mismatch), quantitative perfu-
sion CT and xenon CT.
Recommendations for Blood Pressure
Management in Acute Stroke
1) International Society of Hypertension (ISH)
2) American Stroke Association (ASA)
3) European Stroke Initiative (EUSI)
4) Ministry of Health of the Republic of Croatia
1) International Society of Hypertension (ISH)
Statement on the Management of Blood Pressure in
Acute Stroke (J Hypertens 2003)
Current clinical practice: various published guidelines are
not evidence based and differ in recommendations for the
treatment of hypertension in patients with acute stroke
who have not received thrombolytic therapy. Although not
consistent with evidence based medicine, there is quite a
strong consensus suggesting that elevated blood pressure
should be lowered in patients with cerebral hemorrhage
in order to reduce the risk of hematoma increase or recur-
rent hemorrhage. It is suggested that extremely high blood
pressure (>200/120 mm Hg) in patients with cerebral
hemorrhage should be actively lowered. The latest guide-
lines emphasize the need of blood pressure relative mod-
ification (e.g., reduction by 20% in cerebral hemorrhage).
Proposal for future studies: considering the fact that for
the time being there are no completed large studies inves-
tigating the safety and efficacy of blood pressure modifi-
cation in acute stroke, the neurologists dealing with cere-
brovascular diseases cry out for evidence based medicine
answers to the following questions:
 should blood pressure be lowered in acute ischemic
stroke?  this question is not only important per se but
also because the recommendations for thrombolytic
therapy suggest that blood pressure be monitored dur-
ing the treatment with alteplase;
 should blood pressure be increased in acute ischemic
stroke when there is evidence for hypoperfusion?
 should blood pressure be lowered in cerebral hemor-
rhage?
 should previous antihypertensive therapy be continued
or temporarily interrupted?
 what type or combination of antihypertensives should
be used?
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 when to initiate antihypertensive therapy?
 to what level should blood pressure be increased?
 what is the cost effectiveness of blood pressure thera-
py?
Such future trials and research studies should include
representative patient groups selected according to the
following parameters:
 demographic characteristics
 blood pressure values




 size of brain lesion
Some studies of such a design are just under way or
planned to start:
 COSSACS: Continue Or Stop post-Stroke Antihyper-
tensive Collaborative Study, launched in 2003
 CHHIPS: Hypotension Immediately Post-Stroke, on-
going
 ENOS: Efficacy of Nitric Oxide in Stroke, ongoing
 IMAGES: Intravenous Magnesium Efficacy in Stroke,
ongoing
ISH Conclusions:
 elevated blood pressure (>140/90 mm Hg) is very com-
mon (in ~75% of patients) early after ischemic stroke,
however, its possible effect on functional recovery has
not yet been definitely identified
 elevated blood pressure is very common (>80%) after
cerebral hemorrhage and is associated with a poor out-
come
 low blood pressure values (<120/80 mm Hg) are rare
(5%)
 50% of stroke patients receive antihypertensive ther-
apy
 the lack of large studies entails general uncertainty con-
cerning blood pressure management in ischemic or
hemorrhagic stroke
 optimal treatment of blood pressure in acute stroke re-
mains obscure, therefore there is a great need of large,
randomized studies
2) Stroke Council of the American Stroke Associa-
tion (ASA)
Guidelines for Early Management of Patients with Is-
chemic Stroke
Takve buduæe studije i istraivanja morati æe sadravati
reprezentativne skupine bolesnika prema:
 demografskim znaŁajkama (dob, spol, narodnost)
 vrijednostima krvnog tlaka




 veliŁini lezije mozga
Nekoliko takvih istraivanja su u tijeku ili se planiraju:
 COSSACS  Continue Or Stop post-Stroke Antihyper-
tensive Collaborative Study, zapoŁinje 2003.
 CHHIPS  Hypotension Immediately Post-Stroke, u
tijeku
 ENOS  Efficacy of Nitric Oxide in Stroke, u tijeku
 IMAGES  Intravenous Magnesium Efficacy in Stroke,
u  tijeku
ZakljuŁci ISH:
 povien krvni tlak (>140/90) vrlo je Łest (otprilike u
75% bolesnika) rano nakon ishemijskog MU i zasad nije
sa sigurnoæu utvrðeno ima li utjecaja na funkcionalni
oporavak
 povien krvni tlak je vrlo Łest (>80%) nakon modanog
krvarenja i povezan je s loim ishodom
 niske vrijednosti krvnog tlaka (<120/80 mm Hg) su ri-
jetke (5%)
 50% bolesnika s MU prima antihipertenzivnu terapiju
 nedostatak velikih pokusa dovodi do globalne nesi-
gurnosti glede stava o lijeŁenju krvnog tlaka u ishe-
mijskom ili hemoragijskom MU
 optimalno lijeŁenje krvnog tlaka u akutnom MU osta-
je nepoznato i postoji velika potreba za randomiziranim
i velikim studijama
2) Smjernice za rano lijeŁenje bolesnika s
ishemijskim modanim udarom
Vijeæa za modani udar AmeriŁke asocijacije za modani
udar (Stroke Council of the American Stroke Association, ASA)
Prve preporuke za lijeŁenje ishemijskog MU ASA je
objavila 1994. godine. Nakon to je Uprava za hranu i lije-
kove (Food and Drug Administration) odobrila primjenu re-
kombiniranog tkivnog aktivatora plazminogena (rtPA) iz-
dane su nove, usklaðene preporuke 1996. godine.
¨injenice: nedostatak pouzdanih podataka i studija, dosa-
danji rezultati proturjeŁni, nema znanstvenog pokriæa ni
kliniŁki dokazane koristi od sniavanja krvnog tlaka, kod
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veæine bolesnika krvni tlak se spontano sniava bez speci-
fiŁne medicinske terapije, optimalno lijeŁenje krvnog tla-
ka u akutnom MU nije utvrðeno,
 ... u veæini situacija krvni tlak uglavnom ne treba
sniavati 
Iako se teka hipertenzija moe smatrati indikacijom
za lijeŁenje, nema podataka o definiranim vrijednostima
krvnog tlaka koji bi zahtijevali hitno lijeŁenje.
Ipak postoji konsenzus o tome da antihipertenzivne
lijekove treba ordinirati onda kad je sistoliŁki tlak >220
mm Hg ili dijastoliŁki tlak 120 mm Hg.
Stanja koja takoðer mogu zahtijevati hitnu antihiper-
tenzivnu terapiju u akutnom MU su
 hipertenzivna encefalopatija
 aortna disekcija
 akutna bubrena insuficijencija
 akutni pluæni edem
 akutni infarkt miokarda
Takoðer, uz opæe mjere lijeŁenja bolesnika treba smje-
stiti u tihu sobu, isprazniti mu mjehur, kontrolirati bol, sni-
ziti eventualno povien intrakranijski tlak. Ako postavi in-
dikacija za antihipertenzivnu terapiju, sputanje krvnog
tlaka treba oprezno provoditi. Kod bolesnika koji se lijeŁe
trombolitiŁnim sredstvima potrebno je stalno praæenje tla-
ka i eventualno ispravljanje i to tijekom davanja rtPA i kroz
prva 24 sata zbog opasnosti od komplikacija u smislu
modanog krvarenja. TrombolitiŁnu terapiju ne davati ako
je sistoliŁki RR >185 mm Hg ili dijastoliŁki >110 mm Hg.
Pristup povienom krvnom tlaku u akutnom MU
A) bez trombolitiŁne terapije
sistoliŁki RR <220 ili dijastoliŁki <120
 opservacija, praæenje
 tretirati eventualne bolesti drugih organa
 lijeŁiti druge simptome MU (glavobolja, povraæanje,
povien intrakranijski tlak, epileptiŁni napadaji, hi-
poglikemija)
sistoliŁki RR >220 ili dijastoliŁki >120
 labetalol 10-20 mg i.v. kroz 1-2 minute (moe se
ponavljati svakih 10 minuta do maksimalne doze od
300 mg)
 nikardipin 5 mg/h i.v. kao poŁetna doza (titrirati do
eljenog uŁinka poveæavajuæi dozu za 2,5 mg/h sva-
kih 5 minuta do najvie 15 mg/h
dijastoliŁki >140
 nitroprusid 0,5 mg/kg/min i.v. infuzija kao poŁetna
doza uza stalno praæenje RR
The first ASA guidelines for the treatment of ischem-
ic stroke were published in 1994. The guidelines were
revised in 1996, upon FDA had issued approval for recom-
binant tissue plasminogen activator (rtPA).
Facts: lack of reliable data and studies; controversial
results reported to date; no scientific basis or clinically
demonstrated benefit of blood pressure reduction; in most
patients, blood pressure declines spontaneously without
any specific medical therapy; optimal treatment of blood
pressure in acute stroke has not been determined.
... in most circumstances, the blood pressure should
generally not be lowered ...
Although severe hypertension can be considered as an
indicator for treatment, there are no data on defined blood
pressure values that would require urgent treatment.
Yet, there is a consensus that antihypertensive agents
should be prescribed when systolic blood pressure is >220
mm Hg or diastolic blood pressure >120 mm Hg.
The following conditions may require urgent antihy-
pertensive therapy in acute stroke:
 hypertensive encephalopathy
 dissection of aorta
 acute renal insufficiency
 acute pulmonary edema
 acute myocardial infarction
Along with general therapeutic measures, the patient
should be placed in a quiet room, his bladder should be
voided, pain control should be introduced, and the possi-
bly elevated intracranial pressure should be lowered. May
an indication for antihypertensive therapy be made, blood
pressure should be lowered with caution. In patients treat-
ed with thrombolytic agents continuous blood pressure
monitoring and possibly due correction should be done
during rtPA administration and for the next 24 hours be-
cause of the risk of complications in terms of cerebral hem-
orrhage. Thrombolytic therapy should not be used if sys-
tolic pressure is >185 mm Hg or diastolic pressure >110
mm Hg.
Approach to elevated blood pressure in acute stroke
A) without thrombolytic therapy:
systolic BP <220 mm Hg or diastolic BP <120 mm Hg
 observation, monitoring
 treatment of other possible organ diseases
 treatment of other stroke symptoms (headache, vo-
miting, elevated intracranial pressure, epileptic se-
izures, hypoglycemia)
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B) s trombolitiŁnom terapijom
sistoliŁki >185 mm Hg ili dijastoliŁki >110 mm Hg
 labetalol 10-20 mg i.v. kroz 1-2 minute, ponoviti ili
Nitropasta 1-2 inŁa (ako krvni tlak ne padne na za-
dovoljavajuæe vrijednosti, treba odustati od primje-
ne rtPA)
 tijekom praæenja bolesnika koji je primio tromboli-
tiŁnu terapiju  u sluŁaju povienih vrijednosti RR da
vati labetalol ili nikardipin kako je opisano, prema po-
trebi zapoŁeti i s nitroprusidom
3. European Stroke Initiative (EUSI) Recommen-
dations for Stroke Management  Update 2003
(Cerebrovascular Dis 2003.)
Praæenje i lijeŁenje krvnog tlaka vani su jer mnogi
bolesnici s akutnim MU imaju povien krvni tlak. Neki
podaci govore u prilog tom lijeŁenju, ali postoje i dokazi
protiv njega. Ciljni sistoliŁki krvni tlak od 180 mm Hg i
dijastoliŁki od 100-105 mm Hg preporuŁuju se kod bolesni-
ka s prethodnom hipertenzijom. U drugim sluŁajevima
poeljne vrijednosti krvnog tlaka su 160-180/90-100 mm
Hg. OŁito ekstremno visoke vrijednosti nisu prihvatljive
(iako se u SAD prihvaæaju i vrijednosti do 240-130 mm Hg).
SistoliŁki krvni tlak >220 mm Hg ili dijastoliŁki >120 mm
Hg predstavljaju indikaciju za ranu ali opreznu upotrebu
antihipertenziva, izbjegavajuæi naglo i jako ruenje vrijed-
nosti krvnog tlaka.
U sluŁaju supostojeæih bolesti, npr. akutni infarkt mi-
okarda, srŁana insuficijencija, akutna bubrena insuficijen-
cija, disekcija luka aorte, poeljno je takoðer sputanje vri-
jednosti krvnog tlaka.
Kod bolesnika koji primaju trombolitiŁnu ili heparin-
sku terapiju trebalo bi izbjegavati krvni tlak vii od 180 mm
Hg.
Kod intracerebralnih hematoma, subduralnih hemato-
ma, kao i kod subarahnoidnih krvarenja takoðer se lijeŁe
poviene vrijednosti krvnog tlaka.
Antihipertenzivi koji se mogu rabiti u akutnom MU:
inhibitor ACE  kaptopril 6-12,5 mg s.c.
sredinji simpatikolitik  klonidin 0,075 mg s.c. ili 0,2 mg
   in. i potom 0,1 mg/h (do 0,8 mg)
   i.v.
vazodilatatori  nitroprusid 0,25-10 mg/kg min. i.v.
 nitroglicerin 5-100 mg/kg min. i.v.
 dihidralazin 6,5-20 mg i.v. bolus i.v.
Beta blokator  propranolol 1-10 mg i.v.
Alfa blokator  labetalol 20-80 mg bolus i.v. i potom 2 mg/
   min. i.v. infuzija
systolic BP >220 mm Hg or diastolic BP >120 mm Hg
 labetalol 10-20 mg i.v. over 1-2 min (can be repeat-
ed every 10 minutes up to the maximal dose of 300
mg)
 nicardipine 5 mg/h i.v. as initial dose (titrated to the
desirable effect by increasing the dose by 2.5 mg/h
every 5 minutes up to the maximal dose of 15 mg/h)
diastolic BP >140 mm Hg
- nitroprusside 0.5 mg/kg/min i.v. infusion as initial dose
with continuous BP monitoring
B) with thrombolytic therapy:
systolic BP >185 mm Hg or diastolic BP >110 mm Hg
 labetalol 10-20 mg i.v. over 1-2 minutes, then repeat
it or administer 1-2 inches of Nitropast (if blood pres-
sure does not fall to a satisfactory level, the use of
rtPA should be discontinued)
 in case of elevated blood pressure values observed on
monitoring a patient who has received thrombolytic
therapy, labetalol or nicardipine should be adminis-
tered as described above, and nitroprusside should
be initiated as necessary
3) European Stroke Initiative (EUSI) Recommen-
dations for Stroke Management  Update 2003
(Cerebrovasc Dis 2003)
Blood pressure monitoring and treatment are impor-
tant because many patients with acute stroke have elevat-
ed blood pressure. Some data are in favor of blood pressure
treatment, however, there also is evidence against it. A
target systolic blood pressure of 180 mm Hg and diastolic
blood pressure of 100-105 mm Hg is advised in patients
with pre-existing hypertension. In other cases, desirable
blood pressure levels are 160-180/90-100 mm Hg. Clearly,
extremely high blood pressure values are not acceptable
(although values of up to 240/130 mm Hg are accepted in
the USA). A systolic blood pressure of >220 mm Hg or
diastolic blood pressure of >120 mm Hg is an indication
for early but cautious use of antihypertensives while avoid-
ing abrupt and massive blood pressure reduction.
In case of concomitant diseases such as acute myocar-
dial infarction, cardiac insufficiency, acute renal insufficien-
cy, aortic arch dissection, blood pressure reduction is also
desirable.
In patients receiving thrombolytic or heparin therapy
blood pressure levels higher than 180 mm Hg should be
avoided.
In intracerebral hematoma, subdural hematoma and
subdural hemorrhage, elevated blood pressure should also
be properly treated.
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 urapidil 10-50 mg bolus i.v. i potom 9-30
   mg/h i.v. infuzija
4. Smjernice za lijeŁenje modanog udara
Ministarstva zdravstva Republike Hrvatske
Sastavio ekspertni tim na Łelu s Prof. dr. Vidom Dema-
rin  nalaze se na web stranicama Ministarstva zdravstva
RH.
Glede lijeŁenja povienog krvnog tlaka, u svim odred-
nicama su sukladne smjernicama EUSI.
The following antihypertensives can be used in stroke
patients:
ACE inhibitor  captopril 6-12.5 mg s.c.
central sympaticolytic  clonidine 0.075 mg s.c. or 0.2 mg
in., then 0.1 mg/h (up to 0.8 mg) i.v.
vasodilatators  nitroprusside 0.25-10 mg/kg/min i.v.
 nitroglycerin 5-100 mg/kg/min i.v.
 dihydralazine 6.5-20 mg bolus i.v.
beta-blocker  propranolol 1-10 mg i.v.
alfa-blockers  labetalol 20-80 mg bolus i.v., then 2
   mg/min i.v. infusion
 urapidil 10-50 mg bolus i.v., then 9-30
   mg/h i.v. infusion
4. Ministry of Health of the Republic of Croatia
Guidelines for Stroke Treatment
Developed by the expert team headed by Professor
Vida Demarin, M.D., Ph.D.; available at the Ministry of
Health web sites.
Considering elevated blood pressure management,
these guidelines are consistent with EUSI guidelines.
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Uvod
Svako izlaganje o modalitetima lijeŁenja modanog
udara moralo bi zapoŁeti nabrajanjem osnovnih riziŁnih









Naime, moguænosti lijeŁenja akutnog modanog udara
jo uvijek su znaŁajno ograniŁene. Shvatimo li pojam
lijeŁenja u irem smislu, onda moemo kazati da je zasad
najuŁinkovitija metoda lijeŁenja modanog udara preven-
tivni pristup  tj. uklanjanje ili modificiranje prije nabro-
jenih Łimbenika rizika. Dokazano je da porast dijastolnog
arterijskog tlaka za 7 mm Hg  ili sistolnog tlaka za 12 mm
Hg  podie rizik modanog udara za 50%!  Tako bi se 
teoretski  uŁinkovitim lijeŁenjem arterijske hipertenzije
broj modanih udara u SAD mogao umanjiti za 360.000
sluŁajeva na godinu1.
Nedavno je zavren niz velikih kliniŁkih studija koje su
dijelom ili u cijelosti promijenile odreðena stajalita u
lijeŁenju i prevenciji modanog udara, osobito u pogledu
antikoagulacijskog i antiagregacijskog lijeŁenja, kao i
primjene odreðenih postupaka intevencijske radiologije.
Neke od tih studija omoguæile su bolje razumijevanje i
uŁinkovitije lijeŁenje prije nabrojenih Łimbenika rizika.
KonaŁno, niz kliniŁkih istraivanja koja su trenutno u tijeku
veæ sada daju odreðene smjernice za lijeŁenje i prevenciju
modanog udara.
Antikoagulantna (antitrombotska) sredstva u
prevenciji modanog udara
Metaanaliza pet velikih randomiziranih kliniŁkih
istraivanja primjene kumarina u nevalvularnoj atrijskoj
NEW MODALITIES IN THE TREATMENT OF STROKE
NOVOSTI U LIJE¨ENJU MODANOG UDARA
Ivo Luiæ
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Introduction
Any report on stroke treatment modalities should start
with listing the following major risk factors for stroke that









The possibilities of acute stroke treatment are still
quite limited. Taking the term of treatment in a broad
sense, preventive approach remains the most efficient
method of treatment, i.e. elimination or modification of
the above listed risk factors. A rise in diastolic arterial pres-
sure by 7 mm Hg or systolic pressure by 12 mm Hg has
been demonstrated to increase the risk of stroke by 50%!
Thus, the number of strokes in the USA could theoreti-
cally be reduced by 360,000 cases per year with efficacious
treatment of arterial hypertension1.
A number of large clinical studies have recently been
completed which have in part or completely changed some
concepts of the treatment and prevention of stroke, espe-
cially considering anticoagulation and antiaggregation ther-
apy as well as the use of particular procedures of interven-
tional radiology. Some of these studies have enabled bet-
ter understanding and more efficacious management of the
above listed risk factors. In addition, a number of clinical
studies that have just been under way have already pro-
duced some guidelines for the treatment and prevention
of stroke.
Anticoagulation (Antithrombotic) Agents in Stroke
Prevention
A meta-analysis of five large randomized clinical stud-
ies of the use of coumarin in nonvalvular atrial fibrillation
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fibrilaciji (NVAF) rezultirala je zakljuŁkom da se primje-
nom kumarina u NVAF postie 68%-tno snienje rizika za
modani udar u odnosu na kontrolnu skupinu. Premda je
ista metaanaliza potvrdila da je acetilsalicilna kiselina
(ASK) takoðer uŁinkovita u prevenciji modanog udara u
bolesnika s NVAF,  postignuto smanjenje rizika uz primjenu
ASK za tu indikaciju dostizalo je najvie 20%. Kumarin je
oŁito najuŁinkovitije sredstvo prevencije modanog udara
u osoba s NVAF.
Prema opæe prihvaæenom stajalitu kumarin je indici-
ran za sve bolesnike s NVAF ako iskazuju jo jedan od
slijedeæih Łimbenika rizika za modani udar:
 prethodni modani udar, TIA ili sistemska embolija
 arterijska hipertenzija
 kongestivna kardiomiopatija
 ivotna dob ≥75 godina
 oslabljena funkcija lijeve komore
UŁinkovita dnevna doze kumarina odreðuje se drukŁije
za razliŁite indikacije. Ciljne vrijednosti INR-a su slijedeæe:
 nevalvularna AF INR 2-3, doivotno
 tromb lijeve komore INR 2-3, 3-6 mjeseci
 akutni infarkt miokarda INR 2-3, 6 mjeseci
 umjetna valvula INR 3-4, doivotno
U meðuvremenu na tristu se je pojavio novi peroralni
izravni inhibitor trombina, ksimelagatran. U odnosu na
kumarin, ovaj lijek posjeduje odreðene prednosti:
 veæu terapijsku irinu
 nema potrebe za badarenjem doze ili za nadzorom
INR
 interakcije ksimelagatrana s hranom ili drugim lijekovi-
ma vrlo su rijetke
Usporedba uŁinkovitosti ksimelagatrana i kumarina u
NVAF bila je tema dviju kliniŁkih studija, SPORTIF III. i
SPORTIF V. To su bili randomizirani kliniŁki pokusi us-
poredbe prilagoðene doze varfarina  (ciljna vrijednost INR-
a 2-3) i fiksne doze ksimelagatrana (2x36 mg na dan) u
riziŁnih bolesnika s NVAF2.  SPORTIF III. bila je tzv.
otvorena studija, dok je SPORTIF V. zamiljena kao dvo-
struko slijepo ispitivanje. Primarni cilj studije bio je mo-
dani udar ili sistemska embolija.
Rezultati studija bili su slijedeæi (napomena: negativ-
na vrijednost  bolji ksimelagatran):
 SPORTIF III.:  0,66% (95% CI,  1,4% do 0,1%)
 SPORTIF V.: +0,45% (95% CI,  0,1% do 1,1%)
 Metaanaliza:  0,03% (95% CI,  0,6% do 0,6%)
U pogledu moguæih komplikacija, uŁestalost krvaren-
ja bila je nia kod primjene ksimelagatrana (SPORTIF III.:
(NVAF) has led to a conclusion that the use of coumarin
for NVAF resulted in 68% stroke risk reduction as com-
pared with the control group. Although the same meta-
analysis confirmed the efficacy of acetylsalicylic acid (ASA)
in the prevention of stroke in NVAF patients, the risk re-
duction with the use of ASA for this indication did not
exceed 20%. Coumaring is obviously the most efficacious
agent for prevention of stroke in patients with NVAF.
It has been generally accepted that coumarin is indi-
cated for all NVAF patients if exhibiting some of the fol-
lowing stroke risk factors:
 previous history of stroke, transient ischemic attack
(TIA) or systemic embolism
 arterial hypertension
 congestive cardiomyopathy
 age ≥75 years
 impaired function of the left chamber
Considering efficacious daily dose of coumarin, it is
variably determined for various indications. The target
INR values are as follows:
 nonvalvular atrial fibrillation INR 2-3, lifelong
 left chamber thrombus INR 2-3, 3-6 months
 acute myocardial infarction INR 2-3, 6 months
 artificial valve INR 3-4, lifelong
In the meantime, ximelagatran, a new peroral direct
thrombin inhibitor, has appeared on the market. This drug
has some advantages over coumarin:
 greater therapeutic range
 no need of dose calibration or INR control
 interactions of ximelagatran with food or other drugs
are very rare
Comparison of the efficacy of ximelagatran and cou-
marin in NVAF was investigated in two clinical studies,
SPORTIF III and SPORTIF V. These were randomized
clinical trials comparing adapted doses of warfarin (target
INR 2-3) and fixed dose of ximelagatran (2x36 mg/day)
in risk patients with NVAF2. SPORTIF III was an open-
label study, whereas SPORTIF V was designed as a dou-
ble-blind study. The primary study endpoint was stroke or
systemic embolism. In brief, the studies produced the
following results (note: negative value  better ximelagat-
ran):
 SPORTIF III:  0.66% (95% CI, 1.4% to 0.1%)
 SPORTIF V: +0.45% (95% CI, 0.1% to 1.1%)
 meta-analysis:  0.03% (95% CI, 0.6% to 0.6%)
As for possible complications, the rate of hemorrhage
was lower with the administration of ximelagatran (SPOR-
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25,5% prema 29,5%, SPORTIF V.: 37% prema 47%), dok
su testovi jetrenih funkcija pokazali znaŁajnija odstupanja
kod primjene ksimelagatrana (6,1% prema 0,8%).
Prihvatimo li tvrdnju da je kumarin najuŁinkovitije ras-
poloivo sredstvo za bolesnike s visokim rizikom od kar-
dioembolijskog modanog udara, postavlja se logiŁno pitanje:
Kako lijeŁiti bolesnike s modanim udarom uzrok kojega
je bolest malih krvnih ila ili bolesnike s aterotrombotskim
modanim udarom u sklopu bolesti velikih krvnih ila aort-
nog luka, kao i bolesnike s kriptogenim modanim udarom
 tj. modanim udarom bez jasne etiologije? Je li antiko-
agulantno lijeŁenje indicirano i za prevenciju ovih vidova
modanog udara?
S tim je ciljem zamiljena studija WARSS (Warfarin vs.
Aspirin Recurrent Stroke Study) koja je trebala odgovoriti na
pitanje uŁinkovitosti antikoagulacijskog lijeŁenja u bolesni-
ka s s ne-kardioembolijskim modanim udarom3. Radilo se
o multicenriŁnom, dvostruko slijepom randomiziranom
kliniŁkom istraivanju sekundarne prevencije modanog
udara. Bilo je ukljuŁeno 2206 bolesnika s ne-kardioembo-
lijskim ishemijskim modanim udarom, koji su randomi-
zirani u dvije skupine. Jedna je skupina primala kumarin
(prilagoðena doza, INR 1,4-2,8), a druga ASK 325 mg na
dan tijekom 2 godine. Primarni krajnji ishod studije bio je
modani udar ili smrt. Nijedna od ispitnih podskupina
(lakunarni modani udar, aterotrombotski modani udar,
bolesnici s antifosfolipidnim sindromom) nije imala bolju
prognozu s varfarinom. Kvocijent rizika za modani udar
iznosio je 1,13 (kumarin prema ASK), a uŁestalost krvarenja
bila je 2,22 na 100 bolesnik-godina za kumarin prema 1,49
za ASK. Dakle, uz manju uŁinkovitost kumarin je imao i
znatno veæu uŁestalost komplikacija.
Slijedeæa zanimljiva studija vezana za odnos uŁinkovi-
tosti kumarina i ASK u ovoj indikaciji je WASID (Warfarin
Aspirin Symptomatic Intracranial Disease Trial)4. Kriterij izbora
ispitanika bila je simptomatska bolest velikih intrak-
ranijskih arterija (>50%-tno suenje ICA, MCA, vertebral-
ne ili bazilarne arterije). Ukupno je bilo ukljuŁeno 569 ispi-
tanika koji su primali kumarin (ciljna vrijednost INR-a 2-
3) ili ASK u dozi od 1300 mg na dan. Studija je prekinuta
zbog sigurnosnih razloga. Naime, nije utvrðena nikakva
razlika u smanjenju rizika za modani udar, no smrtni ishod
zabiljeen je u 10% bolesnika na kumarinu u odnosu na isti
ishod u 4% bolesnika koji su primali ASK. ZnaŁajnije
krvarenje opaeno je u 8% bolesnika na kumarinu u odno-
su na 3% bolesnika koji su primali ASK.
TIF III: 25.5% vs. 29.5%; SPORTIF V: 37% vs. 47%),
whereas liver function tests showed greater deviation with
the use of ximelagatran (6.1% vs. 0.8%).
If we accept that coumarin is the most efficacious agent
available for patients at a high risk of cardioembolic stroke,
it appears logical to pose the following question: How to
treat patients with stroke due to microvascular disease or
patients with atherothrombotic stroke as part of aortic arch
macrovascular disease or those with cryptogenic stroke, i.e.
a stroke without clear etiology? Is anticoagulation therapy
also indicated for prevention of these stroke types?
The WARSS (Warfarin vs. Aspirin Recurrent Stroke
Study) trial was so designed as to address this goal, i.e. to
answer the question of anticoagulation therapy efficacy in
patients with noncardioembolic stroke3. It was a multi-
center, double-blind, randomized, clinical study of second-
ary prevention of stroke. The study included 2206 patients
with noncardioembolic ischemic stroke, randomized into
two groups. One group received coumarin (adapted dose,
INR 1.4-2.8), and the other group received ASA 325 mg/
day for 2 years. The primary endpoint was stroke or death.
None of the study subgroups (lacunar stroke, atherothrom-
botic stroke, patients with antiphospholipid syndrome)
had better prognosis with warfarin. The stroke risk quo-
tient was 1.13 (coumarin vs. ASA), and the rate of hemor-
rhage was 2.22 and 1.49 per 100 patient-years for coumarin
and ASA, respectively. Thus, besides lower efficacy, cou-
marin was associated with a considerably higher rate of
complications.
Another interesting study related to the efficacy of
coumarin and ASA for this indication was WASID (Warfarin
Aspirin Symptomatic Intracranial Disease Trial)4. The cri-
terion for patient selection was symptomatic disease of
great intracranial arteries (>50% stenosis of ICA, MCA,
vertebral or basilar artery). A total of 569 study patients
were administered coumarin (target INR 2-3) or ASA at a
dose of 1300 mg/day. The study was discontinued for safety
reasons, as no difference in the stroke risk reduction was
observed, whereas lethal outcome was recorded in 10% of
patients on coumarin vs. 4% of patients administered ASA.
Major hemorrhage was observed in 8% and 3% of patients
on coumarin and ASA, respectively.
Antiaggregation Agents in Stroke Prevention
While the efficacy of antiaggregation agents in the pre-
vention and treatment of stroke is unquestionable, many
questions are still a matter of discussion and subject of
numerous clinical studies. ACE study (Aspirin for patients
undergoing Carotid Endarterectomy) appears to be of
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Antiagregacijska sredstva u prevenciji modanog
udara
Premda je uŁinkovitost antiagregacijskih sredstava u
prevenciji i lijeŁenju modanog udara nesporna, mnoga su
pitanja jo uvijek predmet rasprava i cilj brojnih kliniŁkih
istraivanja. Posebno je zanimljiva studija ACE (Aspirin for
patients undergoing Carotid Endarterectomy), randomizirano
kliniŁko istraivanje kojim je bilo obuhvaæeno 3000 bolesni-
ka koji su podvrgnuti karotidnoj endarterektomiji5. Naime,
ova nam je studija pruila odgovor na pitanje koje se pro-
vlaŁi veæ dugi niz godina, tj. otkako su otkrivena antiagre-
gacijska svojstva acetilasilicilne kiseline: koja je optimalna
doza ASK u prevenciji modanog udara?
Ispitanici su primali jednu od 4 moguæe doze ASK
tijekom perioperacijskog razdoblja: 81 mg, 325 mg, 650 mg
ili 1300 mg na dan. S obzirom na to da su rezultati u ispi-
tanika koji su primali nie doze (81 i 325 mg), kao i rezul-
tati ispitanika na viim dozama (650 i 1300 mg) ASK bili
sliŁni, Łetiri ishodine skupine konaŁno su svedene na dvije.
Ispitanici koji su primali neku od niih doza (81 ili 325 mg)
imali su znaŁajno manju uŁestalost komplikacija u smislu
modanog udara, infarkta miokarda ili smrti. Stoga je i za-
kljuŁak studije slijedeæi: doze ASK vie od 325 mg na dan
u cilju prevencije modanog udara nemaju opravdanja.
Slijedeæa studija vezana za antiagregacijska sredstva je
ESPS-2 (European Stroke Prevention Study 2), multicen-
triŁno, randomizirano, dvostruko slijepo, placebom kontro-
lirano istraivanje cilj kojega je bila procjena uŁinkovitosti
ASK, dipiridamola, te kombinacije ovih dvaju lijekova u
prevenciji modanog udara6. UkljuŁeni su bili ispitanici koji
su preboljeli TIA ili ishemijski modani udar unutar 3
mjeseca prije ukljuŁivanja u studiju. Praæenje je trajalo dvije
godine, a ispitanici su podijeljeni u Łetiri skupine kojima
je dodijeljena jedna od slijedeæih shema lijeŁenja:
 200 mg dipiridamola s produljenim otputanjem (ER-
DP) dva puta na dan
 25 mg ASK dva puta na dan
 25 mg ASK + 200 mg ER-DP dva puta na dan
 placebo dva puta na dan
Rezultati ovoga istraivanja ukazali su na Łinjenicu da,
premda su i ASK i dipiridamol uŁinkovita antiagregacijska
sredstva u prevenciji modanog udara  kombinacija ovih
dvaju lijekova posjeduje dodatnu uŁinkovitost, tj. da se radi
o sinergizmu ovih dvaju antiagregacijskih sredstava. Ovo
je ujedno i prvo kliniŁko istraivanje koje je dokazalo bio-
loku vrijednost kombinacije dvaju antiagregacijskih sred-
stava razliŁitih mehanizama djelovanja.
special interest. It was a randomized clinical trial includ-
ing 3000 patients submitted to carotid endarterectomy5.
This study has answered a question open for a long time
now, i.e. since the discovery of the antiaggregation prop-
erties of ASA: What is the optimal dose of ASA in the pre-
vention of stroke? Study subjects received one of the 4 ASA
doses during the perioperative period: 81 mg, 325 mg, 650
mg or 130 mg per day. As the results recorded in subjects
receiving lower doses (81 and 325 mg) and in those on
higher doses (650 and 1300 mg) of ASA were similar, the
original four groups were finally reduced to two groups.
Then, the subjects on either of the lower doses (81 or 325
mg) of ASA showed a significantly lower rate of complica-
tions including stroke, myocardial infarction and death.
Thus, the conclusion derived from the study was that ASA
doses higher than 325 mg/day for stroke prevention were
not justifiable.
The next study related to antiaggregation agents was
ESPS-2 (European Stroke Prevention Study 2), a multi-
center, randomized, double-blind, placebo controlled study
aimed at assessing the efficacy of ASA, dipyridamole, and
a combination of the two in the prevention of stroke6. The
study included subjects who had sustained TIA or ischemic
stroke within 3 months prior to inclusion in the study, with
a 2-year follow-up period. Study subjects were divided into
four groups randomized to any of the following treatment
protocols:
 200 mg extended release dipyridamole (ER-DP) twice
daily
 25 mg ASA twice daily
 25 mg ASA + 200 mg ER-DP twice daily
 placebo twice daily
Results of this study indicated that, although both ASA
and dipyridamole are efficacious antiaggregation agents in
stroke prevention, the combination of the two showed
additional efficacy, i.e. a synergistic action of these two
antiaggregation agents. This was the first clinical study
demonstrating the biologic value of the combination of
these two antiaggregation agents with different mecha-
nisms of action.
Clopidogrel, a novel antiaggregation drug, has recent-
ly appeared on the market. Comparison of the efficacy of
this drug with ASA as an established antiaggregation agent
was simply unavoidable. The topic was addressed in the
CAPRIE study (Clopidogrel versus Aspirin in Patients at
Risk of Ischemic Events)7, a prospective, randomized,
double-blind clinical study that included 19,185 patients
with atherosclerotic vascular disease from 304 hospital
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Relativno nedavno na tritu se je pojavio i novi anti-
agregacijski lijek, klopidrogel. Usporedba uŁinkovitosti
ovoga lijeka s etabliranim antiagregacijskim sredstvom 
ASK  bila je neizbjena. Ova je tema obraðena u studiji
CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischem-
ic Events)7. Radilo se je o prospektivnom, randomiziranom,
dvostruko slijepom kliniŁkom istraivanju kojim je bilo
obuhvaæeno 19.185 bolesnika s aterosklerotskom boleæu
krvnih ila u 304 bolniŁka centra. U podskupinu modanog
udara bili su ukljuŁeni bolesnici koji su preboljeli modani
udar unutar 6 mjeseci prije ukljuŁivanja. Radnomizirane
skupine primale su klopidogrel u dozi od 75 mg ili ASK u
dozi od 325 mg. LijeŁenje je trajalo do 3 godine (prosjeŁno
1,6 godina).
Premda su rezultati ove studije dali blagu prednost
klopidrogelu (8,7% manja uŁestalost novog modanog
udara u odnosu na ASK), pravo je pitanje slijedeæe: pred-
stavlja li kombinacija ASK i klopidrogela uŁinkovitije sred-
stvo u prevenciji modanog udara u odnosu na njihovu
pojedinaŁnu djelotvornost?
Na to je pitanje odgovorila studija CURE (Clopidogrel
in Addition to Aspirin in Patients with Acute Coronary Syndrome),
prospektivno, randomizirano, dvostruko slijepo kliniŁko
istraivanje kojim je bilo obuhvaæeno 12.562 ispitanika s
akutnim koronarnim sindromom8. Primarni ishodi studije
bili su kardiovaskularna smrt, infarkt miokarda ili modani
udar. Ispitanici su primali jednu od dviju kombinacija: ASK
(75-325 mg na dan) + placebo ili kombinaciju ASK + 75
mg klopidrogela. LijeŁenje je trajalo najmanje 12 mjeseci.
I ova je kombinacija (ASK + klopidrogel) bila uŁinkovitija
od primjene same ASK, i to prosjeŁno oko 20% za sve
moguæe ishode.
Neke od velikih studija vezane za antiagregacijske lije-
kove jo su u tijeku, te nam rezultati nisu dostupni. Iz te
skupine izdvajam studiju SPS3 (Secondary Prevention of
Small Subcortical Strokes), randomizirani 2x2 Łimbenski
pokus kojim se planira obuhvatiti ukupno 2.500 bolesnika
s malim subkortikalnim infarktima. Ovo kliniŁko istrai-
centers. The stroke subgroup included patients with pri-
or stroke within the last 6 months before entering the
study. Randomized patient groups were administered clo-
pidogrel at a dose of 75 mg or ASA at a dose of 325 mg for
up to 3 years (mean 1.6 years). Although the results of this
study suggested a slight preference to be given to clopi-
dogrel (the rate of recurrent stroke lower by 8.7% than with
ASA), the true question is: Is the combination of ASA and
clopidogrel more efficient in the prevention of stroke than
the individual action of either agent?
This question was answered by the CURE study (Clo-
pidogrel in Addition to Aspirin in Patients with Acute
Coronary Syndrome), a prospective, randomized, double-
blind clinical trial that included 12,562 patients with acute
coronary syndrome8. The study primary endpoints were
cardiovascular death, myocardial infarction or stroke. Study
subjects received either of two combinations: ASA (75-325
mg/day) + placebo or ASA + 75 mg clopidogrel. The treat-
ment was continued for at least 12 months. This combi-
nation (ASA + clopidogrel) also proved more efficacious
than ASA alone, this by 20% on an average for all study
endpoints.
A number of large studies of antiaggregation therapy
are still under way, thus their results have not yet become
available. However, mention should be made of the SPS3
study (Secondary Prevention of Small Subcortical Strokes),
a randomized, 2x2 factorial trial, planning to include a to-
tal of 2500 patients with small subcortical infarcts. This
clinical trial, sponsored by the American NIH (National
Institutes of Health), has been designed at two levels. At
the first level, ASA alone, and ASA + clopidogrel combi-
nation are compared, whereas the second level will com-
pare the usual arterial blood pressure control (target val-
ues of systolic blood pressure, 130-149 mm Hg) and inten-
sive control arterial blood pressure (systolic pressure, £129
mm Hg).
Another study just about to be completed is PRoFESS
(Prevention Regimen for Effectively Avoiding Second
Stroke), a randomized, double-blind, 2x2 factorial study
Table 1. ESPS-2: relativno smanjenje rizika u pojedinim skupina-
ma
Terapija Modani udar Modani udar ili smrt






Tablica 1. ESPS-2: relative risk reduction according to groups
Therapy Stroke Stroke or death
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vanje koje sponzorira ameriŁki NIH (National Institutes of
Health) zamiljeno je na dvjema razinama. U prvoj se pro-
vodi usporedba djelotvornosti same ASK i kombinacije ASK
i klopidogrela, dok se u drugoj eli usporediti uobiŁajenu
kontrolu visine arterijskog tlaka (ciljne vrijednosti sistol-
nog tlaka od 130-149 mm Hg) i intenzivni nadzor arte-
rijskog tlaka (sistolni tlak 129 mm Hg ili manje).
Slijedeæa studija koja je pred zavretkom je PRoFESS
(Prevention Regimen for Effectively Avoiding Second Strokes),
randomizirani, dvostruko slijepi, 2x2 Łimbenski pokus us-
poredbe kombinacije klopidogrela i ASK s dipiridamolom,
te usporedbe telmisartana i placeba. Studijom je obu-
hvaæeno 15.500 ispitanika, a rezultati æe biti objavljeni kra-
jem ove (2004.) godine.
Kirurko lijeŁenje bolesti karotida
U ovom je podruŁju najpoznatija veæ klasiŁna studija
NASCET (Surgical Endarterectomy for Extracranial Carotid
Disease) kojom su obuhvaæeni ispitanici sa simptomatskom
stenozom karotide viom od 70%9. Ispitanici su randomi-
zirani u skupinu koja je lijeŁena medikamentno i u kirur-
ki lijeŁenu skupinu. Ipsilateralni modani udar doivjelo
je tijekom razdoblja od dvije godine 26% medikamentno
lijeŁnih ispitanika u odnosu na 9% kirurki lijeŁenih
bolesnika. Bolesnici sa simptomatskom stenozom karotide
od 50%-69% imali su slabije rezultate, premda jo uvijek
bolje od medikamentno lijeŁenih bolesnika, dok su za asim-
ptomatske bolesnike sa stenozom karotide bez obzira na
stupanj suenja rezultati bili jo loiji. Problem su predstav-
ljale perioperacijske komplikacije:
 smrt ili modani udar 5,8%
 lezija kranijskog ivca 7,6%
 hematom 5,5%
 infekcija rane 3,4%
 srŁane komplikacije 4,0%
Upravo su navedene komplikacije bile razlogom sve
Łeæih pokuaja primjene metoda interventne radiologije
comparing a combination of clopidogrel and ASA with dipy-
ridamole, and telmisartan with placebo. The study in-
cludes 15,500 subjects, and the results will be published
towards the end of 2004.
Surgical Therapy for Carotid Diseases
The classic NASCET study (Surgical Endarterectomy
for Extracranial Carotid Disease) is best known in the field.
The study included subjects with >70% symptomatic
carotid stenosis9. Study subjects were randomized to a
group on medicamentous therapy and a group treated with
surgical therapy. Over a 2-year period, ipsilateral stroke
occurred 26% of medicamentously treated and 9% of sur-
gically treated patients. Less favorable results, yet better
in medicamentously treated patients, were obtained in the
subgroup with 5%-69% symptomatic carotid stenosis. Poor-
er results were recorded in asymptomatic patients with
carotid stenosis irrespective of the degree of stenosis. The
following perioperative complications posed a problem:
 death or stroke 5.8%
 cranial nerve lesion 7.6%
 hematoma 5.5%
 wound infection 3.4%
 cardiac complications 4.0%
These complications were the reason for ever more
frequent attempts at using the methods of interventional
radiology for stroke prevention. There have been a num-
ber of randomized clinical studies of the use of carotid
stenting.
CAVATAS (Carotid & Vertebral Artery Transluminal
Angioplasty Study) was a multicenter, randomized, clini-
cal study comparing endovascular stent and carotid endar-
terectomy in the management of carotid stenosis10. The
study includes 504 patients with carotid stenosis (96%
with symptomatic disease) followed-up for 3 years. In the
group treated with endovascular technique, stent was
placed in 26% and balloon angioplasty was performed in
the remaining 74% of patients. Angioplalsty and/or stent-
Tablica 2. CURE: uŁestalost smrti i modanog udara u ispitnim
skupinama
ASK + ASK +
placebo klopidrogel    
% RR CI
Broj ispitanika 6.303 6.259
Kardiovaskularna smrt 11,41% 9,30% 0,80 0,72-0,90
Modani udar 1,38% 1,20% 0,86 0,63-1,18
Table 2. CURE: prevalence of death and stroke in study groups
ASK + ASK +
placebo klopidrogel    
% RR CI
Broj ispitanika 6.303 6.259
Kardiovaskularna smrt 11,41% 9,30% 0,80 0,72-0,90
Modani udar 1,38% 1,20% 0,86 0,63-1,18
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u prevenciji modanog udara. Postoji Łitav niz randomi-
ziranih kliniŁkih pokusa primjene karotidnog stenta.
CAVATAS (Carotid & Vertebral Artery Transluminal Angio-
plasty study) je multicentriŁno randomizirano kliniŁko
istraivanje usporedbe endovaskularnog stenta i karotidne
endarterektomije u lijeŁenju suenja karotida10. U istra-
ivanje je ukljuŁeno 504 bolesnika sa stenozom karotide
(96% sa simptomatskom boleæu), koji su praæeni tijekom
3 godine. U skupini koja je lijeŁena endovaskularnom teh-
nikom stent je postavljen u 26% ispitanika, dok je u preo-
stalih 74% izvrena balon-angioplastika. Angioplastika i/ili
stentiranje pokazali su se tehniŁki uspjenim u 89% sluŁa-
jeva. UŁestalost ponovnog modanog udara i/ili smrti
tijekom prvih 30 dana bila je podjednaka u objema skupi-
nama (10%), dok je uŁestalost znaŁajne restenoze bila
znatno via u endovaskularno lijeŁenoj skupini (14% pre-
ma 4%).
Studija CREST (Cerebral Revascularization Endarterec-
tomy versus Stenting) je randomizirano kliniŁko istraivanje
usporedbe endovaskularnih tehnika i karotidne endarte-
rektomije, kojim se planira obuhvatiti 2.500 ispitanika sa
simptomatskim suenjem unutarnje karotide viim od
50%11. Ispitanici su praæeni tijekom 4 godine, a dosad (kraj
2003. godine) 691 bolesnik lijeŁen je stent-tehnikom.
Postotak bolesnika koji su doivjeli novi modani udar ili
su umrli tijekom zahvata iznosi 3,5%, to je znatno manje
od oŁekivanog postotka takvog ishoda kirurkog zahvata
(6%-10%).
SSYLVIA (Stenting of Symptomatic Atherosclerotic Lesions
in the Extracranial Vertebral and Intracranial Arteries) je otvoren
pokus angioplastike ili stentiranja12. Kriterij ukljuŁivanja su
simptomatska aterosklerotska suenja na ekstrakranijskim
(vertebralnim) ili intrakranijskim arterijama, a kliniŁko
praæenje trajalo je godinu dana uz ponavljanje CAG nakon
6 mjeseci. Ispitanici su primali klopidogrel tijekom 4 tjed-
na nakon angioplastike ili stentiranja, te zatim i ASK ti-
jekom godine dana. UkljuŁeno je 60 ispitanika u 12 cent-
ara, a postignuto je 95% tehniŁkog uspjeha (ostatna stenoza
manja od 50%). Smrt tijekom samog postupka nije zabi-
ljeena, no zabiljeena su 4 sluŁaja modanog udara tijekom
prvih 30 dana nakon intervencije, te 4 sluŁaja modanog
udara tijekom daljnjeg praæenja (365 dana). Opaen je i
relativno visok postotak ponovnih stenoza, osobito u sluŁa-
ju ostijalnih vertebralnih suenja.
ZakljuŁci
 Novi antikoagulacijski i antiagregacijski lijekovi omo-
guæuju pouzdanu zatitu bolesnika s Łimbenicima ri-
zika za modani udar (ili za recidiv modanog udara).
ing proved technically successful in 89% of cases. The rate
of stroke recurrence and/or death during the first 30 days
was comparable in the two groups (10%), whereas the rate
of significant restenosis was considerably higher in the
group treated with endovascular technique (14% vs. 4%).
CREST study (Cerebral Revascularization Endarter-
ectomy versus Stenting) is a randomized clinical trial com-
paring endovascular techniques and carotid endarterecto-
my, anticipating to include 2500 subjects with >50%
symptomatic carotid stenosis11. Study subjects have been
followed-up for 4 years, and 691 patients were treated by
stent technique till the end of 2003. The percentage of
patients sustaining recurrent stroke or death was 3.5%,
which is considerably lower than the expected proportion
of these surgical procedure outcomes (6%-10%).
SSYLVIA (Stenting of Symptomatic Atherosclerotic
Lesions in the Extracranial Vertebral and Intracranial Ar-
teries) is an open-label study of angioplasty or stenting12.
Inclusion criterion were symptomatic atherosclerotic
stenoses of extracranial (vertebral) or intracranial arteries,
whereas clinical follow-up took one year with repeat CAG
at 6 months. Study subjects received clopidogrel for 4
weeks after angioplasty or stenting, then also ASA for one
year. The study included 60 subjects from 12 centers, and
has reported on 95% technical success (residual stenosis
<50%). There was no death during the procedure, how-
ever, there were 4 cases of stroke during the first 30 days
of intervention, and 4 cases of stroke during further follow-
up (365 days). A relatively high rate of restenosis was ob-
served, especially in case of ostial vertebral stenosis.
Conclusions
 New anticoagulation and antiaggregation agents allow
for reliable protection of patients with risk factors for
stroke (or for stroke recurrence).
 Novel endovascular interventional techniques are a
promising option for some of these patients.
 The true potential of these methods has yet to be con-
firmed in clinical trials.
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Saetak
Prema nedavno objavljenim podacima iz velikih randomi-
ziranih kliniŁkih studija snienje povienog krvnog tlaka i snienje
povienog kolesterola povezani su sa znaŁajnim padom rizika za
nastanak modanog udara. Pretpostavlja se da primjena lijekova
iz skupine inhibitora konvertaze angiotenzina (inhibitori ACE),
blokatora angiotenzinskih receptora, antagonista kalcijevih kanala
i statina ima uz regulaciju krvnog tlaka i snienje serumskog
kolesterola i neke dodatne povoljne uŁinke. Inhibitori ACE i
blokatori angiotenzinskih receptora mogu poboljati funkciju
endotelnih stanica i usporiti napredovanje ateroskleroze. Anta-
gonisti kalcijevih kanala, poglavito oni koji su izrazito lipofilni,
imaju i neka antioksidacijska svojstva. Oni smanjuju oksidaciju
Łestica LDL i sprjeŁavaju njihov ulazak u stijenke arterijskih
krvnih ila. Amlodipin, lacidipin ili nifedipin suzbijaju stvaranje
trombocita u hipertenzivnih bolesnika. Statini pospjeuju va-
zodilataciju, utjeŁu na upalni odgovor u endotelnim stanicama,
smanjuju stvaranje krvnih ugruaka i adheziju trombocita na rup-
turirani plak, te utjeŁu na stabilizaciju aterosklerotskog plaka.
Ostala antiaterosklerotska obiljeja statina ukljuŁuju: smanjeno
nakupljanje upalnih stanica u aterosklerotskom plaku, inhibici-
ju proliferacije glatkih miiænih stanica krvne stijenke, inhibici-
ju funkcije trombocita i poboljanje funkcije vaskularnih stanica
endotela.
KljuŁne rijeŁi: hipertenzija, antihipertenzivi, hiperlipidemija, pre-
vencija modanog udara
THE ROLE OF NEW ANTIHYPERTENSIVE AND LIPID LOWERING DRUGS
IN STROKE PREVENTION
ULOGA NOVIJIH ANTIHIPERTENZIVA I STATINA U PREVENCIJI MODANOG UDARA
Vida Demarin
University Department of Neurology, Sestre milosrdnice University Hospital, Zagreb, Croatia
Klinika za neurologiju, KliniŁka bolnica Sestre milosrdnice, Referentni centar za neurovaskularne poremeæaje Ministarstva
zdravstva Republike Hrvatske, Zagreb
Summary
Recently published data from large, randomized clinical tri-
als show that lowering of blood pressure and elevated cholester-
ol reduction is associated with significant decrease in stoke risk.
Besides blood pressure and cholesterol lowering it seems that
the use of angiotensin-converting enzyme inhibitors (ACEI),
angiotensin receptor blockers (ARB), calcium antagonists (CA)
and statins could provide some additional beneficial effects.
ACEI and ARB could improve endothelial function, cardiac and
vascular remodeling, thus retarding progression of atherosclero-
sis. CA, especially the highly lipophilic ones, may have some
antioxidant properties. They reduce the oxidation of LDL and
its influx into the arterial wall. Amlodipine, lacidipine or nife-
dipine suppress platelet production in hypertensive patients.
Statins could have beneficial effects such as improvement of
endothelial-dependent flow-mediated vasodilatation, modulat-
ing the inflammatory response, decreasing clot formation, and
decreasing the adherence of platelets to the ruptured plaque
thus stabilizing the atherosclerotic plaque. Other antiathero-
sclerotic properties of statins include reducing of accumulation
of inflammatory cells in atherosclerotic plaques, inhibiting vas-
cular smooth muscle cell proliferation, inhibiting platelet func-
tion, and improving of vascular endothelial function.
Key words: treatment of hypertension, antihypertensives, treatment
of hypercholesterolemia, statins
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Uvod
Prema definiciji Svjetske zdravstvene organizacije,
modani udar je kliniŁki sindrom vaskularne etiologije koji
se oŁituje naglim nastankom arinog ili globalnog
modanog deficita to traje due od 24 sata ili dovodi do
smrtnog ishoda. Modani udar je jedan od triju najŁeæih
uzroka smrti u svijetu i znaŁajan javno-zdravstveni prob-
lem. Oko 80% svih modanih udara uzrokovano je ishemi-
jom (tromboza ili embolija), a oko 20% nastaje zbog hemo-
ragije (intracerebralno krvarenje ili subarahnoidno krvare-
nje). Veæina modanih udara uzrokovana je ateroskle-
rotskim promjenama na stijenkama arterija te bolestima
srca. Stoga se brojni kardiovaskularni riziŁni Łimbenici
ubrajaju u riziŁne Łimbenike za nastanak modanog udara.
Iako je posljednjih godina u lijeŁenju modanog udara
postignut znaŁajan napredak, prevencija je i nadalje naj-
uŁinkovitija metoda za smanjivanje uŁestalosti modanog
udara1,2. Rezultati velikih kliniŁkih studija pokazuju kako
sniavanje povienog krvnog tlaka koje se postie primje-
nom nekih skupina antihipertenziva (inhibitori konvertaze
angiotenzina /inhibitori ACE/, blokatori angiotenzinskih
receptora i antagonisti kalcijevih kanala), te sniavanje
serumskog kolesterola primjenom statina (inibitori reduk-
taze 3-hidroksi-3-metil-glutaril koenzima-A /HMG-CoA/)
imaju povoljan uŁinak u prevenciji modanog udara.
LijeŁenje antihipertenzivima
Hipertenzija je jedan od najvanijih Łimbenika rizika
za nastanak i recidiv modanog udara. Sniavanje povie-
nog krvnog tlaka smanjuje rizik od nastanka modanog
udara. U primarnoj prevenciji modanog udara postupak
sniavanja krvnog tlaka postie se primjenom razliŁitih
vrsta antihipertenziva (beta-blokatori, inhibitori ACE,
antagonisti kalcijevih kanala, diuretici itd.), ali je lijek pr-
vog izbora za lijeŁenje hipertenzije jo uvijek teko odre-
diti. KliniŁke studije o antihipertenzivnoj terapiji uglav-
nom procjenjuju uŁestalost kardiovaskularnih incidenata
kao mjeru uspjenosti terapije.
U studiji ALLHAT (Antihypertensive and Lipid-Low-
ering Treatment to Prevent Heart Attack) usporeðivao se
je uŁinak tiazidskog diuretika klortalidona (12.5-25 mg/
dan), kalcijevog antagonista amlodipina (2.5-10 mg/dan) i
inhibitora ACE lizinoprila (10-40 mg/dan). U skupini
bolesnika koji su lijeŁeni lizinoprilom stopa modanog
udara bila je via u odnosu na klortalidonsku skupinu (6.3%
vs 5.6%). Diuretici su se pokazali djelotvornijima u preven-
ciji veæine kardiovaskularnih incidenata, a s obzirom na to
Introduction
Stroke is defined by the World Health Organization as
a clinical syndrome of rapid onset of focal or global cere-
bral deficit, lasting for more than 24 h or leading to death,
with no apparent cause other than a vascular one. Stroke
could be ischemic, approximately 80%, or hemorrhagic,
approximately 20% of all strokes in white populations.
Stroke is a major public health burden worldwide. It is one
of the three most common causes of death worldwide.
Most of all strokes are probably due to changes that ath-
erosclerosis produces on arterial tree and on the heart.
Therefore, most conventional vascular risk factors for ath-
erosclerosis are also considered as risk factors for stroke.
Although there has been great improvement in stroke
treatment in recent years, prevention of stroke still has a
pivotal role in the approach to stroke1,2.
In this paper results of clinical trials dealing with ele-
vated blood pressure and elevated cholesterol plasma con-
centrations in stroke prevention are presented, with spe-
cial emphasis on the potential new beneficial actions of
some groups of antihypertensives (angiotensin-converting
enzyme inhibitors (ACEI), angiotensin receptor blockers
(ARB), and calcium antagonists (CA) and 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase inhib-
itors, i.e.statins.
Antihypertensive Treatment
Hypertension is one of the most potent risk factors for
first ever and recurrent stroke. Lowering of blood pressure
has been known for years to reduce the risk of a first stroke.
Blood pressure lowering for primary prevention of stroke
could be undertaken using a variety of therapeutic agents:
beta-blockers, ACEI, ARB, CA, diuretics, etc. The choice
of first line antihypertensive drug is still difficult.
ALLHAT trial showed in 33,357 participants with
hypertension no difference in combined fatal coronary
heart disease or nonfatal myocardial infarction between the
groups treated with a thiazide diuretic chlorthalidone (12.5
to 25 mg/d), CA amlodipine (2.5 to 10 mg/d) or ACEI lis-
inopril (10 to 40 mg/d). The lisinopril group a had higher
stroke rate than the chlorthalidone group (6.3% vs 5.6%).
The authors suggest the use of thiazide diuretics because
they are superior in preventing one or more major forms
of cardiovascular disease and are less expensive. Therefore,
they should be preferred as first-step antihypertensive
therapy3. The PROGRESS trial showed the relative-risk
reduction by about 25% to be associated with a decrease
of 9 mm Hg in systolic and 4 mm Hg in diastolic blood
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da su najjeftiniji, zakljuŁak je da se oni trebaju prvi upotri-
jebiti u antihipertenzivnoj terapiji3.
U studiji PROGRESS (Perindopril Protection Against
Recurrent Stroke Study) bolesnici su bili randomizirani u
skupinu koja je primala perindopril, perindopril i indapa-
mid ili u skupinu koja je primala placebo. Studija je poka-
zala 25%-tno smanjenje relativnog rizika za modani udar
(ishemijskog i hemoragijskog inzulta) uz prosjeŁno sni-
enje krvnog tlaka za 9/4 mm Hg4.
Noviji kliniŁki dokazi upuæuju na to da inhibitori ACE
imaju znaŁajan uŁinak u prevenciji ishemijskih dogaðaja te
da zaustavljaju proces aterogeneze13. Pretpostavlja se da
inhibitori ACE i blokatori receptora angiotenzina mogu
poboljati funkciju endotelnih stanica, usporiti progresiju
ateroskleroze te smanjiti rizik od srŁanog i modanog
udara5.
Prva studija u kojoj je dokazan uŁinak inhibitora ACE
bila je studija HOPE (Heart Outcomes Prevention Study).
Studija je pokazala kako sniavanje sistoliŁnog krvnog tla-
ka za samo 3.3 mm Hg i dijastoliŁnog za 1.4 mm Hg uz
ramipril dovodi do relativnog 32%-tnog smanjenja mo-
danog udara i 20%-tnog smanjenja srŁanog infarkta u odno-
su na skupinu koja je primala placebo. Visok postotak sma-
njenja cerebrovaskularnih incidenata objasnio se je mo-
guæom nezavisnom ulogom ramiprila, uz njegov uŁinak na
sniavanje tlaka.
Studija LIFE (Losartan Intervention For Endpoint
reduction in hypertension study) nije pokazala razliku u
uŁinku blokatora angiotenzinskih receptora losartana i beta
blokatora atenolola na snienje krvnog tlaka. Tijekom
razdoblja praæenja od 4,8 godina uoŁeno je 25%-tno sni-
enje relativnog rizika za modani udar u bolesnika koji su
uzimali losartan. Ovi rezultati pokazali su kako losartan ima
i druge povoljne uŁinke uz regulaciju hipertenzije7.
U studiji SCOPE (The Study on Cognition and Prog-
nosis in the Elderly) bili su randomizirani bolesnici s bla-
gom do umjerenom hipertenzijom koji su uzimali bloka-
tor angiotenzinskih receptora kandesartan ili placebo te bili
praæeni tijekom 4,5 godine. Primjena kandesartana poka-
zala je 27,8%-tno smanjenje modanih udara koji nisu zavr-
ili fatalno te 23,6%-tno smanjenje svih modanih udara.
Rezultati studije upuæuju na to da bi kandesartan uz pri-
marno antihipertenzivno djelovanje mogao imati i neke
dodatne povoljne uŁinke u prevenciji modanog udara8.
Antagonisti kalcijevih kanala, osobito visoko lipofilni
amlodipin i lacidipin, pokazali su i neka svojstva antioksi-
dacijskog djelovanja. Istraivanja na ivotinjskim modeli-
ma su pokazala kako ovi lijekovi smanjuju oksidaciju Łes-
tica LDL te sprjeŁavaju njihovo nakupljanje u stijenkama
pressure4. In the PROGRESS trial a combination of per-
indopril and indapamide as well as perindopril alone were
tested. The reduction in stroke risk was approximately of
the size that could be predicted from epidemiological
observations, meaning that there was probably no addition-
al effect of the drugs tested over and above their blood
pressure-lowering effect2.
However, recent clinical evidence reveal ACEI as po-
tent agents in preventing ischemic events and in block-
ing an array of ischemic processes, including atherogene-
sis13. It seems that ACEI and probably ARB could improve
endothelial function, cardiac and vascular remodeling, re-
tard the anatomic progression of atherosclerosis, and re-
duce the risk of myocardial infarction, stroke and cardio-
vascular death5. The first trial that showed other poten-
tial beneficial effects of ACEI beyond blood pressure re-
duction was Heart Outcomes Prevention Evaluation
(HOPE). The HOPE trial showed in 9297 high-risk pa-
tients that lowering of systolic blood pressure by only 3.3
mm Hg and diastolic blood pressure by only 1.4 mm Hg
using ramipril 10 mg once daily per os caused relative risk
reduction of stroke by 32% compared with placebo. The
high percentage of stroke risk reduction was supposed to
be due to independent, additional effect of ramipril be-
sides blood pressure lowering6. The Losartan Intervention
For Endpoint Reduction in Hypertension Study (LIFE)
did not show any difference in blood pressure lowering in
9193 participants aged 55-80 with essential hypertension
between ARB losartan and beta blocker atenolol groups,
but during the follow up period of 4.8 years a 25% lower-
ing of the relative risk for stroke was observed in the losa-
rtan group. The results of this study could mean that the
ARB losartan could confer benefits beyond reduction in
blood pressure7. The Study on Cognition and Prognosis in
the Elderly (SCOPE) randomized 4964 elderly patients
with mild to moderate hypertension to the ARB cande-
sartan or placebo, and followed them up for 4.5 years. The
candersatan group showed a 10.9% relative risk reduction
for stroke, myocardial infarction or death. The candesartan-
based treatment reduced nonfatal stroke by 27.8% and all
stroke by 23.6%. The great reduction of nonfatal and all
stroke could implicate that the ARB candasartan could
have some additional effects in stroke prevention besides
blood pressure lowering8.
The Valsartan Antihypertensive Long-term Use Eval-
uation (VALUE) trial was a randomized, double-blind,
parallel-group comparison of therapy based on valsartan or
amlodipine in hypertensive patients at high cardiovascu-
lar risk. Blood pressure was reduced by both treatments
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arterijskih krvnih ila i smanjuju aterosklerotske lezije9. Uz
to, amlodipin, lacidipin i nifedipin suzbijaju proizvodnju
trombocita u bolesnika s hipertenzijom. Rezultati novijih
viegodinjih studija upuæuju na to da blokatori kalcijevih
kanala smanjuju napredovanje ateroskleroze u bolesnika s
hipertenzijom i koronarnom bolesti srca.
U studiju VALUE (Valsartan Antihypertensive Long-
term Use Evaluation) su hipertenzivni bolesnici s visokim
kardiovaskularnim rizikom randomizirani u skupinu koja
je primala valsartan ili amlodipin i bili praæeni tijekom 4,2
godine. Snienje povienog krvnog tlaka postignuto je u
objema skupinama, a uŁinak amlodipina bio je izraeniji,
naroŁito na poŁetku ispitivanja (krvni tlak je bio za 4,0/2,1
mm Hg nii u amlodipinskoj skupini u odnosu na valsar-
tansku skupinu veæ nakon mjesec dana, te za 1,5/1,3 mm
Hg nakon godine dana; p<0,001)38.
Studija REGRESS (Regression Growth Evaluation
Statin Study) pokazala je kako istodobno uzimanje amlo-
dipina ili nifedipina u kombinaciji s pravastatinom uzrokuje
znaŁajno smanjenje novih angiografskih lezija10,11.
Studija VHAS (Verapamil in Hypertension and Athero-
sclerosis Study) pokazala je bolju uŁinkovitost verapamila
u regresiji karotidnih lezija i smanjenju incidencije cere-
brovaskularnih incidenata u usporedbi s klortalidonom12.
U studiji PREVENT (Prospective Randomized Eva-
luation of the Vascular Effects of Norvasc Trial) amlodipin
je usporio progresiju poŁetne koronarne ateroskleroze u
bolesnika s koronarnom bolesti srca13.
Studija INSIGHT (Intervention as a Goal in the Hy-
pertension Treatment) pokazala je znaŁajno smanjenje
debljine intime i medije (intima-media thickness, IMT) pod
utjecajem nifedipin gastrointestinalnog transportnog su-
stava (GITS) u usporedbi s hidroklortiazidom + amilo-
ridom14.
Jedna od kliniŁkih studija koja je uzela u obzir uŁinak
antihipertenziva na arterijsku stijenku je studija ELSA
(Europe Lacidipine Study) u kojoj je usporeðivan uŁinak
lacidipina i atenolola. Studija je bila prospektivna, rando-
mizirana, dvostruko slijepa, a primarni cilj je bio odrediti
uŁinak ovih lijekova na IMT u zajedniŁkim karotidnim
arterijma i karotidnoj bifurkaciji. Nakon Łetverogodinjeg
praæenja znaŁajno smanjenje godinje stope progresije IMT
ustanovljeno je u skupini bolesnika koji su primali laci-
dipin, a broj bolesnika kod kojih je dolo do poveæanja
aterosklerotskih plakova bio je manji. UŁestalost kardio-
vaskularnih incidenata i snienje krvnog tlaka bili su pod-
jednaki u objema skupinama, premda je relativni rizik za
modani udar, kardiovaskularne incidente i smrtnost bio
neto nii u skupini bolesnika koji su primali lacidipin15.
but the effects of the amlodipine-based regimen were
more pronounced, especially in the early period (blood
pressure lower by 4.0/2.1 mm Hg in amlodipine than in
valsartan group after 1 month; 1.5/1.3 mm Hg after 1 year;
p<0.001 between groups)37.
On the other hand, CA and especially the highly lipo-
philic amlodipine and lacidipine may have some antioxi-
dant properties. These drugs reduce the oxidation of LDL
and its influx into the arterial wall, and reduce atheroscle-
rotic lesions in animals. Platelet production is suppressed
by amlodipine, lacidipine or nifedipine in hypertensive
patients. Thus, selective CA could be potential antiath-
erosclerotic agents9. New evidence from longterm clinical
trials of CA indicates that these drugs can reduce the rate
of progression of atherosclerosis in hypertensive and coro-
nary heart disease patients. In the Regression Growth
Evaluation Statin Study (REGRESS), coadministration of
CA, amlodipine or nifedipine with pravastatin caused a
significant reduction in the appearance of new angiograph-
ic lesions10,11. In the Verapamil in Hypertension and Ath-
erosclerosis Study (VHAS), verapamil was more effective
than chlorthalidone in promoting regression of thicker
carotid lesions in parallel with a reduction in the incidence
of cardiovascular events12. In the Prospective Randomized
Evaluation of the Vascular Effects of Norvasc Trial (PRE-
VENT), amlodipine slowed the progression of early coro-
nary atherosclerosis in patients with coronary artery dis-
ease13. In a subprotocol of the Intervention as a Goal in the
Hypertension Treatment (INSIGHT) study, nifedipine
gastrointestinal-transport-system (GITS) significantly
decreased the intima-media thickness (IMT) as compared
to coamilozide (hydrochlorothiazide + amiloride)14. The
European Lacidipine Study on Atherosclerosis (ELSA) was
a randomized, double-blind trial in 2334 patients with
hypertension comparing the effects of 4-year treatment
with either lacidipine or atenolol on IMT in the walls of
common carotids and bifurcations. Although clinical blood
pressure reductions were identical with both treatments,
the yearly IMT progression rate was 0.0145 mm/y in
atenolol-treated and 0.0087 mm/y in lacidipine-treated
patients (40% reduction). Patients with plaque progres-
sion were significantly less common, and patients with
plaque regression were significantly more common in the
lacidipine group. No significant difference between treat-
ments was found in cardiovascular events, although the
relative risk for stroke, major cardiovascular events and
mortality showed a trend favoring lacidipine15.
In recently published overviews of trials comparing
active treatment regimens with placebo, the overview of
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Pregled dosadanjih placebom kontroliranih studija
pokazuje da inhibitori ACE smanjuju modani udar za oko
30%, koronarnu srŁanu bolest za oko 20% i kardiovaskularne
incidente za oko 21%. Rezultati studija inhibitora kalcijevih
kanala pokazali su 39%-tno smanjenje modanog udara i
28%-tno smanjenje kardiovaskularnih dogaðaja16.
Sniavanje hipertenzije u primarnoj prevenciji modanog
udara moe se postiæi primjenom razliŁitih antihiperten-
ziva, ali Łini se da inhibitori ACE, blokatori angiotenzin-
skih receptora i inhibitori kalcijevih kanala imaju i doda-
tan povoljni uŁinak u prevenciji modanog udara17.
Ciljne vrijednosti krvnog tlaka u veæine bolesnika i
zdravih pojedinaca trebale bi se odravati ispod 130/70 mm
Hg, kako bi se sprijeŁio nastanak modanog udara i ostalih
kardiovaskularnih komplikacija2,18. Naglo sniavanje krvnog
tlaka u akutnoj fazi modanog udara ima pogubne uŁinke19,
stoga antihipertenzivnu terapiju treba uvoditi polako na-
kon akutne faze.
LijeŁenje statinima
Za razliku od hipertenzije koja je odavno prepoznata
kao vaan riziŁni Łimbenik za nastanak modanog udara,
Łesto se raspravljalo oko povienih koncentracija koleste-
rola kao moguæeg riziŁnog Łimbenika. Rezultati dosada-
njih studija o meðusobnoj povezanosti povienog serum-
skog kolesterola i modanog udara nisu bili dosljedni. Neki
od njih pokazali su znaŁajnu pozitivnu korelaciju20,21, dok
ostale studije nisu potvrdile navedene rezultate22,23.
U Framinghamskoj studiji pronaðena je pozitivna ko-
relacija izmeðu nastanka modanog udara i povienih vri-
jednosti kolesterola u mukaraca u dobi izmeðu 50 i 59
godina, s koncentracijom kolesterola viom od 6,24 mmol/
L24.
Rezultati novijih studija pokazali su kako sniavanje
koncentracije kolesterola ipak smanjuje rizik od modanog
udara.
Rezultati ispitivanja Scandinavian Simvastatin Survival
Study (4S) jasno su potvrdili povoljan uŁinak sniavanja
koncentracije kolesterola na kardiovaskularni rizik nakon
preboljelog srŁanog infarkta te u bolesnika s pektoralnom
anginom. Studija 4S pokazala je 28%-tno smanjenje rizika
za cerebrovaskularne dogaðaje (modani udar i TIA) uz
24%-tno smanjenje rizika za modani udar26,27.
Studija CARE (Cholesterol And Recurrent Events) u
kojoj su randomizirani bolesnici uzimali pravastatin ili pla-
cebo pokazala je 32%-tno smanjenje svih modanih udara
i 27%-tno smanjenje modanog udara ili TIA u onih ispi-
tanika koji su primali pravastatin28.
placebo-controlled trials of ACEI (4 trials, 12124 patients
mostly with coronary heart disease) revealed reductions in
stroke of 30%, coronary heart disease (20%), and major
cardiovascular events (21%). The overview of placebo-
controlled trials of CA (2 trials, 5520 patients mostly with
hypertension) showed reductions in stroke (39%) and
major cardiovascular events (28%)16. Blood pressure low-
ering for primary prevention of stroke could be undertak-
en using a variety of therapeutic agents, but it seems that
ACEI, ARB and CA could have some additional beneficial
effects on stroke prevention besides blood pressure reduc-
tion17. Control of blood pressure must take into account
adverse effects in individual patients. Generally, the low-
er the pressure the better, with target levels of blood pres-
sure in the vast majority of patients and healthy individu-
als of below 130/70 mm Hg to minimize the occurrence of
stroke and other cardiovascular complications, providing
that adverse effects are acceptable to the patient2,18.
Recently it has been shown that blood pressure reduc-
tion in the acute phase of stroke has detrimental effects19.
Therefore, blood pressure reducing should wait until the
acute phase of stroke has resolved. After that blood pres-
sure lowering should probably be introduced slowly.
Lipid Lowering Treatment
Unlike hypertension that was long time ago recognized
as a risk factor for stroke, there was considerable debate
whether elevated cholesterol concentrations could be a risk
factor for stroke. Previous results on the association be-
tween raised serum cholesterol levels and stroke were in-
consistent. Some studies found a significant positive cor-
relation20,21, whereas in others no significant correlation
could be found22,23. In the Framingham study positive cor-
relation was found between the occurrence of stroke and
elevated levels of cholesterol in men aged 50-59, if the
cholesterol level exceeded 6.24 mmol/L24.
However, recent studies have shown that lowering of
cholesterol concentration definitely decreases the risk of
stroke. The risk of stroke, myocardial infarction, and the
need of vascular procedures were reduced by about 25%
with cholesterol concentration reduction by approximately
20% in the Heart Protection Study25. Results of the Scan-
dinavian Simvastatin Survival Study (4S) clearly and con-
vincingly demonstrated the beneficial effect of cholester-
ol lowering on cardiovascular risk in postmyocardial infarc-
tion and angina patients. 4S provided some evidence for a
beneficial effect of simvastatin on fatal plus nonfatal cere-
brovascular events. The risk reduction in cerebrovascular
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Placebom kontrolirana studija LIPID (Long-term In-
tervention with Pravastatin in Ischemic Disease) ispitiva-
la je uŁinak pravastatina na smrtnost od koronarne srŁane
bolesti u bolesnika s preboljelim infarktom miokarda i
nestabilnom pektoralnom anginom. Rezultati studije su
pokazali 19%-tno smanjenje rizika za modani udar u
bolesnika koji su primali pravastatin29.
U studiji ASAP (Aggressive versus conventional lipid
lowering on Atherosclerosis Progression in familial hyper-
cholesterolemia) usporeðivao se je uŁinak pojedinih stati-
na. Prospektivno praæenje IMT u karotidnim arterijama
tijekom 2 godine pokazalo je da se kod ispitanika koji su
uzimali atorvastatin IMT znaŁajno smanjila, za razliku od
onih iz skupine koja je primala simvastatin30.
Studija CARDS (Collaborative Atorvastatin Diabetes
Study) ispitivala je uŁinak atorvastatina (10 mg/dan) u
primarnoj prevenciji glavnih kardiovaskularnih dogaðaja u
oboljelih od eæerne bolesti tipa 2 koji nisu imali visoku
koncentraciju LDL kolesterola u serumu. Bolesnici su ran-
domizirani u skupinu koja je uzimala atorvastatin ili u sku-
pinu koja je dobivala placebo, a praæeni su tijekom 3,9 go-
dina. Rezultati studije pokazali su 36%-tno smanjenje
akutne koronarne bolesti srca i 48%-tno smanjenje moda-
nog udara. Stopa smrtnosti smanjena je za 27% u skupini
na atorvastatinu, ukazujuæi na uŁinkovitost primjene ator-
vastatina u primarnoj prevenciji kardiovaskularnih bolesti
i modanog udara u onih bolesnika sa eæernom boleæu
tipa 2 koji nemaju povien LDL kolesterol39.
Studija HPS (Heart Protection Study) ukljuŁila je u
ispitivanje bolesnike kod kojih je bilo malo izravnih doka-
za o potencijalnoj koristi od uzimanja statina (dijabetiŁari,
starije osobe, osoobe s normalnim vrijednostima koleste-
rola). Bolesnici su dobivali 40 mg simvastatina ili placebo,
a praæeni su prosjeŁno 5 godina. U skupini koja je primala
simvastatin zabiljeeno je smanjenje ukupne smrtnosti,
veæinom zbog definitivnog 17%-tnog proporcionalnog
smanjenja stope smrtnosti vaskularne etiologije. U simva-
statinskoj skupini zabiljeeno je i znaŁajno 25%-tno pro-
porcionalno smanjenje incidencije modanog udara te broja
ispitanika koji su imali bar jednu epizodu TIA25.
U studiji ALLHAT-LLT (Antihypertensive and Li-pid-
Lowering Treatment to Prevent Heart Attack), u koju su
bili ukljuŁeni stariji bolesnici s dobro kontroliranom hi-
pertenzijom i umjereno povienim LDL-C, pravastatin nije
pokazao znaŁajno smanjenje ukupne smrtnosti niti koronar-
ne bolesti srca31.
Nedavno objavljena meta-analiza koja je ukljuŁila 164
kratkoroŁne, randomizirane placebom kontrolirane studije
o utjecaju statina na sniavanje LDL kolesterola, 58 ran-
events (stroke and TIA) was 28%. The risk reduction in
stroke was 24%26,27. Two studies of pravastatin therapy were
designed with stroke as a prespecified endpoint. The
Cholesterol And Recurrent Events (CARE) study involved
4159 patients. Patients were randomized to receive prav-
astatin 40 mg once daily or placebo. Compared with pla-
cebo, pravastatin therapy resulted in a 32% reduction in
all-cause stroke and 27% reduction in stroke or TIA (28).
Longterm Intervention with Pravastatin in Ischemic Dis-
ease (LIPID) trial compared the effects of pravastatin 40
mg once daily on mortality due to coronary heart disease
(the primary end point) with the effects of placebo among
9014 patients with a history of myocardial infarction or
unstable angina. The risk reduction for total stroke (fatal
and non-fatal) in the LIPID trial was 19% with pravasta-
tin compared with placebo, but pravastatin had no effect
on hemorrhagic stroke29. In the Aggressive versus conven-
tional lipid lowering on atherosclerosis progression in fa-
milial hypercholesterolemia (ASAP) trial, carotid IMT
measured by quantitative B-mode ultrasound decreased
(-0.031 mm) in the atorvastatin group (80 mg daily) after
2 years, whereas in the simvastatin group (40 mg daily) it
increased (0.036 mm) in 325 patients with familial hyper-
cholesterolemia30. The Collaborative Atorvastatin Diabe-
tes Study (CARDS) was a multicenter randomized place-
bo-controlled trial testing the efficacy of atorvastatin in
primary prevention of cardiovascular disease in type 2 di-
abetes. Assessed separately, the acute coronary disease
events were reduced by 36%, coronary revascularizations
by 31%, and the rate of stroke by 48%. Atorvastatin reduced
death rate by 27%. Results of the study showed atorvasta-
tin 10 mg daily to be safe and efficacious in reducing the
risk of first cardiovascular disease events including stroke
in patients with type 2 diabetes without high LDL-cho-
lesterol38.
In the Heart Protection Study allocation to 40 mg sim-
vastatin daily significantly reduced all-cause mortality
chiefly due to the definite 17% proportional reduction in
death rate from vascular causes in 20,536 high-risk indi-
viduals. In the simvastatin group there was a significant
25% proportional reduction in the incidence of first stroke.
This was mainly due to a definite 30% proportional reduc-
tion in the incidence of strokes attributed to ischemic
stroke, whereas there was no apparent difference in hem-
orrhagic stroke. Also, there was a significant reduction in
the number of subjects who had at least one episode of
transient cerebral ischemia25.
Although most of recent studies showed beneficial
effect of statins in reducing the risk of stroke, the Antihy-
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domiziranih studija o utjecaju sniavanja kolesterola na
ishemijsku bolest srca i modani udar i 9 kohortnih studi-
ja pokazala je kako statini mogu smanjiti koncentraciju
Łestica LDL za 1,8 mmol/L, to smanjuje rizik od ishe-
mijske bolesti srca za oko 60% i modanog udara za oko
17%. U bolesnika s veæ postojeæom vaskularom bolesti
smanjenje modanog udara iznosilo je 36%32.
¨ini se da postoji statistiŁka povezanost izmeðu po-
vienog LDL i snienog HDL kolesterola i ishemijskog
modanog udara te smanjenja vaskularnog rizika uz pri-
mjenu statina u bolesnika s koronarnom bolesti srca. Doka-
zi upuæuju na to da statini smanjuju napredovanje plaka, a
snienje ukupnog kolesterola u serumu smanjuje inciden-
ciju modanog udara33.
Povien apolipoprotein B (apoB) je vaan Łimbenik
rizika za koronarnu bolest srca, a poremeæena regulacija
metabolizma lipoproteina koji sadravaju apoB povezana
je s napredovanjem ateroskleroze. Statini smanjuju kon-
centraciju cirkulirajuæeg aterogenog apoB-lipoproteina
smanjujuæi proizvodnju VLDL u jetri34. Pretpostavlja se da
uza sniavanje koncentracije kolesterola statini mogu po-
boljati vazodilataciju poveæavajuæi bioraspoloivost ni-
triŁnog oksida te da mogu stabilizirati plak smanjujuæi
upalni odgovor u stijenci krvne ile. Nadalje, statini mogu
umanjiti stvaranje krvnog ugruka smanjujuæi adheziju
trombocita na rupturiranom plaku djelujuæi preko vanjskog
puta aktivacije koagulacije35. Statini posjeduju protuupal-
na svojstva te smanjuju nakupljanje upalnih stanica u ate-
rogenom plaku, suzbijaju funkciju trombocita i poboljavaju
vaskularnu funkciju endotela poveæavajuæi koncentraciju
nitriŁnog oksida36.
ZakljuŁak
LijeŁenje hipertenzije i hiperkolesterolemije ima vanu
ulogu u primarnoj i sekundarnoj prevenciji modanog
udara. Rezultati velikih randomiziranih kliniŁkih studija
pouzdano su pokazali da je snienje krvnog tlaka i povie-
nog kolesterola povezano sa znaŁajnim smanjenjem rizika
od nastanka modanog udara.
Inhibitori ACE i blokatori angiotenzinskih receptora
mogu poboljati funkciju endotela i usporiti napredovanje
ateroskleroze. Antagonisti kalcijevih kanala koji su visoko
lipofilni imaju i neka antioksidacijska svojstva. Rezultati na
ivotinjskim modelima pokazali su kako statini smanjuju
oksidaciju i ulaz Łestica LDL u stanice arterijske stijenke.
Amlodipin, lacidipin i nifedipin suzbijaju stvaranje trom-
bocita u bolesnika koji boluju od hipertenzije, te maju po-
tencijalna antiaterosklerotska svojstva.
pertensive and Lipid-Lowering Treatment to Prevent
Heart Attack Trial (ALLHAT) in 10,355 older participants
with well-controlled hypertension and moderately elevat-
ed LDL-C receiving either pravastatin 40 mg daily or usual
care revealed a similar all-cause mortality for the 2 groups.
Pravastatin failed to reduce either all-cause mortality or
coronary heart disease significantly when compared with
usual care31.
In a recently published meta-analysis of 164 short-term
randomized placebo controlled trials of six statins and LDL
cholesterol reduction; 58 randomized trials of cholesterol
lowering by any means and ischemic heart disease events;
and nine cohort studies and the same 58 trials on stroke,
it is concluded that statins can lower low density lipopro-
tein-cholesterol (LDL cholesterol) concentration by an
average of 1.8 mmol/L, which reduces the risk of ischemic
heart disease events by about 60% and of stroke by only
17%. In people with existing vascular disease the reduc-
tion of stroke is 36%32.
In conclusion, it seems that there is a statistical link
between elevated low-density lipoprotein cholesterol or
decreased high-density lipoprotein cholesterol and is-
chemic stroke, and a reduction in vascular risk with statins
in randomized trials in patients with coronary heart disease.
Also, there is evidence for a decreased plaque progression
under statins; and pooled analyses of primary and second-
ary prevention trials showing that reduction of total serum
cholesterol reduces the incidence of stroke, especially with
the highest rate of cholesterol reduction, and in patients
with the highest risk of stroke33.
Elevated apolipoprotein B (apoB) is known to be an
important risk factor for coronary heart disease, and dys-
regulation of the metabolism of apoB-containing lipopro-
teins is involved in the progression of atherosclerosis. St-
atins reduce circulating concentrations of atherogenic
apoB-containing lipoproteins by decreasing the production
of VLDL in the liver34.
It seems that besides the cholesterol lowering poten-
tial statins may improve endothelial-dependent flow-me-
diated vasodilatation by increasing the bioavailability of
nitric oxide. They may stabilize the plaque by modulat-
ing the inflammatory response within the vessel wall. They
also may decrease clot formation by decreasing the adher-
ence of platelets to the ruptured plaque and by acting on
the extrinsic coagulation cascade pathway35.
Statins possess anti-inflammatory properties, as evi-
denced by their ability to reduce the accumulation of in-
flammatory cells in atherosclerotic plaques; they inhibit
vascular smooth muscle cell proliferation (a key event in
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Uza sniavanje koncentracije kolesterola statini pospje-
uju vazodilataciju, stabiliziraju plak, utjeŁu na upalni odgo-
vor u endotelnim stanicama, smanjuju stvaranje krvnih
ugruaka i smanjuju adheziju trombocita na rupturiranom
plaku.
Ostala antiaterosklerotska svojstva statina ukljuŁuju
smanjenje nakupljanja upalnih stanica u plaku, inhibiciju
proliferacije glatkomiiænih stanica krvne stijenke, inhi-
biciju funkcije trombocita i poboljanje vaskularne funkcije
endotelnih stanica. Na temelju navedenog moemo pret-
postaviti da bi ira primjena novijih antihipertenziva i sta-
tina mogla znaŁajno poboljati prevenciju svih cere-
brovaskularnih bolesti, a poglavito modanog udara37.
atherogenesis), they inhibit platelet function, and they
improve vascular endothelial function, largely through
augmentation of nitric oxide generation36.
Conclusion
Nowadays there is no doubt that treatment of hyper-
tension and hypercholesterolemia has significant role in
primary and secondary prevention of stroke. Data from
large randomized clinical trials published recently convinc-
ingly show that lowering of blood pressure and reduction
of elevated cholesterol are associated with a significant
decrease in the risk of stroke. Furthermore, it seems that
the use of ACEI, ARB, CA and statins could provide some
additional beneficial effects besides blood pressure and
cholesterol lowering39.
ACEI and ARB could improve endothelial function,
cardiac and vascular remodeling, and retard the anatomic
progression of atherosclerosis. CA, especially the highly
lipophilic ones, may have some antioxidant properties.
They reduce the oxidation of LDL and its influx into the
arterial wall, thus reducing atherosclerotic lesions in ani-
mals. Amlodipine, lacidipine or nifedipine suppress plate-
let production in hypertensive patients. Thus, selective CA
could be potential antiatherosclerotic agents.
Besides cholesterol reduction, statins could have oth-
er beneficial effects such as improvement of endothelial-
dependent flow-mediated vasodilatation, stabilizing ath-
erosclerotic plaque, modulating the inflammatory re-
sponse, decreasing clot formation, and decreasing the ad-
herence of platelets to the ruptured plaque. Other anti-
atherosclerotic properties of statins include reducing of
accumulation of inflammatory cells in atherosclerotic
plaques, inhibiting vascular smooth muscle cell prolifera-
tion, inhibiting platelet function, and improving of vascu-
lar endothelial function.
Taking into account all these data it could be supposed
that a wider use of these drug classes could significantly
improve our ability to prevent all vascular diseases and
stroke in particular. The data from large randomized clin-
ical trials shed bright light for stroke prevention in the
forthcoming future.
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MICROVASCULAR END ENDOVASCULAR MANAGEMENT OF CEREBRAL ANEURYSMS
MIKROVASKULARANE I ENDOVASKULARNE METODE LIJE¨ENJA MODANIH
ANEURIZMATSKIH TVORBA
Vili Bero1, Velimir Lupret1 and Zoran Klanfar2
1University Department of Neurosurgery, 2University Department of Radiology,
Sestre milosrdnice University Hospital, Zagreb, Croatia
1Klinika za neurokirurgiju, 2KliniŁki zavod za radiologiju KliniŁke bolnice Sestre milosrdnice, Zagreb
LijeŁenje cerebralnih aneurizmatskih tvorba predstav-
lja velik izazov te s njim u vezi jo uvijek postoje brojna pro-
turjeŁja naznaŁene napretkom kako mikroneurokirurkih
tako i interventnih neuroradiolokih metoda, koji navede-
nim metodama lijeŁenja daje novu ulogu i znaŁenje.
Nakon dijagnosticiranja aneurizmatske tvorbe neu-
rokirurg treba odluŁiti kako i kada obliterirati aneuriz-
matsku tvorbu. U ranom razdoblju razvoja neurokirurgije
operacijski zahvat odgaðao se je do kraja drugog ili treæeg
tjedna, s namjerom da se izbjegnu tehniŁke potekoæe pri
prepariranju aneurzimatskog kompleksa vezane uz posto-
janje edema modanog parenhima. Ovakav naŁin ope-
racijskog lijeŁenja, tj. odgoðena operacija, smanjuje stope
pobola i smrtnosti zahvata, meðutim, ukupni rezultati lije-
Łenja nisu uvijek bolji zbog visoke uŁestalosti ponovnog
krvarenja i patofiziolokih procesa uzrokovanih vazospaz-
mom.
Napretkom tehnologije mijenja se dijelom i strategija
u lijeŁenju cerebralnih aneurizma i to s obzirom na:
1. razvoj mikroneurokirurke tehnike u lijeŁenju cere-
bralnih aneurizma;
2. razvoj novih endovaskularnih tehnika u lijeŁenju cere-
bralnih aneurizma.
Najprimjereniji naŁin lijeŁenja rupturiranih cerebralnih
aneurizmatskih tvorba je rana neurokirurka operacija s
ciljem okludiranja vrata aneurizme te njenim iskljuŁenjem
iz cirkulacije i na taj naŁin sprjeŁavanjem ponovne rupture.
Postupak prepariranja aneurizmatskog kompleksa i
prikazivanja vrata i tijela aneurizme izvodi se upotrebom
operacijskog mikroskopa (magnifikacija i iluminacija) te
specijalnih mikroneurokirurkih instrumenata. Cilj neu-
rokirurkog lijeŁenja je postavljanje metalnog klipiæa na vrat
aneurizme. Na taj naŁin aneurizma se iskljuŁuje iz cirku-
lacije, te ako je aneurizma primjereno klipana rizik od po-
novne rupture je sveden na minimum.
Ovakav naŁin lijeŁenja vrlo je djelotvoran i praæen je
niskom stopom pobola i smrtnosti.
The management of cerebral aneurysms is still a sub-
ject of controversy in spite of recent advances in micron-
eurosurgery and interventional neuroradiology. This ad-
vancement has brought a new aspect in the treatment of
aneurysms.
After an aneurysm is demonstrated arteriographically,
the neurosurgeon must decide how and when to obliter-
ate the aneurysm. In the earlier days of aneurysm treat-
ment, surgery was delayed until the second or third week
after the initial hemorrhage to avoid difficulty related to
swollen brain during surgery. Although this lowered surgi-
cal morbidity and mortality rates, management results were
not always good because of a high incidence of rebleeding
and difficulty in managing vasospasm.
Currently there are two main topics in this field which
are correlated with technical development:
1. advances in microsurgical techniques regarding the
management of cerebral aneurysms, and
2. advances in endovascular techniques regarding the
management of cerebral aneurysms.
The most desirable treatment for aneurysmal sub-
arachnoid hemorrhage (SAH) is early surgery to clip the
aneurysm and prevent further bleeding. Microsurgical
treatment for aneurysms involves a surgical procedure to
expose the aneurysm by slipping under and around the
brain using delicate instruments and high powered mag-
nification. The goal of surgical treatment is usually to place
a clip across the neck of the aneurysm to exclude the an-
eurysm from the circulation. With the aneurysm appropri-
ately clipped, the risk of rehemorrhage is avoided.
Intracranial clipping of a ruptured aneurysm is curative
and can usually be done with low morbidity. After an an-
eurysm has ruptured, the timing of surgery is important
for patient outcome. The past practice was to wait for
approximately 2 weeks after the SAH before surgery, based
on the premise that the patient was a better surgical can-
didate once cerebral edema had subsided and he/she was
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Vrijeme operacijskog lijeŁenja nakon rupture aneu-
rizme jedan je od vanijih Łimbenika koji utjeŁu na ishod
tijeka bolesti.
U ranijoj fazi razvoja neurokirurgije vie se je primje-
njivao odgoðeni operacijski zahvat, tj. kasna operacija (2 do
3 tjedna nakon rupture), to se je zasnivalo na premisi da
je operaciju tehniŁki primjerenije izvoditi nakon stabili-
ziranja opæeg stanja bolesnika i regresije edema modanog
parenhima. Meðutim, odgaðanjem operacije poveæava se
incidencija dviju najŁeæih komplikacija subarahnoidne
hemoragije: ponovne rupture aneurizmatske tvorbe i pro-
gresije vazospazma. Nakon niza ispitivanja iz multicen-
triŁnih studija kojima je bio cilj utvrditi optimalno vrijeme
provoðenja operacije moemo reæi kako danas vrijedi pravi-
lo da bolesnike s kliniŁkim stanjem prema Huntovoj i Hes-
sovoj ljestvici I. i II., a u odreðenim uvjetima i III. operira-
mo hitnom operacijom, tj. unutar 48 do 72 sata od rupture
aneurizme.
Bolesnike s kliniŁkim stanjem IV. i V. stupnja operiramo
odgoðenom operacijom ako doðe do stabilizacije stanja.
Bolesnike u stanju modane kome nije indicirano ope-
racijski lijeŁiti zbog izrazito visoke smrtnosti. KliniŁko sta-
nje bolesnika prije operacije najvaniji je prognostiŁki Łim-
benik u lijeŁenju ovih tvorba.
Kirurki pobol i smrtnost uvjetovani su nizom Łimbe-
nika poput: lokalizacije, veliŁine i oblika aneurizmatske
tvorbe; opæeg i neurolokog statusa bolesnika; razvoja
brojnih komplikacija subarahnoidnog krvarenja.
Odabir vrste neurokirurkog zahvata i specifiŁnih teh-
nika posebno je vaan u sluŁajevima postojanja aneurizma
specifiŁne lokalizacije, veliŁine i oblika.
Odgovarajuæa cerebralna angiografija koja nam otkriva
detalje navedenih morfolokih znaŁajka aneurizmatskih
tvorba od najveæe je vanosti pri planiranju operacijskog
zahvata.
Nie su opisani neki od specijalnih operacijskih pri-
stupa na cerebralne aneurizme.
Selektivna ekstraduralna prednja klinoidektomija
(SEAC, selective extradural anterior clinoidectomy), kojom
moemo pristupiti na paraklinoidno lokalizirane aneurizme
i aneurizme raŁvita bazilarne arterije kojima je vrat aneu-
rizme lokaliziran iznad razine stranjeg klinoida.
Subtemporalni pristup uz prednju petrosektomiju
omoguæava nam pristup na aneurizme raŁvita bazilarne
arterije kojima je vrat lokaliziran ispod razine stranjeg
klinoida.
Lateralni subokcipitalni pristup uz parcijalnu okcipi-
talnu kondilektomiju omoguæava nam pristup na aneu-
rizme lokalizirane na vertebralnoj arteriji.
medically stabilized. However, a delay of 2 weeks spans the
peak times for two of the most dangerous complications
of SAH, rebleeding and vasopasm. As the result of several
multicenter studies to determine the optimum time of
surgery, there has been a definite trend toward surgery
within 48 to 72 hours of  SAH for patients in Hunt and Hess
clinical grades I and II and, in some situations, grade III.
Patients in grades IV and V are treated medically for po-
tential future surgery at a later date. Surgery is usually not
performed at all in the presence of coma or severe neuro-
logic deficits due to the low recovery and high mortality
rate.
The current standard of surgical practice calls for mi-
crosurgical dissection and clipping of the aneurysmal neck
whenever possible. Surgical morbidity is determined by
numerous factors, including the location, size, and config-
uration of the aneurysm; the medical and neurologic con-
dition of the patient; and the coincidence of other com-
plications of SAH. Decisions about the timing of surgery,
the surgical approach, and specific technical adjuncts to
surgery must be based on the individual clinical setting.
Special strategies are mandatory for optimal surgical
management of aneurysms of special location, size and
form. Appropriate selection of surgical approaches is of
cardinal importance in the management of aneurysms,
especially those with special locations and size. This is to
be done in accordance with the angioanatomical findings
of aneurysms.
For example: selective extradural anterior clinoidecto-
my (SEAC) covers special aneurysms of the anterior cir-
culation, especially of paraclinoid aneurysms along with
aneurysms of the upper portion of the basilar artery with
aneurysmal neck located above the level of the posterior
clinoid process.
Subtemporal approach with anterior petrosectomy
covers aneurysms of the basilar artery with aneurysmal
neck below the level of the posterior clinoid process.
The lateral suboccipial craniotomy combined with
partial occipital condilectomy solves the problems of spe-
cial aneurysm arising from the vertebral artery.
The supracerebellar transtentorial approach enables us
to reach distal parts of the posterior cerebral artery aneu-
rysms.
Microsurgical techniques have been around for many
years and are constantly advancing. Long-term follow-up
of patients after microsurgical clipping is available and
shows an excellent success rate in preventing rebleeding.
During the past decade, endovascular methods have
been developed to treat intracranial aneurysms. Inter-
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Supracerebeleranim transtentorijalnim pristupom mo-
guæe je operacijski lijeŁiti aneurizme distalnog dijela
stranje cerebralne arterije.
Mikroneurokirurka tehnika je veæ due vrijeme u
upotrebi, no i dalje napreduje, prvenstveno zahvaljujuæi
razvoju boljih optiŁkih pomagala  mikroskopa i mikro-
neurokirurkog instrumentarija.
Danas imamo brojne statistiŁke serije praæenja uspje-
nosti neurokirurkog lijeŁenja cerebralnih aneurizma, koje
ukazuje na vrlo dobre, za pojedine lokalizacije aneurizma i
odliŁne rezultate u lijeŁenju ovih tvorba.
Sa druge strane, u posljednjem desetljeæu razvijaju se
i endovaskularne metode u lijeŁenju intrakranijskih aneu-
rizmatskih tvorba. Tako se je razvila i intervencijska neu-
roradiologija, nova radioloka subspecijalnost koja nam
prua nove moguænosti za lijeŁenje cerebralnih aneurizma.
Ova metoda nailazi na sve iru primjenu i kao takva posta-
je pravom alternativom  kirurkoj terapiji.
Temelj endovaskularne terapije je upotreba odvojivih
zavojnica (coils), najŁeæe platinastih, koje se supraselek-
tivnim kateterima uvode endovaskularnim putem u aneu-
rizmu. Aneurizma se potom puni zavojnicama radi obli-
teracije njenog fundusa i time iskljuŁenja iz cirkulacije.
U poŁetku su se ovom vrstom terapije lijeŁili samo
bolesnici koji nisu bili prikladni za operacijsko lijeŁenje:
bolesnici loeg kliniŁkog stanja i bolesnici s aneurizmama
teih lokalizacija.
Embolizacija aneurizma zavojnicama relativno je sigur-
na metoda s niskim periproceduralnim morbiditetom i
mortalitetom. Meðutim, rezultati sprjeŁavanja ponovne
rupture (rerupture) nisu zadovoljavajuæi u sluŁajevima ne-
potpune obliteracije aneurizme zavojnicama. Komplilka-
cije ovakvih zahvata su: ruptura aneurizme, cerebralna
ishemija, ponekad razvoj cerebralne infrakcije.
Glavna krvna ila na kojoj je razvijena aneurizma moe
se okludirati zavojnicama, ako one iziðu iz aneurizme,
gdje se primarno postavljaju.
Usprkos nedostacima endovaskularne metode imaju
svoju ulogu u lijeŁenju cerebralnih aneurizma, a zahvalju-
juæi tehnolokom napretku predstavljaju obeæavajuæu te-
rapijsku opciju.
U ovom trenutku jo ne postoje dugoroŁni statistiŁki
rezultati lijeŁenja bolesnika ovom metodom, meðutim, u
tijeku je niz velikih serija kojima je cilj usporedba kirurkog
i endovaskularnog lijeŁenja aneurizma.
Zasad postoje analize morfolokih promjena aneurizme
u bolesnika s nepotpunom obliteracijom aneurizme upo-
trebom zavojnica.
ventional neuroradiology, a new subspecialty in radiology,
has created new options for the management of cerebral
aneurysms. This metod has become widely accepted as an
alternative to direct surgery.
Intravascular detachable coils therapy involves use of
superselective catheters that can enter the vessels previ-
ously inaccessible with normal catheters. Generally, pa-
tients selected for this option are poor surgical candidates.
Such patients have aneurysms that are anatomically unclip-
pable or that are located in accessible areas. A catheter is
inserted into the patients peripheral artery and navigat-
ed by using an angiogram as a road map to the area where
the aneurysm is located. Once found, the aneurysm is then
filled from the inside with tiny platinum coils. The coils
react with the surrounding blood causing it to clot there-
by obliterating the aneurysm.
Coils embolization is a relatively safe treatment with
low incidence of periprocedural morbidity, and has been
successful in preventing acute subsequent bleeding,
whereas follow-up results are less satisfactory in cases in-
volving incompletely obliterated lesions. Complications of
intravascular coils therapy also include rupture of the an-
eurysm, hemorrhage, cerebral ischemia, or cerebral infarc-
tion leading to a stroke syndrome. The parent vessel that
supplies blood to the area of the aneurysm may also be
occluded using this method. The risk of rebleeding after
treatment with detachable coils may be similar to that for
incompletely clipped aneurysms.
Endovascular treatment for cerebral aneurysms is a
promising new technique. However, its long-term effec-
tiveness is not yet known and some patients may require
close follow-up or possibly additional treatments.
Published reports of early clinical and angiographic
results have been promising, but long-term efficacy of this
method remains to be determined. Some analysis evalu-
ated the anatomical evolution of the neck remnant in the
aneurysms treated with coils. About 25% of aneurysms with
neck remnant exhibited progressive thrombosis, 26% re-
mained unchanged, and 49% displayed recanalization on
follow-up angiography. The size of aneurysm neck corre-
lates well with the initial morphological results of the en-
dovascular treatment. In cases of wide-necked aneurysm,
neointimal formation across the aneurysm neck was rare-
ly completed, furthermore, looser packing with coils may
prevent neointimal and neoendothelial proliferation across
the neck of aneurysm.
Both the microsurgical and endovascular therapies have
advantages and disadvantages. A treatment that is appro-
priate for one patient may not be appropriate for another.
Treatment plan is carefully individualized to each patient.
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U oko 25% sluŁajeva s ostatnim vratom aneurizme
dolazi do daljnje obliteracije aneurizme uvjetovane trom-
bozom, u 26% sluŁajeva ne dolazi do promjena, dok u Łak
49% sluŁajeva dolazi do rekanalizacije na kontrolnim an-
giografijama.
Takoðer je poznato da veliŁina vrata aneurizme izravno
korelira s rezultatima lijeŁenja aneurizma endovaskularnim
metodama.
Velik vrat je u veæini sluŁajeva neporemostiva prepre-
ka neointimalnoj i neoendotelijskoj proliferaciji i obliteraciji
aneurizme.
Naposlijetku moemo reæi da kako neurokirurke tako
i endovaskularne metode lijeŁenja cerebralnih aneurizma
imaju svoje prednosti i nedostatke.
Terapijski plan treba paljivo procijenjivati u svakom
pojedinaŁnom sluŁaju posebno. Odluka o tome u ovlasti je
tima koji Łine neurokirurg, neuroradiolog, neurolog i anest-
eziolog. Danas je uvrijeeno miljenje da se odluka donosi
individualno za svakog bolesnika, ovisno o njegovom kli-
niŁkom statusu i lokalizaciji aneurizme.
Mlaði bolesnici prikladniji su za kirurko lijeŁenje zbog
visoke uŁestalosti ponovnog krvarenja kod neprimjereno
obliteriranih aneurizma lijeŁenih endovaskularno. Aneu-
rizme teih lokalizacija, poput aneurizma raŁvita bazilarne
arterije Łeæe se lijeŁe upotrebom endovaskularnih tehni-
ka zbog visokog periproceduralnog pobola i smrtnosti pri
kirurkom lijeŁenju aneurizma ove lokalizacije.
Neke kompleksne aneurizme moguæe je lijeŁiti i ko-
mbinacijom obiju tehnika: neurokirurke i endovaskularne
obliteracijske tehnike.
Whether to obliterate an aneurysm surgically through
a craniotomy and clipping or to use endovascular methods
is a decision made by the neurosurgeon and endovascular
radiologist as a team, based on which approach best suits
each patients aneurysm. The general consensus today is
that treatment depends on the age and clinical status of
the patient, and on the location of the aneurysm. Younger
patients tend to undergo surgical clipping because coiling
has a high recurrence rate. Posterior fossae aneurysms (es-
pecially the basilar artery tip) tend to be treated with the
coil procedure. In most major aneurysm centers, most cases
are still obliterated by surgical clipping, but coiling is be-
ing ever more frequently used. Some complex aneurysms
may require a combination of both major treatment tech-
niques or even other types of procedures.
Given the complexity of evaluation, treatment and
management of aneurysmal SAH, a team approach to the
problem has proved useful. Neurosurgeons, intervention-
al neuroradiologists, neurologists and anesthesiologists
work together on specific management issues to select and
implement treatment to optimize outcome.
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Saetak
Prikazana su iskustva i rezultati s karotidnom endarterek-
tomijom (KEA) u razdoblju od sijeŁnja 1970. do 31. kolovoza
2004. godine. Ukupno su izvedena 2342 postupka KEA u 2223
bolesnika (5,4% obostranih operacija), od Łega 692 (31,1%) ene
i 1531 (68,9%) mukarac. Srednja dob operiranih bila je 65,8–9,3,
raspon 38-98 godina. Veæina operacija uŁinjena je u opæoj anes-
teziji, a od 14. listopada 2002. godine 90% u lokoregionalnoj anes-
teziji. Primijenjene su tehnike otvorene, konvencionalne i ever-
zijske KEA (od 1985. godine). Najbolje rezultate u periope-
racijskom razdoblju do 30 dana nakon operacije postigli smo ope-
rirajuæi asimptomatske bolesnike (341 KEA, 14,5% od ukupnog
broja). Nismo imali smrtnog ishoda, a stopa modanog udara
bila je 0,3%. Ukupno je operirana 2001 simptomatska stenoza,
tj. 1098 nakon prolaznog ishemijskog napadaja (TIA), 894 na-
kon zavrenog modanog udara, te 9 u modanom udaru u evolu-
ciji sa stopama modanog udara i smrtnosti od 1% 3,1% odnosno
55,5%. Rezultati kod operiranih asimptomatskih i simptomatskih
stenoza (osim onih u progresivnom modanom udaru) su vrlo
zadovoljavajuæi i usporedivi s najboljima u svijetu. Zbog kata-
strofalnih rezultata operacija u modanom udaru u evoluciji
smatramo kako u naim okolnostima indikacije nisu opravdane,
te da je bolje bolesnike lijeŁiti u jedinicama intenzivne neuro-
loke skrbi. Usprkos zapaenom trendu i ohrabrujuæim rezulta-
tima hitne karotidne kirurgije mi nemamo vlastitih iskustava.
Raspravlja se o suvremenim indikacijama za KEA, proturjeŁjima
u indiciranju kod asimptomatskih bolesnika, s osvrtom na ne-
davno objavljene rezultate (2004.) studija ACST i ACSRS. OŁi-
to je kako kategorizacija bolesnika kandidata za KEA, koja se
temelji samo na stupnju stenoze i prisutnosti/odsutnosti neuro-
lokih simptoma, nije dovoljno precizna za procjenu stvarnog
pojedinaŁnog rizika od modanog udara. Kako je KEA nedvojbeno
znanstveno dokazana kao uŁinkovita metoda kirurkog lijeŁenja
okluzivne karotidne bolesti i prevencije modanog udara, treba
maksimalno iskoristiti sve njene moguænosti. Naalost, u Hr-
vatskoj se operira samo 15% od stvarnih potreba za KEA.
Buduænost endovaskularnog pristupa ne bi se trebala zasnivati
Summary
Own experience and results obtained with carotid endart-
erectomy (CEA) from January 1970 till August 31, 2004 are pre-
sented. A total of 2342 CEA procedures were performed in 2223
patients (bilateral operation in 5.4% of patients), 692 (31.1%)
women and 1531 (68.9%) men, mean age 65.8–9.3 (range 38-
98) years. Most operations were performed in general anesthe-
sia, and from October 14, 2002 90% of the procedures were done
in locoregional anesthesia. The techniques of open, conventional
and eversion CEA (from 1985) were employed. The best re-
sults in the perioperative period to postoperative day 30 were
recorded on operating on asymptomatic patients (341 CEA;
14.5% of total). There was no lethal outcome, and the rate of
stroke was 0.3%. A total of 2001 symptomatic stenoses were
operated on, i.e. 1098 after transient ischemic attack (TIA),
894 after completed stroke, and 9 on stroke in evolution, yield-
ing the respective rates of stroke and mortality of 1%, 3.1% and
55.5%. The results obtained in asymptomatic and symptomatic
stenoses operated on (except those in progressive stroke) are
very satisfactory and comaparable with the best in the world.
Due to the disastrous results of the procedure performed on
stroke in evolution, we believe that, in our circumstances, this
indication is not justifiable and that these patients are better
treated at neurologic intensive care units. In spite of the ob-
served trend and encouraging results of urgent carotid surgery,
we have no such experience of our own. The current indications
for CEA and controversies about indications in asymptomatic
patients are discussed, with special reference to recently (2004)
published results of the ACST and ACSRS studies. It is quite
clear that categorization of patients candidates for CEA, which
is  based solely on the degree of stenosis and presence or ab-
sence of neurologic symptoms is not precise enough for assess-
ment of the real individual risk of stroke. As CEA has been def-
initely scientifically verified as an efficient method of surgical
treatment for carotid occlusive disease and for stroke preven-
tion, all the possibilities it offers should be maximally used.
Unfortunately, in Croatia only 15% of the real needs for CEA are
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na kompeticiji, nego na komplementarnosti, ali uz istu znanst-
venu valorizaciju kao i za KEA.
KljuŁne rijeŁi: karotidna endarterektomija, prevencija modanog
udara, karotidna okluzivna bolest, ateroskleroza
Uvod
Ateroskleroza Łini oko 90% patologije ekstrakranijskih
cerebralnih arterija i do u 75% sluŁajeva prevladava loka-
lizacija na karotidnoj bifurkaciji zahvaæajuæi najranije i na-
jvie unutarnju karotidnu arteriju. Oblik (geometrijski Łim-
benik rizika aterogeneze!) i hemodinamika karotidne bi-
furkacije odgovorni su za najŁeæe sijelo ateroskleroze na
precerebralnim arterijama1.
Karotidna okluzivna bolest (carotid occlusive disease,
COD) je uza srŁane aritmije najŁeæi izravan uzrok ishe-
mijskog modanog udara, ali i biljeg koronarne i periferne
aterosklerotske obliterativne bolesti. (Perifernu ateroskle-
rotsku obliterativnu bolest ima oko 35% bolesnika s COD,
a oko 40% kandidata za karotidnu endarterektomiju ima
teku koronarnu bolest.)
Prema podacima SZO2, modani udar je drugi vodeæi
uzrok smrtnosti u svijetu, a prema dobi standardizirana
prevalencija modanog udara u ljudi od 65 godina starosti
navie iznosi 46-72 na 1000 te populacije3. Prema rezulta-
tima vie studija, ishemijski modani udar prevladava kao
podtip i odgovoran je za 67%-81% svih modanih udara, a
njegova jednomjeseŁna  smrtnost je oko 16%3. Godine
1990. modani je udar bio esti vodeæi uzrok invalidnosti i
onesposobljenosti, a predviða se da æe 2020. godine biti na
Łetvrtom mjestu4. Cijena kotanja lijeŁenja po bolesniku
nakon ishemijskog udara za vrijeme trajanja ivota iznosi
60.000-230.000 USD5.
U Hrvatskoj 2000. godine meðu deset vodeæih uzroka
smrti modani udar (nespecificiran kao krvarenje ili ishe-
mijski infarkt) nalazi se na prvom mjestu sa  6.614 umrlih
(13.2%) i sa stopom smrtnosti od 151/100.000 stanovni-
ka6. Probir na tri izravna uzroka modanog udara, tj. na hi-
pertenziju, srŁane aritmije i COD, uz primarnu prevenci-
ju najvaniji je dio strategije za smanjenje tereta modanog
udara7.
Karotidna endarterektomija (KEA) i nove endovasku-
larne karotidne intervencije (karotidna balonska angioplas-
tika /carotid balloon angioplasty, CBA/ sa stentingom ili bez
njega /carotid artery stenting, CAS/) imaju prvenstveno pre-
ventivan koncept u sveukupnom pristupu lijeŁenja mo-
danog udara, te nalaze svoje mjesto u sekundarnoj preven-
ciji. Njihov je cilj sprjeŁavanje akutnog i teeg recidivnog
ishemijskog modanog udara, s njim povezanog tekog
invaliditeta i smrti, ali i sprjeŁavanje prolaznih disfunkcija
managed by this method. The future developments of endo-
vascular approach should not be based on competition but on
complementarity, however, provided the same validation as for
CEA.
Key words: carotid endarterectomy, stroke prevention, carotid oc-
clusive disease, atherosclerosis
Introduction
Atherosclerosis accounts for about 90% of extracranial
cerebral artery pathology, predominantly localized at carot-
id bifurcation (75% of caes), with earliest and most com-
mon internal carotid artery involvement. The shape (the
geometrical risk factor for atherogenesis!) and hemody-
namics of carotid bifurcation are responsible for the most
common seat of atherosclerosis in precerebral arteries1.
Besides cardiac arrhythmias, carotid occlusive disease
(COD) is an immediate cause of ischemic stroke as well
as a marker of coronary and peripheral atherosclerotic oblit-
erative disease. (Peripheral atherosclerotic obliterative
disease is present in 35% of patients with COD, whereas
40% of candidates for carotid endarterectomy have severe
coronary disease.)
According to the WHO2, stroke is the second leading
cause of mortality woldwide. The age adjusted prevalence
of stroke among individuals aged ‡65 is 46-72 per 10003.
Several studies have shown that ischemic stroke is a pre-
dominant subtype that accounts for 67%-81% of all strokes,
with a one-month mortality rate of 16%3. In 1990, stroke
was the sixth most common cause of disability and disable-
ment, and is estimated to be the fourth one by the year
20204. The cost of treatment per patient following ischemic
stroke during life is 60,000-230,000 USD5. In Croatia in
2000, stroke (unspecified as hemorrhage or ischemic inf-
arction) was the first of ten leading causes of death with
6,614 (13.2%) deaths and mortality rate of 151/100,000
population6. Screening for the three direct causes of stroke,
i.e. hypertension, cardiac arrhythmias and COD along with
primary prevention is the most important part of the strat-
egy to reduce stroke burden7.
Carotid endarterectomy (CEA) and novel endovascu-
lar carotid interventions (carotid balloon angioplasty (CBA)
with or without stenting, carotid artery stenting (CAS))
primarily imply a preventive concept in the overall ap-
proach in the management of stroke, and have found place
in secondary prevention. Their aim is to prevent the oc-
currence of acute and recurrence of even more severe is-
chemic stroke as well as the associated disability and death,
and to prevent transient cerebral dysfunction. A rational
requirement is that the results of treatment should be
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superior to the natural course of the disease as well as to
best possible medicamentous therapy with modification
of risk factors for atherosclerosis, and that longterm out-
come results in improved quality of life and prolonged life
expectancy.
Over the 50 years of its use in practice8,9, CEA has
proved its efficiency and durability in the prevention of
stroke in symptomatic as well as asymptomatic stenoses.
Numerous international prospective randomized studies
supported by multidisciplinary consensus reports and ad
hoc professional association reports10-17 have emphasized
and elaborated its value. Today, CEA is the best scientifi-
cally validated method of treatment in vascular surgery.
Yet, over the last few years, the trend in indications for
CEA has been observed to change. The effect of general
and local anesthesia on CEA outcome has been investigat-
ed. The dispute about justifiability of indications for CEA
and CAS in asymptomatic carotid disease has heated up.
The Asymptomatic Carotid Atherosclerosis Study
(ACAS)11 has been strongly criticized. Urgent CEA is be-
coming an ever greater challenge for vascular surgeons and
neurologists.
In 25 years of its presence, CBA has been technically
improved by stenting (at first for recurrent stenoses, then
recommended as a routine procedure for all carotid stenos-
es, and enthusiastically as an alternative to conventional
CEA), and later by a number of devices for cerebral pro-
tection18,19. All these have increased the complexity of the
procedure and cost of intervention. In the lack of scientif-
ic clinical validation, longterm results, and with fast tech-
nological development and competition of numerous prod-
ucts, this endovascular approach has posed many questions
about the future trends in the management of carotid
stenoses. To date, results of five randomized studies have
been published, two of them prematurely discontinued for
poor results and complications, allegedly because of inad-
equate training of the participants, whereas one small
study lacked due credibility. The only large study, CAVA-
TAS20, found no difference in excessive combined rates of
stroke and mortality between CEA and CAS, whereas lo-
cal complications were more frequent in CEA. The SAP-
PHIRE trial included high risk patients. Concerning com-
plications, only a significantly higher rate of cardiac infarc-
tions was recorded in CEA in comparison with CAS. This
study also had to be prematurely discontinued for inade-
quate patient recruiting, and the results have not yet been
published21. New studies have been launched, however,
their results can only be expected in a few years.
The aim of this presentation is to illustrate our expe-
rience and results obtained with CEA, to discuss the
mozga. Racionalan je zahtjev da rezultati lijeŁenja moraju
biti bolji od prirodnog tijeka bolesti i najboljeg moguæeg
medikamentnog lijeŁenja s modifikacijom riziŁnih Łimbe-
nika za aterosklerozu, te da dugoroŁni ishod rezultira pobo-
ljanjem kvalitete ivota i produenjem ivotnog vijeka.
Karotidna endarterektomija je kroz 50 godina postoja-
nja8,9 dokazala svoju uŁinkovitost i trajnost u prevenciji
modanog udara kod simptomatskih, ali i asimptomatskih
stenoza. Mnoge su meðunarodne, prospektivne, rando-
mizirane studije poduprte izvjetajima multidisciplinskih
konsenzusa i ad hoc odbora strukovnih udruenja10-17 is-
taknule i razjasnile njenu vrijednost. KEA je danas najbolje
znanstveno valorizirana metoda lijeŁenja u vaskularnoj ki-
rurgiji.
Ipak, posljednjih se godina zapaa promjena trenda u
indikacijama za KEA. Ispituje se utjecaj opæe i lokalne
anestezije na ishod KEA. Zaotrila se je rasprava o oprav-
danosti indikacije za KEA i CAS u asimptomatskoj karotid-
noj bolesti. Teke kritike doivljava ACAS (Asymptoma-
tic Carotid Atherosclerosis Study)11. Urgentna KEA po-
staje sve veæi izazov za vaskularne kirurge i neurologe.
Kroz 25 godina postojanja karotidna balonska angiop-
la-stika (CBA) je tehniŁki unaprijeðena stentingom (prvo
za opetovane stenoze, zatim je preporuŁena kao rutina za
sve karotidne stenoze i entuzijastiŁki kao alternativa za
konvencionalnu KEA), a nakon toga i s brojnim naprava-
ma za cerebralnu zatitu18,19. To je sve poveæalo sloenost
zahvata i cijenu kotanja intervencije. U nedostatku znan-
stvene kliniŁke valorizacije, dugoroŁnih rezultata, brzog te-
hnolokog razvoja i kompeticije mnogobrojnih proizvoda
ovaj je endovaskularni pristup nametnuo mnoga otvorena
pitanja o buduænosti lijeŁenja karotidnih stenoza. Do danas
su objavljeni rezultati ukupno pet randomiziranih studija
od kojih su dvije prerano prekinute zbog loih rezultata i
kom-plikacija, navodno zbog neprimjerene uvjebanosti
sudio-nika, a treæa je mala studija neuvjerljiva. CAVATAS,
jedina veæa studija20, nije nala razlike u previsokim kom-
biniranim stopama modanog udara i smrtnosti izmeðu
KEA i CAS, dok su lokalne komplikacije bile Łeæe kod
KEA. Studija SAPPHIRE  je ukljuŁila visoko riziŁne
bolesnike. Od kom-plikacija jedino je zabiljeeno znaŁaj-
no vie srŁanih infarkta kod KEA (u usporedbi s CAS). I
ova je studija prerano prekinuta zbog premalog broja
prikladnih bolesnika, a rezultati jo nisu objavljeni21. Pokre-
nute su i nove studije, ali na njihove rezultate treba
priŁekati nekoliko godina.
Cilj ovoga rada je prikazati naa dosadanja iskustva i
rezultate s KEA, raspraviti sadanje stanje u tom podruŁju
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present state in this field of vascular surgery with special
reference to indications for CEA, and to outline some
guidelines for further work.
Material and Methods
At the Department of Vascular Surgery, Sestre milos-
rdnice University Hospital, Zagreb, Croatia, 2342 CEA
procedures were performed in 2223 patients (119 or 5.4%
of bilateral operations) from January 1970 till August 31,
2004. There were 692 (31.1%) women and 1531 (68.9%)
men, mean age 65.8–9.3 (range 38-98) years. The results
recorded so far have been successively reported22. Over the
last 5 years, the number of operations has been on a steady
increase, with a mean of 160 procedures per year.
During the last 7 years, preoperative patient prepara-
tion included arteriography (DSA) in only 24% of cases.
Using appropriate ultrasonographic studies (CDFI, Pow-
er Doppler, qualitative plaque analysis, TCD, vasoreactiv-
ity testing and HITS recordings), arteriography is only
indicated in multiple localization of the disease, proximal
disease of the aortic arch, and in symptomatic patients with
borderline or poorly assessable degree of stenosis on du-
plex. Brain computed tomography (CT) is included in
routine examination, especially in patients with fixed neu-
rologic deficit and confounded clinical picture.
At our Department, CEA has always been restrictively
and selectively indicated in asymptomatic stenoses as well
as in symptomatic stenoses after a completed stroke22,23.
During the last two years, the number of CEA indicated
in asymptomatic patients has considerably decreased,
while the number of these procedures after transient is-
chemic attacks (TIA) has increased; in this indication, we
tend to perform it within an interval not exceeding 6-8
weeks. Our experience with ischemic stroke in evolution,
regressive and minor stroke, and acute major stroke is rath-
er limited. The procedure was indicated in hospitalized
patients with a known potential cause (ICA thrombosis
following arteriography or CEA), and not later than 6 hours
of the symptom onset. Unstable ischemic neurologic syn-
dromes such as crescendo TIA and fluctuating ischemic
neurologic deficit have are not present in our casuistics.
Indications for CEA according to symptoms are present-
ed in Table 1.
Until October 14, 2002, all procedures were carried out
in general anesthesia with selective to routine use of tem-
porary intraluminal shunting (USCI shunt of an adequate
diameter). Since October 14, 2002, the majority of opera-
tions (about 90%) have been performed in locoregional
vaskularne kirurgije, osobito s obzirom na indiciranje KEA,
te naznaŁiti smjernice za daljnji rad.
Materijal i metode
U razdoblju od sijeŁnja 1970. do 31. kolovoza 2004.
godine na Odjelu za vaskularnu kirurgiju KB «Sestre milo-
srdnice» ukupno je uŁinjeno 2342 KEA na 2223 bolesnika
(119, odnosno 5,4% obostranih operacija). Operirane su
692 (31,1%) ene i 1531 (68,9%) mukarac. Srednja dob
operiranih bila je 65,8–9,3 raspon od 38-98 godina. O dosa-
danjim rezultatima redovito smo izvjetavali22. U posljed-
njih 5 godina broj operacija je u stalnom porastu, s pro-
sjekom od oko 160 operacija na godinu.
U posljednjih sedam godina u prijeoperacijskoj obradi
bolesnika arteriografija (DSA) je rabljena u samo 24% sluŁa-
jeva. Uz odgovarajuæu ultrasonografsku obradu (CDFI,
Power Doppler, analizom kvalitete plakova, TCD, testira-
njem vazoreaktivnosti i registracijom HITS), arteriografi-
ju indiciramo samo kod viestruke lokalizacije bolesti,
proksimalne bolesti grana luka aorte, te kod simptomatskih
bolesnika s graniŁnim ili teko procjenjivim stupnjem
stenoza na dupleksu. Kompjutorizirana tomografija (CT)
mozga spada u rutinsku obradu, osobito kod bolesnika s
fiksiranim neurolokim deficitom i zbunjujuæom kliniŁkom
slikom.
Mi smo uvijek restriktivno i selektivno indicirali KEA
kod asimptomatskih stenoza, ali i onih simptomatskih
nakon zavrenog modanog udara22,23. U posljednje dvije
godine znatno opada broj KEA indiciranih u asimpto-
matskih bolesnika, a poveæan je broj operacija nakon pro-
laznih ishemijskih napadaja (transient ischemic attack, TIA)
koje nastojimo operirati u razmaku ne duem od 6-8
tjedana. S ishemijskim modanim udarom u evoluciji, re-
gresivnim i manjim modanim udarom te s akutnim ve-
likim modanim udarom imamo vrlo ograniŁena iskustva.
Operacije smo indicirali samo kod veæ hospitaliziranih
bolesnika s poznatim moguæim uzrokom (tromboza ICA
nakon arteriografije ili KEA) i najkasnije do 6 sati od nas-
tupa simptoma. Nestabilni ishemijski neuroloki sindromi,
kao crescendo TIA i fluktuirajuæi ishemijski neuroloki
deficit nisu zastupljeni u naoj kazuistici. Indikacije za KEA
prema simptomima prikazane su na tablici 1.
Sve su operacije do 14. listopada 2002. godine izvedene
u opæoj anesteziji uz selektivnu do rutinsku upotrebu
privremenog intraluminalnog premotenja (USCI shunt
primjerenog promjera). Od 14. listopada 2002. godine naj-
veæi broj operacija (oko 90%) izveden je u lokoregionalnoj
anesteziji, a na je Odjel ukljuŁen u multicentriŁno ran-
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domizirano ispitivanje utjecaja opæe prema lokalnoj aneste-
ziji na rezultate KEA (The GALA Trial: a randomised trial
of General versus Local Anaesthesia for carotid endarte-
rectomy)24. U proteklom vremenu rabili smo razliŁite kirur-
ke tehnike KEA (vidi tablicu 2.).
Kod otvorene, konvencionalne KEA u poŁetku smo
najŁeæe za zatvaranje arteriotomije rabili izravan av (tack-
ing, direct suture), a od osamdesetih godina najŁeæe angio-
plastiku razliŁitim vrstama zakrpa (patch)22. Od 1985. go-
dine uvedena je everzijska KEA22 koju sada sve Łeæe rabi-
mo (skraæeno trajanje operacije, uteda potronog mate-
rijala neuporabom aloplastiŁne zakrpe, manja moguænost
infekcije) kod svih oblika karotidne bifurkacije. Otvorenoj
KEA s patch angioplastikom prednost dajemo kod ena s
asimptomatskim uznapredovalim stenozama s eholucent-
nim plakovima, kao i s istovrsnim simptomatskim stenoza-
ma kada je lumen karotidnih arterija izrazito uzak.
Rezultati
Perioperacijske komplikacije do 30 dana nakon KEA
iskazane su prema incidenciji prolaznog (TIA) i trajnog
neurolokog deficita (modani udar), te smrti operiranih.
U bolesnika s progresivnim i akutnim modanim
udarom (samo 9 operiranih) zabiljeili smo katastrofalne
rezultate sa smrtnoæu od 22,2% (dva umrla od 9 operi-
anesthesia, and our Department has been included in the
multicenter, randomized study of the effect of general
versus local anesthesia on CEA results (the GALA Trial: a
randomized trial of General versus Local Anesthesia for
carotid endarterectomy)24. During the past period present-
ed here, various surgical techniques of CEA have been
employed (see Table 2).
On open, conventional CEA, a tacking, direct suture
was initially most frequently used for arteriotomy closure,
whereas since the 1980s, angioplasty with various patch
types has been most commonly employed22. Eversion CEA
has been introduced since 198522, and is ever more fre-
quently used now (reduced duration of the procedure,
saving accessories using no alloplastic patch, reduced pos-
sibility of infection) for all types of carotid bifurcations.
Open CEA with patch angioplasty is preferred in women
with asymptomatic advanced stenoses with echolucent
plaques, and in those with such symptomatic stenoses
when the carotid artery lumen is extremely narrow.
Results
Perioperative complications to up to day 30 of CEA are
presented according to the incidence of TIA, and of per-
manent neurologic deficit (stroke) and death. In patients
with progressive and acute stroke (only nine patients oper-
Table 1. Indications for CEA: 1970  August 31, 2004 (N=2342)
Indication n %
Asymptomatic stenosis 341 14.5
Symptomatic stenosis (total) 2001 85.44
Amaurosis fugax/retinal artery occlusion 154 7.70
Contralateral symptoms 603 30.13
Ipsilateral symptoms 186 9.29
Vertebrobasilar symptoms 155 7.75
Stroke in evolution 9 0.45
Completed stroke 894 44.68
Table 2. CEA operative details 1970-2004 (N=2342)
Operative detail n  %
Conventional CEA  6 76.7
Eversion CEA 46 23.3
Tacking (direct) sutures 522 22.3
Patches 1274 54.3
Shunt 1526  65.2
Drain 2342 100
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ranih) i stopom smrti od modanog udara od 55,5%. Zbog
takvih rezultata, u naim okolnostima smatramo da indi-
kacija za KEA u akutnom modanom udaru nije razumna.
Bolji se rezultati mogu postiæi lijeŁenjem u jedinicama
intenzivne neuroloke skrbi.
Najbolje smo rezultate postigli operirajuæi asimptom-
atske stenoze. Nismo imali smrtnih ishoda, a stopa mo-
danog udara do 30 dana nakon operacije iznosila je 0,3%
(1/341) te prolaznog neurolokog deficita (TIA) 0,9% (3/
341).
Operirali smo 1098 (46,9% svih operiranih) bolesnika
sa simptomatskim stenozama nakon TIA. U tih je bolesni-
ka stopa modanog udara i smrti u opserviranom periope-
racijskom razdoblju iznosila 1% (po 0,5% svakoga, odnos-
no 5/1098), a prolaznog neurolokog deficita 0,7% (8/1098).
Nakon zavrenog modanog udara operirali smo uku-
pno 894 (38,4% svih operiranih) bolesnika, a stopa moda-
nog udara (1,8%, 16/894) i smrti (1,3%, 12/894) iznosila je
3,1%, dok je prolazni neuroloki deficit zabiljeen u 10
(1,1%) bolesnika.
Ukupna stopa modanog udara i smrti za sve operirane
iznosila je 1,9% (44/2342).
Kombinirana stopa udruenog neurolokog (prolaznog
i trajnog) deficita i smrtnosti za sve operirane iznosila je
2,9% (67/2342), a za sve operirane sa simptomatskim ste-
nozama (II., III. i IV. kliniŁki stadij cerebrovaskularne boles-
ti) 3,1% (63/2001).
Rasprava
Veæ je trivijalna  rasprava o rezultatima KEA u pojedin-
im serijama koje su postigli timovi vaskularnih kirurga neke
ustanove, ali svakako nai rezultati spadaju meðu najbo-
lje. Smatramo da je za to zasluna dobra prijeoperacijska
obrada, dobar odabir kandidata za KEA, minuciozna kirur-
ka tehnika, te dobar rad anesteziologa.
Pozornost zasluuje rasprava o indikacijama za KEA,
osobito kod asimptomatskih karotidnih stenoza koje su i
dalje kontroverzne.
Izvjeæe Veterans Affairs Cooperative Study Group
(VA)10 i  studija pod naslovom The Asymptomatic Caro-
tid Atherosclerosis Study (ACAS)11 potvrðuju dobrobit
KEA u prevenciji rizika neurolokog deficita kod asim-
ptomatskih karotidnih stenoza veæih od 60% prema krite-
riju NASCET12 (odgovara stenozama >77% prema krite-
riju ECST). U studiji ACAS nije zabiljeena statistiŁki
znaŁajna razlika za prevenciju modanog udara u ena, kao
ni za prevenciju tekog onesposobljavajuæeg modanog
udara u usporedbi medikamentno lijeŁenih bolesnika i onih
ated on) disastrous results with a 22.2% mortality rate (two
deaths of nine patients operated on) and 55.5% stroke-
death rate were recorded. Based on such poor results, we
believe that in our circumstances indicating CEA for acute
stroke is quite injudicious. Better results can be achieved
by treatment at neurologic intensive care units. At our
Department, best results were achieved when operating
on asymptomatic stenoses. There were no lethal outcomes,
whereas 30-day postoperative stroke rate was 0.3% (1/341),
and of TIA 0.9% (3/341).
We operated on 1098 (46.9% of total) patients with
symptomatic stenoses following TIA. In these patients,
the cumulative rate of stroke and death during the perio-
perative period of observation was 1% (0.5% each or 5/
1098), and of TIA 0.7% (8/1098).
CEA upon stroke completion was performed in 894
(38.4% of total) patients. The cumulative rate of stroke
(1.8%, 16/894) and death (1.3%, 12/894) was 3.1%, and of
TIA 1.1% (10/894).
The cumulative stroke and death rate for all patients
operated on was 1.9% (44/2342).
The cumulative rate of associated neurologic (transient
and permanent) deficit and mortality for all patients op-
erated on was 2.9% (67/2342), and for those with symp-
tomatic stenoses (clinical stage II, III and IV cerebrovas-
cular disease) 3.1% (63/2001).
Discussion
Discussing the results of CEA achieved in particular
cohorts by vascular surgery teams from an institution may
appear trivial, however, our results definitely keep abreast
of the best ones. We believe that this is so because of proper
preoperative preparation, proper candidate selection for
CEA, meticulous surgical technique, and appropriate work
of the anesthesiologists.
Discussion about the indications for CEA deserves due
attention, especially in asymptomatic carotid stenoses, as
there is still much controversy on the issue.
The Veterans Affairs Cooperative Study Group (VA)10
and Asymptomatic Carotid Atherosclerosis Study
(ACAS)11 confirmed the benefit of CEA in preventing the
risk of neurologic deficit in asymptomatic carotid stenos-
es >60% according to NASCET criterion12 (correspond-
ing to >77% stenoses according to ESCT criterion). ACAS
failed to achieve a statistically significant difference in the
prevention of stroke in women or of severe, debilitating
stroke between medicamentously treated patients and
those treated by CEA. The absolute 5-year reduction in
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the risk of ipsilateral stroke and death by 5.9% implies that
about 17 patients should be operated on to prevent a sin-
gle ipsilateral stroke and death over 5 years. One-year re-
duction of stroke alone by 2% to 1% per year11 means that
approximately 20 procedures should be done in asymptom-
atic patients to prevent a single stroke over a 5-year peri-
od. The American Heart Association (AHA) issued recom-
mendations (A degree) in 1995, 1998 and 200116,17,25, stat-
ing that the only demonstrated indication for CEA in as-
ymptomatic stenoses >60% (according to NASCET cri-
terion) is if the perioperative risk of stroke and death is less
than 3%, this in patients life expectancy of at least 5 years.
It is suggested that CEA in asymptomatic advanced
stenoses be exclusively performed by experienced and
recognized teams, and that those patients be identified
and operated on in whom the one-year stroke risk is esti-
mated to >4%. Obviously, the criterion risk assessment
only the basis of stenosis percent, and possibly on the pres-
ence of massive plaque ulceration, or on the existence of
contralateral stenosis/obliteration does not appear to be
adequate. Not even in 2003 was the beneficial effect of
CEA in the management of advanced asymptomatic carot-
id stenoses properly scientifically verified or demonstrat-
ed, but numerous operations have been carried out all over
the world and with very satisfactory results. On the one
hand, it has been concluded that operative intervention
and angioplasty on asymptomatic carotid arteries do not
prevent debilitating stroke, on the contrary, that in some
well designed studies the operation caused more strokes
than it prevented, and that antilipid therapy (pravastatin)
efficaciously prevents at least 50% of strokes due to asymp-
tomatic carotid stenoses, is well tolerated and safe26. On
the other hand, it has been concluded that the interven-
tion is mandatory in patients with asymptomatic stenoses
provided a favorable life expectancy, with selection of can-
didates at a high risk of stroke based primarily on duplex
sonography plaque features27, which is more important
than the estimated degree of stenosis. Finally, the results
of two studies we have long been waiting for have been
published. The aim of the Asymptomatic Carotid Steno-
sis and Risk of Stroke (ACSRS) study was to upgrade risk
stratification by use of clinical and ultrasonography factors
which, along with the degree of stenosis, have a consider-
able impact on this risk28. The study included 1058 pa-
tients with asymptomatic stenoses (ECST 50%-99%) and
follow-up of 0.5-5 years. The type of plaque (Geroulakos
classification29) was found to be a more significant predic-
tor of the risk of ipsilateral stroke than stenosis degree.
Duplex ultrasonography study of plaque density in com-
nakon KEA. Apsolutno smanjenje rizika od istostranog
modanog udara i smrti od 5,9% za petogodinje razdoblje
znaŁi da bi trebalo operirati oko 17 bolesnika kako bi se
sprijeŁio jedan istostrani modani udar i smrt kroz pet
godina. Jednogodinje smanjenje samo modanog udara od
2% do 1% na godinu11 zapravo znaŁi da bi trebalo izvesti
priblino 20 operacija kod asimptomatskih bolesnika kako
bi se sprijeŁio jedan modani udar kroz razdoblje od pet
godina. AHA (American Heart Association) je 1995., 1998.
i 2001. godine16,17,25 donijela preporuku (stupnja A) o tome
da je jedina dokazana indikacija za KEA kod asimpto-
matskih stenoza >60% (prema kriteriju NASCET), ako
je perioperacijski rizik modanog udara i smrti manji od 3%,
i to kod bolesnika s oŁekivanim ivotnim vijekom od naj-
manje pet godina. Pledira se da kod asimptomatskih
uznapredovalih stenoza zahvat KEA izvode samo timovi
dokazane uspjenosti te da se operiraju i identificiraju oni
bolesnici kod kojih se jednogodinji rizik modanog udara
procijeni veæim od 4%. OŁito je nedostatan kriterij procjene
rizika koji se uglavnom osniva na postotku stenoze, even-
tualno na prisutnosti velike ulceracije plaka ili postojanju
i kontralateralne stenoze/obliteracije. Niti do 2003. go-
dine26,27 nije bilo dovoljno znanstveno potvrðeno ni eviden-
tirano da je profilaktiŁna KEA blagotvorna u lijeŁenju
uznapredovalih asimptomatskih karotidnih stenoza, ali je
uŁinjeno puno operacija svuda po svijetu s vrlo zadovolja-
vajuæim rezultatima. S jedne je strane zakljuŁeno da kirur-
ka intervencija i angioplastika na asimptomatskim karotid-
nim stenozama ne sprjeŁavaju onesposobljavajuæi modani
udar, nego da je, naprotiv, u nekim dobro provedenim studi-
jama kirurgija uzrokovala vie modanih udara nego to ih
je sprijeŁila, te da antilipidna terapija (pravastatin) uŁin-
kovito sprjeŁava najmanje 50% modanih udara zbog asim-
ptomatskih karotidnih stenoza, da se takva terapija dobro
podnosi i da je sigurna26. S druge pak strane, zakljuŁeno je
kako postoji mandat za intervenciju kod bolesnika s asim-
ptomatskim stenozama, ako je njihov oŁekivani ivotni
vijek dobar, uz odabir kandidata s visokim rizikom moda-
nog udara temeljen prvenstveno na dupleks sonografskim
znaŁajkama plakova27, koja je vanija od procijenjenog stup-
nja stenoze. KonaŁno su objavljeni dosadanji rezultati dviju
dugo Łekanih studija. Studija ACSRS (Asymptomatic Ca-
rotid Stenosis and Risk of Stroke) imala je za cilj pobolj-
ati dosadanju stratifikaciju rizika upotrebom kliniŁkih i
ultrazvuŁnih Łinitelja koji, uza stupanj stenoze, znatno
utiŁu na rizik28. Studija je ukljuŁila 1058 bolesnika s asim-
ptomatskim stenozama (50%-99%, ECST) s razdobljem
praæenja od 0,5 do 5 godina. Ustanovljeno je da je vrst pla-
ka (Geroulakosova klasifikacija29) znaŁajniji predskazatelj
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bination with computer assisted image analysis and gray
scale median (GSM) calculation revealed the hypo-
echogenic, soft plaques with low GSM (10-25) to corre-
late well with the incidence of cerebral events. Using the
ACSRS model of risk stratification, in >60% stenoses only
20% of patients with a 5-year cumulative risk of stroke
could be identified from 21% (4.2% risk per year) of those
who could be recommended CEA. Using the ACSRS cri-
teria, two-thirds of low risk patients could be saved unnec-
essary operation, while only 6 operations are needed to
prevent a single stroke over 5 years.
Another study, the Asymptomatic Carotid Surgery Trial
(ACST), has recently been published in The Lancet30. In
asymptomatic patients below age 75, with ‡70% stenoses
assessed by ultrasonography (many of them were on aspi-
rin, antihypertensive and statin therapy), immediate CEA
halved the 5-year risk of stroke (in comparison with those
allocated to medicamentous, delayed treatment) from 12%
to 6%  (including the 3% perioperative hazard). A half of
this 5-year benefit included severe or fatal stroke. The
benefit did not refer to those older than 75, of whom a half
died during the 5-year period from unrelated causes. The
authors note that inappropriate patient selection and less
sophisticated operative technique may preclude such a
beneficial impact of CEA when performed elsewhere, i.e.
not at the institutions included in the study.
Comparing the results of ACAS and ACST trials it
appears that there is no substantial difference between the
ultimate benefit from surgical treatment of asymptomat-
ic stenoses and that from most appropriate medicamen-
tous therapy, and that we are still quite far from the scien-
tifically based and generally accepted criteria for patient
selection for CEA.
There is no need to discuss about indicating CEA for
symptomatic stenoses, as these indications have been
widely adopted upon completion of some large studies12-
17, especially NASCET and ECST.
Patients with major, debilitating stroke should be ad-
vised conservative treatment at neurologic intensive care
units, and indications for CEA should be considered after
4-6 weeks.
Our early results and observations about the effect of
locoregional anesthesia on CEA outcome will be reported
in separate.
rizika istostranog modanog udara od stupnja stenoze.
Dupleks ultrasonografsko ispitivanje gustoæe plaka u ko-
mbinaciji s raŁunalnom analizom slike i raŁunanjem medi-
jana sive skale (GSM) pokazalo je kako hipoehogeni, meki
plakovi s niskim vrijednostima GSM (10-25) dobro kore-
liraju s incidencijom modanih dogaðaja. Primjenom mod-
ela ACSRS za stratifikaciju rizika kod stenoza >60% moe
se identificirati samo 20% bolesnika s petogodinjim ku-
mulativnim rizikom modanog udara od 21% (godinji rizik
4,2%), kojima se moe preporuŁiti KEA. Uz primjenu kri-
terija ACSRS dvije treæine bolesnika s malim rizikom mogu
biti poteðeni nepotrebne operacije, a potrebno je samo 6
operacija da se sprijeŁi jedan modani udar kroz pet godi-
na.
Druga je studija, ACST (Asymptomatic Carotid Sur-
gery Trial), nedavno objavljena u Lancetu30. Kod asimpto-
matskih bolesnika mlaðih od 75 godina, sa stenozama od
70% i vie  procijenjenih pomoæu UZV (mnogi od njih bili
su i na aspirinu, antihipertenzivnoj i statinskoj terapiji)
neposredna KEA je prepolovila petogodinji rizik mo-
danog udara (u usporedbi s onima koji su bili na medika-
mentnoj, odgoðenoj terapiji) s 12% na 6% (ukljuŁen peri-
operacijski rizik od 3%). Polovica od ove petogodinje
koristi odnosila se je na teki ili smrtonosni modani udar.
Korist se ne odnosi na osobe starije od 75 godina od kojih
u petogodinjem razdoblju umre polovica zbog nevezanih
uzroka. Napominje se kako izvan ustanova ukljuŁenih u
studiju neodgovarajuæi odabir bolesnika i loa kirurka te-
hnika mogu osujetiti takovu dobrobit KEA.
Usporeðujuæi rezultate studija ACAS i ACST Łini se da
nema bitne razlike u konaŁnoj dobrobiti kirurkog lijeŁenja
asimptomatskih stenoza prema dobrobiti najbolje medika-
mentne terapije, te da smo jo uvijek daleko od znanstveno
dokazanih i opæeprihvaæenih kriterija za odabir bolesnika
za KEA.
O indikacijama za KEA kod simptomatskih stenoza ne
treba raspravljati, jer su one opæe prihvaæene nakon
provedenih multicentriŁnih studija12-17, poglavito studija
NASCET i ECST.
Bolesnicima s velikim, onesposobljavajuæim modanim
udarom treba preporuŁiti konzervativno lijeŁenje u jedini-
cama intenzivne neuroloke skrbi, a nakon 4-6 tjedana raz-
motriti indikaciju za KEA.
O ranim rezultatima i naim zapaanjima o utjecaju
lokoregionalne anestezije na ishod KEA posebno æemo
izvijestiti.
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ZakljuŁak
Svuda u svijetu KEA je najŁeæe izvoðena vaskularna
operacija. Prema epidemiolokim podacima procijenjeno
je da u Hrvatskoj ima 3.800 simptomatskih i vie od 30.000
asimptomatskih bolesnika, te da prosjeŁna godinja potreba
za KEA/CAS iznosi 3.200 zahvata na godinu. Vaskularni
kirurzi u Hrvatskoj obave samo 15% realnih potreba31.
Nakon objavljivanja rezultata multicentriŁnih, prospe-
ktivnih, randomiziranih studija Łinilo se je da je KEA po-
tvrðena kao zlatni standard u prevenciji modanog udara,
osobito u simptomatskih bolesnika s hemodinamski zna-
Łajnim stenozama, ali i kod asimptomatskih, to je potkri-
jepljeno konsenzusima16,17,25. U konfliktu s praksom da se
je velik broj operacija s dobrim rezultatima izvodio na asim-
ptomatskim bolesnicima, studije su pokazale kako su upit-
ni ili minimalni dokazi za dobrobit KEA kod ovih bolesni-
ka. Argumenti za preventivnu KEA u asimptomatskih
bolesnika bili su da se u njih CT-om mozga moe verifici-
rati 5%-12% tzv. tihih modanih udara i da ima malo
modanih udara nagovijetenih kroz TIA, te da svi asim-
ptomatski bolesnici nisu isti, kao to nisu isti niti svi oni
simptomatski. Na primjer, oŁni TIA nosi manji rizik od
hemisfernih simptoma i modanog udara, a neki se sim-
ptomatski oŁituju vertebrobazilarnim simptomima, iako
su bez oŁitih stenoza tog sliva. Iz cijele rasprave nameæe
se zakljuŁak da je kategorizacija bolesnika kandidata za
KEA koja se temelji samo na stupnju stenoze i prisutnosti
ili odsutnosti neurolokih simptoma nedovoljno precizna
za procjenu stvarnog rizika u svakog bolesnika. Vie svjet-
la u problem indikacija za KEA kod asimptomatskih bo-
lesnika donijele su novije studije (ACST i ACSRS)28,30, ali
su otvorena i nova pitanja.
Buduænost lijeŁenja karotidnih stenoza teko je pred-
vidjeti. U sadanjoj fazi razvoja raspolaeno uŁinkovitom
metodom kirurkog lijeŁenja karotidne okluzivne bolesti i
prevencije modanog udara, te svakako treba iskoristiti sve
njene moguænosti. Buduænost endovaskularnog pristupa
(CBA/CAS) ne bi trebala biti kompeticija zahvatu KEA,
nego komplementarnost, ali i te metode treba znanstveno
valorizirati kao i KEA.
Conclusion
Carotid endarterectomy is the most commonly per-
formed vascular operation worldwide. According to epide-
miologic data, it is estimated that there are 3,800 symp-
tomatic and 30,000 asymptomatic patients in Croatia,
whereas the annual CEA/CAS requirements amount to
3,200 procedures. Vascular surgeons in Croatia perform
only 15% of these requirements31.
Upon publication of the results of multicenter, prospec-
tive, randomized studies CEA seemed to be confirmed as
a gold standard in the prevention of stroke, especially in
symptomatic patients with hemodynamically significant
stenoses, and also in symptomatic patients, which was
supported by consensus16,17,25. In contrast to practice with
a great number of operations performed in asymptomatic
patients with favorable results, studies have shown the
evidence for CEA benefit in these patients to be question-
able or minimal. The arguments for preventive CEA in
asymptomatic patients are that 5%-12% of so-called silent
strokes could be verified by CT in these patients, that not
many strokes are predicted by TIA, and that not all as-
ymptomatic patients, likewise the symptomatic ones,
are identical. For example, ocular TIA carries a lower risk
of hemispheric symptoms and stroke, whereas some
symptomatic patients present with vertebrobasilar
symptoms although otherwise free from evident stenoses
of the respective basin. This discussion generally points
to a conclusion that categorization of patients candidates
for CEA, which is based solely on the degree of stenosis
and presence or absence of neurologic symptoms is not
precise enough to reliably assess the real risk in each indi-
vidual patient. Recent studies (ACST and ACSRS)28,30
have shed additional light upon the issue of indicating CEA
in asymptomatic patients, however, they have also opened
some new questions.
The future of the management of carotid stenoses is
difficult to predict. In the present phase of development,
an efficacious method of surgical therapy for COD and
stroke prevention is available and its possibilities should
certainly be properly utilized. The future of endovascular
approach (CBA/CAS) should not be competition to CEA
but the methods should be considered complementary,
however, they require scientific validation, just like CEA.
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CAROTID SURGERY IN 2004: STATE-OF-THE ART, PROGNOSES AND PROSPECTS
KAROTIDNA KIRURGIJA 2004: STANJE, PROGNOZE I PERSPEKTIVA
Tomislav oa, Marko Ajduk, Lidija Erdelez and Andrija kopljanac
Merkur University Hospital, Zagreb, Croatia
KliniŁka bolnica Merkur, Zagreb
Karotidna kirurgija nije jednostavna kirurgija organa. To
je kirurgija osobnosti i due, jer rjeava sloene psihofiziŁke
probleme bolesnika s cerebralnom ishemijom. Najistra-
enije je podruŁje kirurgije, podvrgnuto strogim kriteriji-
ma evaluacije. Karotidna kirurgija postala je prototip za
medicinu poduprtu dokazima (EBM*). Istrauje se ne-
prekidno 50 godina1-3. U suradnji s neurolozima izvedeno
je najvie prospektivnih istraivanja na ovom polju, naprav-
ljeno je vie prospektivnih, randomiziranih studija svakog
segmenta karotidne kirurgije, ustanovljena je stroga kon-
trola kvalitete u Centrima izvrsnosti, bolesnici se algori-
tamski i viedimenzijski prate doivotno, uspostavljeni su
Łvrsti odnosi troka i dobitka (cost/benefit) i troka i uŁinka
(cost/effectiveness) za KEA/KAS, napravljeno je najvie kon-
senzusa ba u karotidnoj kirurgiji4-6. Ako pretpostavimo ova-
kovu analizu u nekim drugim granama medicine, ostalo bi
otvoreno pitanje opsega njihove dananje primjene.
Karotidna kirurgija ima znaŁajan utjecaj na najvaniju
znaŁajku dananje vaskularne kirurgije, a to je kvaliteta
ivota operiranih bolesnika7,8.
Epidemiologija karotidne bolesti u Hrvatskoj
U RH imamo do 10.000 MU na godinu i u ukupnom
broju aterosklerotskih smrti udio MU je 33%. Preko 8100
MU su ishemijski (44% infarkt, 21% TIA, 21% emboliza-
cije). Aterotromboza uzrokuje 4900 MU na godinu. Uku-
pni trokovi MU u RH iznose 120 milijuna USD na go-
dinu. U SAD trokovi KEA iznose 8500 USD, dok troko-
vi veæeg, zavrenog MU iznose 34000 USD prve godine, a
zatim svake slijedeæe godine po 18000 USD. Trokovi KEA
u RH iznose 4000 kn!9-12.
Koliki je stvarni problem? Na 200.000 stanovnika ima
0,08% bolesnika s TIA/MU i 1500 asimptomatskih bolesni-
ka. U RH, dakle, ima oko 3800 simptomatskih bolesnika s
karotidnom boleæu (COD) i oko 10 puta vie asimpto-
matskih bolesnika (oko 34.000). Sukladno izraŁunima o 38-
99 potrebnih KEA/100.000 stanovnika, u RH je potrebno
napraviti 1800-4500 KEA svake godine. ProsjeŁna potreba
bi bila 3200 operacija (0,07% KEA na broj stanovnika).
Carotid surgery is not a simple organ surgery. This is
the surgery of soul and personality for its solving complex
psychophysical problems in patients with cerebral is-
chemia. However, it is the most thoroughly investigated
area of surgery, subjected to the meticulous criteria of eval-
uation. Carotid surgery has become a prototype for the
EBM. Continuous investigations have been performed for
the last 50 years1-3, with surgeons investigating it together
with neurologists; one can find a great number of prospec-
tive studies of each particular segment of carotid surgery;
strict Quality Control has been established at Centers of
Excellence; patients are followed up by use algorithms and
multidimensional facilities; stable Cost/Benefit and Cost/
Effectiveness relationships are well known for CEA and
CAS; and the highest number of consensuses has been
published just in carotid surgery4-6. If we assume such anal-
ysis in some other medical branches, very soon we would
come to the open question of their use in the contempo-
rary medical treatment. Carotid surgery has a significant
influence upon the most important todays characteristic
of Vascular Surgery, the patients QOL7,8.
Carotid Epidemiology in Croatia
In Croatia, there are 10,000 strokes/year. In the total
number of atherosclerotic deaths, stroke accounts for 33%.
Over 8100 strokes are ischemic (44% infarct, 21% TIA, 21%
embolization). Atherothrombosis causes 4900 strokes/year.
The total costs of stroke in Croatia are 120 million USD/
year. In the USA, the costs of CEA are 8500 USD, while
the costs of the major stroke are 34,000 USD in the first
year, and 18,000 USD every next year. The costs of CEA
in Croatia are 700 USD!9-12
What is the real extent of the problem? Knowing that
we have 0,08% TIA/stroke patients and 1500 asymptom-
atic patients per 200,000 population, we can easily calcu-
late that in Croatia there are about 3800 symptomatic and
34,000 asymptomatic patients with carotid occlusive dis-
ease (COD). According to the EBM supported calculations
of the need of 38-99 CEA/100,000, in Croatia we need
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1800-4500 CEA/year. Thus, the average need is 3200 op-
erations (0.07 CEA/population). Framed with the acessi-
ble possiblities, the Croatian vascular surgeons can meet
15% of the real needs for CEA each year.
Key Points
In the year 2004, carotid surgery has to consider mu-
tual links of the following:
 patient selection
 evaluation and preoperative care
 operative treatment
 postoperative care
All these lead us to lowering of the stroke/death rate,
improvement of the patients QOL, diminishing the per-
centage of restenosis, prolonged life expectancy, and rise
in the cost/effectiveness of carotid surgery. The historical
cost/benefit question of how many CEA procedures we
need to perform to prevent one death or stroke has now
been answered by the lately published studies. In patients
with 80%-99% stenosis, we need to perform 5.6 CEAs to
prevent one death/stroke. This is, of course, under the
condition that CEA is performed by a team who have re-
ported their own stroke/death rate of 1%-2%. So, in com-
parison with other surgical branches, CEA is a very cost/
benefit procedure. Considering lowering of the costs, we
should keep in mind that only 1% of lesions are beyond
ultrasound analysis, that routine angiography contributes
to decision making in less than 2% of patients, that lean-
ing on duplex does not interfere with the operation suc-
cess, that the widespread use of LRA is common today13,14,
that strictly indicated CAT scan analysis contributes to
lowering of the postoperative complications, and that the
length of hospital stay is significantly shortened from 8 to
3-5 days. CFD and MIA analyses are efficacious in the CEA
quality control and also diminish the risk of preoperative
care to the minimum15. TCD points out dysfunction of the
circle of Willis and circulatory reversion. Brain CT scan
should be used when there is suspicion of a tumor or inf-
arct, in the acute stage of stroke, to differentiate scars from
hemorrhagic transition, colliquation or leukoariaosis. It is
also useful in search for the true asymptomatic patients15.
Patient selection
Prospective randomized studies 1980-2004 have led us
to the need of multidisciplinary, multicenter EBM consen-
suses regarding surgical therapy of carotid atherosclerosis16.
So, EBM has been implanted in the carotid field. The data
concerning carotid surgery should be  interpreted by the
OgraniŁeni moguænostima, vaskularni kirurzi u Hrvatskoj
mogu podmiriti 15% stvarnih potreba za KEA.
KljuŁne toŁke
Karotidna kirurgija 2004. mora uzimati u obzir meðu-
sobnu povezanost:
 izbora bolesnika za kirurgiju
 evaluacije i prijeoperacijske pripreme
 lijeŁenja operacijom
 poslijeoperacijskog lijeŁenja
Sve ovo vodi ka smanjenju perioperacijskog udjela MU
i smrtnosti (stroke/death rate), unaprijeðenju bolesnikove
QOL, smanjenju postoka ponovljene stenoze, produlje-
nju oŁekivane duljine ivota i poveæanju C/E karotidne
kirurgije.
Na povijesno C/B pitanje koliko treba napraviti CEA
da bi se sprijeŁila jedna smrt ili MU odgovoreno je obja-
vom rezultata ACST. U bolesnika s 80%- do 99%-tnom
stenozom UKA, pod uvjetom da operaciju izvodi tim koji
ima stopu s/d od 1%-2%, potrebno je napraviti 5,6 CEA da
bi se sprijeŁila jedna smrt ili MU. U usporedbi s drugim
granama kirurgije CEA je,  dakle, vrlo isplativa operacija.
U smanjenju trokova treba misliti na to da samo 1% le-
zija nadilazi moguænosti dupleks analize, da rutinska arte-
riografija doprinosi odluci u manje od 2% bolesnika, da
oslanjanje na dupleks ne utjeŁe na uspjeh operacije, da je
na potezu iroka upotreba LRA13,14, da indicirana upotre-
ba CT analize doprinosi smanjenju poslijeoperacijskih
komplikacija i da je duljina hospitalizacije znaŁajno skraæe-
na s 8 na 3-5 dana. CFD i MRA su uŁinkovite prilikom
kontrole kvalitete KEA i smanjuju rizik prijeoperacijske
obrade na minimum15. TCD ukazuje na disfunkciju Wil-
lisova kruga i obrat cirkulacije. CT mozga treba rabiti kod
sumnje na tumor ili infarkt, u akutnoj fazi MU, da se razlu-
Łi oiljke od hemoragijske tranzicije, kolikvacije i leukoar-
iaoze, te da se pronaðu stvarno asimptomatski bolesnici15.
Izbor bolesnika
Prospektivne randomizirane studije (1980.-2004.)
dovele su nas do potrebe multidisciplinskih, multicen-
triŁnih EBM konsenzusa u odnosu na kirurku terapiju
karotidne ateroskleroze16. I tako je EBM ujahala u karotid-
no polje. Podatke koji se odnose na karotidnu kirurgiju tre-
ba tumaŁiti u granicama kategorije dokaza i razine preporu-
ka (Ellis i sur., BMJ 1998.), ali u nedostatku najjaŁih doka-
za (dokazi prve razine), Łestom u kliniŁkoj medicini, svaki
kirurg treba biti oprezan i oslanjati se na vlastite epidemi-
oloke i perioperacijske rezultate17-19.
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Categories of Evidence and Strength of Recommendation
(Ellis et al., BMJ 1998), however, in the lack of strong ev-
idence (level 1 evidence), which is by no means rare in
clinical practice, each surgeon should be cautious and lean
on his own epidemiologic and perioperative results17-19.




 patients in advanced age
 patients suitable for urgent/emergent CEA
 patients suitable for surgical therapy of stroke in evo-
lution
 patients for surgical therapy of a completed stroke
 patients who need surgical therapy for TIA/stroke from
external carotid artery (ECA)
Symptomatic patients with the atherosclerotic origin of
the disease from carotid artery benefit from CEA accord-
ing to international agreement. Operative indications in
this group are hemispheric TIA, contemporary monocu-
lar blindness, and minor stroke with good recovery. CEA
in ICA stenosis >70% offers absolute stroke reduction by
17% in 2 years and 40% in 3 years (NASCET/ECST). In
centers with perioperative stroke/death rate <5%, all
symptomatic patients with 70% stenosis should be oper-
ated on.
Asymptomatic patients have come forward when it has
recently been found that CEA/CAS are successfully used
in stroke prevention4,12,20. The International Overseas Con-
sensus Statements have made a step forward and intro-
duced qualitative besides exclusively quantitative plaque
analysis used until that time21-24. The selection criteria for
asymptomatic patients are: >75% bifurcation stenosis,
asymptomatic stenosis progression, GSM 25-31, silent
stroke CAT/MRI confirmed, insufficient collateralization,
ACA collapse, reversed circulation or PSV lowering on
TCD, and patients with carotid occlusive disease and
multifactorial risk (smoking, hypertension, cholesterol).
The causes that subject a patients to the risk of CEA are
refractory, prolonged hypertension, preoperativne neuro-
logic deficit, nephropathy, angina and cardiac arrhythmia.
The factors that contribute to the patient selection are:
elevated serum VEGF-2R (in asymptomatic patients sig-
nificantly falls after CEA)25, elevated TAT, ATIII, t-PA and
D-dimer tests, MES on TCD (18% asymptomatic patients
are MES positive). Impaired cognitive functions are im-
proved in 28% of asymptomatic patients after CEA.
Elderly patients have less opportunity to benefit from




 bolesnike starije dobi
 one za urgentnu/emergentnu CEA
 one pogodne za kirurku terapiju MU u razvoju
 one za kirurku terapiju zavrenog MU
 one kojima treba kirurka terapija TIA/MU iz VKA
Simptomatski bolesnici s aterosklerotskim izvoritem
bolesti iz karotidne arterije imaju koristi od KEA prema
meðunarodnom konsenzusu. Indikacije u ovoj skupini su
hemisferni TIA, privremena monokularna sljepoæa, manji
MU s dobrim oporavkom. CEA u stenozi UKA >70% ima
apsolutno smanjenje MU za 17% u 2 godine i 40% u 3 go-
dine (NASCET/ECST), pa u centrima s perioperacijskom
stopom s/d <5% treba operirati simptomatske bolesnike
sa  70%-tnom stenozom.
Asimptomatski bolesnici izbili su u prvi plan kada je
nedavno utvrðeno da se KEA/KAS uspjeno upotrebljava-
ju za sprjeŁavanje MU4,12,20. International Overseas Con-
sensus Statements napravili su korak naprijed i uveli kva-
litativnu uz dosadanju iskljuŁivo kvantitativnu analizu pla-
ka21-24. Kriteriji izbora za operaciju asimptomatskih bolesni-
ka su: stenoza >75% smjetena na karotidnoj bifurkaciji s
progresijom u UKA, progresija asimptomatske stenoze,
GSM 25-31, tihi MU potvrðen CT/MRI analizom,
nedovoljna kolateralizacija modane cirkulacije, kolaps
SMA, reverzni protok ili usporenje protoka na TCD i
bolesnik s KOB i kombinacijom Łinitelja rizika (puenje,
hipertenzija, povien kolesterol). Uzroci poveæanja rizika
od KEA su refraktorna, viegodinja hipertenzija, prijeo-
peracijski neuroloki deficit, nefropatija, pektoralna angi-
na i znaŁajna srŁana aritmija. ¨ initelji koji doprinose izbo-
ru asimptomatskih bolesnika za operaciju su: povieni se-
rumski VEGF-2R u asimptomatskih bolesnika znaŁajno
pada nakon KEA25, zatim povienje TAT, ATIII, t-PA i D-
dimera, MES otkrivene pomoæu TCD (18% asimptom-
atskih bolesnika su pozitivni za viestruke znakove embo-
lije (multiple embolic signs, MES). Oteæenje kognitivnih
funkcija se poboljava u 28% asimptomatskih bolesnika
nakon KEA.
Stariji bolesnici imaju manje prilike uivati u dobro-
biti karotidne kirurgije. CEA je C/E do 75 godina ivota.
Simptomatski bolesnici od 75-80 godina selektivno se
odabiru za zahvat ako imaju oŁekivanu duljinu ivota do 5
godina. U ovoj i starijoj skupini CEA se radi u asimptom-
atskoj fazi ako je dokazana progresija bolesti u stenozi od
<80% do >80% ili ako je dokazana za ivot opasna komp-
likacija plaka26,27.
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Urgentna/emergentna KEA  jo je uvijek proturjeŁno
podruŁje za raspravu. Nema jasnih EBM Łinjenica koje bi
ju podupirale, kao ni prospektivnih, randomiziranih studija
iz ovog podruŁja. Ipak, brojni multicentriŁni izvjetaji vode
nas do slijedeæih preporuka: emergentnu (neposrednu)
KEA treba izvesti u bolesnika s perioperacijskom trombo-
zom/MU, u trombozi/MU nakon arteriografije/CAS, ako
bolesnik ima jaku stenozu i MU u razvoju/kreendo TIA.
Urgentnu KEA (unutar 48 sati) treba izvesti u bolesnika s
flotirajuæim trombom, s razlistanim plakom i u bolesnika
s frakturom plaka. Nema indikacije za emergentnu/urgent-
nu KEA u bolesnika s brzim oporavkom neurolokog de-
ficita nastalog zbog karotidne tromboze28 (tablica 1.).
U bolesnika sa zavrenim MU KEA se izvodi ako je
manji, fiksni neuroloki deficit uzrokovan visokim stup-
njem stenoze ili predokluzivnom stenozom (rizik od recidi-
va ili proirenja infarkta je 20% unutar 6 tjedana). Ako nema
hemoragijske tranzicije infarkta, KEA je preporuŁljiva 11-
15 dana nakon MU7.
Kod TIA/MU iz VKA koja nosi 3% modanog proto-
ka neuroloki ispadi nastaju zbog embolizacije, a ne hipo-
perfuzije. ¨esti su amaurosis fugax i nespecifiŁni ipsilate-
ralni simptomi. Embolusi ulaze kroz periorbitalne, lemp-
tomeningealne, okcipitalne, duralne i hipoglosalne kola-
terale u bazen UKA. Endarterektomija UKA i VKA je me-
toda izbora. Ako je UKA okludirana, iskljuŁuje se, a VKA
se nakon endarterektomije pokriva zakrpom7.
Symptomatic patients aged 75-80 are selected if their life
expectancy is 5 years. In this and older age groups, CEA
should be preformed in the asymptomatic stage if the dis-
ease progression is documented in <80% to >80% steno-
sis, or if the patient has a life-threatening plaque compli-
cation26,27.
Urgent/emergent CEA is still controversial and a subject
of discussion. There are neither EBM supported facts to
support it nor prospective, randomized trials from this area.
However, numerous multicenter reports lead us to the fol-
lowing recommendations: emergent CEA  should be per-
formed in patients with perioperative thrombosis or stroke,
in thrombosis/stroke after angiography/CAS, if the patient
has severe stenosis and stroke in evolution or crescendo
TIAs. Urgent CEA (within 48 hours) should be performed in
patients with flotating thrombus, frayed plaque, or plaque
fracture. There is no indication for emergent/urgent CEA
in patients with good and fast recovery of the neurologic
deficit originating from carotid thrombosis28 (Table 1).
In patients with completed stroke CEA can be performed if
minor, fixed neurologic deficit is caused by a high-grade
stenosis (the risk of recurrence or infarct progression is 20%
within 6 weeks). If there is no hemorrhagic transition, CEA
is recommended to be done 11-15 days after stroke7.
In TIA or stroke from the ECA, which gives 3% of the
cerebral flow, neurologic deficit is caused by embolization,
and not by hypoperfusion. Amaurosis fugax and nonspe-
cific ipsilateral symptoms are frequent. Emboli enter
through periorbital, leptomeningeal, occipital, dural and
Fig. 1. Number of CEA at Merkur University Hospital 1992-2003
Slika 1. Broj KEA u KliniŁkoj bolnici Merkur 1992.-2003.
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hypoglossal collaterals in the ICA pool. Endarterectomy of
the ICA and ECA is the method of choice. If the ICA is
occluded, the best method is its exclusion, while ECA is
endarterectomized and patched7.
Patient evaluation and preoperative care
After the first CEAs based on ultrasound (US) in 1979,
in the last 15 years the rapid development of noninvasive
diagnostics has contributed to the establishment of the
new gold standard. Since 1995, the non-operator depen-
dent criteria for US and computed tomography (CT) di-
agnosis have been set up15. Health Care Commissions
started approving US Centers of Excellence. CFD, Power
Doppler, GSM and TCD offer us qualitative analysis of the
COD including determination of the degree of stenosis.
SonoCT, carotid CAT scan and XRES-CFD technology
depict the future of the preoperative carotid diagnosis29-31.
CFD charactheristics that indicate CEA irrespective of
symptoms are:
 stenosis >70%
 ulceration or ulcer thrombosis
 thrombosis of the stenotic site
 echolucency (GSM 25-32)
 soft-core or lypoid plaque
 plaque hemorrhage
 frayed plaque
Parameters that enable non-operator dependent crite-
ria on CFD devices are: PSV, measurement of the degree
of stenosis and GSM. We could propose the following for-
mula for the non-operator dependent criteria score (NODCSc)
as an indicator for CEA:
                              degree of stenosis
     NODCSc = 
                                        GSM
Evaluacija i prijeoperacijska priprema
Nakon prvih KEA na temelju UZV dijagnostike 1979.
godine, posljednjih 15 godina brzi razvoj neinvazivne di-
jagnostike doprinosi ustanovljenju novog zlatnog standar-
da. Od 1995. postavljeni su subjektivno neovisni kriteriji
UZV i CT dijagnostike (non-operator dependent criteria)15.
Health Care Commissions su zapoŁele odobravanje ultraz-
vuŁnih Centara izvrsnosti. CFD, Power Doppler, GSM i
TCD daju kvalitativnu analizu karotidne bolesti uz odre-
ðivanje stupnja stenoze. SonoCT, CT karotidnih arterija i
tehnologija XRES-CFD zacrtavaju buduænost prijeope-
racijske karotidne dijagnostike29-31.
ZnaŁajke CFD koje indiciraju KEA bez obzira na sim-
ptome su:
 stupanj stenoze >70%
 ulceracija plaka
 tromboza u ulkusu ili mjestu stenoze
 eholucentnost (GSM 25-32)
 mekan (soft-core) ili lipemiŁni plak
 krvarenje u plak
 razlistanost plaka
Parametri koji omoguæuju uspostavu subjektivno neo-
visnih kriterija na CFD ureðajima su: mjerenje brzine pro-
toka, mjerenje stupnja stenoze i odreðivanje GSM. Prijed-
log non-operator dependent criteria score(NODCSc) kao in-
dikacije za KEA mogao bi biti:
  stupanj stenoze
       NODCSc = 
Grey Scale Median
NODCSc >2,4 = apsolutna indikacija za KEA (70/25)
NODCSc >2,0 = indikacija za KEA 60/30)
NODCSc < 20 = moguænost BMT (60/40)
Tablica 1. Rezultati na Ljestvici teine neurolokih ispada (NESS)
nakon urgentne/emergentne KEA u KliniŁkoj bolnici Merkur
Zadovoljavajuæe Nezadovoljavajuæe Smrt
SIE (10) 8 2 0
NDAO (20)
KEA <3 h (18) 15 2 1
CEA >3 h (2) 1 1 0
CTIA (6) 5 1 0
AC (16) 14 2 0
SIE=modani udar u evoluciji, NDAO=neuroloki deficit uzrokovan
arterijskom okluzijom, CTIA=crescendo prolazni ishemijski napadaji
(TIA), AC=anatomska pitanja, KEA=karotidna endarterektomija
Table 1. Neurologic Events Severity Score (NESS) after urgent/
emergent CEA at Merkur University Hospital
Result Satisfactory Unsatisfactory Death
SIE (10) 8 2 0
NDAO (20)
CEA <3 h (18) 15 2 1
CEA >3 h (2) 1 1 0
CTIA (6) 5 1 0
AC (16) 14 2 0
SIE=stroke in evolution, NDAO=neurologic deficit caused by artery
occlusion, CTIA=crescendo TIA, AC=anatomical considerations,
CEA=carotid endarterectomy
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NODCSc >2.4 = absolute indication for CEA (70/25)
NODCSc >2.0 = CEA could be indicated (60/30)
NODCSc <2.0 = BMT is the favorite option (60/40)
Angiography should be used when CCA stenosis is
present, in smooth stenosis, in unequivocal CFD findings
and when CFD laboratory is not reliable, in patients who
cannot stand MRA, and when there is a clear indication
for CAS15.
There is no trustworthy method for predicting the
perioperative mortality and stroke. Ischemic tolerance of the
brain parenchyma could be assumed but not predicted. Xe-
non CAT scanning with the acetazolamide tolerance test
seems to be a useful method for determining the group at
risk of stroke during CABG. LRA is becoming the gold
standard in the treatment of patients with uncertain is-
chemic tolerance during CEA32-34.
Operative treatment
CEA should be performed in:
 asymptomatic patient if the operators stroke/death
rate is <2%
 symptomatic patient if the operators stroke/death rate
is <5%
 using a gentle, detailed technique
 using intraoperative US quality control
 using the most realiable neurologic monitoring
LRA during CEA is the best neurologic monitoring. During
the procedure, the cerebrovascular reflexes are spared, the
need of shunting is reduced 5 times, the incidence of he-
matoma is 10 times lower, the rate of nerve injury is 11
times lower, perioperative mortality fell from 1.3% to 0%,
the incidence of stroke is by 0.3% lower, hospital stay is
reduced 2 times, the CEA costs are by 35% lower and brain
perfusion is improved (reports 2002/2003)13,14.
Eversion CEA (ECEA) is an acceptable alternative in the
hands of a surgeon who have learned the method under a
mentor supervision, at institutions that follow the CEA
results with CFD and at hospitals that have published
results harmonized with the existing ECEA studies. ECEA
is indicated in patients prone to restenosis (CEA 5.2%,
ECEA 2.5% EVEREST 1996/2000), in patients with dis-
tal stenosis but not at the skull base, if contralateral flow
is not impaired, and if there are no radiologic signs of ce-
rebral infarction35,36.
An important alternative to CEA is percutaneous trans-
luminal carotid angioplasty (PTCA). In the years 1995/
1997, PTCA carried an 8%-10% stroke/death rate, 10%-
Arteriografiju treba upotrebljavati kod stenoze CCA, pri
glatkoj restenozi, kod kontroverznih CFD nalaza i nepo-
uzdanog CFD laboratorija, u bolesnika koji ne podnose
MRA i ako postoji indikacija za CAS15.
Ne postoji sigurna metoda za predviðanje periopera-
cijske smrtnosti i MU. Ishemijska tolerancija modanog paren-
hima moe se pretpostaviti, ali ne i sigurno predvidjeti. Ske-
niranje pomoæu Xenon CT s testom tolerancije na aceta-
zolamid korisna je metoda za odreðivanje riziŁne skupine
za razvoj MU u tijeku CABG. LRA postaje zlatni standard




 u asimptomatskog bolesnika ako je stopa s/d operat-
era<2%
 u simptomatskog bolesnika ako je stopa s/d operatera
<5%
 preciznom, detaljistiŁkom i njenom tehnikom
 upotrebom intraoperacijske UZV kontrole
 upotrebom najpouzdanijeg neurolokog monitoringa
LRA prilikom KEA jest najbolji neuroloki monitoring. Za
vrijeme operacije oŁuvani su cerebrovaskularni refleksi,
smanjuje potrebu za shuntom 5 puta, incidencija hemato-
ma manja je 10 puta, ozljeda kranijskih ivaca 11 puta,
peripoperacijska smrtnost je smanjena s 1,3% na 0%, za
0,3% je manja incidencija MU, skraæuje boravak u bolnici
2 puta, pojeftinjuje cijenu operacije do 35% i poveæava
perfuziju mozga (izvjetaji 2002./2003.)13,14.
Everzijska KEA prihvatljiva je inaŁica lijeŁenja u ruka-
ma kirurga koji je izuŁio metodu pod nadzorom mentora u
ustanovama koje prate rezultate KEA CFD analizom i u
bolnici koja objavljuje rezultate u skladu s rezultatima
postojeæih studija EKEA. EKEA je indicirana u bolesnika
sklonih stvaranju restenoze (KEA 5,2%, EKEA 2,5% EVE-
REST 1996./2000.), u bolesnika s distalnom stenozom ali
ne do baze lubanje, ako je oŁuvan kontralateralni karotid-
ni protok i ako nema CT/MRI znakova za modani in-
farkt35,36.
Vana inaŁica operacijske tehnike je i perkutana trans-
luminalna karotidna angioplastika (PTKA). U godinama
1995./1997. PTKA je nosila 8%-10% stope s/d, 10%-15,7%
neurolokih komplikacija i 16% rane restenoze u 6 mjese-
ci37. Zbog toga je uveden karotidni stenting (KAS) i 1998.
je stopa s/d iznosila 3%-4,7%, a druge neuroloke kom-
plikacije 4,6%-6,3% nakon primarnog stentinga. Krajem
1990-ih, razvile su se metode cerebralne zatite (CPD) i
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vie nije bilo dvojbe oko izbora KAS/PTKA, jer je KAS sa
CPD smanjio neuroloke komplikacije do 0,5%38,39. Ipak,
KAS se primjenjuje u izabranoj skupini bolesnika i daleko je
od pogodnosti za sve kandidate za KEA. Prema konsenzusi-
ma 1999.-2003. KAS nije prikladan: ako imamo bolesnika
niskog rizika za KEA, za dugu kalcificiranu leziju karotide,
ako postoji intraluminalni tromb, u bolesnika sa svjeim
CVI ili crescendo TIA, ako postoje tortuozne arterije, ako je
otean pristup za KAS ili ako se ne moe postaviti stent ili
CPD te ako postoji udruena stenoza ZKA i UKA40,41. Broj
embolijskih Łestica osloboðenih za vrijeme KAS izravno je
povezan s GSM pripadnog plaka i znaŁajno je veæi za
bolesnika s GSM <25. U takovih bolesnika razvija se 71,4%
periproceduralnih komplikacija, za razliku od 7,2% kom-
plikacija u bolesnika s GSM >50. Ipak, treba reæi da su,
kada nastupe, embolijski dogaðaji tei u skupini s GSM
>50%, jer se u ovoj skupini oslobaðaju veæe embolijske
Łestice. Kada uzmemo u obzir da je podudarnost GSM
analize u analizi meðu promatraŁima veæa od 89% i da je
GSM analiza potpuno sukladna patoloko-anatomskoj
analizi u 46% bolesnika, treba reæi da morfologija plaka zna-
Łajno utjeŁe na prognozu bolesnika i na postavljanje indikacije za
KEA ili KAS22. U usporedbi KEA i KAS metode rezultati
na manjim skupinama bolji su u skupini KEA ako bolesni-
ci nisu selekcionirani. Ako su strogo izabrani za KAS, rezu-
ltati usporedbe KEA i KAS se podudaraju21,41.
Prema dananjim kriterijima, ne treba svaku karotidnu
bolest lijeŁiti angioplastikom, a izbor bolesnika za KAS ne bi trebao
biti isti kao izbor bolesnika za KEA. Indikacije za KAS su:
 stenoze supraaortnih grana
 bolesnik visokog rizika
 vrlo visoka stenoza UKA
 vrat nepristupaŁan za KEA
 glatka homogena stenoza
 bolesnik s kraæom oŁekivanom duljinom ivota42.
Primijeæene su frakture stentova unutar 5 godina, kao
i in-stent stenoze i okluzije stenta. Usporedne studije KEA
i KAS nakon restenoze karotidne arterije pokazuju da je
smrtnost u objema skupinama 0%. Meðutim, skupina KAS
ima 16% TIA (KEA 0%), 18% in-stent restenoza u 3 godi-
ne, a u 7,5% bolesnika trebalo je kirurki ukloniti stent unu-
tar 3 godine od zahvata43,44.
Kirurgija ima loije rezultate ako postoji tandemska steno-
za, disfunkcija Willisova kruga, udruena koronarna bolest,
srŁana grjeka ili aritmija i trajni neuroloki deficit. Serije
iz 2003.  godine pokazuju da je tromboza UKA rijetko
uzrokovana tehniŁkom grjekom. Uzrok su multisegment-
na KOB, duge, kritiŁne stenoze, tandemske lezije i string
15.7% rate of neurologic complications and 16% rate of
restenosis in 6 months37. Therefore, carotid stenting (CAS)
took place and in 1998 the stroke/death rate was 3%-4.7%,
and the rate of other neurologic complications 4.6%-6.3%
after primary stenting. By the end of the 1990s, the cere-
bral protection devices (CPD) were developed and the
dilemma between CAS and PTCA was solved. CAS low-
ered the rate of neurologic complications down to 0.5%38,39.
However, CAS is always perforemd in a selected group of
patients and is far from suitable for all CEA candidates.
According to the 1999-2003 consensuses, CAS is not suit-
able for patients with a low risk of CEA, when there is a
long petrified carotid lesion, if intraluminal thrombus ex-
ists, in patients with recent stroke or crescendo TIAs, in
tortuous arteries, if there is no access for CAS, if stent or
CPD cannot be applied, or if there is combined CCA and
ICA stenosis40,41. The number of embolic particles freed dur-
ing CAS is directly related to the plaque GSM value and
is significantly higher in patients with GSM <25. Such
patients have a 71.4% rate of periprocedural complications,
whereas in patients with GSM >50 the complication rate
is  7.2%. Yet, it should be noted that embolic events in the
GSM >50 group, when present, are more disastrous due
to the bigger embolic particles. When we bear in mind that
the GSM in the interobserver analysis is complementary
in more than 89% of patients, and that GSM findings are
completely complementary to histology in 46% of patients,
we must admit that plaque morphology significantly influences
the patient prognosis as well as the CEA/CAS indications22. CEA
vs CAS studies in small groups of patients showed better
results in CEA groups if the patients were not selected.
But, when the patients were selected for CAS, the results
were equal21,41. According to the current criteria, not every
carotid disease should be subjected to angioplasty, and the selection
criteria for CAS should not be identical with those for CEA. Indi-
cations for CAS are:
 stenoses of the supraaortic branches
 patients at high risk
 high ICA stenosis
 hostile neck
 smooth stenosis
 patients with short life expectancy42
Within 5 years, stent fractures as well as in-stent stenos-
es and occlusions are noticed. Comparative studies of CEA
and CAS after carotid restenosis showed the mortality in
both groups was 0%. However, the CAS group had 16% of
TIAs (CEA 0%), 18% of in-stent restenoses in 3 years, and
in 7.5% of patients the stent had to be surgically removed
within 3 years43,44.
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sign. U ovakovim sluŁajevima peri/intraoperacijska okluz-
ija UKA dogaða se u 0,8% bolesnika45.
Vrijeme je i za pozornu reviziju tzv. bolesnika visokog ri-
zika. MulticentriŁna analiza 1906 bolesnika s visokim ri-
zikom pokazala je da je kumulativni sd/r u ovoj skupini
1,3% i da su rezultati KEA u visoko riziŁnih usporedni s re-
zultatima u bolesnika niskog rizika, osobito nakon uvoðenja
LRA. Na kraju, C/E za KEA kao sigurnog zahvata povolj-
niji je od rutinske primjene KAS44,45.
U bolesnika s udruenom koronarnom i karotidnom boleæu
(u RH ima 8%-10% takovih koronarnih bolesnika) KEA/
KAS treba izvoditi prema slijedeæim kriterijima46,47:
 stabilna angina u bolesnika visokog rizika = KAS
                              u bolesnika niskog rizika   = KEA
 u kandidata za PTCoA s KOB
s niskim srŁanim rizikom = PTCoA pa KEA
 s visokim srŁanim rizikom = PTCoA i KAS
 u kandidata za CABG s KOB
u hitnoæi sa simptomatskom KOB = operacija
u jednom aktu
u hitnoæi s asimptomatskom KOB = jedan akt
samo ako je KOB bilateralna
bez hitnoæe sa simptomatskom KOB = prvo
KAS, potom CABG
bez hitnoæe s asimptomatskom KOB = CABG
pa KAS ili KEA.
ZakljuŁak
Na kraju moemo zakljuŁiti da broj operiranih bolesnika
sigurno raste. Broj KEA u KliniŁkoj bolnici Merkur od 1992.
do 2003. prikazan je na slici 1. Broj KEA prema centrima u
Europi i SAD pokazuje nam dananje stanje KEA kao rutin-
ske i isplative operacije koja nudi moguænost izljeŁenja
neselekcioniranoj skupini bolesnika s KOB (slika 2.). Udio
asimptomatskih kandidata prema centrima pokazuje kako
se stvarni postotak asimptomatskih bolesnika koji trebaju
KEA kreæe oko 30%-40% (slika 3.). Perioperacijski rezul-
tati KEA prema autorima u tijeku 3 desetljeæa pokazuju
stalan pad udjela MU i smrtnosti unatoŁ znatnom proi-
renju indikacija za KEA od 1976. do 2003. godine (slika 4.).
Otvorena pitanja 2004. su:
 to uŁiniti s karotidnom stenozom <50% udruenom
s neurolokim deficitom?
 Koje osobine plaka povezati sa stupnjevima neurolo-
kog deficita24?
 Kada æe poslijeoperacijska CFD kontrola postati stan-
dardom15,33?
Surgery has worse results if there is a tandem stenosis,
circle of Willis dysfunction, concomitant coronary disease,
heart failure or arrhythmia, and if a permanent neurologic
deficit exists. Series from 2003 show that ICA thrombosis
is rarely caused by technical failure. The causes of throm-
bosis appear to be multisegmental COD, longterm criti-
cal stenosis, tandem lesions, and the string sign. In such
cases, peri/intraoperative ICA occlusion occurs in 0.8% of
patients45. It is time for careful revision of the so-called high-
risk patients. Multicenter analysis of 1906 high-risk pa-
tients showed a cumulative stroke/death rate of 1.3%, and
the results of CEA in high-risk patients were comparable
with the low-risk group, especially after LRA reappeared
on the scene. At the end, the CEA cost/effectiveness  is
by far more favorable than that of the routine use of
CAS44,45.
In patients with concomitant coronary and carotid disease (in
Croatia there are 8%-10% of such coronary patients), CEA/
CAS should be performed under the following criteria46,47:
 stable angina in high-risk patient = CAS
in low-risk patient  = CEA
 in candidate for PTCoA with COD
with low cardiac risk = PTCoA, then CEA
with high cardiac risk = PTCoA and CAS
 in CABG candidate with COD
if urgent with symptomatic COD = one act pro
cedure
if urgent with asymptomatic COD = one act pro
cedure only if COD is bilateral not urgent with
symptomatic COD = CAS first, then CABG
not urgent with asymptomatic COD = CABG first,
then CAS or CEA
Conclusion
The number of patients operated on is rising. The
number of CEAs perfomed at Merkur University Hospi-
tal between 1992 and 2003 is shown in Table 2. The num-
ber of CEAs at European and USA centers tells us the
state-of-the-art of CEA as a routine and cost/effective pro-
cedure, which offers acceptable results and treatment to
the nonselected group of patients with COD (Table 3).
The percentage of asymptomatic patients in various cen-
ters shows us that the real rate of asymptomatic patients
that need CEA could be around 30%-40% (Table 4). Peri-
operative CEA results of the author during the past 3 de-
cades show a continuous decrease in the stroke/death rate
in spite of broadening the indication spectrum for CEA
from 1976 to 2003 (Table 5).
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 Kako se moe unaprijediti zatita mozga od ishe-
mije13,14,31,33,36,38?
 Kako predvidjeti ishemijsku toleranciju modanog
parenhima49?
 Koji je optimalni omjer KEA/KAS40?
 to je Best Medical Treatment KOB?
 Genska terapija i KOB48?
 Razmotriti razvoj VEGF165 i VEGF121 u sprjeŁava-
nju razvoja ateromatoznog plaka25?
 Odmjeriti vanost sekundarne prevencije KOB?
*TumaŁ kratica: EBM=Evidence Based Medicine,
KEA=karotidna endarterektomija, MU=modani udar,
KAS=karotidni stenting, UKA=unutarnja karotidna arte-
rija, VKA=vanjska karotidna arterija, s/d r=stroke/death
rate, QOL=Quality of Life, GSM=grey scale median, C/
E=cost/effectiveness, C/B=cost/benefit, SMA=srednja
modana arterija, LRA=loko-regionalna anestezija,
KOB=karotidna okluzivna bolest, CABG=coronary artery
Open questions in 2004 are:
 What to do with carotid stenosis <50% combined with
neurologic deficit?
 Which plaque characteristics can be connected with
various grades of neurologic deficit24?
 When the postoperative CFD control will become a
standard15,33?
 How can we improve ischemic cerebral protec-
tion13,14,31,33,36,38?
 How can we predict ischemic tolerance of the brain pa-
renchyma49?
 What is the optimal CEA/CAS rate40?
 What is the best medical treatment for COD?
 Gene therapy and carotid occlusive disease48?
 Clear up the role of the VEGF165 and VEGF121 in pre-
venting the carotid plaque development25?
 How to measure the importance of secondary preven-
tion of carotid occlusive disease?
Fig. 2. Number of CEA at institutions in Europe and USA in 2003
Slika 2. Broj KEA u centrima Europe i SAD tijekom 2003. godine
Fig. 3. Proportion of asymptomatic patients for CEA in international vascular surgery centers in 2003
Slika 3. Udio asimptomatskih bolesnika za KEA prema svjetskim centrima vaskularne kirurgije u 2003.godini
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*Abbreviations: EBM=Evidence Based Medicine,
CEA=carotid endarterectomy, CAS=carotid stenting,
ICA=internal carotid artery, ECA=external carotid artery,
s/d r=stroke/death rate, QOL=Quality of Life,
GSM=grey scale median, C/E=cost/effectiveness, C/
B=cost/benefit, MCA=middle cerebral artery, LRA=loco-
regional anesthesia, COB=carotid occlusive disease,
CABG=coronary artery bypass graft, US=ultrasound,
ECEA=eversion carotid endarterectomy, CPD=cerebral
protection device, CCA=common carotid artery,
PTCoA=percutaneous transluminal angioplasty of coro-
nary arteries, MES=multiple embolic signs, VEGF =vas-
cular endothelial growth factor, CFD=color flow duplex
bypass graft, UZV=ultrazvuk, EKEA=everzijska karotid-
na endarterektomija, CPD=cerebral protection device,
ZKA=zajedniŁka karotidna arterija, PTCoA=perkutana
transluminalna angioplastika koronarnih arterija, MES=
multiple embolic signs, VEGF=vascular endothelial
growth factor, CFD=color flow duplex
Fig. 4. Perioperative stroke/death rate according to literature reports 1976-2003
Slika 4. Udio perioperacijske smrtnosti i modanog udara prema literaturnim izvjeæima od 1976. do 2003. godine
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Migrena i modani udar predstavljaju neurovaskularne
poremeæaje s kojima se svakodnevno susreæemo. Poveza-
nost migrene s modanim udarom nasluæuje se veæ od 19.
stoljeæa, a suvremena istraivanja to i potvrðuju. Opisani
su i pojedinaŁni sluŁajevi hemoragijskog modanog udara
u migreniŁara, ali njihova meðusobna povezanost jo uvijek
je ostala upitna i nedovoljno istraena.
Klasifikacija glavobolja prema Meðunarodnom drut-
vu za glavobolje iz 1988. godine  doivjela je reviziju 2004.
godine, u kojoj pod toŁkom 1.5 Komplikacije migrene stoji
podtoŁka 1.5.4. Migrenski infarkt (MI). Ova dijagnoza
podrazumijeva nastanak infarkta mozga tijekom migren-
ske glavobolje s aurom, koji je ujedno potvrðen na CT ili
MR mozga1.
U razliŁitim dijelovima svijeta uŁinjeno je vie epide-
miolokih ispitivanja koja se odnose na povezanost migrene
i MI:  kliniŁke studije, kontrolirane studije i kohortne stu-
dije. Autori se na osnovi dobivenih rezultata uglavnom slau
da se MI javlja vrlo rijetko i to uglavnom u mladih ena do
45. godine ivota. Tako su u jednom od posljednjih epide-
miolokih ispitivanja Abroix i sur. nali da je u skupini od
2000 bolesnika lijeŁenih zbog modanog udara tijekom
desetgodinjeg razdoblja dijagnosticirano samo 9 sluŁaje-
va MI i to iskljuŁivo u mladih ena2,3.
Zbog Łega migrena poveæava rizik nastanka ishemijskog
modanog udara u mladih ena jo uvijek nije u potpuno-
sti razjanjeno. Donaghy i sur. navode da su znatno veæem
riziku za nastanak MI izloeni migreniŁari koji pate od
migrene due od 12 godina, te ako su glavobolje posljed-
njih mjeseci postale znatno uŁestalije. Uz dugotrajnost i
uŁestalost migrenskih glavobolja poveæan rizik naroŁito
MIGRAINE AND STROKE  IS THERE AN ASSOCIATION?
MIGRENA  I  MODANI  UDAR  POSTOJI LI POVEZANOST?
Ksenija Willheim
University Department of Neurology, Rijeka University Hospital Center, Rijeka, Croatia
Klinika za neurologiju, KliniŁki bolniŁki centar Rijeka, Rijeka
Migraine and stroke are neurovascular disorders en-
countered in practice on a daily basis. The association of
migraine and stroke has been postulated since the 19th
century, and has been confirmed by recent studies. Indi-
vidual cases of hemorrhagic stroke in migraineurs have
been described, however, their interrelatedness remains
questionable and as yet inadequately explored.
The International Headache Society classification of
headaches from 1988 was revised in 2004, now including
the entity of migrainous infarction (MI) as a subheading
(1.5.4) of the heading 1.5 Migraine Complications. This
diagnosis refers to the onset of brain infarction during
migrainous headache with aura, which has been verified
by brain CT or MR1.
A number of epidemiologic studies of the association
between migraine and MI have been conducted world-
wide, including clinical, case-control and cohort studies.
Based on the results obtained, the authors generally agree
that MI occurs very rarely, mostly in young women aged
below 45. In one of the latest studies, Abroix et al. found
only nine cases of MI to be dignosed in a cohort of 2000
patients treated for stroke over a 10-year period, all nine
in young women2,3.
It has not yet been explained why migraine increases
the risk of ischemic stroke in young women. Donaghy et
al. report on a considerably higher risk of MI in individu-
als suffering from migraine for more than 12 years, provid-
ed the headaches have increased in frequency over the past
few months. Besides longterm presence and high frequen-
cy of migrainous headaches, migraine with aura also in-
creases the risk of MI4.
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Migraine as well as mitral valve prolapse, patent fora-
men ovale (PFO) and atrial septum aneurysm (ASA) have
recently been ever more frequently implicated as the risk
factors for stroke. PFO has been found to be the source of
embolism leading to MI at a young age. It should be not-
ed that PFO and ASA also are potential vascular causes of
migraine with aura, which in turn implies the risk of MI5.
The risk of migrainous stroke is additionally increased
by the use of oral contraceptives that contain high estro-
gen, then with the presence of diabetes mellitus, hyper-
tension and smoking.
The platelet theory explains the onset of migraine by
the platelet-leukocyte interaction, suggesting an associa-
tion of migraine and stroke at the cellular level6.
Migraine is a multifactorial as well as a genetic disor-
der, therefore history, i.e. familial migrainous burden, needs
to be carefully considered. In familial hemiplegic migraine,
mutations on the CACNA1a gene on chromosome 19 or a
mutation on chromosome 1 have been demonstrated.
Migraine is usually the first symptom of CADASIL, which
in addition to migrainous headaches implies lacunar stroke
or transient ischemic attacks and progressive dementia. In
this entity, mutations on chromosome 19 have been de-
tected. Current genetic studies have pointed to the genet-
ic basis of association between migraine and MI7,8.
The clinical picture, course and prognosis of MI have
been investigated by many authors. Most of them agree
that it is a rare entity, usually with a mild clinical picture
and complete or satisfactory recovery. As the disorder does
show a tendency of recurrence, the prognosis is good. Thus,
MI differs from other ischemic strokes by its occurrence
at a young age, female predominance, mild clinical picture,
and favorable outcome9.
Migraine and stroke are neurovascular disorders that
appear to bear some association, however, a number of open
questions yet remain in the field despite considerable
advances in neuroscience and genetics.
References / Literatura
1. Headache Classification Subcommittee. The International Classi-
fication of Headache Disorders, 2nd edition. Cephalalgia 2004;24
(Suppl 1):1-160.
2. TZOURIO C et al. Migraine and risk of ischemic stroke: a case-con-
trolled study. BMJ 1993;307:289-92.
3. ARBOIX A et al. Migrainous cerebral infarction in the Sagrat Cor
Hospital of Barcelonas registry. Cephalalgia 2003;23:389-94.
4. DONAGHY M et al. Duration, frequency, recency, and type of mi-
graine and the risk of ischemic stroke in women of childbearing age.
J Neurol Neurosurg Psychiatry 2002;73:747-50.
predstavlja migrena s aurom4. Migrena te prolaps mitral-
ne valvule, otvoreni foramen ovale (PFO) i aneurizma sep-
tuma atrija (ASA) u novije vrijeme se sve vie spominju kao
Łimbenici rizika za nastanak modanog udara. Zapaeno
je da PFO predstavlja izvor embolija koje uzrokuju MI u
mladoj ivotnoj dobi. Zanimljivo je da PFO i ASA predstav-
ljaju i moguæi vaskularni uzrok za migrenu s aurom  koja
kao takva predstavlja rizik za nastanak MI5.
Rizik za  nastanak migrenskog modanog udara dodat-
no poveæavaju oralna kontracepcijska sredstva koja sadre
veæe koliŁine estrogena, zatim eæerna bolest, hipertenzi-
ja i puenje.
Trombocitna teorija tumaŁi nastanak migrene inter-
akcijom trombocit-leukocit, ukazujuæi na  povezanost mi-
grene i modanog udara na staniŁnoj razini6.
Migrena je vieŁimbenski, ali i genetiŁki poremeæaj, pa
je neobiŁno vano obratiti pozornost na anamnezu, tj.
obiteljsku optereæenost migrenom. Kod obiteljske hemi-
plegiŁne migrene dokazane su mutacije na CACNA 1a
genu kromosoma 19 ili pak mutacija na kromosomu 1.
Migrena je najŁeæe prvi simptom CADASIL-a koji uz
migrenske glavobolje podrazumijeva lakunarne modane
udare ili prolazne ishemijske napadaje i progresivnu de-
menciju. Kod ovog entiteta su dokazane mutacije na kro-
mosomu 19. Suvremena genetiŁka istraivanja ukazala su
na genetsku podlogu povezanosti migrene i MI7,8.
KliniŁka slika, tijek i prognoza  MI zaokuplja zanima-
nje niza autora. Veæina ih se slae kako se radi o rijetkom
entitetu koji obiŁno ima blagu kliniŁku sliku s potpunim
ili dobrim oporavkom. Kako se uglavnom ne ponavlja, prog-
noza mu je dobra. Prema tome, MI se razlikuje od ostalih
ishemijskih modanih udara po tome to se javlja u mlaðoj
ivotnoj dobi, Łeæe je zastupljen u ena, ima blagu kli-
niŁku sliku i povoljan konaŁni ishod9.
Migrena i modani udar su neurovaskularni poremeæaji
izmeðu kojih postoji povezanost, ali usprkos znaŁajnom
napretku neuroznanosti i genetike jo uvijek ostaje Łitav
niz otvorenih pitanja na koja treba naæi odgovore.
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Demencija je zajedniŁki pojam za sindrom postupnog
propadanja sposobnosti pamæenja i drugih intelektualnih
funkcija praæen poremeæajem osobnosti i ponaanja. Vasku-
larna demencija (VD) je nakon Alzheimerove bolesti (AB)
drugi najŁeæi uzrok demencije, a neuropatoloki ukljuŁuje
demenciju uvjetovanu ishemijskim ili hemoragijskim le-
zijama mozga, kao i demenciju nakon ishemijsko-hipok-
siŁnih stanja povezanih sa srŁanim zatajenjem. Za dijagnozu
VD potrebna je prije svega vremenska uzroŁno posljediŁ-
na povezanost lezije mozga i nastupa demencije, to Łesto
puta u kliniŁkoj praksi nije moguæe utvrditi.
Na vaskularnu demenciju otpada oko 20% svih demen-
cija, dok u jo oko 20% bolesnika s AB postoje neuropato-
loke promjene u mozgu znakovite za VD1. Incidencija i
uŁestalost VD raste sa ivotnom dobi, tako da je uŁesta-
lost VD u populaciji starijoj od 70 godina oko 3%2.
VD nastaje zbog poremeæaja modanog krvnog opto-
ka, a zbog naravi vaskularne bolesti mozga moe se kliniŁ-
ki oŁitovati na nekoliko naŁina. NajŁeæa je multi-infarkt-
na demencija (MID) koja se razvija postupno ili naglo
prateæi brojne mini-ishemijske modane udare ili prolazne
ishemijske napadaje (TIA). Ovaj tip demencije se katka-
da naziva kortikalnim tipom, a kliniŁki se oŁituje kao am-
nezija, agnozija, apraksija ili afazija. Subkortikalni tip VD
je poznat kao Binswangerova bolest ili sindrom difuzne in-
farkcije bijele tvari, gdje se nalaze difuzna ili viearina
podruŁja periventrikularne demijelinizacije s gubitkom
aksona i reaktivna glioza, to je najŁeæe posljedica aterosk-
Dementia is a generic term used for the syndrome of
gradual deterioration of memory capacity and other intel-
lectual functions accompanied by personality and behav-
ior disorders. Vascular dementia (VD) is the second most
common cause of dementia, immediately following Alzhe-
imers disease (AD), and it includes the dementia caused
by ischemic or hemorrhagic lesions of the brain as well as
the dementia following states of ischemia and hypoxia
associated with heart failure. In order to diagnose VD, it is
necessary to establish the causal connection between brain
lesion and onset of dementia, which is often impossible in
clinical practice.
Vascular dementia accounts for 20% of all cases of de-
mentia, while at the same time in 20% of AD patients there
are pathologic changes in the brain characteristic of VD1.
The incidence and prevalence of VD increase with age, so
that the VD prevalence in the population older than 70 is
about 3%2. VD occurs due to a disorder of blood circula-
tion in the brain and, being of the nature of a vascular dis-
ease of the brain, it can manifest clinically in several ways.
The most common is the multi-infarct dementia (MID),
which progresses gradually or rapidly, following numerous
mini-ischemic strokes or transitory ischemic attacks (TIA).
This type of dementia is sometimes called cortical type and
is manifested clinically as amnesia, agnosia, apraxia or apha-
sia. The subcortical type of VD is known as Binswangers
disease or syndrome of diffuse infarction of the white
matter, where there are diffuse or multifocal areas of
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periventricular demyelination with the loss of axons and
reactive gliosis, which is most frequently the consequence
of atherosclerotic changes in penetrating arteries and ar-
terioles in the white matter. These changes occur in 80%
of patients with VD regardless of the cause, and are not
rare in AD (15%-50)3. It is believed that these changes are
associated with arterial hypertension and/or diabetes, and
that the syndrome of dementia occurs due to disruption
of connections between the cortex and subcortex.
The subcortical type of VD can also occur due to is-
chemic lesions of lacunae, which besides dementia results
in psychomotor reduction, mental obtusion, anhedonia,
dysphagia, dysarthria, and walking disorder reminding of
parkinsonism. It occurs typically in former or current smok-
ers, with arterial hypertension and/or diabetes.
A strategically positioned single ischemic infarct or
hemorrhage can result in a sudden onset of dementia,
which is frequently the leading symptom of stroke. This
type of dementia is characteristic of a stroke in the angu-
lar gyrus of the dominant hemisphere, dorsomedial part of
the thalamus of the dominant hemisphere, and infarct in
the area of hippocampus.
Risk factors for VD are in the first place age and cere-
brovascular disease with all its risks, such as arterial hyper-
tension, smoking, diabetes, hyperlipidemia, etc. If VD
occurs in younger patients, hereditary types of cerebrovas-
cular disorders like CADASIL (cerebral autosomal domi-
nant arteriopathy with subcortical infarct and leukoen-
cephalopathy) should be considered4.
The diagnosis of VD is based on the occurrence of a
cerebrovascular disease and dementia with a history of risk
factors for cerebrovascular disease, different focal neuro-
logic signs, and a positive neuroimaging report. Unfortu-
nately, the diagnostic criterion established in such a man-
ner is too flexible and thus allows many variations that are
not desirable from the aspect of evidence based medi-
cine. Therefore several different criteria for the diagno-
sis of VD have been developed, but unfortunately none of
them are universal and without objections5. The key role
in the diagnosis is played by neuroimaging, especially pro-
ton and T2 sequence of brain MRI, where in case of sub-
cortical dementias zones of enhanced signal can be seen
periventricularly (leucoaraiosis) or multiple small lesions
in basal ganglia and pons.
Differential diagnosis includes other causes of demen-
tia (AD, Lewy body dementia, etc.) but also the conditions
like Parkinsons disease, progressive supranuclear paraly-
sis, multisystem atrophies, brain tumors, hydrocephalus,
etc.
lerotskih promjena u penetrantnim arterijama i arteriola-
ma u bijeloj tvari. Ove promjene se nalaze u oko 80%
bolesnika s VD bez obzira na uzrok, ali nisu rijetke niti kod
AB (15%-50%)3. Vjeruje se da su ove promjene povezane s
arterijskom hipertenzijom i/ili dijabetesom, a da sindrom
demencije nastupa zbog prekida veza izmeðu korteksa i
subkorteksa.
Subkortikalni tip VD moe nastati i zbog lakunarnih
ishemijskih lezija, to uz demenciju rezultira psihomotor-
nom usporenoæu, mentalnom tupoæu, anhedonijom, dis-
fagijom, disartrijom, poremeæajem hoda koji podsjeæa na
parkinsonizam itd. TipiŁno se javlja u bivih ili aktulanih
puaŁa, s arterijskom hipertenzijom i/ili dijabetesom.
Strateki pozicioniran jednokratni ishemijski infarkt ili
krvarenje moe rezultirati naglim nastupom demencije
koja je Łesto vodeæi simptom modanog udara. Ovakav tip
demencije znakovit je za modani udar u angularnom gi-
rusu dominantne hemisfere, dorzomedijalni dio talamusa
dominantne hemisfere, te infarkt u podruŁju hipokampusa.
RiziŁni Łimbenici za nastup VD su prije svega ivotna
dob i cerebrovaskularna bolest sa svim svojim rizicima
poput arterijske hipertenzije, puenja, dijabetesa, hiperli-
pidemije itd. Ako se VD pojavi u mlaðoj ivotnoj dobi tre-
ba razmiljati o nasljednim oblicima cerebrovaskularnih
poremeæaja poput CADASIL (cerebralna autosomna domi-
nantna arteriopatija sa subkortikalnim infarktom i leu-
koencefalopatijom)4.
Dijagnoza VD poŁiva na prisutnosti cerebrovaskularne
bolesti i demencije uz anamnezu riziŁnih Łimbenika za
nastup cerebrovaskularne bolesti, razliŁitim arinim neu-
rolokim znacima, te pozitivnom nalazu neurolokog sli-
kovnog prikazivanja. Naalost, ovako postavljen dijag-
nostiŁki kriterij je isuvie fleksibilan pa doputa mnotvo
varijacija koje nisu poeljne sa stajalita medicine zasno-
vane na dokazima. Stoga je razvijeno nekoliko razliŁitih
kriterija za dijagnozu VD, no naalost niti jedan nije uni-
verzalan i bez zamjerka5. KljuŁnu ulogu u dijagnostici ima
neuroloko slikovno prikazivanje, poglavito proton i T2
sekvenca MRI mozga, gdje se u sluŁaju subkortikalnih
demencija vide zone pojaŁanog signala periventrikularno
(leukoaraioza) ili viestruke male lezije u bazalnim gangliji-
ma i ponsu.
Diferencijalna dijagnoza ukljuŁuje ostale uzroke de-
mencije (AB, demencija Lewyevih Łestica itd.), ali i sta-
nja poput Parkinsonove bolesti, progresivne supranukle-
arne paralize, multisistemskih atrofija, tumora mozga, hi-
drocefalusa itd.
LijeŁenje VD se svodi na prevenciju cerebrovaskularne
bolesti i njenih rizika, dok u sluŁaju postojanja neurolo-
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The treatment of VD comes down to the prevention
of a cerebrovascular disease and its risks. If there is evi-
dence of neurologic signs, one can consider physical ther-
apy of the motor deficit and walking, treatment of aphasia
by a speech pathologist, etc. Concerning specific drugs for
the improvement of cognitive functions, they have been
proven successful in the symptomatic treatment of cog-
nitive disorders of AD, e.g., donepezil and galantamine,
thus a similar effect is also expected in VD, and this has
partially been confirmed in clinical studies.
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Summary
Cerebrovascular diseases are currently the leading public
health problem in industrialized countries, and depression is
the fourth major health problem. Today the association between
depression and stroke is considered definite. Depression is the
most common psychiatric disorder associated with cerebrovas-
cular diseases, occurring in 26% to 34% of patients within two
years post-stroke. There is a correlation between the severity of
post-stroke depression and localization of cerebral lesion, i.e.
the closer the lesion to the left frontal lobe region, the higher
the incidence and severity of depression. Early detection and
treatment have become the basic goals of modern medicine.
Attempts at preventing the development of post-stroke depres-
sion have been less successful to date. Treatment is quite suc-
cessfully performed with the use of psychotherapy, psychophar-
macotherapy, electroconvulsive therapy and rehabilitation. The
biopsychological model provides an insight into the multifacto-
rial etiology of the mental and physical disorders of post-stroke
depression, which is a precondition for comprehensive and fully
successful treatment.
Key words: depression, stroke, epidemiology, diagnosis, antidepres-
sants
Saetak
Cerebrovaskularne bolesti predstavljaju danas vodeæi
zdravstveni problem u zemljama zapadnog svijeta, a depresija je
Łetvrti najveæi zdravstveni problem. Danas se smatra da je po-
vezanost izmeðu depresije i modanog udara nedvojbena.
Depresija je najŁeæi psihijatrijski poremeæaj povezan sa cere-
brovaskularnim bolestima, javlja se u 26 do 34 posto bolesnika
unutar dvije godine poslije modanog udara. Postoji povezanost
izmeðu teine poslijeinzultne depresije i lokacije lezije mozga:
to su oteæenja mozga blie podruŁju lijevog frontalnog renja,
uŁestalost i teina depresije je veæa. Rano otkrivanje i lijeŁenje
postaje jedan od temeljnih ciljeva suvremene medicine. Pokuaji
sprjeŁavanja razvoja poslijeinzultne depresije dosad su bili ma-
nje uspjeni. LijeŁenje se uspjeno provodi primjenom psihote-
rapije, psihofarmakoterapije, elektrokonvulzivne terapije i re-
habilitacije. Biopsiholoki model omoguæuje razumijevanje
vieŁimbenske etiologije psihiŁkih i fiziŁkih poremeæaja poslijein-
zultne depresije kao preduvjeta za sveobuhvatno i uspjeno
lijeŁenje.
KljuŁne rijeŁi: depresija, modani udar, epidemiologija, dijagnosti-
ka, antidepresivi
kih znakova u obzir dolazi fizikalna terapija motornog de-
ficita i hoda, logopedsko lijeŁenje afazije itd. Od specifiŁnih
lijekova za poboljanje spoznajnih funkcija, koji su se poka-
zali donekle uspjenima u simptomatskom lijeŁenju kog-
nitivnog poremeæaja u okviru AB, poput donepezila i ga-
lantamina, oŁekuje se sliŁan uŁinak i u VD, to su djelo-
mice potvrdila dosdanja kliniŁka istraivanja.
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Introduction
Depression is a disorder as old as the human race, and
occurs as a universal human experience present across all
cultures. More than a half of humans have experienced
mild depression at least once in life, while not being aware
of the disorder. In contrast to transient low mood, when
we use to say Today I feel depressed, however, depres-
sion can also be a serious disease. It is considered that 50%
of depressed patients remain unrecognized, some 70% are
not treated, and only 10% are treated according to current
therapeutic principles1.
Post-stroke depression develops in 26% to 34% of
stroke patients representing a major challenge to modern
medicine because of its high morbidity, absenteeism, dis-
ability and mortality2. Depression and cerebrovascular dis-
ease cause great distress because of reduced daily, recre-
ative and working abilities.
Early detection and treatment have therefore become
one of the main goals of modern medicine.
Epidemiology
Depression has been on an increase worldwide, so that
it was the fourth major public health problem in world in
1990, and has been estimated to be the second one in 2020.
In women the rate of depression is two-to fourfold that in
men. Every fifth woman and every tenth man experience
at least one serious depressive episode in their lives. The
prevalence of depressive disorders in the general popula-
tion is 3.6-6.8 or greater in some European countries1,2. In
Croatia, it is estimated that there are about 200,000 indi-
viduals with various depressive disorders. Depression pre-
dominates in the 35-60 age groups. The rate of suicide
ranges from 10% to 15% in individuals with major depres-
sion1. The number of depressive disorders has been on a
continuous increase during the past and present centuries
in all industrialized countries, which is not exclusively at-
tributable to better diagnosis.
Types of depressive disorders
According to etiologic factors:
 primary depressive disorders F32-F39
 secondary, organic or symptomatic depressive disorders
F06.3
 depressive reaction to stress; short-term F43.20 or pro-
longed F43.21
According to clinical picture severity:
 mild depression F32.0
 moderate depression F32.1
Uvod
Depresija je stara koliko i ŁovjeŁanstvo i javlja se kao
univerzalno ljudsko iskustvo prisutno u svim kulturama.
Blagu je depresiju doivjelo barem jednom u ivotu vie od
polovice ŁovjeŁanstva, a da pritom mnogi nisu ni znali o
Łemu se radi. Meðutim, depresija moe biti vrlo ozbiljna
bolest za razliku od prolaznog neraspoloenja kada smo
skloni reæi «Danas sam depresivna/depresivan». Smatra se
da 50 posto depresivnih bolesnika ostaje neprepoznato, da
ih se oko 70 posto ne lijeŁi, a da se samo 10 posto depre-
sivnih bolesnika lijeŁi sukladno suvremenim terapijskim
naŁelima1.
Depresija poslije modanog udara javlja se u 26 do 34
posto bolesnika i predstavlja znaŁajan izazov za suvremenu
medicinu zbog visokog pobola, bolovanja, invaliditeta i
smrtnosti2. Depresija i cerebrovaskularna bolest u bolesnika
izazivaju velike duevne boli zbog smanjenja opæih ivot-
nih, rekreativnih i radnih sposobnosti. Rano otkrivanje i
lijeŁenje postaje jedan od temeljnih ciljeva suvremene
medicine.
Epidemiologija
Depresija je u cijelom svijetu u porastu i veæ je 1990.
godine bila na Łetvrtom mjestu javnozdravstvenih proble-
ma u svijetu, a procjenjuje se da æe 2020. godine biti na
drugom mjestu. Depresija je dva do Łetiri puta Łeæa u ena
nego u mukaraca. Svaka peta ena i svaki deseti mukarac
tijekom ivota doive barem jednu ozbiljnu depresivnu
epizodu. UŁestalost depresivnih poremeæaja u opæoj po-
pulaciji je 3,6-6,8 posto ili veæa u nekim europskim zemlja-
ma1,2. Vjerojatno u Hrvatskoj ima oko 200.000 osoba s ra-
zliŁitim depresivnim poremeæajima. Depresija prevladava
u dobi od 35 do 60 godina. Stopa samoubojstva se kreæe od
10-15 posto u osoba s velikim depresivnim poremeæajem1.
Broj depresivnih poremeæaja je u neprestanom porastu
tijekom prolog i ovog stoljeæa u svim razvijenim zemljama,
a nije iskljuŁivo posljedica bolje dijagnostike.
Vrste depresivnih poremeæaja
Prema etiolokim Łimbenicima:
 primarni depresivni poremeæaji F32-F39
 sekundarni, organski i simptomatski depresivni pore-
meæaji F06.3
 depresivna reakcija na stres; kratka F43.20 ili produena
F43.21
Prema teini kliniŁke slike depresija se dijeli na:
 blagu depresiju F32.0
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 moderate depression with somatic symptoms F32.2
 severe depression with psychotic symptoms F32.3
How to recognize depressive disorder
Depressive disorders manifest with the occurrence of
depressive episodes characterized by combinations of a
variable number of the mentioned 9 (DSM-IV: Diagnos-
tic and Statistical Manual of Mental Disorders  4th Revi-
sion)3 or 10 (ICD 10: International Classification of Dis-
eases  10th Revision)4 symptoms. At least 4, 5 and 7 symp-
toms persisting for at least two weeks are needed to make
the diagnosis of mild, moderate and severe depression,
respectively.
Table 1. Symptoms of depressive episode according to ICD-10 and
DSM-IV
ICD-10 DSM-IV
  1 Depressive mood Depressive mood (1)
  2 Loss of interest and Decreased interest and
pleasure satisfaction (2)
  3 Reduced energy Fatigue or lack of energy
or increased fatigue almost daily (6)
  4 Loss of self-confidence Feeling of worthlessness
and self-esteem or guilt (7)
  5 Inappropriate feeling
of self-reproach or guilt
  6 Recurrent thoughts Recurrent thoughts
of death or suicide of death or suicide (9)
  7 Difficult thinking and Difficult thinking
concentration; uncertainty and concentration (8)
  8 Agitation or retardation Agitation or retardation
almost daily (5)
  9 Sleep disturbances Insomnia
or hypersomnia (4)
10 Loss of appetite Significant weight loss or
and body weight change weight gain by more
than 5% (3)
In diagnostic algorithm, mental and somatic diseases
should be taken in consideration and ruled out by differ-
ential diagnosis, e.g., thyroid diseases, Parkinsons disease,
dementia, and exhaustion of coping abilities. It is estimat-
ed that 20% of depressive patients suffer from a thyroid
dysfunction, mostly hypothyroidism.
Depression and Stroke
Depression is a common comorbidity in various somatic
diseases such as cerebrovascular, cardiovascular and malig-
 umjereno teku depresiju F32.1
 umjereno teku depresiju sa somatskim simptomima
F32.2
 teku depresiju s psihotiŁnim simptomima F32.3
Kako prepoznati depresivni poremeæaj
Depresivni poremeæaji oŁituju se pojavom depresivnih
epizoda koje obiljeavaju razliŁite kombinacije razliŁitog
broja od navedenih 9 (DSM-IV: Diagnostic and Statisti-
cal Manual of Mental Disorders  4. revizija)3 ili 10 (MKB-
10: International Classification of Diseases  10. revizija)4
simptoma. Da bi se mogla postaviti dijagnoza blage de-
presije potrebno je najmanje 4, za srednju 5 te za teku 7
simptoma koji moraju postojati najmanje dva tjedna.
Tablica 1. Simptomi depresivne epizode prema  MKB-10  i  DSM-
IV
MKB-10 DSM-IV
  1. Depresivno raspoloenje Depresivno raspoloenje
(1)
  2. Gubitak interesa i uitka Smanjen interes i
zadovoljstvo (2)
  3. Smanjenje energije ili Umor ili gubitak energije
pojaŁano zamaranje skoro svaki dan (6)
  4. Gubitak samopouzdanja i Osjeæaj bezvrijednosti ili
samopotovanja krivnje (7)
  5. Neprimjereno samooptuivanje
ili osjeæaj krivnje
  6. Ponavljajuæe misli o smrti Ponavljajuæe misli o smrti
ili samoubojstvu ili samoubojstvu (9)
  7. Oteano miljenje Oteano miljenje
i koncentracija; neodluŁnost i koncentracija (8)
  8. Agitacija ili retardacija Agitacija ili retardacija
skoro svaki dan (5)
  9. Poremeæaj spavanja Insomnija ili
hipersomnija (4)
10. Poremeæaj apetita ZnaŁajan gubitak ili po
i promjena tjelesne rast teine vie od 5% (3)
tjelesne teine
U dijagnostiŁkom algoritmu svakako treba voditi raŁu-
na o psihiŁkim i somatskim bolestima koje diferencijalno
dijagnostiŁki treba iskljuŁiti, npr. poremeæaji titnjaŁe,
Parkinsonova bolest, demencija i iscrpljenost prilagodbe-
nih moguænosti. Smatra se da oko 20 posto depresivnih
bolesnika boluje od nekog poremeæaja funkcije titnjaŁe,
najŁeæe hipotireoze.
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nant diseases, Parkinsons disease and chronic pain syn-
dromes, which then additionally mask depression, hamper
diagnosis and treatment, and further aggravate prognosis
of both diseases. The rate of depression in particular so-
matic diseases is presented in Table 2.
Table 2. Somatic diseases and associated prevalence of depression
Somatic disease Rate of depression (%)
Malignant disease 20-45
Stroke 26-34
Chronic pain syndromes 33-35
Cardiovascular diseases 15-33
Parkinsons disease 40
Cerebrovascular diseases, especially stroke, are charac-
terized by an abrupt onset and severe disablement due to
somatic symptoms such as motor, speech, swallowing, vi-
sion and hearing disturbances, central pain syndromes, etc.
Such a sudden change of physical abilities is a major stress
for every man, and for the majority of patients a traumatic
experience they cannot sublimate but become disheart-
ened, lose self-confidence, hope and life enthusiasm,
which leads to depression, and considerably increases the
risk of suicide and mortality in cerebrovascular patients.
The clinical picture of depression frequently also includes
somatic symptoms, headache and other pain syndromes,
vertigo, nausea, loss of appetite and body weight, general
physical fatigue and bed-ridden state, which are very sim-
ilar to the symptoms of cerebrovascular diseases5.
Also, a number of recent studies have shown that pre-
morbid characteristics of mood disorder persisting for 10 to
15 years may significantly increase the risk of stroke. Somatic
symptoms greatly hamper detection of depression in stroke
patients. It is quite obvious that somatic disturbances and
neuropathic central pain occurring in some 8% post-stroke
patients will increase the risk of depression. On the other
hand, functional disorders such as depression, anxiety and
sleep disturbances are significantly associated as comorbid-
ities with stroke and post-stroke pain syndrome, which
should always be taken in consideration on differential di-
agnosis. The causal relationship between depression and
stroke remain an area for additional research6.
On differential diagnosis, the physician should differ-
entiate depression occurring in response to traumatic stress
caused by a severe somatic disease such as stroke in an
intellectually preserved individual from the organic depres-
sive disorder due to brain lesion. Such depression should
be differentiated from the possible vascular dementia,
Parkinsons disease and hypothyroidism.
Depresija i modani udar
Depresija je Łest pratilac razliŁitih somatskih bolesti,
kao to su cerebrovaskularne, kardiovaskularne, maligne,
Parkinsonova bolest i kroniŁni bolni sindromi, koje dodat-
no maskiraju depresiju, oteavaju dijagnostiku i lijeŁenje
te znatno pogoravaju prognozu i jedne i druge bolesti.
UŁestalost pojave depresije uz pojedine tjelesne bolesti
prikazana je u tablici 2.
Tablica 2. Tjelesne bolesti i uŁestalost javljanja depresije
Tjelesna bolest UŁestalost depresije (%)
Maligna bolest 20-45
Modani udar 26-34
KroniŁni bolni sindromi 33-35
Kardiovaskularne bolesti 15-33
Parkinsonova bolest 40
Cerebrovaskularne bolesti, osobito modani udar, na-
staju naglo i Łesto s tekim invaliditetom zbog somatskih
simptoma kao to su poremeæaj motorike, govora, gutanja,
vida, sluha, centralnih bolnih sindroma i sliŁno. Tako na-
gla promjena fiziŁkih sposobnosti za svakog Łovjeka je in-
tenzivan stres, a za velik dio bolesnika predstavlja traumats-
ko iskustvo koje nisu u stanju sublimirati nego postaju
potiteni, gube samopouzdanje, nadu i volju za ivotom,
to dovodi do depresije, znatno poveæava rizik od samo-
ubojstva i smrtnost cerebrovaskularnih bolesnika. KliniŁ-
ka slika depresije Łesto ukljuŁuje i somatske simptome,
glavobolju i druge bolne sindrome, vrtoglavicu, muŁninu,
gubitak apetita i tjelesne teine, opæu tjelesnu slabost i
zadravanje u krevetu, vrlo sliŁne simptomima cerebro-
vaskularnih bolesti5.
Takoðer, vie studija u novije vrijeme pokazuje kako
premorbidne osobine poremeæaja raspoloenja kroz deset
do petnaest godina mogu znaŁajno poveæati rizik za nas-
tanak modanog udara. Somatski simptomi znaŁajno
oteavaju otkrivanje depresije u cerebrovaskularnih bole-
snika. Potpuno je jasno da æe tjelesni poremeæaji i neuro-
patska centralna bol koja nastaje nakon modanog udara u
oko 8 posto bolesnika poveæati rizik nastanka depresije. S
druge strane, funkcionalni poremeæaji, kao to su depresi-
ja, anksioznost i poremeæaj spavanja, znaŁajno su komor-
bidno povezani sa cerebrovaskularnim inzultom i poslije-
inzultnim bolnim sindromom, to diferencijalno dijag-
nostiŁki uvijek treba uzeti u obzir. Utemeljenost uzroŁno-
posljediŁne povezanosti izmeðu depresije i modanog
udara ostaje kao vano podruŁje za daljnja istraivanja6.
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Risk Factors Linking Depression and
Cerebrovascular Disease
Depression frequently occurs consequentially to
stroke, however, the premorbid mood disorder and depres-
sion as a risk factor for cerebrovascular disease should not
be neglected either. Depression and stroke show a signif-
icant causal relationship through their common risk fac-
tors of stress, inadequate physical activity, loss of energy,
alcohol abuse and alcoholism, tobacco smoking, coagula-
tion and heart rate impairments, hypertension, cardiac
infarction, and type 2 diabetes1,7,8. The following risk fac-
tors are most commonly related to the occurrence of post-
stroke depression: a history of depression, a history of other
mental disorders, post-stroke feeling of loneliness and
social isolation, dysphasia and functional impairments,
central pain syndromes, advanced age, low socioeconomic
status, previous social problems, reduced daily activities,
and reduced sexual performance1,9.
Treatment
Attempts have been made to prevent depressive mood
and development of major depression in stroke patients
by psychotherapy and psychopharmacotherapy in order to
improve their physical and mental state. Psychotherapy
definitely has a favorable effect mood improvement, how-
ever, there is no efficient method to prevent depression
in stroke patients.
Proper understanding of the psychodynamics of the
relationship between cerebrovascular disease and depres-
sion, explained through frequent psychotherapeutic con-
versation between the physician and the patient, is high-
ly relevant for therapeutic outcome. The most efficient
treatment of depression and stroke comorbidity includes
a combination of brief psychotherapeutic procedures such
as behavioral, cognitive-behavioral and interpersonal psy-
chotherapy with psychopharmaceuticals, primarily SIPPS
class antidepressants1,5,6.
 The aim of cognitive-behavioral psychotherapy is to
make the patient aware of the character, course and
prognosis of the disease, and to instruct him on the best
methods of treatment, at the same time stimulating
him for additional efforts in ever greater use of the re-
sidual psychophysical abilities.
 Interpersonal psychotherapy administered for 12-16
weeks is aimed at detecting the patients interperson-
al problems and improving his ability for interpersonal
communication. Antidepressants are frequently add-
ed to psychotherapy.
Diferencijalno dijagnostiŁki lijeŁnik treba razlikovati
depresiju koja se javi kao reakcija na traumatski stres uzro-
kovan tekom tjelesnom boleæu kao to je modani udar
u intelektualno oŁuvane osobe od organskog depresivnog
poremeæaja koji je posljedica oteæenja mozga. Takoðer
depresiju treba razlikovati od moguæe vaskularne demen-
cije, Parkinsonove bolesti i hipotireoze.
RiziŁni Łimbenici povezuju depresiju i cere-
brovaskularnu bolest
Depresija se javlja Łesto kao posljedica modanog udara,
a ne treba zanemariti premorbidni poremeæaj raspoloenja
i depresiju kao Łimbenik rizika za nastanak cerebrovasku-
larne bolesti. Depresija i modani udar znaŁajno su uzroŁno
povezani zajedniŁkim riziŁnim Łimbenicima: stresom,
smanjenjem fiziŁke aktivnosti, gubitkom energije, zloupo-
rabom alkohola i alkoholizmom, puenjem duhana, pore-
meæajem koagulacije i srŁanog ritma, hipertenzijom, srŁa-
nim infarktom i eæernom boleæu tipa 21,7,8. S nastankom
poslijeinzultne depresije najvie se povezuju slijedeæi riz-
iŁni Łimbenici: anamneza depresije, anamneza drugih psi-
hiŁkih poremeæaja, usamljenost i socijalna izolacija poslije
modanog udara, disfazija i funkcionalna oteæenja, cen-
tralni bolni sindromi, starija dob, slabiji socioekonomski
status, prijanji socijalni problemi, smanjene aktivnosti
tijekom dana i smanjenje seksualnih sposobnosti1,9.
LijeŁenje
Postoje pokuaji da se psihoterapijom i psihofarmako-
terapijom sprijeŁi depresivno raspoloenje i razvoj velikog
depresivnog poremeæaja kod bolesnika s modanim
udarom i na taj naŁin pobolja njihovo tjelesno i psihiŁko
stanje. Psihoterapija svakako ima pozitivan uŁinak na po-
boljanje raspoloenja, no zasad nema uŁinkovite metode
sprjeŁavanja depresivne bolesti u bolesnika koji su doivjeli
modani udar.
Za ishod lijeŁenja znaŁajno je razumijevanje psihodi-
namike odnosa cerebrovaskularne bolesti i depresije, koja
se razjanjava kroz Łeste psihoterapijske razgovore izmeðu
lijeŁnika i bolesnika. Najdjelotvornije lijeŁenje depresije u
komorbiditetu s modanim udarom je ono pomoæu kom-
biniranih kratkih psihoterapijskih postupaka kao to su
bihevioralna, kognitivno-bihevioralna i interpersonalna
psihoterapija uz pomoæ psihofarmaka, prvenstveno anti-
depresiva iz skupine SIPPS1,5,6.
 Kognitivno-bihevioralna psihoterapija treba bolesniku
osigurati spoznaju o naravi, tijeku i prognozi bolesti te
upute o najboljim metodama lijeŁenja uz poticaj za
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 Besides their antidepressive and anxiolytic action, an-
tidepressants, selective inhibitors of serotonin re-
uptake (SIPPS) also act on the platelet membrane
serotonin carrier, thus reducing the platelet serotonin
level and platelet coagulability, and have a heart rate
and blood pressure regulating activity mediated by the
central nervous system.
 Electroconvulsive therapy (ECT) is used in cases re-
sistant to psychotherapy and psychopharmacotherapy,
and when a rapid antidepressive effect has to be
achieved.
Conclusions
1. Cerebrovascular diseases currently present a leading
health problem in western countries, and depression
is the fourth health problem worldwide.
2. Today, the association between depression and stroke
is considered unquestionable.
3. Depression is the most common psychiatric disorder
associated with cerebrovascular diseases; it occurs in
26% to 34% of stroke patients within two years of
stroke.
4. There is a correlation between the severity of post-stroke
depression and cerebral lesion localization, i.e. the clos-
er the brain lesion to the left frontal lobe region, the
higher the prevalence and severity of depression.
5. Early detection and treatment have been defined as the
main goals of modern medicine.
6. Attempts at preventing post-stroke depression have
been less successful.
7. The treatment is successfully performed by use of psy-
chotherapy, psychopharmacotherapy, electroconvulsive
therapy, and rehabilitation.
8. The biopsychological model provides proper under-
standing of the multifactorial etiology of mental and
physical disturbances of post-stroke depression, which




 fourth major health problem in western countries
 mood disorder
 clinical picture characterized by mental and physi-
cal symptoms
 most common mental disorder associated with
stroke
 all of these
dodatno unapreðivanje i uporabu preostalih psihofi-
ziŁkih sposobnosti.
 Interpersonalna psihoterapija u trajanju od 12 do 16
tjedana usmjerana je na otkrivanje bolesnikovih meðu-
ljudskih problema i poboljanje sposobnosti meðuljud-
skih komunikacija. Antidepresivi se Łesto pridodaju uz
psihoterapiju.
 Uz njihovo antidepresivno i anksiolitiŁno djelovanje, an-
tidepresivi, selektivni inhibitori ponovne pohrane se-
rotonina (SIPPS) utjeŁu na trombocitni membranski
nosaŁ serotonina tako da smanjuju koliŁinu serotonina
u trombocitima i njihovu koagulabilnost, a posredstvom
sredinjeg ivŁanog sustava reguliraju srŁani ritam i
krvni tlak.
 Elektrokonvulzivna terapija (EKT) se primjenjuje u
sluŁajevima otpornim na psihoterapiju i psihofarmako-
terapiju te kada je potrebno postiæi brz antidepresivni
uŁinak.
ZakljuŁci
1. Cerebrovaskularne bolesti predstavljaju danas vodeæi
zdravstveni problem u zemljama zapadnog svijeta, a
depresija je Łetvrti najveæi zdravstveni problem.
2. Danas se smatra da je povezanost izmeðu depresije i
modanog udara nedvojbena.
3. Depresija je najŁeæi psihijatrijski poremeæaj povezan
s cerebrovaskularnim bolestima, javlja se u 26 do 34
posto bolesnika unutar dvije godine poslije modanog
udara.
4. Postoji povezanost izmeðu teine poslijeinzultne
depresije i lokacije lezije mozga: to su oteæenja mozga
blie podruŁju lijevog frontalnog renja, uŁestalost i
teina depresije je veæa.
5. Rano otkrivanje i lijeŁenje postaje jedan od temeljnih
ciljeva suvremene medicine.
6. Pokuaji sprjeŁavanja poslijeinzultne depresije dosad su
bili manje uspjeni.
7. LijeŁenje se uspjeno provodi primjenom psihoterapije,
psihofarmakoteraije, elektrokonvulzivne terapije i re-
habilitacije.
8. Biopsiholoki model omoguæuje razumijevanje vieŁim-
benske etiologije psihiŁkih i fiziŁkih poremeæaja
poslijeinzultne depresije kao preduvjeta za sveobuhvat-
no, timsko uspjeno lijeŁenje.
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2. Post-stroke depression occurs in:
 10% of patients
 15%-20% of patients
 26%-34% of patients
 35%-40% of patients
 50% of patients





 psychotherapy and antidepressants
4. Symptoms of depression are:
 depressive mood
 loss of interest
 decreased energy and increased fatigue
 sleep disturbances
 all of these
5. Post-stroke depression most commonly occurs in the
lesion of:
 left frontal lobe
 left temporal lobe
 right occipital lobe
 right parietal lobe
 left parietal lobe
Pitanja
1. Depresija je:
 Łetvrti najveæi zdravstveni problem zemalja zapad-
nog svijeta
 poremeæaj raspoloenja
 kliniŁka slika se oŁituje psihiŁkim i fiziŁkim simpto-
mima
 najŁeæi psihiŁki poremeæaj povezan s modanim
udarom
 sve od navedenog











 psihoterapijom i antidepresivima
4. Simptomi depresije su:
 depresivno raspoloenje
 gubitak interesa
 smanjenje energije i poveæano zamaranje
 poremeæaj spavanja
 sve navedeno
5. Poslijeinzultna depresija najŁeæe se javlja kod oteæenja:
 lijevog frontalnog renja
 lijevog temporalnog renja
 desnog okcipitalnog renja
 desnog parietalnog renja
 lijevog parietalnog renja
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Unutar mjesec dana od nastanka modanog udara umi-
re 20% bolesnika, dok ih 30% postaje ovisno o tuðoj pomoæi,
25% ih nastavlja lijeŁenje i njegu u specijaliziranim ustano-
vama, a 10% bolesnika ostaje vezano uz krevet. Rehabili-
taciju bolesnika nakon modanog udara treba zapoŁeti to
ranije, toŁnije odmah, u jedinicama za lijeŁenje modanog
udara kada je bolesnik u medicinski stabilnom stanju. Ranu
rehabilitaciju treba zapoŁeti interdisciplinski u jedinici za
lijeŁenje modanog udara koja po svojoj organizaciji omo-
guæuje sastanke osoblja barem jedanput na tjedan, a reha-
bilitaciju u trajanju od barem tri sata na dan.
Pokazalo se je da je kljuŁ uspjene rehabilitacije u
usklaðenom timskom radu specijalista lijeŁnika, bolesni-
ka i njegove obitelji.
Prema dosadanjem poznavanju patofiziologije oporav-
ka od modanog udara pozitivnim uŁinkom rehabilitacije
smatralo se je uŁenje bolesnika novim kompenzirajuæim
tehnikama (npr. uporaba nezahvaæene ruke u postizanju
neovisnosti) te izbjegavanje intezivne terapije oslabljenog
ekstremiteta. Dananje spoznaje nam govore kako se pozi-
tivan uŁinak rehabilitacije postie opetovanim sudjelova-
njem bolesnika u aktivnom programu fizikalne terapije,
Łime se postie izravan utjecaj na proces funkcionalne re-
organizacije u mozgu i poboljanje neurolokog oporavka.
Danas postoje dvije glavne teorije oporavka nakon
modanog udara: teorija o kolateralnom grananju iz intakt-
nih stanica u denervirano podruŁje i teorija o demaskira-
nju neuralnih putova i sinapsa koje se inaŁe rabe, a koje se
mogu ukljuŁiti nakon sloma dominantnog sustava.
Smatra se kako postoje dva mehanizma oporavka neu-
roloke funkcije:
1. Prestanak tetnog uŁinka lokalnih Łimbenika (rezolu-
cija lokalnog edema, resorpcija lokalnih toksina, pobo-
ljanje lokalne cirkulacije, oporavak ishemijom djelo-
mice oteæenih neurona), koji dovodi do ranog sponta-
nog oporavka nakon modanog udara unutar prvih 3 do
6 mjeseci.
NEW OPTIONS IN NEUROREHABILITATION
NOVE  MOGU˘NOSTI  U  NEUROREHABILITACIJI
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About 20% of stroke patients die within a month of
stroke onset, whereas another 30% are dependent on oth-
er peoples help, 25% continue treatment and care at spe-
cialized institutions, and 10% are bed ridden. Post-stroke
rehabilitation should be initiated as early as possible, it
means, immediately when a stable medical condition is
achieved, and preferably at stroke units. Early rehabilita-
tion should be initiated by an interdisciplinary approach
at stroke units that are structured so as to allow for at least
weekly staff meetings and patient rehabilitation of at least
3 hours daily. A well coordinated team work of the special-
ist physician, patient and his patient family has been shown
to be crucial for successful rehabilitation.
Until recently, the concepts of the pathophysiology of
post-stroke rehabilitation considered training patients in
new, compensating techniques (e.g., use of unaffected arm
in achieving independence) and avoiding intensive ther-
apy of the affected extremity as a favorable effect of reha-
bilitation.
Current concepts, however, indicate that a favorable
effect of rehabilitation can be achieved by repeated patient
participation in active physical therapy program, thus di-
rectly addressing the process of functional reorganization
in the brain and neurologic improvement.
Nowadays, there are two main theories on post-stroke
recovery: theory of collateral branching from intact cells
into denervated area, and theory of demasking the neural
pathways and synapses otherwise used that can be includ-
ed upon the dominant system breakdown.
It is believed that there are two mechanisms of neuro-
logic function recovery:
1) cessation of the adverse effect of local factors (resolu-
tion of local edema, resorption of local toxins, improve-
ment of local circulation, recovery of neurons partially
damaged by ischemia), leading to early spontaneous
recovery within 3-6 months of stroke; and
2) the principle of brain neuroplasticity, i.e. the nervous
system ability to modify structures and functional or-
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ganization, based on collateral expansion of new syn-
aptic links and demasking of latent functional pathways
by taking functions over through alternative neural
pathways, diaschisis reversibility, denervation super-
sensitivity and regenerative proximal expansion of in-
terrupted axons.
The polypeptide growth factors (basic fibroblast
growth factor, bFGF) stimulating neuronal branching and
endogenous proliferation of progenitor cells in experimen-
tal animals, may also play a role in the post-stroke function-
al recovery, whereas bFGF dimer has been shown to im-
prove neurologic recovery in subacute treatment (days,
weeks).
Medications that modify the level of specific central
neurotransmitters were experimentally demonstrated to
influence post-stroke functional recovery of the brain. The
substances that decrease the concentration of norepineph-
rine (a1-adrenergic receptor blockers, a2-adrenergic recep-
tor agonists) reduce post-stroke recovery, whereas those
increasing the concentration of norepinephrine (a2-adren-
ergic receptor antagonists, sympatomimetics, e.g., amphet-
amine) improve post-stroke recovery.
Classic rehabilitation services are categorized into phys-
ical therapy, work therapy and speech therapy. Physical
therapy is based on specific functional training performed
through traditional therapeutic techniques (extent of
movement, musculature strengthening, mobilization,
technique mastering), using methods according to Knott
and Voss (proprioceptive neuromuscular facilitation),
Brunnstrom (stimulating specific synergy by use of cuta-
neous/proprioceptive central facilitation) and Bobath
(training of neural development). Physical and work ther-
apy are based on the substitutional action of unaffected
parts of the body and biologic principles of brain plastici-
ty. Forced movement induction stimulates enhanced func-
tioning of the unaffected hemisphere relative to the affect-
ed part of the body, and forced directing patients atten-
tion to the paretic extremity through high-intensity func-
tional training results in better recovery.
Unfortunately, the process of rehabilitation seems to
terminate with the patients stay at special institutions.
However, there is now an alternative to classic rehabilita-
tion, i.e. tele-rehabilitation or computer aided rehabilita-
tion and care.
The idea of treating patients with aphasia by use of
computer has been launched some ten years ago. The lat-
est approach to this mode of treatment implies so-called
face-to-face therapy, i.e. the patient presenting to a spe-
cial institution immediately upon the onset of stroke symp-
2. NaŁelo neuroplastiŁnosti mozga, odnosno sposobnos-
ti ivŁanog sustava za modificiranje strukture i funk-
cionalne organizacije, koje se temelji na kolateralnom
irenju novih sinaptiŁnih veza i na demaskiranju latent-
nih funkcionalnih putova, preuzimanju funkcije kroz
alternativne neuralne putova, reverzibilnosti dijashize,
denervacijskoj superosjetljivosti i regenerativnom
proksimalnom irenju prekinutih aksona.
Moguæu ulogu u funkcionalnom oporavku nakon ishe-
mijskog modanog udara imaju i polipeptidni faktori rasta
(basic fibroblast growth factors, bFGF) koji potiŁu grananje
neurona i endogenu poliferaciju progenitornih stanica kod
pokusnih ivotinja, a pokazalo se je da dimer bFGF u sub-
akutnom lijeŁenju (dani, tjedni) poboljava neuroloki
oporavak.
U eksperimentalnim uvjetima dokazano je kako lije-
kovi koji mijenjaju razinu specifiŁnih sredinjih neurotrans-
mitora utjeŁu na oporavak funkcije mozga nakon modanog
udara. Tvari koje smanjuju koncentraciju norepinefrina
(blokatori alfa 1-adrenergiŁnih receptora, agonisti alfa 2-
adrenergiŁkih receptora) smanjuju oporavak, a tvari koje
povisuju koncentraciju norepinefrina (antagonisti alfa 2-
adrenergiŁnih receptora, simpatomimetici kao amfetamin)
poboljavaju oporavak nakon modanog udara.
KlasiŁne rehabilitacijske slube dijele se na fizikalnu
terapiju, radnu terapiju i terapiju govora. Fizikalna terapi-
ja osniva se na specifiŁnom funkcionalnom vjebanju, a
provodi se putem tradicionalne terapije (opseg pokreta,
jaŁanje muskulature, mobilizacija, usvajanje tehnike),
metodom Knotta  i Vossa (proprioceptivna neuromusku-
larna facilitacija), Brunnstroma (poticanje specifiŁne si-
nergije uporabom kutano/proprioceptivne centralne faci-
litacije) i Bobatha (trening neuralnog razvoja). Fizikalna i
radna terapija zasnivaju se na supstitucijskom radu neza-
hvaæenih dijelova tijela i biolokim naŁelima plastiŁnosti
mozga. Prisilnim izazivanjem kretnja postie se pojaŁano
funkcioniranje neoteæene hemisfere u odnosu na oslab-
ljeni dio tijela, a forsiranom uporabom i usmjeravanjem
bolesnikove pozornosti na paretiŁni ekstremitet funkcio-
nalnim treningom visokog inteziteta postie se bolji opo-
ravak.
¨ini se da nakon boravka u specijaliziranim ustanova-
ma rehabilitacija bolesnika, naalost, zavrava. Meðutim,
danas postoji i alternativa klasiŁnoj rehabilitaciji, kao to
je tele-rehabilitacija, rehabilitacija i lijeŁenje uz pomoæ
raŁunala. Zamisao o lijeŁenju bolesnika s afazijom pomoæu
raŁunala stara je veæ dvadesetak godina. Najnoviji pristup
takovom lijeŁenju predstavlja tzv. terapija licem u lice,
koja pretpostavlja dolazak bolesnika u specijaliziranu
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toms, making the diagnosis of aphasia, initiating face-to-
face therapy and combining classic therapy for aphasia with
computer aided therapy at patients home. Thus, the
speech therapist can evaluate therapeutic results imme-
diately upon therapy completion,  assess therapeutic
progress and plan further treatment by use of data trans-
fer. This therapy is preferable for higher patient motiva-
tion and self-confidence and absence of age restrictions,
however, its shortcomings are the fact that stroke patients
suffer from depressed cognitive abilities and a limited
number of exercises provided with respective software for
the treatment of aphasia.
By use of so-called virtual reality, i.e. computer simu-
lation producing an impression of real 3D environment,
intensified learning of the mechanisms is achieved by
sending information on patients movements to the cen-
tral nervous system in real time via audio-visual feedback
connection, thus allowing for individual adjustment of the
rehabilitation therapy intensity. The use of virtual reality
in neurologic patients is based on three main points:
1) applicability, by use of a helmet attached to the head
(visual image, earphones and 3D position sensor), pre-
venting the patients attention to decrease, and virtu-
al environment projected to the wall in a pleasant, dark
room for motor rehabilitation;
2) patients utilizing the mechanism of  enhanced learn-
ing by use of information sent to the central nervous
system in real time, acquired via audio-visual feedback
connection for movements that interact with correct
movements presented in virtual environment; and
3) extrapolation of the movements learned through vir-
tual reality to the real life, thus achieving considerable
improvement in the results of extremity motor func-
tions on clinical evaluation scales in post-stroke pa-
tients; the intensity of rehabilitation exercise can be
increased or otherwise adjusted to each individual pa-
tient.
Tele-rehabilitation programs via regular telephone or
special digital connection increase the availability of spe-
cial rehabilitation service to patients, caretakers and stu-
dents in remote and rural areas; it also allows for audio-
visual link between patients and their tele-therapists, and
there is no idling in the process of rehabilitation due to
temporal, spatial,  geographical or communication distance.
ustanovu odmah nakon nastanka simptoma modanog
udara, dijagnosticiranje afazije i poŁetak terapije licem u
lice, te kombiniranje klasiŁne terapije afazije s terapijom
uz pomoæ raŁunala u bolesnikovu domu. Takovom terapi-
jom logoped ocjenjuje rezultat terapije odmah nakon nje-
zinog zavretka i procjenjuje napredak lijeŁenja te planira
daljnje lijeŁenje putem prenoenja podataka. Prednosti
takve terapije su veæa motiviranost i samopouzdanje
bolesnika te nepostojanje dobne granice za provoðenje
terapije, a ograniŁenja su Łinjenica da je kod bolesnika s
modanim udarom smanjena kognitivna sposobnost i og-
raniŁen broj vjeba s postojeæim raŁunalnim programom za
lijeŁenje afazije.
Pomoæu takozvane virtualne stvarnosti, odnosno
raŁunalne simulacije koja stvara dojam stvarnog 3D okru-
enja postie se pojaŁano uŁenje mehanizama slanjem
informacija sredinjem ivŁanom sustavu u stvarnom vre-
menu preko audio-vizualne povratne veze o bolesnikovim
pokretima i postie se moguænost individualnog prilagoða-
vanja intenziteta  rehabilitacijske terapije. Tri su temeljne
toŁke u primjeni virtualne stvarnosti kod neurolokih bo-
lesnika:
1. Uporabljivost, pomoæu kape koja se priŁvrsti na gla-
vu (vizualni prikaz, slualice i 3D poloajni senzori),
Łime se onemoguæuje bolesnikovo opadanje pozornosti,
te s virtualnim okruenjem projiciranim na zidu ugod-
ne, tamne prostorije za motornu rehabilitaciju.
2. Bolesnikova uporaba mehanizma pojaŁanog uŁenja
koritenjem informacija upuæenih sredinjem ivŁa-
nom sustavu u stvarnom vremenu, dobivenih preko au-
dio-vizualne povratne veze svojih kretnja, koje su u
interakciji s pravilnim kretnjama prikazanim u virtual-
nom okruenju.
3. Prijenos nauŁenih kretnja putem virtualne stvarnosti
u stvaran ivot, Łime se postie znaŁajan porast rezul-
tata motornih funkcija ekstremiteta na kliniŁkim ocjen-
skim ljestvicama kod bolesnika nakon modanog udara
i moguænost poveæanja intenziteta rehabilitacijskih
vjeba i prilagodbe svakom pojedinom bolesniku.
Tele-rehabilitacijskim programima putem redovne
telefonske linije ili specijaliziranih digitalnih veza postie
se bolja dostupnost specijaliziranih rehabilitacijskih usluga
bolesnicima, njegovateljima i studentima u udaljenim i
seoskim podruŁjima; omoguæuje se bolesnicima i njihovim
tele-terapeutima audiovizualna povezanost; i nema praz-
nog hoda u procesu rehabilitacije uzrokovanog vremen-
skom, zemljopisnom ili prometnom udaljenoæu.
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CURRENT METHODS IN THE MANAGEMENT OF NICOTINE ADDICTION IN
PATIENTS WITH CEREBROVASCULAR DISORDERS
SUVREMENE METODE LIJE¨ENJA OVISNOSTI O NIKOTINU KOD BOLESNIKA S
POREME˘AJIMA MODANE CIRKULACIJE
Nevenka ¨op-Blaiæ
University Department of Neurology, Reference Center for Neurovascular Disorders of the Ministry of Health, Republic of
Croatia, Sestre milosrdnice University Hospital, Zagreb, Croatia
Klinika za neurologiju, KliniŁka bolnica Sestre milosrdnice, Referentni centar za neurovaskularne poremeæaje Ministarstva
zdravstva Republike Hrvatske, Zagreb
Dependence on any drug including nicotine is basically
a cerebral disorder. Neurobiologic investigations suggest
a qualitative difference between the brain of an addict and
the brain of a person free from any addiction. On the oth-
er hand, behavioral science points out that the brain of an
addict is abnormally conditioned, so that some environ-
mental factors become substantial elements of addiction
and dependent behavior. One of the specificities of ciga-
rette smoking relative to other dependences is that in
addition to nicotine, which is extremely addictive, a smoker
on inhaling tobacco smoke on twenty or more occasions
daily at the same time not only strengthens his nicotine
dependence but also takes more than 4000 adverse chem-
ical substances, among them about 50 carcinogens.
Cigarette smoking has been associated with at least 30
different diseases that rank high on the morbidity and
mortality scale, among the stroke. Stroke is more frequent
in smokers than in nonsmokers. It should be noted that
there is no healthy level of tobacco smoking, because nic-
otine, carbon monoxide, carcinogenic substances and thou-
sands of other harmful chemicals are taken to the body
while inhaling the smoke of each cigarette. Each cigarette
impairs breathing, paralyzes ciliary apparatus, deprives the
body of oxygen, narrows blood vessels, accelerates heart
Ovisnost o bilo kojoj drogi, pa tako i o nikotinu, u os-
novi je bolest mozga. Neurobioloka ispitivanja govore u
prilog kvalitativne razlike izmeðu mozga ovisnika i mozga
osobe koja nije ovisnik. S druge strane bihevioralna znanost
istiŁe da je mozak ovisnika nenormalno kondicioniran, tako
da neki Łimbenici okoline postaju bitni dijelovi ovisnosti,
odnosno ovisniŁkog ponaanja. Jedna od specifiŁnosti
puenja u odnosu na druge ovisnosti je u tome to puaŁ
uz nikotin, koji je izrazito adiktivan, udisanjem duhanskog
dima dvadesetak i vie puta na dan istodobno ne samo
uŁvræuje svoju ovisnost o nikotinu, veæ unosi u tijelo pre-
ko Łetiri tisuæe tetnih kemijskih sastojaka meðu kojima
je oko pedeset kancerogena.
Puenje se povezuje s najmanje tridesetak razliŁitih
bolesti visoko stupnjevanih na ljestvici pobola i smrtnosti,
meðu kojima je i modani udar. Modani udar se kod
puaŁa javlja Łeæe i ranije nego u nepuaŁa. Treba istak-
nuti da ne postoji zdrava razina puenja duhana, jer se udi-
sanjem dima svake cigarete u tijelo unosi nikotin, ugljiŁni
monoksid, kancerogene tvari i tisuæe drugih tetnih kemi-
kalija. Svaka cigareta remeti disanje, paralizira cilijarni apa-
rat, oduzima tijelu kisik, suava krvne ile, ubrzava rad srca
i podie krvni tlak, djeluje bifaziŁno na sredinji ivŁani
sustav, teti zdravlju osobe koja je uz puaŁa i vodi prema
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ovisnosti. Invaliditet i smrti vezane uz puenje nisu
neizbjene, nego ih je moguæe sprijeŁiti. Uklanjanjem
puenja kao riziŁnog Łimbenika moe se oŁekivati ne samo
manji broj modanih udara, nego i veæi postotak bolesnika
s dobrim oporavkom.
Suvremene metode lijeŁenja ovisnosti o nikotinu uklju-
Łuju kombinaciju bihevioralne i kognitivne strategije s po-
moænim farmakolokim sredstvima (nikotinska zamjenska
terapija, bupropion kao prvo nenikotinsko pomoæno sred-
stvo u procesu odvikavanja od puenja).
Bez obzira na duinu puaŁkog staa i broj popuenih
cigareta svaki puaŁ moe prestati puiti. Uz to, svaki puaŁ
ima pravo dobiti potporu i pomoæ u procesu odvikavanja
od puenja koji se sastoji od vie faza. To se osobito odnosi
na puaŁe oboljele od modanog ili srŁanog udara, jer su
uspjeno lijeŁenje i rehabilitacija nespojivi s nastavkom
puenja.
Kako se radi o vrlo sloenoj ovisnosti, veæina bolesnika
puaŁa uspijeva apstinirati kratko vrijeme kad se jave sim-
ptomi bolesti, nakon Łega se vraæaju cigareti. Iskustvo mno-
gih je da se dugo vremena vrte u zaŁaranom krugu prolazeæi
kroz faze razmiljanja o potrebi prestanka puenja, faze
poduzimanja odreðenih konkretnih koraka, faze kraæeg
prestanka i nakon toga ponovnog vraæanja puenju.
Programe odvikavanja od puenja stoga treba uklopiti
u redovite ambulantne, bolniŁke i poslijebolniŁke tera-
pijske postupke u ambulantama i na pojedinim klinikama
gdje se lijeŁe bolesti povezane s puenjem. VisokoriziŁnim
bolesnicima s brojnim pokuajima prestanka puenja i ni-
skom razinom samopouzdanja zbog opetovanih neuspje-
ha potrebna je posebna potpora i pomoæ kako bi im se
omoguæilo ne samo da postanu, nego i da ostanu nepuaŁi.
PuaŁi na razne naŁine pokuavaju prestati puiti. Bez
obzira na to za koju metodu se odluŁe treba istaknuti kako
ne postoji magiŁna formula kojom bi se puaŁa moglo
pretvoriti u nepuaŁa. Prestanak puenja nije dogaðaj nego
proces tijekom kojega se puaŁ korak po korak pribliava
cilju. Mentalno odvikavanje od puenja traje jo dugo vre-
mena nakon to je puaŁ zapalio zadnju cigaretu. U cijelom
tom procesu  bitno je usredotoŁiti se na viestruke pred-
nosti i dobiti u vidu poboljanja i Łuvanja zdravlja i novaca.
Veæ nakon prva 24 sata apstinencije smanjuje se rizik
iznenadne smrti zbog infarkta, sniava se razina CO u krvi,
vie kisika dolazi u mozak i druge organe, krvni tlak se
sputa, a rad srca se normalizira. Nakon nekoliko dana okus
i miris se popravljaju, etnja je manje naporna, disanje je
lake, dah vie nije tako kratak i poveæava se osjeæaj snage.
LijeŁnici i ostali medicinski djelatnici koji sudjeluju u
dijagnostiŁkim i terapijskim postupcima mogu kratkom
rate and elevates blood pressure, acts biphasically on the
central nervous system, has detrimental health effects for
the persons close to the smoker, and leads to addiction.
Disability and deaths related to smoking are not unavoid-
able but preventable. With the elimination of smoking as
a risk factor, not only a lower number of strokes but also a
higher proportion of patients with good recovery can be
expected.
Current methods in the management of nicotine de-
pendence include a combination of behavioral and cogni-
tive therapy with adjuvant pharmacologic agents (nicotine
replacement therapy, bupropion as the first non-nicotine
adjuvant in the process of cessation).
Each smoker can quit smoking irrespective of the du-
ration of smoking habit and number of cigarettes smoked.
Also, each smoker has the right to get support and assis-
tance in the process of cessation, which consists of a num-
ber of steps. This especially holds for smokers who have
experienced a stroke or heart attack, because successful
treatment and rehabiliation are incompatible with continu-
ing smoking.
As smoking is a very complex addiction, most patients-
smokers manage to abstain for a short period of time when
symptoms of the disease occur, whereafter they turn back
to cigarettes. Many of them report on finding themselves
in a sort of a vicious circle, being through a stage of con-
sidering the need of quitting, stage of taking some concrete
steps, stage of brief cessation, then turning back to smok-
ing.
The smoking cessation programs should be incorporat-
ed in the regular outpatient, hospital and post-hospital
therapeutic procedures in outpatient clinics and at partic-
ular hospital departments where smoking related diseas-
es are treated. High risk patients with a history of numer-
ous attempts at quitting smoking and low level of self-
confidence because of repeated failures require special
support and help to allow them not only to become but
also to stay nonsmokers.
Smokers try to stop smoking in a number of different
ways. Irrespective of the method they choose, it should be
noted that there is no magic formula to transform a smok-
er into a nonsmoker. Smoking cessation is not an event but
a process during the course of which the smoker approach-
es his goal step by step. Mental cessation persists for a long
time after the smoker had his last cigarette. In this long-
term process it is of utmost importance to focus on the
multiple benefits and gains in terms of improving and pro-
tecting both ones health and money. In only 24 hours of
abstinence, the risk of sudden death from infarction is
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reduced, the blood level of CO is lowered, the oxygen
supply to the brain and other organs increase, blood pres-
sure declines and heart rate shows normalization. After
several days of abstinence, the sense of taste and smell
improves, the walk is better tolerated, the breathing is
easier, the breath is not short anymore, and the feeling of
strength improves.
Physicians and other medical personnel involved in
diagnostic and therapeutic procedures can help the patient
by brief intervention in the process of smoking cessation.
Brief intervention means that each patient should be
asked about smoking, and if a smoker he should be advised
to stop smoking, to assess whether he is willing to do it
immediately or within a one-month period, to help him set
a date for cessation and advise him how to successfully cope
with withdrawal discomforts, and to follow-up the course
of abstinence at an intensive rate for the first two weeks,
then less frequently, once a week for one month, and then
monthly for one year.
5 A Ask Assess Attend
Advise Assist
Using motivating interview the patient can be attract-
ed to decide, if he has not yet done so, to stop smoking,
for his own reasons rather than for some general facts about
the detrimental effects of cigarette smoking.
What do you like in smoking?
What do you dislike in smoking?
Where are you in this relationship of love and hate for
smoking?
It is crucial to make a good plan. Motivation is of par-
amount importance, because the stronger the motivation
the greater the chance for success. Upon setting a date for
quitting smoking, which should not be to distant, an ap-
propriate support from the family and friends as well as
professional help should be ensured. During the develop-
ment of nicotine addiction, smokers at first fool themselves
thinking they can simply stop smoking whenever they
want to, however, the true is far from this. Most smokers
wish to stop smoking, one third try to stop at least once a
year, but only five percent of them manage to abstain by
the end of the one-year period.
Nicotine dependence test
How many cigarettes do you smoke daily?
How much time usually elapses between your standing up
until your first cigarette?
intervencijom pomoæi bolesniku u procesu prestanka pu-
enja. Kratka intervencija  sastoji se u tome da se svakog
bolesnika obvezno pita pui li, da mu se savjetuje prestanak
puenja, da se procjeni je li voljan to uŁiniti odmah ili unu-
tar mjesec dana, da mu se pomogne odrediti datum pre-
stanka puenja i kako se uspjeno suoŁiti s apstinencijskim
potekoæama, te da se prati tijek apstinencije intenzivno
kroz prva dva tjedna, a zatim rjeðe, jedanput na tjedan kroz
mjesec dana, potom svakog mjeseca kroz godinu dana.
5 P Pitati Procijeniti Pratiti
Posavjetovati Pomoæi
Pomoæu motivirajuæeg razgovora bolesnika se moe
zainteresirati da, ako jo nije, donese odluku o prestanku
puenja utemeljenu na osobnim razlozima, a ne zbog nekih
opæih Łinjenica o tetnosti puenja.
to Vam se sviða u puenju?
to ne volite kod puenja?
Gdje ste Vi u tom odnosu ljubavi i mrnje prema puenju?
Svakako je kljuŁno naŁiniti  dobar plan. Motivacija je
jako vana, jer to je ona veæa to je veæa i moguænost uspje-
ha. Nakon odreðivanja datuma prestanka puenja koji ne
bi trebao biti predalek, vano je osigurati odgovarajuæu
potporu prijatelja i obitelji te struŁnu pomoæ. Tijekom raz-
voja ovisnosti o nikotinu puaŁi se isprva zavaravaju milju
kako mogu jednostavno, kadgod zaele, prestati puiti.
Stvarnost je drukŁija. Veæina puaŁa eli prestati, treæina
barem jedanput na godinu pokuava ostaviti cigarete, a
svega ih pet posto uspijeva apstinirati do kraja godine.
Test ovisnosti o nikotinu
Koliko cigareta puite na dan?
Koliko vremena proðe ujutro nakon ustajanja do paljenja
prve cigarete?
Je li Vam teko izdrati bez cigarete na mjestima gdje
puenje nije doputeno ili u prilikama kad to nije primje-
reno?
Onaj tko pui najmanje deset cigareta na dan prvu ciga-
retu zapali tijekom trideset minuta nakon buðenja ujutro,
jer osjeæa nelagodu ako to ne uŁini i teko mu je izdrati u
prigodama gdje se ne smije puiti i jedva Łeka priliku da
zapali cigaretu s velikom vjerojatnoæu je razvio ovisnost o
nikotinu.
PuaŁi godinama uŁvræuju sloenu puaŁku naviku.
Kupovanje cigareta, otvaranje kutije, vaðenje cigarete, pri-
noenje ustima, paljenje, stavljanje i vaðenje cigarete iz usta
nekoliko stotina puta na dan, gaenje i odlaganje opuaka
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postaje rutina. Pri rjeavanju svakodnevnih problema i
stresova puaŁ obvezno pali cigaretu i doivljava ugodu
vezano uz aktiviranje dopaminergiŁnog sustava nikotinom.
Ne moe zamisliti ivot bez cigarete koju rabi poput take
za oslonac kad mu je teko. U sluŁaju nestanka cigareta i
pada razine nikotina pojavljuju se neugodni apstinencijski
simptomi poput udnje za cigaretom, razdraljivosti, os-
jeæaja frustracije ili ljutnje, anksioznosti, potekoæa koncen-
tracije, umora, poveæanog teka, usporenog rada srca i dru-
gi, koji se povlaŁe Łim puaŁ ponovno zapali cigaretu i nami-
ri potrebu za nikotinom. Stoga nije neobiŁno to to su re-
cidivi kod veæine puaŁa uobiŁajeni i to su na neki naŁin
normalan dio procesa prestanka puenja. PuaŁ koji pui
kutiju cigareta na dan svakoga dana, sto ezdeset puta
udahne nikotin (pri puenju jedne cigarete duhanski dim
se inhalira oko osam puta), odnosno na godinu 57.400 puta
podupire i uŁvræuje svoju ovisnost o nikotinu.
Na Klinici za neurologiju KB «Sestre milosrdnice»
primjenjuje se, u skladu s preporukama SZO, tzv. kratka
intervencija i organiziraju se specijalni programi za puaŁe
s visokim stupnjem ovisnosti kojima kratka lijeŁniŁka in-
tervencija nije dovoljna. Program odvikavanja od puenja
temelji se na naŁelima Breathe free plan to stop smoking
ameriŁkih autora Folkenberga i Mc Farlanda. Radi se o
psihoterapijsko-edukacijskom modelu. Kod nekih puaŁa
smo za ublaavanje apstinencijskih simptoma rabili ni-
kotinsku zamjensku terapiju, najŁeæe u obliku flastera.
Razina nikotina u krvi kod primjene nikotinskih flastera
je nia nego pri puenju cigareta, no jo uvijek dovoljno
visoka da ublai ili ukloni nikotinski apstinencijski sindrom
i odvikavanje od puenja uŁini lakim. Uz to, uklonjeni su
svi drugi tetni sastojci koje puaŁ unosi uz nikotin pue-
njem cigareta. Flasteri se lijepe na intaktnu kou bez dlaŁi-
ca i svakodnevno se mijenjaju. Na raspolaganju su flasteri
s razliŁitom koliŁinom nikotina (2l mg , 14 mg, 7 mg). Kod
puaŁa koji pue preko 20 cigareta na dan primjenjuju se
flasteri od 21 mg. Trajanje primjene flastera bilo je razliŁi-
to, najŁeæe oko tjedan dana. Osim lake iritacije koe kod
nekih puaŁa, nije bilo drugih izrazitijih nuspojava primjene
nikotinskih flastera. Nismo zabiljeili nijedan sluŁaj pogor-
anja neuroloke simptomatologije tijekom primjene ni-
kotinske zamjenske terapije.
Bupropion (Zyban) kao prvo nenikotinsko pomoæno
sredstvo u odvikavanju od puenja, koji se primjenjuje sam
ili u kombinaciji s nikotinskom zamjenskom terapijom od
1997. godine kod nas jo, naalost, nije registriran, no pos-
tupak registracije je u tijeku. Prema podacima iz literature
uspjeno se primjenjuje, naroŁito kod puaŁa koji boluju od
depresije. Daje ga se jedan do dva tjedna prije planiranog
Is it hard for you to abstain from smoking at places where
smoking is forbidden or in some situations when it would
not be appropriate?
Those smoking at least ten cigarettes daily and have
their first cigarette some 30 minutes of waking up in the
morning because they do not feel comfortable unless they
do it, and those who can hardly stand situations where
smoking is inappropriate and cannot wait to have a ciga-
rette, have probably developed nicotine dependence.
Smokers fix their complex smoking habit for years.
Buying cigarettes, opening the pack, taking the cigarette
out of the pack and lighting it, taking it to and from the
mouth hundreds of times daily, stubbing it out, and dis-
posing butts becomes a routine. On solving daily problems
and stresses, a smoker will light a cigarette and feel com-
fortable due to the nicotine activation of the dopaminer-
gic system. He cannot imagine living without cigarettes,
which uses like a sort of crutches to rely on when tired
or oppressed with problems. In case of cigarette shortage
and nicotine level decline, unpleasant withdrawal symp-
toms occur such as desire for cigarette, irritability, frustra-
tion or anger, anxiety, concentration difficulties, fatigue,
increased appetite, retarded heart rate, etc., which disap-
pear as soon as he lights a cigarette and meets the nico-
tine requirement. Therefore it is no surprise that relapses
are quite usual in most smokers and are considered a nor-
mal part of the process of smoking cessation. A smoker
using a pack of cigarettes per day inhales nicotine 160 times
every day (on smoking one cigarette, tobacco smoke is
inhaled about eight times), which means that he supports
and reinforces his nicotine dependence 57,400 times a year.
At University Department of Neurology, Sestre milos-
rdnice University Hospital, the so-called brief intervention
has been used and special programs are organized for smok-
ers with high-grade dependence for whom the former is
inadequate. The program of smoking cessation is based on
the Breathe free plan to stop smoking principles of the
American authors Folkenberg and McFarland. This is a
psychotherapeutic-educational model. In some smokers,
the nicotine replacement therapy, mostly in the form of
adhesive strip, has been used to alleviate withdrawal symp-
toms. With the use of nicotine adhesive strips, the blood
level of nicotine is lower than with cigarette smoking but
yet high enough to alleviate or eliminate the nicotine with-
drawal syndrome and to facilitate cessation. In addition,
all harmful constituents taken on cigarette smoking are
removed from the strips. Strips are applied on intact, hair-
less skin and daily exchanged. There are strips with a vari-
able amount of nicotine (21 mg, 14 mg, 7 mg). The 21-
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mg strips are used in smokers having more than 20 ciga-
retters daily. The length of strip application varied, most-
ly about a week. Except for mild skin irritation, there no
major side effects of nicotine strip application. No case of
neurologic symptom exacerbation was observed during the
use of nicotine replacement therapy.
Unfortunately, bupropion (Zyban), the first non-nic-
otine adjuvant in smoking cessation, which has been used
alone or in combination with nicotine replacement thera-
py since 1997, has not yet been registered in Croatia, how-
ever, the process of registration in under way. According to
literature data, it has been used with success, especially
in smokers suffering from depression. It is administered
one to two weeks before the scheduled date of stopping
smoking (150 mg tbl) to continue with therapy for at least
4 to 6 weeks of smoking cessation. Bupropion decreases
the desire for smoking and mitigates withdrawal symp-
toms. It is well tolerated. Bupropion is not recommended
in patients with epilepsy.
An attractively illustrated handbook entitled You also
can quit smoking, of slightly greater dimensions than a
cigarette-pack format, 80 pages, has been issued for those
who have decided to quit smoking. It helps a smoker to
identify which type of smoker he belongs and and how to
turn to a nonsmoker through 15 steps, at a pace that suits
him, reading and applying the suggested, simple proce-
dures.
The majority of successful abstinents from smoking
had at least two to three serious attempts at quitting smok-
ing before they have reached continuous abstinence. Ac-
cording to studies, the length of previous periods of absti-
nence is important in predicting continuous, longterm
abstinence. Besides inappropriate preparation for the pro-
cess of cessation, the most common reason for smoking
relapse within 2-3 weeks of stopping smoking is the pres-
ence of nicotine withdrawal syndrome. After 3-4 months
of abstinence, a relapse usually occurs due to an attempt
to solve an anxious state or to get free from depressive
symptoms. A stressful event may provoke a relapse at any
time. The smokers who have followed the Breathe free
plan to stop smoking, where special attention is paid to
coping with stressful situations, are more successful in
solving daily stresses and will less frequently reach for cig-
arette again in such a situation. Experience shows that
desire for cigarette never lasts for more than three minutes.
Therefore, the use of so-called 4 P strategy is highly
efficient.
The WBWW Wait for a while Water (take a glass of)
strategy Breathe deeply Walk
datuma prestanka puenja (150 mg tbl) i nastavlja se s
terapijom najmanje Łetiri do est tjedana nakon prestanka
puenja. Bupropion smanjuje elju za puenjem i ublaava
apstinencijske smetnje. Podnoljivost mu je dobra. Kod
bolesnika s epilepsijom se ne preporuŁa uzimanje bupro-
piona.
Za puaŁe koji su odluŁili prestati puiti  tiskan je odgo-
varajuæi, zgodno ilustriran priruŁnik dimenzija neto veæih
od kutije cigareta, od osamdeset stranica, pod naslovom I
Vi moete prestati puiti, pomoæu kojega svaki puaŁ
moe identificirati kojem tipu puaŁa pripada i u petnaest
koraka, tempom koji njemu odgovara, Łitajuæi i primjenju-
juæi predloene jednostavne postupke, postati nepuaŁ.
Veæina uspjenih apstinenata od puenja imala su prije
stalne apstinencije najmanje dva do tri ozbiljna pokuaja
prestanka puenja. Prema provedenim ispitivanjima duina
trajanja prethodnih razdoblja apstinencije je vaan pred-
skazatelj za stalnu dugotrajnu apstinenciju. Razlog za re-
cidiv puenja unutar dva do tri tjedna od prestanka puenja
je najŁeæe, uz neodgovarajuæu pripremu za proces prestan-
ka, prisutnost nikotinskog apstinencijskog sindroma. Na-
kon tri do Łetiri mjeseca apstinencije recidiv nastaje obiŁno
zbog pokuaja da se cigaretom rijei anksiozno stanje ili
oslobodi depresivnih simptoma. U bilo koje doba recidiv
se moe dogoditi zbog stresogenog dogaðaja. PuaŁi koji su
proli kroz Breathe free plan to stop smoking, u kojem se
posebna pozornost posveæuje suoŁavanju sa stresogenim
situacijama, uspjeniji su u rjeavanju svakodnevnih stre-
sova i rjeðe im se dogaða da u stresnoj situaciji ponovno
zapale cigaretu. Iskustvo je pokazalo da udnja za cigare-
tom nikad ne traje due od tri minute. Stoga je primjena
tzv. strategije 4 P vrlo djelotvorna.
Strategija 4 P: PriŁekaj Popij Łau vode
PoŁni duboko disati Proeæi
Tijekom programa odvikavanja od puenja puaŁe se
poduŁava i o naŁelima zdrave prehrane kako ne bi nakon
prestanka puenja zbog suvinih kilograma ponovno pro-
puili. Ima vie razloga za moguæe debljanje nakon prestan-
ka puenja. Metabolizam se vraæa na normalu, oporavlja se
osjet okusa i mirisa pa hrana bolje prija, a neki bivi puaŁi
kojima nedostaje cigareta poseu Łesto za slatkiima i dru-
gom visokokaloriŁnom hranom. Stoga se preporuŁa piti
dosta vode (6-8 Łaa na dan), unos vlaknatih tvari (itarice,
voæe, povræe), ustati od stola nakon obroka, jesti polagano
i to tri uobiŁajena uravnoteena obroka, unijeti u organizam
dosta vitamina (puenjem se unitavaju vitamini A i C),
birati nemasno meso, prednost dati ribi, piti niskokaloriŁ-
na piæa, izbjegavati alkohol i redovito vjebati.
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During the smoking cessation program, smokers are
also education on dietary principles, so as not to restart
smoking due to wait gain associated with quitting smok-
ing. There are a number of reasons for the possible weight
gain upon stopping smoking. The metabolism returns to
normal, the smell and taste recover and the food tastes bet-
ter; the more so, some former smokers missing their ciga-
rettes may frequently reach for sweets and other high-cal-
orie food. Therefore, water should be taken in abundance
(6-8 glasses a day), along with fibrous food (cereals, fruit
and vegetables), leaving table after having a meal, eating
slowly with the intake properly distributed to the three
main meals, taking adequate vitamins (vitamins A and C
are destroyed by smoking), lean meat, giving preference
to fish, drinking low-calorie drinks, avoiding alcohol, and
regular exercise.
Smokers with high-grade dependence having more
than 25 cigarettes daily, with many previous attempts at
quitting smoking and short periods of abstinence of less
than one week, with low education level, poor socioeco-
nomic status, who have not received proper support from
the family or live with smokers, who suffer from some psy-
chiatric disorder, and are below age 45 belong to a catego-
ry characterized by more frequent relapses and greater
difficulties in establishing continuous abstinence.
An insight into the high risk emotions and situations
that may provoke the subject to reach for cigarette again
is important to maintain abstinence. These include irrita-
bility, anxiety, anger, boredom, depression, feeling of guilt,
presence of some persons, while driving, after meal, dur-
ing break at the workplace, after work hours, the begin-
ning and the end of the day. These emotions and situations,
which are normal part of daily living, in smokers act as trig-
gers to have a smoke. Therefore, one should be prepared
and find an alternative for any risk situation. One should
ask himself: What could I do instead of having a smoke?
Some tempting situations can be avoided. The ABLE ac-
ronym is easy to remember.
A nger L oneliness
B urden E mpty stomach
Anger, burden and fatigue, loneliness and boredom, and
empty stomach giving a feeling of hunger are frequent
triggers for smoking. Therefore it is important to learn
during the process of smoking cessation how to cope with
negative emotions without cigarette.
The smokers who had an opportunity to receive appro-
priate professional help during the process of smoking
cessation continue to live reinforcing the new, healthy
PuaŁi koji imaju visok stupanj ovisnosti, koji pue pre-
ko 25 cigareta na dan, koji imaju iza sebe puno pokuaja
prestanka puenja s kratkim razdobljima apstinencije ma-
njim od tjedan dana, koji imaju niu naobrazbu, koji imaju
slabiji socioekonomski status, koji nemaju odgovarajuæu
potporu obitelji ili ive s puaŁima, koji boluju od neke
psihijatrijske bolesti i koji su mlaði od 45 godina spadaju u
kategoriju onih koji Łeæe recidiviraju i tee uspostavljaju
trajnu apstinenciju.
Za odravanje apstinencije vano je imati uvid u visoko-
riziŁne emocije i situacije koje mogu navesti osobu da opet
zapali cigaretu. To su razdraljivost, tjeskoba, ljutnja, dosa-
da, depresija, osjeæaj krivnje, u drutvu nekih osoba, tije-
kom vonje, poslije obroka, tijekom stanke na poslu, na-
kon zavretka posla, na poŁetku i na kraju dana. Ove emo-
cije i situacije koje su normalan dio svakodnevnog ivota
kod puaŁa postaju pokretaŁi za paljenje cigarete. Zbog
toga se treba pripremiti i naæi alternativu za svaku riziŁnu
situaciju.Treba se pitati: to mogu uŁiniti umjesto da
zapalim cigaretu? Neke situacije kunje mogu se izbjeæi.
Lagani za upamtiti je akronim STOP:
S rdba O samljenost
T eret P razan eludac
Srdba, tereti i umor, osamljenost i dosada, te prazan
eludac koji daje osjeæaj gladi Łesti su pokretaŁi za pue-
nje. Zbog toga je vano tijekom procesa odvikavanja od
puenja nauŁiti kako se suoŁiti s negativnim emocijama bez
cigarete.
PuaŁi koji su imali prilike dobiti odgovarajuæu struŁnu
pomoæ tijekom procesa odvikavanja od puenja nastavlja-
ju ivjeti uŁvræujuæi nove zdrave navike koje uz uklanja-
nje puenja kao jednog od najubojitijih riziŁnih Łimbenika
ubrzavaju oporavak i smanjuju moguænost recidiva cere-
brovaskularnih  bolesti.
ZakljuŁak
Ovisnost o nikotinu je najrasprostranjenija ovisnost
diljem svijeta i prema podacima SZO jo uvijek jedan od
bitnih preventabilnih riziŁnih Łimbenika za razvoj vasku-
larnih i malignih bolesti. Cerebrovaskularne bolesti su uz
kardiovaskularne i maligne bolesti visoko na ljestvici pobola
i smrtnosti u cijelom svijetu. RiziŁnim Łimbenicima za
razvoj ovih bolesti posveæuje se posebna pozornost kako bi
se one riziŁne Łimbenike koji se mogu sprijeŁiti uklonilo,
a one koji to nisu stavilo pod kontrolu. Puenje je vrlo ozbi-
ljan preventabilni riziŁni Łimbenik za razvoj vaskularnih
bolesti, jer dovodi do povienja krvnog tlaka, ubrzanog rada
srca, suavanja perifernih krvnih ila, poveæanja adhezivnos-
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ti i agregacije trombocita, porasta fibrinogena u plazmi,
poveæanja razine karboksihemoglobina u krvi, pada razine
angioprotektivnog HDL i poveæanja razine LDL, povienja
ukupnog kolesterola, te povienja razine slobodnih masnih
kiselina. PuaŁi Łeæe obolijevaju od ishemijskog modanog
udara i subarahnoidnog krvarenja, a na CDFI karotida i
TCD Łeæe se zapaaju patoloke promjene. UnatoŁ pro-
gramima suzbijanja puenja duhana, na razini svijeta sva-
kih osam minuta netko umre zbog posljedica puenja pa
je tako puenje odgovorno za preko Łetiri milijuna smrti na
godinu. Procjenjuje se da u Hrvatskoj na godinu umre
14.000 osoba zbog posljedica puenja.
Svaki puaŁ se kad-tad naðe pred izazovom prestanka
puenja. Veæina puaŁa donosi odluku o prestanku pue-
nja potaknuta zdravstvenim problemima. Kako velik broj
puaŁa nije u stanju  bez potpore i struŁne pomoæi uspos-
ta-viti i odrati apstinenciju od puenja, neophodno je osi-
gurati svima koji to ele odgovarajuæu pomoæ, odnosno pro-
grame odvikavanja od puenja uklopiti u redovite terapijske
postupke u bolniŁkim i izvanbolniŁkim ustanovama. Sva-
ki lijeŁnik pozvan je da u izravnom kontaktu prui svom
bolesniku informaciju o oteæenjima zdravlja nastalim zbog
puenja, koja mora biti to osobnija, odnosno povezana s
potekoæama koje bolesnik navodi, a ne opæenita. Uza
struŁnu lijeŁniŁku potporu i pomoæ treba istaknuti kako je
za odravanje apstinencije bitna potpora i razumijevanje
obitelji, prijatelja i kolega na radnom mjestu. Obitelj
bolesnika mora biti upoznata s osnovnim znaŁajkama ovis-
nosti o nikotinu, s naŁelom sve ili nita, kao i s opasno-
stima pasivnog puenja. U domu i na radnom mjestu bit-
no je sprijeŁiti izloenost pasivnom puenju, odnosno osi-
gurati nepuaŁko ozraŁje.
NepuaŁko ozraŁje na radnom mjestu osigurava i Za-
kon o ograniŁenoj uporabi duhana i duhanskih proizvoda
koji je 1999. g. izglasan u Hrvatskom saboru. Potivanjem
spomenutog zakona ne samo da se titi nepuaŁe, veæ se
bolesnicima, bivim puaŁima pomae da se bre oporave
i odre apstinenciju koja je bitna za oŁuvanje zdravlja i
sprjeŁavanje recidiva cerebrovaskularnih i tridesetak drugih
bolesti povezanih s aktivnim i pasivnim puenjem.
habits which, along with the elimination of smoking as one
of the most detrimental risk factors, accelerate recovery
and reduce the possibility of cerebrovascular disease recur-
rence.
Conclusion
Nicotine dependence is the most widely spread addic-
tion worldwide and according to WHO data still one of the
substantial preventable risk factors for the development
of vascular and malignant diseases. In addition to cardio-
vascular and malignant diseases, cerebrovascular diseases
rank high on the morbidity and mortality scale all over the
world. Risk factors for these diseases are paid special at-
tention in order to eliminate the preventable ones and to
control the others that cannot be influenced upon. Smok-
ing is a very serious preventable risk factor for the devel-
opment of vascular diseases, because elevates blood pres-
sure, accelerates heart rate, narrows blood vessels, increases
platelet adhesion and aggregation, increased plasma fibrin-
ogen and blood carboxyhemoglobin, decreases angiopro-
tective HDL and increases LDL, total cholesterol and free
fatty acids. Smokers have a higher prevalence ischemic
stroke and subarachnoidal hemorrhage, whereas carotid
CDFI and TCD more frequently reveal pathologic chang-
es.
In spite of the programs for tobacco use reduction,
every eight minutes somebody dies in the world from the
consequences of smoking, so that smoking is responsible
for more than 4 million deaths per year. It is estimated that
in Croatia, 14,000 persons die due to the consequences of
smoking per year.
Each smoker is sooner or later challenged with quitting
smoking. Most of them decide on stopping smoking be-
cause of some health problem. As a large proportion of
smokers cannot establish and maintain abstinence from
smoking without proper support and professional assis-
tance, all those who want it should be provided appropri-
ate help, i.e. smoking cessation programs should be inte-
grated in regular therapeutic procedures in both hospital
and outpatient institutions. Each physician should provide
the patient, in direct contact, with due information on
health hazards associated with smoking; this information
should be individualized, i.e. related to the patients com-
plaints, rather than general. It should emphasize that, in
addition to the physicians support and assistance, the same
from the family, friends and colleagues is of utmost impor-
tance for abstinence maintenance. The patients family
members should be informed about the main characteris-
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tics of nicotine dependence, the all or none principle,
and the risks of passive smoking. It is of great importance
to prevent exposure to passive smoking, i.e. to ensure
nonsmoking setting both at home and at work place.
Nonsmoking setting at work place is regulated by the
Act on Restricted Use of Tobacco and Tobacco Products,
enacted by the Croatian Parliament in 1999. Following this
Act provisions does not only protect nonsmokers but also
assists patients, former smokers to recover earlier and
maintain abstinence, which is substantial for health pro-
tection and to prevent recurrence of cerebrovascular dis-
ease and some thirty other diseases known to be associat-
ed with active and passive smoking.
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Danas, zahvaljujuæi napretku medicine, doivjeti sto-
tu godinu vie nije znanstvena fantastika, a kvaliteta doiv-
ljenih godina vanija je od njihovog broja. Dostignuæa bio-
medicinske znanosti sve vie potkrepljuju nadu da moemo
smanjiti oteæenja u starosti i Łak izbjeæi mnoge degenera-
tivne simptome ovog ivotnog razdoblja. Kako bismo to
postigli sami moramo pomoæi prirodi i usvojiti to prije na-
Łin ivota koji ne samo da otklanja preranu smrt, veæ poma-
e da se i visoke godine proive u zdravlju, sreæi i dobroj
kondiciji. A za postizanje sklada duha i tijela zdrav mozak
i ile jedan su od osnovnih preduvjeta. Bolesti krvnih ila
neprijatelj su broj 1 suvremenog Łovjeka i najŁeæi uzrok
smrti i trajne invalidnosti. NajŁeæa bolest krvnih ila je
ateroskleroza.
Pod pojmom cerebrovaskularih bolesti podrazumijeva-
ju se bolesti krvnih ila s manje ili vie izraenim neuro-
lokim ispadima i gotovo uvijek s psihiŁkim promjenama.
Zadnji stadij klasiŁnog oblika cerebrovaskularne bolesti je
mo-dani udar. Sve vrste modanih udara su izravno ili ne-
izravno povezane s bolestima krvnih ila, odnosno s atero-
sklerotskim promjenama na krvnim ilama. Modani udar
je jo uvijek vodeæi uzrok invalidnosti, te treæi po uŁesta-
losti uzorak smrtnosti, odmah nakon kardiovaskularnih i
zloæudnih bolesti.
U zapadnim zemljama, osobito u SAD, broj oboljelih
od modanog udara posljednjih godina se smanjuje, u pr-
vom redu zahvaljujuæi organiziranim preventivnim akcija-
ma i usvajanju zdravog naŁina ivota. Naalost, u naoj
zemlji ne uoŁavaju se ovakvi povoljni trendovi te se moda-
ni udar jo uvijek javlja vrlo Łesto. Osobito je zabrinjavajuæe
to to se modani udar sve Łeæe javlja u sve mlaðim dob-
nim skupinama, tako da se Łak oko 45% modanih udara
javlja u dobnoj skupini od 46. do 59. godine ivota.
Ateroskleroza se, poput drugih degenerativnih bole.sti,
razvija godinama. ¨ initelji koji doprinose razvitku aterosk-
leroze mogu se podijeliti na one:
Owing to great advances in medicine, living to ones
100th is no more science fiction today, while the quality
of living to an advanced age has become more important
than the mere age. Achievements in biomedical sciences
provide ever more support to our hope that various age
related damages could be reduced and even many degen-
erative symptoms characteristic of old age avoided. To
make this endpoint real, we need to assist the nature and
adopt as early as possible such a lifestyle that not only averts
premature death but also helps live to a green old age in
good health, pleasure and shape. Healthy brain and vas-
cular system are one of the main preconditions for body
and soul harmony. Vascular diseases are enemy No. 1 of the
modern human, and the most common cause of death and
permanent disability. Atherosclerosis is the most common
vascular disease.
The term cerebrovascular diseases refers to vascular
diseases associated with more or less pronounced neuro-
logic events, and almost always with mental derangement.
Stroke is the final stage of the classic form of cerebrovas-
cular disease. All stroke types are directly or indirectly re-
lated to vascular disease, i.e. to atherosclerotic lesions of
blood vessels. Stroke remains the leading cause of disabil-
ity and third most common cause of mortality, immediately
following cardiovascular diseases and malignant diseases.
In western countries, especially in the USA, the num-
ber of stroke patients has been on a decrease in recent
years, primarily due to organized preventive actions and
adoption of a healthy lifestyle. In Croatia, unfortunately,
no such favorable trends have yet been observed, and
stroke remains quite a common disease. The fact that
stroke ever more frequently occurs in ever younger age
groups, with as many as 45% of stroke cases being record-
ed in the 46-59 age group, it has become a serious concern.
Likewise other degenerative diseases, atherosclerosis
develops over years. The factors contributing to the devel-
opment of atherosclerosis can be divided as follows:
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    na koje se ne moe utjecati: dob, spol, genetsko na-
sljeðe,
 na koje se moe utjecati: arterijska hipertenzija, hiper-
lipoproteinemija, eæerna bolest, razne srŁane bolesti,
poremeæaji zgruavanja krvi, poviena koliŁina mo-
kraæne kiseline, uzimanje oralnih kontraceptiva, po-
viena razina homocisteina,
 koji su otklonjivi: puenje, alkoholizam, stres, preko-
mjerna tjelesna teina, nedovoljna tjelesna aktivnost.
Prevencija je jo uvijek najuŁinkovitiji i najznaŁajniji
naŁin na koji se moe djelovati na bolesti krvnih ila, pa tako
i na modani udar. Medicinska sestra, kao i ostali zdravstve-
ni djelatnici, treba identificirati sve riziŁne Łimbenike pri-
sutne kod svakog pojedinog bolesnika i voditi brigu o nji-
ma. Medicinska sestra u okviru primarne prevencije otkriva
riziŁne Łimbenike za nastanak modanog udara, te utjeŁe
na bolesnika da se otklone Łimbenici rizika za koje je to
moguæe (puenje, prekomjerno pijenje alkohola, tjelesna
neaktivnost, pretilost itd.). Na taj naŁin ona promiŁe zdrave
navike i zdraviji naŁin ivota (nepuenje, nepijenje, tjele-
sna aktivnost itd.). Za ostale Łimbenike rizika (na koje se
moe utjecati) brine se da ih bolesnik odrava pod kontro-
lom u prihvatljivim granicama (regulacija arterijskog tlaka,
regulacija eæera, masnoæa, mokraæne kiseline u krvi, re-
doviti pregledi i kontrole u specijalistiŁkim ambulantama).
Bolesnici s vie Łimbenika rizika su mnogostruko skloniji
obolijevanju od modanog udara od bolesnika kod kojih je
prisutan samo jedan Łimbenik rizika. Kod takvih bolesni-
ka potrebno je uŁiniti sve da se uklone svi uklonjivi Łim-
benici rizika (u gore navedenom primjeru da bolesnik pre-
stane puiti). Time se moe postiæi znaŁajno smanjenje
uŁestalosti kako modanog udara tako i ostalih krvoilnih
bolesti.
Usprkos i najbolje provedenim preventivnim akcijama
neki bolesnici æe dobiti modani udar. U zbrinjavanju obo-
ljelih od modanog udara medicinska sestra je relativno
samostalan kreativno-inovacijski nositelj zdravstvene nje-
ge, to se ponajprije odnosi na skrb o bolesniku, bilo da
sestra organizira ili provodi tu skrb. Medicinska sestra prati
bolesnika s modanim udarom od hitne neuroloke ambu-
lante preko jedinica za modani udar ili odjela intenzivne
skrbi, neurolokih odjela pa sve do rehabilitacijskih odje-
la. Sestra je, dakle, ukljuŁena u sve faze zbrinjavanja bo-
lesnika s modanim udarom od prijma preko akutnog zbri-
njavanja, subakutnog zbrinjavanja, zapoŁinjanja rane reha-
bilitacije pa sve do kasnije rehabilitacije u stacionarnim
ustanovama. No, s otputanjem bolesnika nakon rehabili-
tacije u stacionarnim ustanovama ne prestaje angairanje
medicinske sestre. U okviru sekundarne prevencije me-
 nonmodifiable factors: age, sex, genetic heritage;
 modifiable factors: arterial hypertension, hyperlipopro-
teinemia, diabetes mellitus, cardiac diseases, coagula-
tion disorders, elevated level of uric acid, oral contra-
ceptives, elevated level of homocysteine; and
 removable factors: smoking, alcoholism, stress, over-
weight, lack of exercise.
Prevention remains the most efficient and most impor-
tant way to influence vascular diseases including stroke.
The nurse as well as other health professionals need to
identify and consider all risk factors present in each indi-
vidual patient. Within the primary prevention measures,
the nurse will detect the risk factors for stroke and advise
the patient to eliminate those that can be removed (smok-
ing, alcohol abuse, lack of physical activity, obesity, etc.),
thus promoting healthy habits and healthier lifestyle (non-
smoking, nondrinking, physical activity, etc.).
Considering the risk factors that cannot be modified,
the nurse will take care for these to be kept within accept-
able limits (due control of arterial blood pressure, blood
glucose, blood lipids and uric acid, regular visits and con-
trol examinations at outpatient specialist clinics). Patients
with multiple risk factors are at a much higher risk of stroke
than those with a single risk factor. In these patients, ev-
ery effort should be made to remove all modifiable risk
factors (in the above example, the patient should quit
smoking). This can result in a considerable decrease in the
prevalence of both stroke and other vascular diseases.
Some patients will sustain a stroke in spite of taking
all preventive actions. On delivering care to stroke patients,
the nurse is a relatively independent creative-innovative
health care provider, which primarily refers to patient care
by either organizing or providing it. The nurse follows up
the stroke patient from the emergency neurology clinic
through stroke unit or neurology intensive care unit to
rehabilitation facility. Thus, the nurse is included in all
steps of stroke patient care, from admission through acute
management, subacute management and early rehabilita-
tion to late rehabilitation at inpatient facilities. The more
so, the nurses engagement extends beyond the patients
discharge from the hospital for home care, as she identi-
fies and takes care of all risk factors present in each indi-
vidual patient as part of secondary prevention. Secondary
prevention also includes providing education to the patient
and his family members on therapy and on the need of
appropriate rehabilitation.
Through the domiciliary care system, the nurse edu-
cates patients with a history of stroke and their family
members on how to live well with the residual neurologic
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dicinska sestra identificira sve riziŁne Łimbenike prisutne
kod svakog pojedinog bolesnika i vodi brigu o njima. Obra-
zuje bolesnika i Łlanove njegove obitelji o terapiji u okviru
sekundarne prevencije i o potrebi rehabilitacije bolesnika.
Kroz patronanu slubu medicinska sestra obrazuje
bolesnike s preboljelim modanim udarom i Łlanove nji-
hovih obitelji o tome kako to kvalitetnije ivjeti sa zao-
stalim neurolokim deficitom. Sestra omoguæava to us-
pjeniju rehabilitaciju i ukljuŁivanje u ivot bolesnika s
preboljelim modanim udarom. Bolesnici i Łlanovi njihovi
obitelji kroz izobrazbu prihvaæaju posljedice modanog
udara, a sestra im pomae u olakavanju ivota s raznim
oblicima neurolokih deficita.
Vrlo je vana uloga medicinske sestre i u izobrazbi ireg
puŁanstva o simptomima i znacima modanog udara, kako
bi se podigla svjesnost populacije o modanom udaru, kao
i o njegovim uzrocima, naŁinima na koje se moe izbjeæi
modani udar, o prednostima zdravog naŁina ivota, o po-
sljedicama modanog udara i o ivljenju s posljedicama
modanog udara. Na taj naŁin æe se postupno promijeniti
jo uvijek prisutno fatalistiŁko shvaæanje modanog udara
i nihilistiŁki pristup u terapiji modanog udara.
Iz svega navedenog moe se vidjeti da je medicinska
sestra u zbrinjavanju oboljelih od modanog udara relativno
samostalan kreativno-inovativni nositelj zdravstvene njege
i skrbi o bolesniku, te da je uloga medicinske sestre u svim
oblicima zbrinjavanja bolesnika s modanim udarom (od
prevencije preko rehabilitacije do patronae i kuæne njege)
vrlo znaŁajna i da je medicinska sestra bitan Łlan tima koji
sudjeluje u zbrinjavanju bolesnika s modanim udarom.
deficit. The nurse ensures the most successful rehabilita-
tion of stroke patients and their resuming the usual daily
activities to the highest possible level. Through education,
stroke patients and their families accept the sequels of
stroke, while the nurse helps them facilitate their daily
living with various forms of neurologic deficit.
The nurse has a prominent role also in education of the
population at large about the signs and symptoms of stroke,
in order to increase the public awareness of stroke and its
causes, ways to avoid its occurrence, advantages of a healthy
lifestyle, stroke sequels and living with them. The fatalist
concept of stroke and the nihilist approach to stroke ther-
apy, that are still widely present in our society, will thus
gradually change.
Accordingly, the nurse is an independent, creative-in-
novative care provider for stroke patients, plays a very
important role in all aspects of stroke care (from preven-
tion through rehabilitation to domiciliary care and home
care), and is a crucial member of the team managing stroke
patients.
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